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ABSTRACT  
 
 
The aim of this thesis is to explore methods to incorporate external effects on decision 
making of public health programmes in a UK setting, using smoking cessation as an 
example. The National Institute for Health and Clinical Excellence (NICE) 
methodological guidance for evaluating public health programmes is missing the 
incorporation of external effects. Therefore there is a need for considering their 
incorporation in such evaluations and to assess what are the appropiate methods to do 
so. Smoking cessation is an example where epidemiological evidence of external effects 
exists but has not generally been incorporated into economic evaluation.  
 
This thesis therefore focused in measuring the impact, in terms of costs and QALYs 
lost, of the incorporation of passive smoking, smoking during pregnancy and 
transmission of smoking behavior into economic evaluation of smoking cessation 
programmes previously developed to inform policy. A static Markov model is used to 
incorporate passive smoking and smoking during pregnancy, whereas transmisison of 
smoking behaviour is incorporated through a dynamic model. 
 
The findings show that some external effects can be incorporated without a system 
dynamic model, when this does occur, a static Markov model may be used to account 
for external effects in economic evaluation. Sometimes, to incorporate external effects, 
the model needs a change of population. Because smoking cessation interventions are 
generally highly cost-effective, the incorporation of external effects does not appear to 
change policy decisions, but there is a clear impact on the magnitude of the ICER. 
Passive smoking and smoking during pregnancy have higher impact in terms of costs 
and QALYs lost than transmission of smoking behaviour. Our discussion considers the 
validity of the methods used; how much the decision making process would be affected 
considering or not external effects on economic evaluation of smoking cessation 
interventions; and other valuation approaches for external effects, such as contingent 
valuation.  
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CHAPTER 1 Introduction 
 
The National Institute for Health and Clinical Excellence (NICE) is responsible for the 
development of guidance on the promotion of good health and the prevention of ill 
health in the UK. NICE informs policy through economic evaluation and provides 
guidance on the prioritisation and allocation of resources for public health interventions. 
Economic evaluation, therefore, is an integral part of the public health guidance 
development process NICE (2009). However, delivering the largest possible 
improvement in public health depends on the existence of a body of knowledge about 
which interventions are the most cost-effective. The Public Health Interventions 
Advisory Committee (PHIAC) and the Programme Development Groups (PDGs) of 
NICE are therefore required to make decisions that are informed by the best available 
evidence on both effectiveness and cost effectiveness. 
Evaluation of public health interventions raises methodological challenges because 
these interventions generate very broad costs and benefits that are often directed at 
populations or communities rather than specific individuals (Weatherly et al, 2009; 
Drummond et al, 2007).  The costs and benefits of individual decisions that accrue to 
the general population are defined as ‘external effects’ but they are difficult to consider 
in economic evaluations. To date, external effects have been both rarely and poorly 
incorporated into economic evaluations of public health interventions. This may be 
attributed to the paucity of approaches to measure and value them. There is some 
recently published literature in this field, mainly about incorporation of the herd-
immunity external effect from vaccination in cost-effectiveness analyses (Brisson and 
Edmunds, 2003; Melegaro and Edmunds, 2004; Claes and Rene Reinert, 2009; 
Rozenbaum et al, 2010), but decision making on vaccination is not driven by 
recommendations from NICE. In the context of NICE, there is a surprising gap between 
guidance on the importance of adopting a broad perspective when considering costs and 
benefits and the current practice on which policy recommendations are based.  
External effects are a key focus of economic theory and have been widely researched 
outside health discipline (Beuthe et al, 2002; De Beer and Friend, 2006; Hamacher et al, 
2001). In public health interventions, external effects have mainly been considered in 
terms of regulation of health interventions (i.e. regulation on tobacco control) but not in 
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terms of their provision (i.e. including external effects into economic evaluation, which 
informs smoking cessation programmes provision in a UK setting). Ignoring external 
effects can lead to biased and inefficient provision of public health interventions 
because social costs (or benefits) incurred by public health programmes are larger (or 
smaller) than private costs. However, private costs are the ones most widely considered 
in economic evaluation (Drummond et al, 2005).  
Smoking cessation programmes are a good example of public health interventions in 
which documented epidemiological data and clinical evidence of external effects are 
used (Royal College of Physicians, 2010; Department of Health, 2004). A long list of 
external effects has been considered on the consumption side including: extra costs to 
the NHS for treating passive-smoking related diseases (WHO, 2008); costs created by 
household fires linked to smoking (Department for Comunities and Local Goverment, 
2010); and cleaning and building maintenance costs due to smoking on the streets 
(Novotny and Zhao, 1999).  On the production side they include: employment generated 
from the cultivation of tobacco or the contribution of the tobacco industry to the 
economy (Chaloupka and Warner, 2000), and damage caused by manufacturing and 
chemical waste from the tobacco industry (Novotny and Zhao, 1999). Choice about 
which external effect to use appears to be decided for a variety of reasons and purposes: 
to establish the full social costs and benefits as a basis for the efficient pricing and 
allocation of resources and to extend the scope of social cost or benefit (De Dios 
Ortuzar et al, 2000; Pretty et al, 2000; Wattage and Soussan, 2003; Lechon et al, 2003); 
to study the implications for economic evaluation of agricultural and food policy (Gray 
and Malla, 1998); and to value Pigovian taxes in order to internalise external effects on 
market prices (i.e internalisation of external effects) (Gibbons and O’Mahony, 2002).   
There are no established criteria for deciding which particular external effects to include 
in economic evaluation. 
There is extensive epidemiological evidence on three important external effects related 
to smoking: (a) passive smoking: the burden of disease not only for smokers’ own 
health but also for that of the people around them. ‘Second-hand’ tobacco smoke kills 
600,000 people each year (WHO, 2008) and there is no safe level of exposure; (b) 
smoking during pregnancy: this could cause serious problems including increased risk 
of miscarriage, premature birth, complications during labour, still birth, low birth-
weight and sudden unexpected death in infancy (Royal College of Physicians, 1992); 
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and (c) transmission of smoking behaviour: when a young person’s decision to smoke is 
influenced by peers’ smoking practices (Gilleskie and Strumpf, 2000). These three 
external effects are the focus of this thesis.  
The overarching aim of this thesis is to quantify and compare the magnitude of external 
effects, in terms of costs and QALYs, and their impacts on an existing economic 
evaluation, which informed decision making in public health programmes, using 
smoking cessation as an example. Despite the range of external effects related to the 
smoking habit, little attention is paid to how these effects could be incorporated into the 
economic evaluation of smoking cessation programmes. A systematic complementary 
review conducted (section 3.1, Chapter 3) confirmed that current economic evaluation 
of smoking cessation programmes have so far failed to incorporate external effects into 
their analyses (Salize et al, 2009; Hall et al, 2005;Mueller-Riemenschneider et al, 2008). 
A number of benefits can be anticipated from the incorporation of external effects into 
economic evaluation. Firstly, it will provide recommendations about methods of 
economic evaluation and the policy decision making process. Secondly, it will help to 
develop the practice of measurement and valuation of external effects in the health 
sector. Finally, it will provide a new direction for research methods for public health 
interventions. 
The thesis is structured in nine chapters.  
 
Chapter 2 explains how economic theory of external effects relates to public health 
interventions and reviews the importance of external effects from an economic 
theoretical point of view. It highlights the particular case for consideration of external 
effects in the health care market and outlines the different types, categories and market 
forces that characterise them. It also reviews a range of solutions to internalise external 
effects, focusing on public health interventions.  
 
Chapter 3 reviews ways in which external effects have been measured and valued across 
other sectors (i.e. transport, environment) noted for their evaluation of external effects. 
An early review identified these sectors as agriculture, environment, innovation, 
technology, telecommunications, network, transport and education. Reviewing the 
methods used in other sectors could lead to: a better understanding of how to value 
external effects in health; a summary of possible ways of incorporating external effects 
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into economic evaluation; and ideas on how to transfer relevant methods into public 
health programmes. The findings of the literature review presented in this chapter 
suggested that most external effects measured and valued had a negative impact. There 
appears to be no established criterion either for measuring and valuing a particular type 
or category of external effect, or for the choice of the most relevant external effects to 
consider. The decision to measure particular external effects appears to be based simply 
on the availability of data and/or the aims of the study. However, the most used 
valuation method is cost-benefit analysis, informed by contingent valuation approaches 
and the broader literature would support its use for capturing cross-sectoral and intra-
sectoral costs and benefits accruing to the population. NICE recommends the use of 
cost-effectiveness as the primary analysis on which to base decisions and CBA as the 
second line analysis (NICE, 2009) because there is still some uncertainty around the use 
of CBA for decision making in the NICE context. As this thesis aims to inform NICE 
policy making, cost-effectiveness and cost-utility analysis are the recommended 
approaches to the analysis and valuation of external effects.  
 
Subsequent chapters focus on empirical analyses of the impact of incorporating external 
effects into decision making, using smoking cessation as a specific example. The broad 
approach adopted is to conduct a literature review on economic evaluations of smoking 
cessation programmes, used to inform NICE decision making, which exclude external 
effects and to select and use one in particular to explore the impact of incorporating 
external effects in terms of costs and QALYs. The purpose of chapter 4 is to find and 
replicate an economic evaluation of smoking cessation programmes that has informed 
NICE decision making which does not incorporate external effects.  Chapters 5, 6 and 7 
incorporate alternative external effects into the replicated economic evaluation of 
smoking cessation programmes in Chapter 4 and study the magnitude of their impact. 
 
Chapter 4 search and replicates an economic evaluation used to inform NICE decision-
making on smoking cessation but which has not included external effects.  The model 
replicated will be referred to as model 1 (M1). Because the aim of this thesis is to 
quantify and compare the magnitude of external effects on current decision making by 
NICE, this thesis incorporates external effects into a model for economic evaluation 
currently used to inform NICE decision making rather than building a new economic 
evaluation from scratch.  The replication of this model will be called model 2 (M2). 
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Then, it demonstrates that the model is replicated appropriately, though as some critique 
is raised, this leads to an adaptation of the model, which is presented as model 3 (M3).   
 
The next three chapters incorporate one external effect after the other in order to study 
the impact of each one on the economic evaluation of smoking cessation programmes.  
 
In Chapter 5, the impact of passive smoking on economic evaluation is assessed using 
the economic evaluation replicated in chapter 4 with changes adopted in the model (M3) 
and, the incorporation of two new groups of population (non-passive and passive never 
smokers). The model excluding passive smoking in this chapter is referred to as model 4 
(M4), and the one which includes passive smoking, as model 5 (M5). An adult 
population was modelled based on smoking habits. However, when accounting for 
external effects, the population was augmented by children who are passive smokers. 
The literature was reviewed to inform the parameters of this model (i.e. health effects 
and costs generated by passive smoking, etc). Although results show that ranking of the 
cost-effectiveness of interventions does not change, as expected, passive smoking 
generates extra costs and loss of QALYs which has an impact on the magnitude of the 
ICER. Existing models which do not incorporate external effects may underestimate the 
population effects of smoking cessation programmes and, therefore, not favour results 
obtained in current economic evaluations of smoking cessation programmes and lead to 
inaccurate decision making. 
 
Chapter 6 investigates the effect of incorporating external effects associated with 
smoking during pregnancy using the same model structure as that used in chapter 5 to 
incorporate passive smoking, though the interventions and the population modelled 
were different. The model not including smoking during pregnancy is referred to as 
model 6 (M6) and that in which it is included as model 7 (M7). The population 
modelled was pregnant women between ages 16 and 44.5 years old, followed for the 
pregnancy period. When the external effect of smoking during pregnancy was 
incorporated, the average number of babies delivered by pregnant woman was also 
introduced in the model.  Literature reviews were conducted to inform the parameters 
for this particular model (i.e. health effects and costs generated by smoking during 
pregnancy, etc). The main question is how to assess the impact of external effects on the 
cost-effectiveness of smoking during pregnancy interventions. Although no impact was 
6 
 
observed in terms of policy decision, as expected, a similar increase in costs and 
QALYs lost was observed to that reported in chapter 5. 
 
Chapter 7 incorporates a third external effect into the economic evaluation of smoking 
cessation interventions - transmission of smoking behaviour. In this case, instead of 
using a static model as in Chapters 5 and 6, a dynamic model with two cohorts was 
created to account for the transmission of smoking behaviour. This was achieved by 
introducing a new concept in the model: that the never smoker’s risk of becoming a 
smoker depends on the prevalence of smoking in the population. This external effect 
was introduced in an adult general smoker population. The impact of the transmission 
of smoking behaviour was studied alone and in combination with passive smoking. 
When the model includes transmission of smoking behaviour but not passive smoking it 
is referred to as model 10 (M10) and when both transmission of smoking behaviour and 
passive smoking are included, as model 11 (M11). This chapter shows that ignoring 
dynamic models can result in misleading estimates of the aggregated effects of smoking 
cessation interventions. When dynamics were introduced in the economic evaluation of 
smoking cessation programmes, differences in lifetime costs and QALYs lost were 
observed, though, in concordance with expectations, there was no impact on the ICER 
ranking.  
Chapter 8 explores the impact of incorporating passive smoking, smoking during 
pregnancy and transmission of smoking behaviour on costs, QALYs lost and net 
monetary benefit (NMB) and, considers the potential impact on decision making for 
public health programmes. It first compares the results obtained from models M4 and 
M5 for a general population, then M6 with M7 for a pregnant population and, finally, 
M8 with M10 and M9 with M11 for a cohort of smokers and passive smokers, and 
assesses the area of measurement and valuation of external effects in the health sector. It 
then reflects on the differences across models, discusses their potential impact on policy 
and makes recommendations for methods of incorporating external effects into 
economic evaluation models and the policy making process.  
Chapter 9 concludes by identifying the key contributions and limitations of this thesis,    
its policy implications and the research agenda. Incorporating external effects into 
economic evaluation of smoking cessation intervention has a positive impact on ICERs 
in terms of lifetime costs and lifetime QALYs lost. Incorporation of the health impacts 
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from transmission of smoking behaviour in economic evaluation appears to have a 
higher impact compared with passive smoking or smoking during pregnancy. However, 
the magnitude of the impact of each particular external effect is difficult to ascertain 
because the populations modelled to incorporate the different external effects differ.  
However, the evidence produced by this thesis indicates that it would be advantageous 
to use available epidemiological evidence to decide whether or not to incorporate 
external effects. The main research agenda for incorporation of external effects would 
be: to study the effects of including external effects on the production side (i.e. benefits 
to manufacturers of tobacco industry). This might be the only way in which the 
incorporation of external effects would change policy making in smoking cessation; 
and, the incorporation into decision making for public health interventions closer to the 
£20,000 threshold. The research agenda for smoking would involve further study the 
impact of transmission of smoking behaviour with better data. 
 
This thesis contributes to knowledge in a variety of ways. Above all, it shows that cost-
effectiveness analyses can incorporate negative external effects on the consumption 
side. The decision analysis presented in this thesis also provides an exemplar that 
complements economic evaluation with the economic theory of external effects.  
Secondly, it tackles the issue of using existing relevant evidence to account for the costs 
and benefits accruing to others but ignored by most economic evaluations of public 
health programmes. Thirdly, it demonstrates that some external effects, such as passive 
smoking or smoking during pregnancy, could be valued using either static or dynamic 
models. Fourthly, it provides the first empirical analysis of smoking cessation 
programmes that consider the impact of passive smoking, smoking during pregnancy 
and transmission of smoking behaviour. Findings indicate that their impact can be 
measured in terms of extra costs and QALYs lost to society at large if they are included 
in an economic evaluation. Moreover, it has measured and valued the impact of external 
effects and has incorporated them into a relevant, existing economic evaluation. 
Although, no impact on the cost-effectiveness ranking of the different interventions was 
observed, because this public health programme uses a cost-effectiveness strategy, the 
inclusion of external effects does have an impact on costs and QALY. It would be 
interesting to discover whether considering external effects in other less cost-effective 
behavioural programmes, such as obesity prevention/reduction, would have a greater 
impact on policy. 
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Research from this thesis has been presented in two editorial papers (See appendix 1.1 
for Trapero-Bertran, 2009a; and, Appendix 1.2 for Trapero-Bertran, 2009b) and the 
author has also been invited to present results from this thesis at the 8th European 
Conference of Health Economics (ECHE), 7th to 10th of July 2010, and in the 5th 
European Conference on Tobacco or Health, 28th to 30th of March 2011.  The Health 
Economics Research Group (HERG) was commissioned to conduct a research project to 
inform commissioners about the relative merits of local and regional tobacco control 
and smoking cessation initiatives. This research was intended to provide a toolkit to 
allow decision makers to estimate the economic impact of tobacco use and how control 
strategies might improve health. The toolkit was based on the M3 model presented in 
this thesis, which is the replication of Flack et al (2007) model with relevant 
adaptations.  NICE has also requested a presentation based on the findings of this thesis 
to consider the place of external effects in the future research agenda.  
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CHAPTER 2 Economic theory of external effects: the case of health 
care markets 
 
2.1 Introduction 
The aim of this chapter is to set out how economic theory of external effects relates to 
public health interventions. The objectives are to:  
(a) describe the resource allocation process and the ‘external effects’ (see paragraph 
2.2.) of the health care market;  
(b) specify the types, categories and the impact of market forces on the external 
effects of health care;  
(c) review methods and solutions used to take into account external effects  
(d) explore the importance of accounting for the external effects of health care in 
economic evaluations in the context of NICE; and,  
(e) explain the need to review the measurement and value methods of external 
effects. 
This chapter is structured in five sections. The first covers the allocation of resources 
within the health care market. The second details the economic theory of external 
effects and sets the context of external effects in the health care market. The third 
describes the types, size of market and categories of external effects and cites the 
existing evidence of categories of external effects. The fourth, explains the two 
solutions for internalising external effects and the fifth draws together the conclusions 
of the chapter.  
 
2.2 Allocation of resources within the health care market: health care as an 
economic good 
The World Health Organization (WHO) defines health as ‘a state of complete physical, 
mental and social well-being and not merely the absence of disease or infirmity’ (WHO, 
1948). The value of health stems from its capacity to allow us to lead more fulfilling 
lives in terms of work and play than we might otherwise do (Mooney, 1986b). Health 
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care is the range of goods and services provided to promote health, or to prevent, 
alleviate or eliminate ill-health (Culyer, 2005). Therefore, the principal objective of all 
health care systems is to maximize the quality of health achieved (Cohen and Patel, 
2009). 
According to this definition, health care is an economic good such as labour, capital and 
raw material which is used to promote health. It is finite and costly and more of its 
resources can be devoted to the production and consumption of health care only by 
diverting them from some other use (Morris et al, 2007a). Our ‘wants’ for health care – 
what we would choose to consume, in the absence of constraints on our ability to pay 
for it as a nation or as a consumer – have no known bounds (Morris et al, 2007a). No 
health care system in the world has achieved levels of spending sufficient to meet all the 
perceived population wants for health care (Frankel, 1991). 
Member states of the European Union devoted an average of 7.4%1 of GDP to health 
care expenditure in 2007 (Eurostat 2007) but technological advances developed much 
more rapidly than the ability and willingness to pay for them (Mooney, 1986a). A 
clearly defined economic approach can improve understanding of a variety of relevant 
issues such as, for example, which resources are available; how they should be used and 
prioritised for the improvement of health care; who should provide access to them and 
how; and who will pay for them. 
The choices that arise are captured in the concept of ‘opportunity cost’, i.e. the benefit 
forgone because those same resources cannot also be used in their next best way. 
Therefore, each action taken in the implementation of health care by patients, health 
care providers or governments, involves the sacrifice of benefits that could have been 
enjoyed if used in an alternative manner.  For example, weighing up the costs and 
benefits of a decision to set up a smoking cessation programme involves assessing the 
potential benefits to smokers of that intervention, and comparing them with the benefits 
that might accrue from using those same resources for other health care interventions, 
such as the reduction of alcohol misuse or investment in education.  Health care is not 
available in an endless supply and the more of it we choose, the more of something else 
                                                 
1
 According to Eurostat the indicator is defined as the share of sickness/health care expenditure in GDP. This expenditure covers [a] 
cash benefits that replace in whole or in part, the loss of earnings during temporary inability to work due to sickness or injury and 
[b] medical care provided in the framework of social protection to maintain, restore or improve the health of the people protected. 
Data for EU15, EU25, CZ, ES (2002 and 2003); IT (2003 and 2004); UK (2003); FR, ES, LV, LT, LU, NL, PL, PT, SI, SK, SE, DE, 
CZ (2004) are provisional; data for UK, EU15, EU25 (2004) are Eurostat estimates.  
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we must sacrifice. Because health care is so important to our welfare as human beings, 
making these choices is difficult and contentious (Morris et al, 2007a) but this is 
essentially what efficiency involves: getting the most out of the limited resources 
available. 
To state that health care is an economic good is not to suggest that it is identical to other 
consumer goods and services. Indeed, a considerable part of past and current research in 
health economics is concerned with questions of whether and how health care is 
different and what implications this might have for the manner in which society 
organises its production and consumption. Economics is concerned with what is 
produced and how and for whom it is produced. The question to ask is should these 
issues be decided differently for health care? (Morris et al, 2007a). 
One way in which these decisions might be made is to allow market forces to determine 
who gets what. This is precisely the way in which production and consumption 
decisions about most economic goods and services are made. Economic models of 
supply and demand predict how firms and consumers behave in such markets and in 
some cases these are relevant to health care (Morris et al, 2007a). 
In most countries, of course, reliance on unfettered market forces for the production and 
distribution of health care services and products is rare. Typically, governments 
intervene in health care markets to a far greater degree than for most other economic 
goods: regulating who may provide a given service, what they may charge and/or the 
profits they may earn; subsidising health care either partially or fully via a range of 
taxes; and in some cases, directly providing health care, especially public hospitals. In 
the UK, the government dominates the funding and provision of health care, so supply 
is largely fixed by political decisions. Most health care is fully subsidised – nothing is 
charged at the point of consumption – so, not surprisingly, demand is higher than it 
would be if patients had to pay. In practice, health care systems are a complex mix of 
private and public sector activities. The main question to be answered, however, is why 
health care should be considered different from any other economic good.   
Arrow (1963) was the first to attempt an analysis of this question. He argued that 
special economic problems of medical care can be explained as adaptations of the 
existence of uncertainty in the incidence of disease and in efficacy of treatment. His key 
premise was that the principal characteristic of medical care is uncertainty because 
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demand, the incidence of illness and the efficacy of treatments are all uncertain. The 
demand for most goods is regular and predictable but ill health occurs randomly and its 
consequences can be severe. Moreover, there is uncertainty about how any given state 
of ill health will respond to health care. Recovery from a disease is as uncertain as its 
future incidence. The variable nature of risk-taking behaviour among health carers also 
makes this market different from those for economic goods. Arrow touched on two 
further main idiosyncrasies of consumer and provider behaviour in medical markets 
without asserting that they were unique and he also claimed that health care is an 
‘extreme’ good. The first difference is that patients do not behave in the same way as 
consumers. They cannot ‘test’ the product before consuming it and it is difficult for 
them to obtain information about the most appropriate medical care for their condition.  
There are also external effects, because they tend to care about the health of each other 
consciously (Morris et al, 2007a) or unconsciously (i.e. herd-immunity effect) (Brisson 
and Edmunds, 2003). The second difference is that doctors do not behave in the same 
way as commercial decision makers. Arrow (1963) lists four ways in which the 
expected behaviour of the doctor is different from that of people in business: (a) 
advertising and overt competition are virtually non-existent among physicians; (b) 
advice given by physicians as to further treatment by themselves or others is supposed 
to be completely divorced from self-interest; (c) treatment administered by the 
physician is dictated by the objective needs of the patients and not limited by financial 
considerations; and (d) the physician is relied on as an expert in certifying the existence 
of illness and injuries for legal and other purposes. It is assumed that the need to convey 
accurate information will, when appropriate, outweigh the decision to please clients 
(Mooney, 1986b). Economic analysis of health care therefore requires specialised 
theoretical approaches that acknowledge these differences.  
 
2.3 External effects: market failure in the provision of goods and services 
‘External effects’, an abbreviation for ‘external economies and diseconomies’ – 
sometimes referred to as ‘externalities’, ‘neighbourhood effects’, ‘side effects’, 
‘spillover effects’, or ‘spillovers’ – first appear as ‘external economies’ in Alfred 
Marshall’s ‘Principles’ in the context of a competitive industry’s downward-sloping 
supply curve. From now on, the term ‘external effects’ will be used to refer to those 
effects which necessarily accompany others that are unrelated to the economic activity 
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in question. In his introductory volume ‘Principles of Economics’ (1920), Marshall 
pointed out that we may divide the economies arising from an increase in the scale of 
production of any kind of goods, into two classes – those dependent on the general 
development of the industry (external economies); and those dependent on the resources 
of the individual houses of business engaged in it, their organization and the efficiency 
of their management (internal economies). Marshall’s early argument about external 
effects, described by Mishan (1971), was that as an industry expands by, say, the 
inclusion of an additional firm, any resulting reduction in the average costs of 
production accrues to all the firms in the industry. The total reduction of costs 
experienced by all the intra-marginal firms is attributed to the entry of the additional 
one. The true or ‘social’ cost of the additional output produced by this marginal firm is 
not the total cost as calculated by that firm, but subtracting from this total cost  the cost 
saved by all the intra-marginal firms. This proposition is important in determining the 
‘correct’ or ‘optimal’ output of the industry. But the marginal cost, or total cost of the 
incremental firm, will be below the average cost by the amount of the total cost-savings 
it confers on the intra-marginal businesses. Therefore, marginal cost will be below the 
market price to the same extent and, following the marginal-cost pricing rule, output 
should be extended beyond the competitive equilibrium until marginal cost is equal to 
price. The existence of external economies in a competitive industry, Marshall 
concludes, entails an equilibrium output that is below optimal.  
According to Mishan (1971), the ‘ideal’, or ‘optimal’, output is identified by the point at 
which the supply curve of the firm intersects its demand curve. This concept, and its 
corresponding construction, he extended in a symmetrical manner to external 
diseconomies, to reveal that the optimal output of a competitive industry was below the 
equilibrium output. These external effects were later shown by well-known economists 
(i.e. Buchanan, Fisher) to have wide applications to companies in determining the 
optimal size of an industry and also to industries themselves. Such effects, however, are 
not exclusive to industry.  
Brent (1997) states that an external effect exists when there is interdependence between 
the utility (or production) function of individuals or firms:  i.e. where an individual or 
firm B’s consumption or production affects that of another person or firm A. This can 
be mathematically presented as equation 2.1 (E2.1): 
UA = UA [XA1,XA2,…,XAm;YB1]   (E2.1) 
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This illustrates that the utility of individual or firm A is dependent on the activities 
(XA1, XA2,…, XAm) that are under his/her control but also on another YB1, which is 
under the control of a second individual or firm B. This outside activity YB1 can 
enhance A’s utility (for example, if B is a gardener who grows beautiful flowers that 
decorate A’s neighbourhood) or can detract from A’s utility (for example, if B is a 
smoker who indirectly causes the non-smoking A to get lung cancer). In other words, 
external effects can enhance individuals’ or firm’s utility, or reduce it, depending on the 
type of external effects. 
External effects appear in two forms (Feldstein, 1979). The first impacts on economic 
efficiency: it is only when all the marginal benefits (MSB) equal all the marginal costs 
(MSC) that the optimal level of output is determined. The second affects redistribution: 
some people receive an external benefit for which they do not compensate those 
providing them, or a cost is imposed on them for which they are not reimbursed. 
There are many definitions of external economies. Arrow (1971) defined external 
effects as the consequences of an action by one individual or group that falls on others, 
and unintentionally alters the utility and/or the production functions of those individuals 
without compensating them for damage caused or their having to compensate for 
advantages that accrue to them from that economic activity. Sometimes it is difficult to 
distinguish the intentionality of such an action in the production side of the market but, 
it is normally assumed that these actions spring from unintentional behaviour.  
 
2.3.1 The particular case of external effects in the health care markets 
This section will explore the relevance of theories of market equilibrium to markets for 
health care. In a competitive market system, economic efficiency of both demand and 
supply cannot normally be achieved when common assumptions underlying that 
competitive markets are violated (Feldstein, 1979).  
Health care markets, however, seem to operate rather differently because of their 
specific characteristics. The following important assumptions of perfect competition are 
unfulfilled in medical care: (a) that consumers have perfect information. Consumers 
lack information concerning their medical diagnosis, treatment needs, the quality of 
different providers and the prices charged by different providers (Feldstein, 1979); (b) 
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that there is complete mobility of resources and patients and providers have an incentive 
to minimize their costs of purchasing and providing medical treatment (Feldstein, 
1979). Barriers to mobility of resources include restrictions on the tasks that various 
personnel are permitted to perform; limited entry into health professions and controlled 
entry by institutions into various institutional markets (Feldstein, 1979); and, (c) the 
presence of external effects. Arrow cites communicable disease in this context: an 
individual who refuses vaccination or diagnosis (e.g. HIV) not only risks his own health 
but that of others. This implies that the market price of a vaccine may not accurately 
capture all the benefits and costs of the market transaction and no feedback mechanism 
exists to reflect the value of the resources used in health care (Scott et al, 2001).  
Health care markets will not lead to Pareto efficiency if external effects are present. In 
theory, individuals in a well-functioning, perfectly competitive market will use medical 
care until the marginal benefits, measured through the demand curve, equal marginal 
costs, which in equilibrium will equal the price. This leads to an efficient level of 
consumption in the absence of external effects but where external effects exist, the 
marginal external cost or benefit to people in society must be added to the marginal 
private cost or benefit, which is measured by the demand curve, leading to the marginal 
social cost or benefit. Therefore free health care markets do not provide optimal 
welfare. 
 
2.3.2 Different ways of categorising external effects 
There are two types of external effects: negative (social costs), and positive (social 
benefits). Negative external effects exist when the market quantity is greater than the 
equilibrium quantity. A clear example would be passive smoking, defined as the 
involuntary inhalation of cigarette smoke in closed spaces that have been contaminated 
by smokers and which is associated with a number of health consequences. Positive 
external effects exist when the market quantity produced is smaller than the equilibrium 
quantity, for example the case of immunization for contagious diseases. Here, people 
outside the market transaction – people who are not presently being immunized – are 
affected by the immunization because the immunized person is less likely to become a 
carrier of the disease.  
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Each type of external effect can occur on the production or consumption side. An 
external effect on the consumption side occurs if in an economic transaction, one 
consumer cares directly about another agent’s production or consumption action 
(Varian, 1996). When the consumption of a good by one person affects the welfare of 
another person or an agent’s production and that effect is not fully taken into account by 
the original person in making her/his decision to consume the good, there will be 
consequences. An example of a consumption external effect would be the adverse effect 
on their babies of women smoking during pregnancy. 
A production external effect arises when the production possibilities of one firm are 
influenced by the choices of another firm or consumer (Varian, 1996). They occur when 
a firm, in producing a given good, affects other agents, firms or individuals but does not 
account for this effect in its production decisions. For instance, hospitals attempting to 
develop treatments for multi-resistant infections while caring for infected patients, and 
not compensating either the patient or society in general for the benefits they have 
obtained from the development of such a treatment. 
One may also categorise external effects, according to their affect on output. The terms, 
‘technological’ and ‘pecuniary’ are used to distinguish between external effects.  They 
were first used by Scitovsky (1954), who defined technological external effects as those 
which occur when the production function of one firm is affected by the production of 
another. In other words, a technological external effect exists when actions taken by one 
firm affect the physical level of output of another, holding constant one firm’s level of 
input (Holcombe and Sobel, 2001). It is important to hold one firm’s level of input 
constant for purposes of comparison, because the actions of the other firm may affect 
the price that it must pay for its inputs, thus changing the input usage chosen to 
calculate its output. This would be a pecuniary external effect, not a technological one, 
because one firm could still produce the same level of physical output with the same 
level of physical inputs (Holcombe and Sobel, 2001). However, it would now be more 
costly for that firm to produce the same level of output using an unchanged input but 
this is a pecuniary effect that does not affect the technological relationship between 
inputs and outputs. 
The distinction between technological and pecuniary external effects predates the use of 
the terminology. According to Holcombe and Sobel (2001), Pigou (1924) discussed 
external effects as a divergence between social and private net product: ‘Here the 
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essence of the matter is that one person A, in the course of rendering some service for 
which payment is made to a second person B, incidentally also renders services or 
disservices to other persons C, D and E, of the sort that technical considerations prevent 
payment being extracted from the benefited parties or compensation being enforced on 
behalf of the injured parties’. According to Holcombe and Sobel (2001), Pigou referred 
to these services or disservices as third-party effects and noted that, unlike pecuniary 
external effects, not all third-party effects lead to inefficient resource allocation. The 
application of corrective taxes and subsidies has been suggested in cases where third-
party effects cause a divergence between private and social costs but not every effect 
creates such a divergence and in such cases social welfare maximization requires that 
such third-party effects occur. Therefore, pecuniary external effects are an integral part 
of the market mechanism. 
To summarize: on the production side, a technological external effect occurs when 
actions taken by one firm directly affect the physical level of output of other agents, 
holding constant the first firm’s level of inputs. Pecuniary external effects occur when 
actions taken by one firm directly affect either the prices that other agents pay or receive 
for outputs, when the first firm’s physical level of output is held constant. However, on 
the consumption side, technological external effects would occur when actions of one 
person directly affect the physical level of household production of others, and 
pecuniary external effects would appear when actions of one person directly either the 
price that other agents pay or receive for outputs. 
 
2.3.2.1 Categories of external effects to health care 
‘Positive ‘and ‘negative’ and ‘technological’ and ‘pecuniary’ economic nomenclature 
has been extensively applied in other sectors such as environment, transport, and 
innovation areas.  In the health sector, however the process is comparatively new, 
though other categories, such as ‘selfish’ or ‘caring’ external effects, have been used 
and an early exploratory review of external effects within different sectors including 
health has been conducted to explore the categorisation and valuation of this term. (See 
Appendix 2.1).  
Little evidence can be found on the identification of external effects in health care. 
Table 2.1 shows a possible grouping of the few examples located, using the categories 
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established in section 2.3.2 of this chapter. The main focus of attention for health care 
has been the ‘technological’ group.  Applying the economic definition in the health 
context would identify technological external effects as those actions or activities which 
affect other people by unintentionally altering, their utilities, health and/or welfare, 
without providing them with compensation or compelling them to compensate others 
for the impact of their unintended actions. Support for the examples cited in Table 2.1 
was found in the classification established by Mooney (1989) for health external effects: 
“those associated with infectious diseases and those arising because of concern for 
others”. There is no evidence so far of pecuniary external effects in health care.  
 
Table 2.1 Effects examples on health care classified according to type, category and market side 
Market side Category of  
external 
effect 
Positive Negative 
 
Consumption  
 
 
 
Technological 
 
 
 
 
 
Pecuniary 
 
• associated with communicable 
diseases; 
• selfish, caring and altruistic; 
• intergenerational/intrageneracional 
• consumer protection/consumption 
 
- 
 
• associated with communicable 
diseases; 
  
• intergenerational/intrageneracional 
 
 
- 
 
Production  
 
  
Technological 
 
Pecuniary 
 
- 
 
- 
 
- 
 
- 
 
The first external effect to be analysed in health economics, according to Jacobsson et al 
(2005) was the herd-immunity effect associated with interventions targeted at 
communicable diseases by Weisbrod (1961) and Lees DS (1960), the focus later being 
defined as “caring external effects” when individuals were seen to benefit from knowing 
that other people were receiving medical treatment.  Knowing that someone is in pain 
simply because they cannot afford medical treatment makes many people upset.  People 
are affected by the health of others because they care about them (Culyer, 1976). Few 
economists distinguish Arrow’s (1963) ‘selfish’ external effect from the ‘caring’ 
external effect. Although caring external effects are most probably of great significance 
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and are sometimes argued to be one of the most important characteristics of the Welfare 
State, current methods of resource allocation do not take them into account (Jacobsson, 
2005). 
It is important to understand that caring ‘for’ others and caring ‘about’ others are two 
distinct technological external effects (Wiseman, 1997). The first implies some form of 
positive action because it involves tending another person. The second is to do with 
feelings ‘for’ another person. Caring ‘about’ someone, in the sense of feeling affection 
for them, is based on feelings of affinity. The well-being of others has a positive weight 
in the individual’s set of preferences. Caring ‘for’ someone may also be based on a 
sense of obligation, i.e. the carer may be paid for her services or provide them because 
she feels generally compassionate for all people in need. Caring in conventional 
economic terms only occurs because it is ‘rational’, in the sense that people derive 
benefit from it and that the benefit exceeds the opportunity cost. These theories can be 
categorised in general terms (Wiseman, 1997) that juxtapose selfish and unselfish 
behaviour and process and outcome utility. Both, selfish and caring behaviour can 
generate positive external effects, because individuals are obtaining benefits from the 
action of other people. A selfish motive refers simply to concern for one’s own 
perceived needs – i.e., that referred to by Arrow. An unselfish motive involves a 
concern for the well-being of others, i.e. the well-being has a positive weight in an 
individual’s utility function. It is also generally assumed that these individuals have, at 
the very least, a selfish component in their psyche. According to Labelle and Hurley 
(1992) selfish external effects are not very common but it is still necessary to measure 
and value their magnitude. Labelle and Hurley (1992) also affirm that if one admits to 
either paternalistic or altruistic interdependencies, then external effects exist for a broad 
array of health care interventions and must be potentially important when evaluating 
health-care programs. ‘Process utility’ is defined here as the satisfaction of happiness 
derived from the act of caring or the act of giving. ‘Outcome utility’ is the satisfaction 
derived from the consequences of caring or giving. 
Kennedy and Welling (1997) identified two types of external effects stemming from the 
provision of parental childcare that could drive a wedge between the equilibrium and 
efficiency levels of parental childcare. The first is an inter-generational external effect 
that stems from the effect that childcare choice made by today’s parents has on the 
productivity of the next generation of workers (Kennedy and Welling, 1997). 
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Depending on the time spent, it could be a positive or negative technological external 
effect. The second is an intra-generational external effect arising from the impact of 
time spent on child care by a working parent. The interaction between these external 
effects determines the efficiency properties of the equilibrium (Kennedy and Welling, 
1997). 
Feldstein (1979) described two positive technological types of external effects. The first 
is the “consumer protection” argument. Given the technical nature of medical care, the 
usual lack in patient’s knowledge regarding diagnosis, treatment needs, and the 
provider’s competence; consumers might benefit from the establishment of certain 
minimum standards and the provision of information. If the private market did not 
provide standards (possibly through the threat of malpractice actions) or the necessary 
information required by consumers, or if all consumers wanted the government to 
ensure some minimum standards, then consumer protection would become an external 
effect and hence a legitimate role for the government (Feldstein, 1979). The other 
external effect of personal medical services is what may be referred to as “external 
effects in consumption”. If healthier and wealthier individuals do not want to see 
persons less fortunate than themselves go without necessary medical care and are 
willing to contribute to such care, then an external effect in consumption arises. This is 
because the utility of individuals depends not only upon the quantity of goods and 
services that wealthy people purchase but also upon the amount of goods and services 
(such as medical care) purchased by others. Under such circumstances, if a person or 
group contributes to the medical care of the less fortunate, then other persons, who 
would also have been willing to contribute, receive an external benefit. In addition, 
many other people will receive the benefit of seeing the less fortunate receive medical 
care, even if they did not contribute to this process. 
This preliminary review has provided a few examples of studies of the external effects 
related to health care. Compared with other sectors such as environment or transport 
which have a long tradition of study in this field, health care has come recently to the 
discipline and is much in need of further exploration. 
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2.4 Methods of internalising the market failure of external effects 
We have discussed why external effects lead markets to an inefficient allocation of 
resources but not how this inefficiency might be redressed. Examining possible 
solutions to this market failure, two main approaches appear to offer improve levels of 
efficiency: the private and the public solution. All proposed remedies share the same 
goal - to move the allocation of resources closer to the social optimum.  
 
2.4.1 Private solutions for efficient provision 
Although external effects tend to increase market inefficiency, government action is not 
always needed to solve the problem because people can develop private solutions 
(Mankiw, 2000) such as moral codes and social sanctions, charities, merging business, 
contracts and the enforcement of property rights. Each of these is discussed below. 
Sometimes, external effects can be overcome by moral codes and social sanctions 
(Mankiw, 2000). For example, most people do not shout at others in the street, because 
it is the ‘wrong’ thing to do. Moral injunctions learnt from our parents cause us to take 
account of how our actions affect other people. In economic terms, it makes us 
‘internalize’ external effects. Charities are another private solution to external effects 
(Mankiw, 2000), many being specifically established to deal with external effects. For 
example, museums and art galleries receive gifts in part because culture has positive 
external effects on society. Integrating or merging different types of business (Mankiw, 
2000) is another solution. Consider, for example, an almond grower and a beekeeper 
located next to each other. Each business confers a positive external effect on the other: 
by pollinating the blossom on the trees, the bees help the farmer produce almonds. At 
the same time, the bees use the nectar they get from the almond trees to produce honey. 
However, when the almond grower is deciding how many trees to plant and the 
beekeeper is deciding how many bees to keep, they may fail to consider the positive 
mutual external effects. If so, the almond grower might plant too few trees and the 
beekeeper keep too few bees. On the other hand, these external effects would be 
internalized if the beekeeper bought the almond orchard or the almond grower the 
beehives. Both activities would then take place within the same organisation and the 
owner could choose the optimum number of trees and bees. Internalizing external 
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effects is one reason why some firms are involved in different types of business 
(Mankiw, 2000). Another way for the private market to deal with external effects is for 
the interested parties to enter into a contract (Mankiw, 2000). In the example above, a 
contract between the almond grower and the beekeeper could solve the problem of too 
few trees and bees. The contract would simply specify the number of each, and perhaps 
involve a payment from one party to the other. Such a contract would solve the 
inefficiency that normally arises from these external effects and make both parties more 
successful. 
The establishment and enforcement of private property rights could provide an alternate 
framework for the resolution of unacceptable external effects. According to Mankiw 
(2000), “A private property right is a legally established title to the sole ownership of a 
scarce resource that is enforceable in the courts”. When property rights exist, and only a 
small number of individuals are involved, the parties can get together to consider and 
internalize the external effects (Brent, 1997). The establishment of property rights, thus, 
creates a framework which allows bargaining and the achievement of a socially optimal 
outcome. However, unacceptable [or negative] external effects persist in situations 
where property rights are poorly defined, have not been secured, or accrue only at 
prohibitive cost (i.e. environmental damage caused by company waste being discharged 
into rivers). Furthermore, satisfying the requirements of a transaction can be costly. 
Valuable resources may have to be used to locate potential trading partners, negotiate 
with them, and enforce an agreement. Economists refer to these costs as transaction 
costs and when they are higher than the gains to be realized from an exchange of 
contract, no exchange will occur. But transaction costs are never zero (Glahe and Lee, 
1981). In some cases, property rights cannot be effectively enforced because transaction 
costs are prohibitive. When this occurs, productive exchanges do not take place and 
resources are not employed in the most effective way, thereby facilitating negative 
external effects (Glahe and Lee, 1981).  
Varian (2006), described a special case in which external effects are independent of the 
assignment of property rights. This is known as the Coase Theorem. According to 
Ronald Coase (1959), whatever the initial distribution of rights may be, if private parties 
can bargain without cost over the allocation of resources, then the private market will 
always solve the problem of external effects and allocate resources efficiently (Mankiw, 
2000). Despite the appealing logic of the Coase theorem, private actors on their own 
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often fail to resolve the problems caused by external effects (Mankiw, 2000) and it is 
the State which has to protect the property rights and ensure the completion of contracts. 
The Coase theorem applies only when the interested parties have no trouble reaching 
and enforcing an agreement. In the real world, however, bargaining does not always 
work, even when a mutually beneficial agreement is possible. Sometimes the interested 
parties fail to avoid an unwanted external effect because of transaction costs. In a recent 
example, the transaction costs were not the expenses of the negotiators but of the 
lawyers required to draft and enforce the contracts (Mankiw, 2000). Reaching an 
efficient bargain is especially difficult when the number of interested parties is large 
because coordinating the negotiations can be costly (Mankiw, 2000). However, if 
private parties are able to bargain over the allocation of resources with little or no cost, 
they can solve the problem of external effects on their own.  
 
2.4.2 Public solutions: regulation, finance, and optimum provision  
To avoid the inefficiency of market equilibrium when private solutions do not work, the 
government can attempt to remedy the problem of external effects (Samuelson and 
Nordhans, 1992). The existence of external effects means that prevailing market prices 
do not always reflect the true social cost of resources and this justifies the involvement 
of the public sector. Policy makers can respond in three main different ways (Barr, 
1987): by regulation, finance or public production. 
 
2.4.2.1 Regulation policies and finance 
The State may try to correct external effects by making regulations. This would be an 
indirect remedy to correct external effects created by market failure. At its most simple, 
regulation is a legislative intervention which modifies individual or company behaviour 
in the context of the legal framework of property rights and contract law that underpins 
the workings of markets (McDowell et al, 2009).  
Alternatively, when an external effect exists (and the conditions of the Coase theorem 
do not hold) a price instrument might be used to set the social optimum. This could be 
Pigovian taxes or subsidies (Brent, 1997). Pigou (1932) suggested that when there is an 
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external diseconomy, taxes should be introduced proportionate to the value of the 
damage done. If external economies exist, then subsidies should be applied (Brent, 
1997). Therefore, the government can internalize [plan to avoid] external effects by 
regulating or taxing activities that have negative external effects and subsidizing those 
that have positive external effects. Taxes enacted to correct the effects of negative 
external effects are called Pigovian taxes, after economist Arthur Pigou (1877-1959), an 
early advocate of their use. 
Economists (Dunnet, 1998; Varian, 1992) usually prefer Pigovian taxes over regulations 
as a way to deal with pollution, for example, because they can reduce it at a lower cost 
to society. A tax is just as effective as a regulation in reducing the overall level of 
pollution. The reason why economists prefer use of the tax is that it reduces costs more 
efficiently. Regulation requires each individual to reduce negative external effects by 
the same amount but an equal reduction is not necessarily the least expensive way to 
clean up the pollution. The Pigovian tax places a price on the ‘right’ to pollute. Just as 
markets allocate goods to those buyers who value them most highly, a Pigovian tax 
allocates the highest price for pollution to those factories that face the highest level of 
pollution.  
Pigovian taxes are unlike most other taxes. Most distort incentives and move allocation 
of resources away from the social optimum. Pigovian taxes correct incentives for the 
presence of external effects and thereby move the allocation of resources closer to the 
social optimum when damages are observable. But this is not the most common case. 
Thus, while Pigovian taxes raise revenue for the government, they also enhance 
economic efficiency. Although it is not an easy task, one must still evaluate external 
effects in order to inform policy makers about the “market price” of these external 
effects and to compensate individuals affected by them. 
 
2.4.2.2 Provision of health care as a “public good” 
The second option would be for the government activity to become a producer of 
intermediate or final goods and services (McDowell et al, 2009). The term ‘public 
goods’ is used to describe certain outputs, which for technical reasons simply cannot be 
produced efficiently if production is left to the interaction of market forces (McDowell 
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et al, 2009). For this reason, although health care could be provided privately, there are 
some cases (e.g. as where external effects exist), when public provision is more 
efficient.  
 
The interest in public health amongst politicians, the media and public has never been 
greater. Promoting health and preventing diseases are major items on the agenda of 
many governments. The UK Government’s increasing emphasis on quality standards, 
outcomes and choice highlights the need for informed health service planning (Griffiths 
et al, 2005). Public health is defined as "the science and art of preventing disease, 
prolonging life, and promoting health through the organized efforts of society" 
(Department of Health, 1988). Among other tasks, public health professionals work 
with other professional groups to plan and carefully evaluate the provision of health 
care.  
The government is able to remedy inefficiencies through the provision of health care. 
However, most health care products and services are not public goods because they are 
both: ‘rival’ (i.e. one person will usually prevent another person from consuming that 
same health care), and ‘excludable’ (i.e. individuals could usually be excluded from 
consuming it). Nevertheless, like public health interventions, some health care 
programmes do have public good properties, non-rivalry and non-excludability. To 
design good public provision schemes, government regulators need to know and access 
information about the range of alternatives available if they are to attain maximum 
efficiency. 
Economic evaluation of public health interventions offers a tool to assess the efficiency 
of the different interventions that might be offered to the population. Evaluation is 
essential and should be a routine part of all public health intervention programs, despite 
the problems of applying economic evaluation in the public health context (Kelly et al, 
2005). 
 
2.5 Discussion and conclusions 
Market failure could result from the existence of negative or positive external effects. 
There are two types of external effects: positive, and negative. External effects could 
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appear on both consumption and production sides of the market. Two main categories 
of external effects were studied: technological external effects, which have a direct 
impact on resources and pecuniary, which have an impact on prices. There is little 
evidence of the identification of external effects in health care. Most of the reviewed 
literature examined caring externalities. 
External effects could arise because individuals may choose to consume levels of public 
health interventions based on the costs and benefits to themselves (private costs and 
benefits), and these may be different from the costs and benefits to society (social costs 
and benefit). Therefore, the evaluation of many public health interventions raises 
methodological challenges, because these interventions generate very broad costs and 
benefits and are often directed at populations or communities rather than specific 
individuals (Kelly et al, 2005). However, the external effects of public health 
interventions could be internalised through government provision to increase the 
quantity provided in the market (i.e. herd-immunity generated by a public vaccination 
program). This provision could compensate those affected by negative external effects 
or charge those who receive extra benefit from positive external effects.  
The existence of external effects legitimizes a role for government in health care but the 
nature of that role is undefined. It is not sufficient merely to claim that external effects 
exist and that government should therefore intervene in the market. Where external 
effects exist, there are two pre-requisites before intervention (Feldstein, 1979). First, the 
government must determine the exact nature and size of the external benefits and costs. 
Second, it must discuss how these external effects should be financed. No further details 
will be provided on the latter role, since it is not within the scope of this thesis.  
Inadequate consideration of external effects in policy making does not imply that 
external effects are non-existent in the health area.  Appendix 2.2-2.4 provides several 
examples of technological, positive and negative, external effects raised by different 
public health interventions. For instance, there is a wide range of evidence of the 
relevance of the positive external effect of herd-immunity effect, within vaccination 
programs (Trotter and Edmunds, 2006). Some examples of technological negative 
external effects occur due to hospital infections (Cooper et al, 2004); alcohol habits; or 
smoking cessation though, there is no known prioritisation criteria for ranking them 
according to their importance.  
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There are a number of different ways to incorporate external effects in the economic 
evaluation of public health interventions: cost-benefit analysis (CBA), cost-
effectiveness analysis (CEA) and cost-utility analysis (CUA) (Drummond, 2007). 
Currently, CEA and CUA dominate and CBA is used relatively infrequently (Labelle 
and Hurley, 1992). An important question to answer, therefore, is whether the existing 
CEA-CUA methodology can be adapted to measure external effects.  There is no 
evidence so far of the most effective way to include external effects in the evaluation of 
public health interventions.   
The importance of external effects in resource allocation is best seen by studying all 
costs and benefits associated with public health interventions. We need to calculate their 
magnitude in public programs to ascertain how and in which ways the decisions of 
policy makers might change if they were to account for external effects but this 
constitutes a major challenge because we are still unsure how to accurately measure and 
value external effects (Kehoe and Freshman, 1994). There is, therefore, no alternative 
but to use economic evaluation in order to understand the impact of external effects in 
health care. So far, however, they have rarely been considered in this context. Now, 
they must be acknowledged and incorporated into analyses by considering the existing 
information, making the assumptions explicit and building them into the analysis in 
order to better inform decisions made in connection with both intersectoral and 
intrasectoral costs and consequences (Drummond et al, 2007). To incorporate and 
internalise external effects, one might understand and use the approaches long 
established in other sectors.   
There is a need to review the literature, consider how external effects have been 
measured and valued in other sectors and investigate this gap in the measurement and 
valuation of external effects in health care. It is also important to review other sectors, 
with long traditions in accounting for external effects, to determine the criteria used to 
identify the effects that are most relevant to health care, categorise those most studied 
and explain why, and decide whether they are capable of being conceptually 
homogenized. 
The next chapter of this thesis presents a literature review of different sectors of types, 
categories, market sides and measurement and valuation approaches to external effects. 
This literature review provides limited evidence to illustrate what could be a relevant 
external effect to incorporate into the evaluation of a public health program.  
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CHAPTER 3 Exploring taxonomies to measure and value external 
effects from other sectors that apply to health 
 
3.1 Introduction 
Chapter 3 aims to review methods of measuring and valuing external effects in different 
sectors of economic evaluation in order to identify possible ways of incorporating 
external effects into the evaluation of public health programmes. A preliminary review 
was undertaken in order to identify those sectors which have been successfully 
measuring and valuing external effects historically. The search was conducted between 
October and December 2006, using the electronic library databases of Brunel University 
and London School of Economics and one on-line database (Google scholar). The free 
text search terms used were “externalit*, “spillover*” and, “economic*”. This review 
identified relevant studies in the following sectors: agriculture, environment, 
innovation, technology, telecommunications, network, transport and education (see 
Appendix 3.1). The objectives of chapter 3 are therefore: (a) to assess the most studied 
types and categories of external effect and side of market which uses them; (b) to 
identify which external effects are of greatest importance; (c) to explore the impact of 
external effects; (d) to review approaches used in valuing external effects; and (e) to 
explore the use of these valuation methods in economic evaluations. Because originally, 
external effects tended to be studied in different sectors, it is important to discuss the 
application of these methods to health care in order to be able to use the results to 
inform the operationalisation of methods for the economic evaluation of public health 
interventions in the context of NICE. The subsequent sections of this chapter cover 
methods of review, results and discussion.   
 
3.2 Methods 
This section describes the search strategy used, and how studies were selected and 
reviewed. 
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3.2.1 Search strategy 
A literature search was conducted between March and June 2007, using two electronic 
databases (Web of Science2 and Econlit), with an iterative review of references. The 
free text terms are presented in Appendix 3.2 and included three different types of 
search terms: (a) one for each particular sector; (b) one referring to type of valuation 
approach used; and (c) one referring to external effects. Search terms were chosen to 
enable retrieval of papers on valuation approaches to external effects in nine3 different 
sectors: agriculture, environment, innovation, technology, telecommunications, 
network, transport, education and health. Due to an unmanageable number of hits 
reached by Web of Science (13546 papers) and Econlit (12856 papers), a limitation was 
placed on the search criteria. As search terms were already restricting the search in each 
sector, different combinations of search terms and language restrictions were tried but 
none achieved an acceptable reduction in the number of hits received. The search for 
literature was therefore limited to the last ten years for each sector (Web of Science, 47 
hits; Econlit, 49 hits). Once papers were retrieved and downloaded to a file, they were 
screened for duplicate and irrelevant records. 
 
3.2.2 Selection criteria 
Each selected paper had to satisfy all of the following criteria. 
1. It measured and/or valued an external effect (according to the definition in section 
2.3).  
2. The approach which it used had been tested empirically and details of this process 
were shown. 
3. It was written in English, [There were no resources for translation]. 
4. It was published during the last ten years, [to increase the likelihood of reflecting 
current valuation approaches]. 
 
                                                 
2
 ISI Proceedings and External collections produced no additional papers and were therefore not included 
in the search. 
3
 See appendix 2.1 for details 
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3.2.3 Review questions 
Selected papers were reviewed against a set of 40 questions designed to extract data in 
five main areas: the background to external effects; specification of the impact 
measurement; valuation approach; main findings and given criticism.   [See Appendix 
3.3]   The potential contribution of each paper, to the evaluation of external effects in 
public health interventions was also considered.  
The questions related to the background data of external effects were designed to 
identify the types, categories and side of the market most studied in the context of 
external effects, according to the definitions of section 2.3.2 of this thesis.  
Knowledge of impact measurement helps to identify which proxies to use such as 
measures of external effects and whether there are any established criteria for the 
prioritization of external effects. Examination of valuation approaches highlighted the 
methodologies most frequently used to incorporate external effects in other sectors, and 
served as a pointer to possible ways of incorporating external effects into health sector 
valuations. Collection of information about ways of measuring and valuing external 
effects on health care was of great relevance to this review of the literature. 
 
3.3 Results 
This section outlines the search results and provides a description of reviewed papers, 
methods used to measure external effects and a summary of the main findings. 
 
3.3.1 Description of studies 
A total of 103 papers produced by the search were screened or duplicated and a shortlist 
of 66 was identified for further examination using the selection criteria. [See Appendix 
3.4]  Seven of these papers did not merit inclusion, leading to the selection of 59 papers. 
See Appendix 3.5 for a list of included papers, and Appendix 3.6 for details of the 
papers reviewed. 46% of papers were found in the ‘Web of Science’ and 48% in the 
‘Econlit’ database, searching by title. See Figure 3.1 for distribution of papers across 
sectors.  
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Figure 3.1 Distribution of studies across sectors 
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Six papers were found using “agriculture” as a search term. Two studies were found 
under “network”. Although strictly, they did not belong to this area, it was decided to 
keep strict with the findings by search term, and include them. Both studies were from 
the transport field and dealt with the external costs of Belgian inter-urban freight traffic 
and a cost-benefit analysis of walking and cycling track networks. The environment and 
transport sectors produced more evidence than others because they have a tradition of 
valuing external effects. Papers on these sectors represented 29% and 24%, of the total, 
respectively.  
More than 50% of publications reviewed were published between 2003 and 2007. 
About 44% (n=26) of the papers stated that their aim was to estimate and quantify 
external effects. The rest sought to: (a) compare and analyse external effects of different 
public interventions; (b) develop models to examine the impact of external effects; (c) 
discuss different methods used to measure external effects; (d) evaluate different 
accounting systems for external effects; (e) discuss and calculate approaches to 
internalize external effects; and (f) explore how assignment of property rights affect 
social efficiency. 
The importance of studying external effects was raised in 54% (n=32) of papers. A  
wide variety of justifications of importance were used including the need to: (a) base 
choice among interventions on true cost; (b) reduce uncertainty about costs in cost-
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benefit results; (c) estimate all the costs reflected in common decisions; (d) avoid a non-
optimal allocation of resources that leads to welfare losses when making decisions; (e) 
be more aware of damage caused and its associated financial effects; (f) provide better 
estimates as a guiding principle for the agreement of further policy; (g) calculate how 
much benefit an intervention could add to the country; (h) identify alternative 
interventions from the current ones in order to become more competitive in the market; 
and, (i) include external effects when calculating prices to increase the precision of 
assessment of national revenues generated in different sectors. 
When specifying the type of external effects, most papers concentrated on negative 
external effects (n=36).   Only 14% of the papers measured and valued positive and 
negative external effects in the same paper (see Graph 3.1). 
 
Graph 3.1 Types of external effects 
 
 
 
 
 
 
Table 3.1 shows that 25% (n=15) of the papers reviewed studied negative external 
effects and that they concentrated in the consumption side.  Only 8% (n=5) of papers 
studying positive external effects were focused on the production side. There were no 
differences in the number of papers dealing with the consumption and production sides 
of the market. Indeed, 12% (n=7) of the papers examined measured and valued external 
effects on both sides of the market in the same papers.  
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33 
 
            Table 3.1 Type of external effects by market side 
 Effects Side Negative Positive Both TOTAL 
Consumption 15 10 1 26 
Production 14 5 7 26 
Both 7 - - 7 
TOTAL 36 15 8 59 
 
The importance of focusing on the production side of the market was explained in 9 
papers (15%). These reasons included: (a) an awareness of increasing costs due to a 
tendency towards increasing production; (b) difficulty in comparing the impact of 
global and regional technologies in terms of monetary damage; (c) the tendency to look 
forward with technology but backwards to environmental costs; (d) the need for a tool 
to evaluate the convenience of a project. Of the 5 papers (8%) on the consumption side, 
the most common reason given for focusing on external effects was the need to carry 
out a societal impact assessment.       
 
Graph 3.2 Categories of external effects 
 
 
 
 
 
 
 
Graph 3.2 shows the wide range of categories of external effects studied. These 
categories were not established uniformly accepted in 86% (n=51) of the papers.  Of 
those, 88% (45/51) were concerned with technological external effects, 2% (n=1) with 
caring external effects, 2% (n=1) with knowledge, 4% (2/51) with pecuniary external 
effects, and 4% (2/51) with both technological and pecuniary external effects. Of the 
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papers using categories, there was a marked consistency between the categories 
established by the papers’ authors and those which I have used for this study (see 
section 2.3.2.1 for definition of external effects categories).  
On the consumption side of the market, technological external effects were the focus of 
88% (n=23) of the papers examined; caring external effects were studied by 8% (n=2); 
and one paper reported on both technological and pecuniary external effects. Papers 
focusing on production external effects used an extended number of categories 
compared with those on the consumption side. 77% (n=20) of the papers were 
concentrated on technological external effects but only 4% (n=1) on pecuniary external 
effects. Two studies looked at knowledge external effects, and one at network external 
effects. Two papers considered pecuniary and technological external effects at the same 
time. Of those studying external effects on both consumption and production sides at 
the same time, technological and pecuniary external effects accounted for 86% (n=6) 
and 14% (n=1) respectively. 
 
3.3.2 Identification of external effects impacts and their importance 
The impact of external effects is often wide-ranging and positive and negative external 
effects may occur at the same time (see Appendix 3.7 to Appendix.3.10). The most 
commonly identified negative external effects (81%, 29/36) were environmental and/or 
health losses.  However, of the 15 papers looking at positive external effects, 47% (n=7) 
studied only their impact on the environment and/or health. The remaining 53% (n=8) 
papers studied impacts on education, infrastructure, welfare, knowledge, innovation and 
employment, competition between firms, industrial development, and investment.  
Of the eight papers looking at positive and negative external effects, five papers were 
concerned with their environmental impact. Other papers (n=3) focused on impacts 
relating to insecurity, health, reforestation, productivity and labour.  
There were no selection criteria established in any paper to lead decisions about which 
external effect impact could or should be measured and why.  
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3.3.3 Measurement of the impact of external effects  
Table 3.2 shows that reduction of air pollution and noise were the measures most 
frequently used to evaluate environmental impacts on the consumption side, whereas 
reduction in accidents was the measure most used to evaluate impacts on health. On the 
production side, increases and reductions in natural resources were the most common 
measure used in studies of environmental impact. Beyond these, there is a great variety 
of measures used within different impacts studied (See appendix 3.7 and 3.10). The 
impact of negative external effects on both consumption and production sides of the 
market include environment, health, infrastructure and real money trade. The most 
common measures used to assess environmental impact were: CO2 emissions, air 
pollution, greenhouse gases, climate change, ecological damage, global warming, noise 
and eutrophication. Impact on health was assessed on the incidence of 
methemoglobinemia (a fatal illness for children), acute and chronic effects, accidents 
injuries and mortality. Measures used to study impacts on the infrastructure included 
materials (i.e. loss of mechanical strength; leakage and failure of protective coatings due 
to degradation of materials).  
Table 3.2 Measures to value negative external effects 
Impact  Consumption  (n=15/26) Production  (n=14/26) 
Environment Air pollution (11/15); noise (10/15); 
congestion (5/15); emissions (2/15); 
climate changes (1/15); ecosystem 
(2/15); resources (1/15); livestock 
(1/15); agriculture (1/15); 
destruction of obsolete pesticides 
(1/15); land use (1/15); and, barrier 
effects (1/15); 
Natural resources (4/14); wildlife, 
ecosystem and biodiversity (2/14); shrimp 
farming (1/14); intense fusion economy 
(1/14); forest and soil (1/14); 
Health Accidents (9/15); respiratory effects 
(1/15); pesticide use (1/15); airbone 
pollutants (1/15); 
Illnesses related to pesticides (2/14); 
emissions (1/14) 
Infrastructure Motorway costs (1/15); road 
damage (1/15); 
Unrecovered costs on provision, operation 
and maintenance of public facilities, 
primarily roads and bridges (1/14) 
Environment and 
Health 
 
- 
Plant construction (2/14); normal 
operation (2/14); decommissioning and 
recycling (2/14); site restoration (1/14); 
municipal solid waste incinerator (1/14); 
emissions (2/14); 
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Positive external effects were measured via a heterogeneous range of measures (see 
Table 3.3, or Appendix 3.9). Studies of the consumption side of positive external effects 
concentrated on their positive impact on environment and health, whereas the 
production side of the market focused on their impact on factors such as knowledge 
transmission and/or industrial development. This suggests that the production side of 
the market does not have a positive impact on, for example, environment or health. 
 
Table 3.3 Measures to value positive external effects 
Impact Consumption (n=10/26) Production (n=5/26) 
Environment Make unsightly a favourite view (1/10); 
tropical forest (1/10); air pollution (1/10); 
noise (1/10); crops (1/10); 
 
- 
Health Reduction on the CHD incidence (1/10); 
accidents (1/10); herd-immunity (1/10); 
mortality (1/10); morbidity (1/10); 
 
- 
Infrastructure Materials (1/10); - 
Education Arts festival (1/10) - 
Welfare Altruism (1/10); health and safety risk 
(1/10); 
- 
Knowledge - Innovation and employment (1/5); 
Innovation - Research and development (1/5); 
Competition 
between firms 
- Interactions between firms (1/5); 
Industrial 
development 
- Employment (1/5); 
Investment - Infrastructure investment (1/5); 
 
Table 3.4 shows that equally heterogeneous impacts may be measured for positive and 
negative external effects. However, the mix of impacts measured varies substantially. 
Only one paper measured the same impact (on welfare) using different proxy measures. 
[See Appendix 3.10]. 
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Table 3.4 Measures used to value negative and positive external effects 
Impact Consumption (n=1/26) Production (n=7/26) 
Environment  
- 
Water control structure (1/7); reforestation (1/7); 
landfill disposal and incineration of waste (1/7); 
resources, natural patrimony, climate and natural 
hazards (1/7); water pollution (1/7); 
Health Accidents (1/1); severe diseases 
and short-term absence (1/1); 
severe diseases and long-term 
absence/disability (1/1); 
 
- 
Infrastructure - Societal and spatial infrastructure (1/7); 
Welfare Insecurity (1/1); Landscape image recreation, education, well-being, 
health and animal well-being (1/7); 
Transport Travel time (1/1); emissions 
(1/1); noise (1/1); congestion; 
- 
Traffic Wear infrastructure (1/1); 
parking costs (1/1); 
- 
Technology - Diffusion of information and communications (1/7); 
Traded goods - Environmental degradation, resource exhaustion, 
habitat destruction and positive cultural external 
effects (1/7); 
 
3.3.4 Methods of valuing external effects 
Most papers (53/59) made an assessment of the value of the impact of an external effect, 
but 25% (13/53) did not specify how this was done. Indeed, the majority of papers 
examined failed to specify either a formula or form of calculation for their valuation 
method (46/53). Of those papers not indicating a value for external effects (6/59), four 
were concerned with positive external effects, one with negative external effects and, 
one reported to measure both positive and negative external effects. A small majority of 
these papers (4/6) related to the production side and 50% (3/6) concentrated on 
technological external effects.  
Table 3.5 provides a summary of the valuation techniques used to assess negative 
external effects, positive external effects and both types together. Those papers 
reporting negative external effects on the consumption side used the widest variety of 
valuation methods across the study as a whole. Contingent valuation of the external 
effect was the method most used on the market side. The next four sections detail the 
methods used for the evaluation of external effects according to type or market side.  
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Table 3.5 Different valuation approaches used across types of external effects 
Valuation 
Approaches 
Negative EE Positive EE Negative & Positive EE 
Consumption 
(n=15) 
Production 
(n=14) 
Both 
(n=7) 
Consumption 
(n=10) 
Production  
(n=5) 
Consumption 
(n=1) 
Production 
(n=7) 
Contingent 
Valuation 
 
x 
 
x 
 
x 
 
x 
   
x 
Hedonic 
pricing 
 
x 
      
x 
Discrete 
Choice 
Modelling 
 
x 
   
x 
   
Human capital 
approach 
 
x 
  
x 
    
Treatment 
costs 
  
x 
     
Replacement / 
restoring costs 
 
x 
 
x 
     
x 
Travel cost  
x 
      
x 
Clean-up costs  
x 
 
x 
     
x 
 
Section 1 Negative external effects:  consumption side 
The valuation methods referred to in this section will be described according to Table 
3.2.  For further details on these methods, see Appendix 3.7. The majority of studies 
(9/11) using air pollution as a measure to value the environmental impact of external 
effects employed the willingness to pay (WTP) approach which utilised concepts such 
as value of life, risk of death, mortality and morbidity.  This involved multiplication of 
emission factors per gram of pollutant by the damage cost per gram of pollutant, and by 
value of life in case of death. The remaining studies (2/11) did not specify valuation 
methods or value external effects. 
Of the studies using noise as a measure of environmental impact, 40% (4/10) multiplied 
a price per decibel by noise levels above the threshold (already set by the government), 
and by the length of road on which the external effect was generated. Observed 
monetary values were obtained from the literature. The remaining papers (5/10) used a 
hedonic (the price of a good changes as the characteristics embodied in the good 
change) housing price market approach to value this negative external effect. In one 
notable case, the authors quantified damage to the neighbourhood using a hedonic price 
based on monetary values calculated using contingent valuation (Mayeres and Van 
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Dender, 2001). Another study used disability adjusted life years (DALYs) to measure 
health changes and mortality risks to value the impact on health of the level of exposure 
to noise (Torfs, 2007). The required data components were the exposure-response 
function, the frequency of the health outcome and the level of exposure. The response 
function or unit risk factor was calculated by contingent valuation.  
The third most used measure to study environmental impact was congestion. Five 
studies, 80% (4/5) of the total, valued the impact of external effects by multiplying the 
loss of time suffered at peak hours by traffic flow (number of km in a period cover by a 
particular mode of transport multiplied by value of time). Speed on roads during peak 
and outside peak hours were computed using a flow speed relationship. The difference 
between these speeds was translated into a loss of time. The value of time was defined 
as ‘all costs linked to particular form of transport’ (e.g. fuel, insurance, maintenance and 
vehicle cost plus the inventory cost of the goods transported). One paper valued this 
impact as the delays imposed on other vehicles.  
Impacts on health were mainly valued in terms of the risk of accidents. Five studies 
(56%) valued reduction of the risk of having an accident through WTP studies. One 
study valued accidents using Choice Modelling. In that study, respondents were invited 
to choose between two alternative states of the highway on the basis on three attributes: 
travel time, accident risk and toll charge. In one study, the human capital approach was 
used to value the impairment of life and health as a result of an accident. The health 
impairment element included the costs of rehabilitation and lost production associated 
with injury and death. Rehabilitation costs included the average cost of medical 
treatment, emergency, police and legal services per fatal and non-fatal injury. The 
estimated costs of lost production were based on national income per person of 
employable age for each financial year. Two other studies contained no explanation of 
the evaluation methods used. 
Respiratory effects were also used in one paper as a means of evaluating the impact of 
external effects on health (Rey et al, 2004). This paper linked health effects to DALYs, 
using estimates of the number of Years Lived Disabled and Years of Life Lost. One 
study valued health through the cost of pesticide use as an expense of medical services 
plus loss of productive work time. WTP for reduced mortality risk was also used in one 
study to value the impact on health of airborne pollutants (De Nocker et al, 1999). 
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Two papers measured impact on the infrastructure. (Mayeres and Van Dender, 2001; 
Baublys and Isoraite, 2005) and another measured the infrastructure costs of a heavy 
vehicle moving along a motorway (Baublys and Isoraite, 2005) but the valuation 
method was not specified. Another study (Mayeres and Van Dender, 2001) used road 
damage repair costs as a measure to value impact on the infrastructure.  
 
Section 2 Negative external effects:  production side 
Five of fourteen studies used contingent valuation to study negative external effects on 
the production side of the market. Specifically, one study valued air pollution using 
WTP estimates to value life lost; one study used the WTP method to value human life 
by calculating the reduction in death risk; two studies used contingent valuation to value 
human life as a dose-response function; and, one paper used WTP to avoid damage to 
health and the environment arising from the emission. Contingent valuation was mainly 
used in papers attempting to value the impact of negative external effects on both health 
and environment (See Appendix 3.8). 
Environmental impacts were essentially valued by treatment cost methods (e.g. the 
expense of cleaning up a pesticide contaminated river), replacement costs4 (e.g. lost 
input to reservoirs) or restoration costs (e.g. species in rivers and clean-up costs (e.g. 
removing pathogens from water). In one study, the value of reduced honey production 
was used to measure the environmental impact of external effects on wildlife and 
ecosystem biodiversity. Other valuation methods to measure impact on environment 
were the cost of additional applications of pesticide due to drops in the population of 
beneficial insects, crop losses associated with a secondary pest; the value of animals’ 
lives and the shadow price of the shrimp farming stock. 
The impact on health of the negative external effects of production was measured using 
agriculture (i.e. effects of pesticides) and emissions related measures, though five 
studies gave no information on valuation methods used and one paper did not value the 
impact of external effects. Of those papers valuing external effects, one used agriculture 
measures to value them [pesticides poisonings and related illnesses]. The costs of 
accidental pesticide poisonings and deaths were calculated using the expenses of 
                                                 
4
 Replacement cost method uses the cost of replacing or restoring a damaged asset to its original state as the proxy value of the 
damage (Pearce & Howarth, 2000). 
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hospitalizations, outpatient treatment, treatment costs for pesticide-induced cancers, 
fatalities and loss of work. The same study examined acute effects caused by pesticides 
using the following formula: value of a symptom-day multiplied by the number of 
farmers off work for one day plus those off for half a day multiplied by the GP 
consultation cost.  
 
Section 3 Positive external effects:  consumption and production sides 
On the consumption side, forty per cent (4/10) of the studies used contingent valuation 
to study a variety of impacts including education’ health and welfare [See Appendix 
3.9]. Of these, one study asked the respondents whether they would be willing to pay an 
extra monthly tax to support an Arts Festival. Another study asked the respondents to 
state a WTP value for the avoidance of health and safety risks from transport and 
analysed household relocation preferences by willingness to accept an increase in the 
level of neighbourhood health risks from the transport of nuclear-waste. One study 
calculated a morbidity measure by asking people to state a WTP value and the overall 
related damage costs of illness. Another paper asked respondents to state their WTP for 
the possibility of someone else being cured from a variety of health conditions. One 
study (1/10) did not specify any valuation method (Brisson and Edmunds, 2003). 
Another paper valued emissions in order to explore the impact of a reduction in the 
incidence of Coronary Heart Diseases (CHD) on health using annual savings from CHD 
reduction multiplied by the percentage of costs external to the individual. One paper 
valued the impact on health through the number of fatal accidents - a relative preference 
value - and noise was measured using Discrete Choice Modelling (DCM). To obtain a 
value for travel time and a subjective value for accident and noise level reduction, 
multinomial logit and mixed logit models were used. One paper valued the environment 
impact using answers to questionnaires about the impact of making a favourite view 
unsightly. Two papers used market prices to value external effects. One valued impacts 
on the infrastructure as measured by materials (such as zinc, galvanised steel, limestone, 
etc), and one focused on valuing environmental impact using crop yield and the costs of 
liming and the benefits of oxidation.  
On the production side, only one paper reported a valuation approach: it attempted to 
capture the impact of research and development (R&D) on innovation using regression 
42 
 
modelling. The potential external effect pool was constructed using proximities as 
weights in a summation of all other firms’ R&D spending. 
 
Section 4 Negative and positive external effects:  consumption and   
  production sides 
On the consumption side, only one paper studied negative and positive external effects 
at the same time and it did not specify the methods used to value the impact of external 
effects. On the production side, however four out of seven papers used the contingent 
valuation method to value negative and positive effects at the same time (see Appendix 
3.10). Of those four papers, two reported using Hedonic Pricing at the same time as 
contingent valuation. Just one of the seven papers used the replacement cost technique 
to value the environmental impact of reforestation and two papers made no mention of 
the valuation method used. 
 
3.3.4.1 Nature of data sources  
When valuing the impact of external effects only 15% of papers (9/59) used primary 
data sources, 66% (39/59) used exclusively secondary data, five others used mixed 
[primary and secondary] sources and the rest (n=6) did not value either negative or 
positive external effects, so no information on type of data used was provided.  
Studies of negative external effects were based mainly on secondary data (29/36). 
However, 47% (7/15) of the papers which valued positive external effects used primary 
data. Studies valuing both negative and positive external effects employed mainly 
secondary data (7/8).  
Table 3.6 shows that primary data has been used principally on the consumption side. 
The production side used mainly secondary data. 86% (n=6) of the papers using primary 
data to study external effects on the consumption side used contingent valuation for this 
purpose. Two of those papers (29%) employed Discrete Choice Modelling and five 
(5/7) studied technological external effects. Approximately 49% (19/39) of the papers 
using secondary data sources valued external effects using Contingent Valuation. Two 
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papers (2/39) on the production side employed Hedonic Pricing, Treatment Cost or 
Clean-up Cost approaches and, 90% of all the papers (35/39) studied technological 
external effects. 
Table 3.6 Type of data used according market side and external effect category 
External effects 
categories 
Primary Secondary Mixed Not valued Total 
C P C+P C P C+P C P C+P C P C+P 
Technological 5 1  13 16 6 3 2  1 2  49 
Tech (caring) 2            2 
Tech (network)           1  1 
Tech (knowledge)  1         1  2 
Pecuniary     1 1       2 
Tech & Pec    2       1  3 
Total 7 2 0 15 17 7 3 2 0 1 5 0 59 
      C: Consumption 
      P: Production 
      C+P: Consumption and Production 
 
3.3.5 Economic evaluation analysis of external effects 
7 out of 59 papers (12%) carried out a cost-benefit analysis after the valuation of 
external effects; three papers measured negative external effects; one paper measured 
positive external effects and three measured negative and positive external effects at the 
same time. 57% of papers (4/7) focused on the production market side. 
 
3.4 Discussion 
The majority of studies valued negative external effects and they were equally divided 
between the consumption and production sides. Studies of positive external effects 
largely concentrated on consumption. Technological external effects were the most 
studied category which makes them, prima facie, the most relevant external effects to 
consider for the empirical work of this thesis. Unfortunately, however, the findings of 
this chapter indicate that no established criteria exist on which one can rely for the 
identification the relative importance of particular external effects. Decisions about 
which external effects to choose depend on the reason for making them. Should they be 
analysed in order (a) to establish the full social costs and benefits as a basis for efficient 
pricing and allocation of resources and to extend the scope of social cost or benefit  (De 
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Dios Ortuzar et al, 2000; Pretty et al, 2000; Wattage and Soussan, 2003; Lechon et al, 
2003); (b) to study the implications for economic evaluation of, for example, 
agricultural and food policy (Gray and Malla, 1998) and (c) to value Pigovian taxes to 
internalise external effects on market prices (i.e internalisation of external effects) 
(Gibbons and O’Mahony, 2002). There are alternative ways to decide which external 
effects are relevant for the society to be modelled in economic evaluation. In 2004, a 
generic methodology of health impact assessment (HIA) was established for use in EU 
policy development (Wismar et al, 2007). This indicated that systematic reviews of 
available research are a particularly useful way of gathering evidence.  
Findings from this chapter indicate that there is neither particular criteria to which 
particular measure nor valuation approach to use for incorporating external effects into 
economic evaluation. The most studied impacts of external effects over time were those 
affecting health and/or the environment. However, transport and environment were the 
two fields in which the greatest numbers of publications were found. A wide range of 
measures have been used to value external effects but no generally agreed criterion 
exists as to which particular measure should be applied. For instance, air pollution and 
noise were the most frequently used measures for environmental impact on 
consumption side, while natural resources was the main focus on the production side. 
On the consumption side, the most common measure for the study of health impacts 
was accidents. Although it was comparatively easy to assess the value of negative 
external effects, there was little consistent patterning of measures to assess positive or 
both, negative and positive, external effects. For example, the impact of positive 
external effects on the environment was only studied on the consumption side and five 
different papers used a range of measurements for this purpose. Interestingly, there was 
no consensus as to how to measure a particular type of external effect on both sides of 
the market. The methodology of these studies is an important consideration. All study 
designs used were vulnerable to a number of potentially important confounders, yet 
many of these were not recorded or, if recorded, were not used as adjusters in any 
analyses (i.e. acceptability of death when measuring road accidents). Furthermore, the 
studies did not describe any measures taken to prevent bias. Recommending a single 
‘best value’ for each external effect and for the total external cost is, therefore, not 
feasible because of the high level of uncertainty of these measurements. Instead, 
displaying recommended values in intervals is more appropriate for use in policy 
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decisions (Eshet et al, 2005). Sensitivity analysis of some parameters might also be a 
solution to this limitation. 
A notable percentage of papers (22%) did not specify which valuation methods were 
used to measure the impact of external effects. This may be due to the predominant use 
of secondary data and inadequate descriptions of methods. Having said that, contingent 
valuation, replacement and/or clean-up costs, in this order, seem to be the most 
frequently used approaches to the valuation of external effects regardless of the type of 
data used. Of the studies which used primary data for the consumption side or 
secondary data for the consumption and production sides, contingent valuation was the 
most used method. Clearly, contingent valuation is most frequently used to value 
external effects although no obvious criterion exists as to how it should be applied to the 
different categories of external effect (Brisson and Edmunds, 2004; Beuthe et al, 2002; 
De Dios Ortuzar, 2000). An earlier paper (Eshet et al, 2005) concluded that different 
valuation methods are appropriate for different types of external effect so 
recommendations of a ‘best method’ were unlikely to follow. As shown in this review, 
sometimes, a full valuation of the external costs of a specfic impact may employ a 
variety of techniques (Eshet et al, 2005). According to a report prepared in 1995 for the 
Department of Transport by Robert Tinch, hedonic pricing (HP) technique has a clear 
role to play in the valuation of negative external effects on transport (i.e. noise, air 
pollution, etc) but this does not necessarily imply that this valuation method would be 
the best way to measure the impacts on health of external effects stemming from public 
health interventions. Although, there is no agreed or best method for valuing external 
effects, this chapter indicates that contingent valuation is the most frequently used 
approach to the valuation of external effects in sectors other than health.  
Technological negative external effects are easy to find in a public health context e.g. 
aggressions or crimes to family or friends due to alcohol intake; passive smoking; 
anxiety among family members due to bulimic or anorexic illness in a member of that 
family; etc. Health impacts have been generally studied on the consumption side and 
therefore it is more common to find examples on the consumption rather than the 
production side, as is the case for all examples cited in this paragraph. Depending on the 
external effects that would be valued in this thesis, measures found in this review, to 
estimate the health impacts, would be of help. Although this chapter has shown that 
contingent valuation is the most frequently used approach to valuation of external 
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effects in different sectors, only 12% of the studies examined conducted an economic 
evaluation. Apart from that, this method is always used to inform cost-benefit analysis, 
which is not generally used to inform public health decisions, particularly in NICE 
context, which uses cost-effectiveness analysis. This thesis aims to incorporate the 
impact of external effects into economic evaluations of public health interventions in a 
UK context. NICE recommends the use of cost-effectiveness analysis as the first 
approach for economic evaluation of public health interventions. Therefore, this is the 
approach that will be used to value and incorporate external effects into a public health 
programme.  
Incorporating external effects in an economic evaluation may involve the adaptation of 
an existing model or the development of a new one. Because the aim of this thesis is to 
study the impact of the inclusion of external effects on current decision making by 
NICE, it is replicating a model used to inform current NICE decision making. 
To do this, it will be necessary to find a cost-effectiveness analysis of a particular public 
health intervention which is being used to inform policy making but does not 
incorporate external effects. There should exists documented epidemiological data, 
clinical evidence, and policy interest of those particular external effects to be 
incorporated in economic evaluation of a particular public health programme. As shown 
in this chapter, no agreed criteria exist about which external effects should be valued in 
a health context or how. Therefore, the incorporation of external effects into a cost-
effectiveness analysis of a particular public health programme will steer subsequent 
chapters.   
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CHAPTER 4 Economic evaluation of smoking cessation 
interventions: replication case study 
 
Chapter one identified smoking as a good example of a health behaviour that produces 
external effects to society but also indicates that, to date, economic evaluation of 
smoking cessation programmes informing policy making has tended not to include 
external effects. Chapter 4 develops a model to allow for inclusion of external effects, 
using smoking as a case study. The chapter is divided into three main sections. This 
chapter presents the first three models of this thesis: model 1 (M1) (Flack et al (2007a) 
model); model 2 (M2) (replication of Flack et al (2007a) model); and, model 3 (M3) 
(replication of Flack et al (2007a) model with relevant changes considered). Section 4.1 
describes evidence about the degree to which external effects have been incorporated 
into economic evaluation of smoking cessation programmes and justifies the selection 
of a model for replication in the empirical analysis. Section 4.2 replicates the selected 
model from section 4.1, and demonstrates how this is done appropriately and adds some 
data and calculations changes which are thought to be appropriate. Section 4.3 discusses 
and incorporates potential changes to the model that allows the incorporation of external 
effects. The discussion considers the procedures of model replication and offers some 
recommendations.  
 
4.1 Description of economic evaluation of smoking cessation programmes and 
selection of a particular case 
4.1.1 Literature reviews 
A systematic review was conducted to ascertain whether previous incorporation of 
external effects was conducted in economic evaluation of smoking cessation programs. 
The search was conducted in the Centre of Reviews and Dissemination (CRD) NHS 
EED and HTA, and Web of Knowledge databases during September 2010. The search 
term used in NHS EED and HTA databases was “smoking cessation”, whereas in the 
Web of Knowledge a combination between “smoking cessation” and “cost-benefit or 
costbenefit or cost benefit or cost-effectiveness or costeffectiveness or cost effectiveness 
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or economic evaluation or cost* or valu* or critical appraisal or model” was used. A full 
description of the review is given in Appendix 4.1. Although some papers5 (Andrews 
and Tingen, 2006; Rasmussen et al, 2005; Feenstra et al, 2005; Pollack, 2001; Cohen 
and Barton, 1998) studied external effects, no economic evaluations of smoking 
cessation interventions were found incorporating external effects of smoking. 
A second literature review was conducted to identify economic evaluation of smoking 
cessation programmes currently used to inform policy making in England. A review of 
Centre of Reviews and Dissemination (CRD – NHS EED), the National Institute for 
Clinical Excellence (NICE) or Health Technology Assessment (HTA) of economic 
evaluation of smoking cessation programmes was carried. A description of the review is 
given in Appendix 4.2. Economic evaluations of smoking cessation interventions were 
found. Among those was a report, (Flack et al, 2007a) undertaken by the York Health 
Economics Consortium, which informs policy making on the cost-effectiveness of 
interventions for smoking cessation. Therefore it was considered appropriate to replicate 
this models as base model to incorporate external effects rather than developing a new 
model because this thesis primarily aims at the incorporation of external effects and not 
developing an economic evaluation of smoking cessation programmes per se.  The 
model used in (Flack et al, 2007a) is described below.  
 
4.1.2 Model structure  
The Markov model developed by Flack et al (2007a), referred in this thesis as model 1 
(M1) calculated costs and QALYs of eleven different smoking cessation interventions, 
from the perspective of the National Health Service (NHS). The ‘patient’ group was 
modelled as a cohort over their lifetime, 100 years of life, in six-monthly cycles. Six 
months was chosen by Flack et al (2007a) because it allowed the model to consider the 
natural progression and resolution of the disease. Choosing a longer period such as 12 
or 24 months would have been too long to allow differences in the probabilities. In each 
                                                 
5
 Andrews JO, Tingen MS. The effect of smoking, smoking cessation, and passive smoke exposure on common laboratory values in 
clinical settings: a review of the evidence. Critical Care Nursing Clinics of North America, 2006; 18(1):63-9. 
Rasmussen SR, Prescott SR, Sorensen TIA,et al. The total lifetime health cost savings of smoking cessation to society. European 
Journal of Public Health, 2005; 15(6):601-6. 
Feenstra TL, Hamberg-van Reenen HH, Hoogenveen RT, et al. Cost-effectiveness of face-to-face smoking cessation interventions: 
A dynamic modelling study. Value in Health, 2005; 8(3):178-90. 
Pollack HA. Sudden infant death syndrome, maternal smoking during pregnancy, and the cost-effectiveness of smoking cessation 
intervention. American Journal of Public Health, 2001; 91(3):432-36. 
Cohen D, Barton G. The cost to society of smoking cessation. Thorax, 1998; 53:S38-S42. 
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cycle, smokers could either remain smoker (S), quit (become former smokers) or die. 
Former smokers (FS) could either remain former smokers, relapse (become smokers) or 
die. Figure 4.1 shows the overall structure of the model. 
 
Figure 4.1 Natural history of smoking 
 
 
 
 
 
 
Transition probabilities used in the model comprised cessation and relapse rates of 
smoking and mortality rates according to smoking status. Table 4.1 shows the data used 
to estimate transition probabilities. 
 
         Table 4.1 Transition probabilities used as input parameters  
Transition probabilities Without 
intervention 
Interventions Source 
Background probability of 
quitting smoking 
2% 2% Stapleton (1998) and 
West (2006) 
Probability of quitting 
smoking 
2% 
(background 
probability) 
Intervention-
dependent 
Stapleton (1998) and 
West (2006) 
Probability of relapse after 
quitting 
0 21% McGhan and Dix Smith 
(1996) 
Mortality rate for smokers Age-
dependent 
Age-
dependent 
Derived (see Appendix 
4.3) 
Mortality rate for former 
smokers 
Age-
dependent 
Age-
dependent 
Derived (see Appendix 
4.3) 
           Source: Flack et al (2007a) 
 
In each cycle, S and FS from the cohort model have a chance of getting five conditions 
including: Lung cancer (LC); Coronary Heart Disease (CHD); Chronic Obstructive 
Pulmonary Diseases (COPD); Myocardial Infarction (MI); Stroke (ST). The possibility 
S 
Death 
FS 
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of multiple conditions was excluded. The costs and QALYs generated by these 
conditions were not included in the Markov model but were generated outside of it. To 
calculate the number of people with each condition in each cycle, the number of S and 
FS was multiplied by smoking status related prevalence. Prevalence of each condition 
was assumed to be dependent on age and sex. Each condition has an associated cost and 
utility. To enable the total costs and utilities of the interventions to be compared with 
‘no intervention’, the number of people with each condition was multiplied by the 
associated cost/utility of that condition in each cycle. This resulted in a total cost/utility 
for each condition. To calculate an overall total cost/utility, these were summed. 
 
4.1.3 Study population 
The hypothetical cohort of 1,000 smokers was representative of all smoking adults in 
the general population, and worked through the model from 16 until the age of 100 
years, when it was assumed that everyone dies. No new entrants were considered in the 
model. Population weights, by sex and age, were derived from population estimates 
provided by the Office for National Statistics and applied to costs and QALYs to ensure 
that the cohort was representative of the whole population. See Appendix 4.4 for the 
specific weights used. The costs and QALY outcomes for each age-gender group were 
then multiplied by these weights to provide total outcomes that were representative of 
the chosen population. 
 
4.1.4 Data 
Several sources of evidence were used by Flack et al (2007a) to inform their analysis. 
The data required for the model were: background smoking cessation rate; relapse 
smoking rate; mortality by gender, smoking status and age; prevalence of each 
condition by age, gender and smoking status; utilities and costs by condition and; 
annual smoking cessation rates and costs by intervention. Flack et al (2007a) conducted 
literature reviews in the Centre for Reviews and Dissemination to get data for those 
parameters.  
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4.1.4.1 Mortality of each condition by smoking status 
Flack et al (2007a) used actual mortality rates: for smokers (mS) and former smokers 
(mFS). However, to allow a similar calculation in this thesis data on non-smokers 
mortality (mNS) is also needed. The authors developed an equation to calculate this 
mortality data. Variables of the equation are described in Appendix 4.5. 
The mortality equation, reproduced from Flack et al (2007a), described as follows: 
(mS * D1) + (mFS * D2) + (mNS * D3) = C    (E4.1) 
mFS/mS = A ;  mNS/mS = B; 
(mS * D1) + (mS * D2 * A) + (mS * D3 * B) = C    (E4.2) 
This allows the Equation 2 to be solved as follows: 
mS = C / ((D1 + (D2 * A) + (D3 * B));     (E4.3) 
mFS = E * A;         (E4.4) 
mNS = E * B;         (E4.5) 
Equations 3, 4 and 5 were repeated for all ages and gender. The mortality rates by age 
and gender, the actuary life tables and the prevalence of smoking are given in Appendix 
4.6, 4.7 and 4.8. The actuarial method (Briggs et al, 2006) was used by Flack et al 
(2007a) to convert this data into transition probabilities and adjust them to 6 month 
cycles. Refer to Appendix 4.3 for transition probabilities used by Flack et al (2007a) 
model. 
 
4.1.4.2 Prevalence of each condition by smoking status 
Data for Flack et al (2007a) model was the prevalence of: smokers (pS), and former 
smokers (pFS), though as well as for mortality data, the estimate for never-smokers 
(pNS) was also needed. To calculate prevalence, similar approach was used. Variables 
of the prevalence equation are described in Appendix 4.9. 
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The prevalence equation was described as follows: 
(pS * D1) + (pFS * D2) + (pNS * D3) = H      (E4.6) 
pFS/pS = I ;  pNS/pS = J; 
(pS * D1) + (pS * D2 * I) + (pS * D3 * J) = H     (E4.7) 
This allows the Equation 7 to be solved as follows: 
pS = H / ((D1 + (D2 * I) + (D3 * J));       (E4.8) 
pFS = pS * I;          (E4.9) 
pNS = pS * J;         (E4.10) 
This process was repeated, by age and gender, for all conditions. The prevalence for 
each condition, relative risk by smoking status, and resulting prevalence by age, gender 
and smoking status are given in Appendix 4.10. The annual prevalence was used for the 
6-month prevalence. 
 
4.1.4.3 Utility scores 
Each condition has an associated utility for the time-period spent in the health state. In 
every cycle the number of people having each condition was multiplied by the 
associated utility.  
The values used in the model by Flack et al (2007a) were provided by secondary data 
sources. Flack et al (2007a) searched the Tengs and Wallace6 database (Health Priority 
Database), Medline, articles cited by others and the National Health Service Economic 
Evaluation Database. Flack et al (2007a) stated that whilst Tengs and Wallace (2000) 
provide utility scores for different severity levels of the conditions, in order for this to 
be reflected in the model there was the need to know how many smokers, former 
smokers and non-smokers are in each of these states at any given time. Averages were 
                                                 
6
 Tengs and Wallace (2000) gathered from publicly available source documents a review of 1,000 health related quality-of-life 
estimates.  
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calculated, according to authors, for the relevant conditions and used for lung cancer, 
coronary heart disease, myocardial infarction and stroke. 
Flack et al (2007a) stated that Rutten-van Molken et al (2006) carried out a study to 
assess the association between country of recruitment and COPD utility. Data were 
taken from a subset of 1,235 patients from 13 countries that completed an EQ-5D 
questionnaire at the baseline of the ‘Understanding the Potential Long-Term 
Implementation on Function with Tiotropim’ (UPLIFT) trial. The UPLIFT trial was a 
four-year randomised, double-blind, placebo-controlled, parallel group trial designed to 
determine whether dopropium reduces the rate of decline of FEV over time. Six 
thousand COPD patients were included in the trial and the EQ-5D utility score was 0.76 
at baseline. The EQ-5D scores were split into six groups based on the severity of COPD 
(moderate, severe and very severe) and whether patients were in the UK or the United 
States. The model used an average of the UK scores for all severities of COPD. 
Tillmann and Silcock (1997) assessed the difference in health status between current 
and former smokers (who have not smoked for five years or more), according to Flack 
et al (2007a). To elicit smokers’ and former smokers’ health status, a questionnaire was 
sent to patients of nine general medical practices in Aberdeen, Scotland. The questions 
comprised SF-36, EuroQol, nine condition-specific questions selected from the MRC 
Questionnaire on Respiratory Symptoms and a range of socioeconomic details. Five 
hundred thousand questionnaires were sent out to former smokers and a further 1,494 
were sent to smokers. Of the respondents, 778 former smokers and 887 smokers had 
valid responses to the questionnaires. The results show that the mean EuroQol score 
was 0.75 for smokers and 0.78 for former smokers, with no differences regarding age 
and gender observed. A summary of data used in the model by Flack et al (2007a) is 
displayed in Table 4.2. The assumptions from this model considered that a person with 
CHD had higher utility than a smoker with no associated diseases. 
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Table 4.2 Health-related quality of life parameters used in the model 
Utility Value Source 
Utility associated with LC 0.58 Tengs and Wallace (2000) 
Utility associated with CHD 0.80 Tengs and Wallace (2000) 
Utility associated with COPD 0.73 Rutten-van et al (2006) 
Utility associated with MI 0.80 Tengs and Wallace (2000) 
Utility associated with ST 0.48 Tengs and Wallace (2000) 
Utility associated  with smokers 
with no comorbidities 
0.75 Tillmann and Silcock (1997) 
Utility associated  with former 
smokers with no comorbidities 
0.78 Tillmann and Silcock (1997) 
Source: Flack et al (2007a) 
 
When an individual had co-morbidities, the criteria of lowest utility was applied (an 
assumption used to overcome concerns of double counting in multiplicative or additive 
assumptions) by Flack et al (2007a). This enabled the total Quality Adjusted Life Years 
(QALYs) of the interventions to be compared to the base case (‘no intervention’). 
Outcomes were discounted at 3.5% per year. 
 
4.1.4.4 Costs 
Flack et al (2007a) used cost data associated with each condition and costs. All costs 
were presented in UK pounds (January 2006 prices). Costs were inflated using the 
Retail Prices Index (monthly index number of retail prices) published by the UK 
National Statistics. 
The lifetime costs included all medical costs that are incorporated in Flack et al (2007a) 
model. As such, they included not only the cost of the intervention, but other costs such 
as treatment of different conditions. Therefore, the cost of ‘no intervention’ was 
expected to be quite substantial, since rates of complications were likely to be high. 
The lung cancer costs were obtained, by authors, from the Health Care Needs 
Assessment (Sanderson and Spiro, 2006). Sanderson and Spiro (2006) acknowledge 
uncertainty surrounding the cost of palliative and terminal care but estimate it to be 
around £2,000 to £7,000 per person (1998 UK sterling). The average of these two 
figures (£4,550) was used in the model (£5,501 at current prices) by authors.  
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The British Heart Foundation (Petersen et al, 2003) estimated the total cost of coronary 
heart disease per year. This cost was divided by the number of people with coronary 
heart disease in the UK to get the total cost per person, according to authors.  
The annual cost of COPD was taken from the National Clinical Guideline on 
Management of Chronic Obstructive Pulmonary Disease in Adults in Primary and 
Secondary Care (2004). This cost included GP visits, medication, oxygen, inpatient stay 
and emergency admission. It is unclear whether the reported figure took account of 
gender differences in the number of people with chronic obstructive pulmonary disease.  
The cost of myocardial infarction, described by Flack et al (2007a), had two 
components: the cost of an event and the ongoing yearly cost. The first was taken from 
reference costs while the latter was based on monthly general practitioner (GP) visits, a 
follow-up cardiology visit every three months and cholesterol lowing drugs 
(Department of Health 2005; Curtis and Netten, 2006; and Health & Social Care 
Information Centre, 2005). 
The National Audit Office (NAO) (National Audit Office, 2006) estimated that the 
direct cost of stroke was 2.8 billion each year (£ 2005). The total cost per person was 
calculated, by authors, using the same approach used for coronary heart disease.  
The annual costs of each health state used are shown in Table 4.3. 
 
Table 4.3 Annual average costs of clinic health state (in 2006 £) parameters used in the model 
Unit costs (£2006) Value Source 
Annual cost for a LC episode £5,501 Sanderson (2000) 
Annual cost for a CHD 
episode 
£1,063 Department of Health (2004), 
Government Actuary’s Department 
(2006), Petersen et al (2003) 
Annual cost for a COPD 
episode 
£926 The National Collaborating Centre 
for Chronic Conditions (2004) 
Annual cost for a MI episode £2,175 Department of Health (2005),  Curtis 
and Netten (2006),     Health and 
Social   Care Information Centre 
(2006) 
Annual cost for a ST episode £2,061 Department of Health (2004), 
National Audit Office (2006), 
Government Actuary’s Department 
(2006) 
                Source: Flack et al (2007a) 
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The number of people with each condition was multiplied by the NHS cost generated by 
each condition in each cycle. This resulted in a total cost for each condition, which were 
summed up to get the overall total cost. Costs were discounted at 3.5% per year, the 
same as outcomes. 
 
4.1.5 No Intervention 
The background quit rate assumed by authors for the no intervention case was 2%, 
which adjusted for the possibility of relapse smoking. This rate was converted into a 
transition probability with the actuarial method and therefore adjusted to 6 months 
cycles according to authors.  
 
4.1.6 Interventions 
The data in Flack et al (2007a) were derived from rapid reviews, where possible, and 
from studies identified by NICE. The required data for each of the interventions 
investigated were: six-monthly cost of intervention, the duration of intervention and the 
annual cessation rates for smoking due to the intervention. The smoking cessation 
interventions described in Flack’s et al (2007a) report were categorised into three types 
of interventions: NHS and workplace, only workplace, and pharmacist-based. 
According to Flack et al (2007a), the interventions related to the NHS and workplaces 
were described by Parrot et al (1998), and included the one-year cessation rates and cost 
per smoker associated with: (a) brief advice (BA); (b) brief advice plus self-help 
material (BAS); (c) brief advice plus self-help material plus nicotine replacement 
therapy (BASNRT); and, (d) brief advice plus self-help material plus nicotine 
replacement therapy plus specialist clinic (BASNRTS). Information regarding the cost 
components of the intervention was provided in Parrott et al (1998). This was used, by 
authors, to calculate the costs of the interventions using the British National Formulary 
(British Medical Association and Royal Pharmaceutical Society of Great Britain, 2006) 
and Curtis and Netten (2005). 
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Regarding specific smoking cessation interventions for the workplace, Javitz et al 
(2004) identified four different smoking cessation programmes: two different bupropion 
regimes crossed with two different counselling approaches (less, LICB, and more, 
MICB, intensive counselling). The British National Formulary recommends those ones 
involving 150mg of bupropion.  
Several interventions using pharmacy-based methods to aid smoking cessation were 
identified by McGhan and Smith (1996) according to Flack et al (2007a). These 
included: (a) nicotine patch and weekly group counselling (NPGC); (b) nicotine patch 
and weekly individual counselling (NPIC); (c) nicotine patch and no counselling 
(NPNC); (d) nicotine patch and pharmacist consultation (NPPC); (e) nicotine patch and 
pharmacist consultation and comprehensive behavioural program (NPPCBP).  
Table 4.4 summarises the costs and annual cessation rates from the eleven different 
interventions studied by Flack et al (2007a). The first four interventions were delivered 
in the primary care setting and workplace; the two next only on the work place 
environment; and the last five were pharmacist-based interventions. 
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Table 4.4 Cessation rates and costs (£ 2006) 
Intervention Cessation rates Costs Source of costs 
1 year 6 month 
Brief advice (BA) 3%  £7.14 Parrott et al (1998), Curtis and Netten (2005), 
British Medical Association and Royal 
Pharmaceutical Society of Great Britain (2006) 
Brief advice plus self-help material 
(BAS) 
4%  £10.67 Parrott et al (1998), Curtis and Netten (2005), 
British Medical Association and Royal 
Pharmaceutical Society of Great Britain (2006) 
Brief advice plus self-help material 
plus Nicotine Replacement Therapy 
(BASNRT) 
6%  £111.10 Parrott et al (1998), Curtis and Netten (2005), 
British Medical Association and Royal 
Pharmaceutical Society of Great Britain (2006) 
Brief advice plus self-help material 
plus Nicotine Replacement Therapy 
plus specialist clinic (BASNRTS) 
15%  £122.96 Parrott et al (1998), Curtis and Netten (2005), 
British Medical Association and Royal 
Pharmaceutical Society of Great Britain (2006) 
Less intensive counselling and 
bupropion (LICB) 
23.6%  £80.21 Curtis and Netten (2005), British Medical 
Association and Royal Pharmaceutical Society of 
Great Britain (2006) 
More intensive counselling and 
bupropion (MICB) 
31.4%  £120.21 Curtis and Netten (2005), British Medical 
Association and Royal Pharmaceutical Society of 
Great Britain (2006) 
Nicotine patch and weekly group 
counselling (NPGC) 
 26% £142.78 Curtis and Netten (2005), British Medical 
Association and Royal Pharmaceutical Society of 
Great Britain (2006) 
Nicotine patch and weekly individual 
counselling (NPIC) 
 20% £95.50 Curtis and Netten (2005), British Medical 
Association and Royal Pharmaceutical Society of 
Great Britain (2006) 
Nicotine patch and no counselling 
(NPNC) 
 15% £45.50 Curtis and Netten (2005), British Medical 
Association and Royal Pharmaceutical Society of 
Great Britain (2006) 
Nicotine patch and pharmacist 
consultation (NPPC) 
 31% £280.50 Curtis and Netten (2005), British Medical 
Association and Royal Pharmaceutical Society of 
Great Britain (2006) 
Nicotine patch, pharmacist 
consultation and comprehensive 
behavioural program (NPPCBP) 
 44% £377.78 Curtis and Netten (2005), British Medical 
Association and Royal Pharmaceutical Society of 
Great Britain (2006) 
Source: Flack et al (2007a) 
 
The costs were also reported by Curtis and Netten (2005) and the Health and Social 
Care Information Centre (2006). 
Flack et al (2007a) assumed that all intervention-related quitting occurred in the first 6 
months (months 6-12 relapse rate), with some people relapsing at a rate of 21%, until 
the first year. Moreover, they assumed that after one year, the quit rate becomes the 
same as the background cessation rate (2%). Flack et al (2007a) indicated that to make 
possible the comparison among interventions, it was assumed thatthe relapse rate 
occurred at the same time between the sixth and twelfth month. Therefore, the annual 
quit rates for the interventions accounted for relapse in the first 6 months. 
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4.1.7 Economic evaluation 
A cost-effectiveness analysis7 (CEA) was undertaken by Flack et al (2007a) to assess 
the relative benefits of a given treatment using patient outcomes and the costs incurred 
in achieving those outcomes.  
Incremental costs8 per QALY gained were estimated by authors for all interventions 
modelled using the following formula: 
 
Box 4.1 Formula to calculate incremental cost-effetiveness ratio 
 
 
The comparator for the CEA was assumed to be the no intervention option. The results 
refer to the ‘average’ smoker included in the model. The results are, therefore, a 
weighted average cost and QALYs for each patient in the cohort according to authors. 
Model 1 (M1) was the nomenclature used to refer to results in terms of costs per person 
and QALY gained by Flack et al (2007a).  
 
4.1.8 Uncertainty 
Flack et al (2007a) carried out a univariate deterministic sensitivity analysis to examine 
the impact on cost-effectiveness of reducing the background quit rate to 1.2%9 and 
reducing the costs of the interventions to zero. 
 
                                                 
7
 Economic evaluation techniques can be used to examine not only the costs of the interventions in relationship to health or smoking 
outcomes, but also the monetary values of many of the individual conditions associated with smoking problems.  
8
 The calculation of the additional unit gain of benefit is known as the incremental analysis and results are presented as incremental 
cost-effectiveness ratios (ICERs). 
9
 Stapleton (1998) suggested a background long-term quit rate of just under 1% per year of those who ever smoked. This figure will 
slightly overestimate the quit rate after middle age because of deaths from continuing smokers. The background quit rate over this 
period as a proportion of those who were current smokers in any given year will be higher because over time, as smokers quit, the 
denominator reduces. Applying this correction to the above figures gives an average quit rate of 1.2%. 
               (Cost intervention – Cost no intervention)  
 
Incremental cost-effectiveness ratio (ICER) =  
             
           (Effects intervention – Effects no intervention) 
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4.1.9 Results 
Average lifetime costs in £2006, QALY gained per person and ICER per intervention 
are shown in Table 4.5. 
Table 4.5 Model estimates (M1) of average lifetime costs per smoker and QALYs lifetime gained per 
smoker (cohort of 1000 smokers; > 16 years; lifetime period reaching 100 years; starting distribution: 
100% smokers; health states: smokers; former smokers; death) 
 
Interventions Average cost 
(£ 2006) 
QALYs 
gained 
ICER for 
M1  
NMB M1 
NI 7232.00 11.9000 -  
BA 7221.00 11.9100 Dominant 211,00 
BAS 7206.00 11.9200 Dominant 426,00 
BASNRT 7268.00 11.9400 £984 764,00 
BASNRTS 7118.00 12.0200 Dominant 2514,00 
LICB 6920.00 12.1000 Dominant 4312,00 
MICB 6818.00 12.1700 Dominant 5814,00 
NPGC 7037.00 12.0700 Dominant 3595,00 
NPIC 7076.00 12.0300 Dominant 2756,00 
NPNC 7098.00 11.9900 Dominant 1934,00 
NPPC 7100.00 12.1000 Dominant 4132,00 
NPPCBP 7010.00 12.2000 Dominant 6222,00 
           Source: Flack et al (2007a) 
 
NPPCBP was the most cost-effective strategy, followed by MICB. Graph 4.1 shows the 
different expected costs and QALYs for different smoking cessation interventions. 
 
Graph 4.1 Expected costs and effects for M1 
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4.1.10 Sensitivity analysis 
Univariate sensitivity analyses were made by Flack et al (2007a) in order to capture 
parameter uncertainty. For M1, Flack et al (2007a) reported that reducing the 
background cessation rate to 1.2%, but keeping everything else the same, led to similar 
results. All interventions apart from the BASNRT intervention dominate ‘no 
intervention’. BASNRT had an ICER of £226. Compared with BA, less cost-effective 
interventions, the results followed the same pattern as comparing smoking cessation 
programmes with no intervention. When the costs of the interventions were assumed to 
be zero, all the interventions were dominant when compared with ‘no intervention’ or 
‘BA’ (the interventions are less costly and result in more QALYs). 
 
4.2 Description of methods used in replication of Flack et al (2007a) model 
For the model replication in this thesis, model 2 (M2), the model structure, and 
parameters from Flack et al (2007a) were used. 
There is no evidence on how to best replicate a published economic evaluation. 
Therefore, the quality of this replication could not be formally assessed. However, the 
results generated from the analysis in this chapter are compared with those from Flack 
et al (2007a), and percentage of differences between lifetime costs and QALYs gained 
are calculated to assess the quality of the model replication. The replication process 
lasted from July 2008 till April 2009. The first step included an exhaustive reading of 
the NICE report, and a close examination of the model structure presented in the report. 
After this, concept of the model was graphically built, before the model was built in 
Excel. To resolve some doubts about data and structure of the model, Matthew Taylor, 
one of the authors of the NICE report, was contacted via email. After some 
clarifications from him, two visits were made to York to see the authors and: double 
check the model, clarify some aspects of the model structure and data, as well as 
compare outputs( in terms of costs and QALYs) between Flack et al (2007a) model and 
the replicatedmodel. Apart from that, expert modellers10 at the Health Economics 
                                                 
10
 Dr.Gethin Griffith and Mrs. Edit Remark. 
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Research Group (HERG) conducted a verification process to match the concept of the 
model with the spreadsheet built in excel11.  
 
4.2.1 Model structure 
To ensure that the Markov model used in the replicated model had the same structure as 
the one built by Flack et al (2007a), the authors were contacted. This was necessary 
because a clear diagram of the natural history of smoking was not provided in Flack et 
al (2007a).  
 
4.2.2 Study population 
The replicated model used the same cohort and starting population as Flack et al 
(2007a). 
 
4.2.3 Data 
In some cases, data reported on Flack et al (2007a) report, such as mortality, prevalence 
according to smoking status, or prevalence of diseases, gave some problems in terms of 
replication. Mortality data by sex was used by Flack et al (2007a) to calculate the 
mortality rate for each condition, whereas only a table with male mortality data was 
attached in the final report. Therefore, data sources referenced in the report were 
consulted. In this particular case, the information used on mortality was not the data 
detailed by the source, and therefore, the complete female mortality table used in the 
model was obtained directly from the authors of NICE report (Flack et al., 2007a). Doll 
et at (1994) observed no death in men under 25 years of age and the total number 
observed at 25-34 years of age was so small (67 out of 2115) that mortality rates in 
different smoking categories were subject to large random variation. Doll et al (1994) 
specified that usefully compared age specific mortality in detailed smoking categories 
only from about 35 years of age upwards. Although Doll et al (1994) also stated that 
under 35 years of age the mortality was higher in current smokers (1.5 per 100,000 per 
                                                 
11
 Particularly, Edit Remark conducted a validation and verification of the model. 
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year, based on 35 deaths) than in non-smokers (1.1 per 100,000 per year, based on 17 
deaths). Doll et al (1994) did not give further comments or details on former smoker 
mortality rates. One of the authors of Flack et al (2007a), Matthew Taylor, said that the 
mortality for <35 years of age (in smokers) was calculated by using a regression 
technique based on the differences between smokers and never-smokers of other ages. 
Specifically, a non-linear (polynomial) regression was used based on the ratios for the 
other age bands and this was extrapolated to the <35 year age bands. Due to the 
inaccessibility of the data, the differences were calculated between current smokers’ and 
former smokers’ mortality rates for each age interval. Then, the average decrease of all 
these differences (29.96%) across ages for smokers was applied to calculate the former 
smokers death rate aged under 35, which was 0.1050.  
Prevalence data of each condition by smoking status gave also some problems. 
Although the report contained complete tables of prevalence rates by age and sex, zero 
values were specified for young ages on lung cancer, coronary heart disease and 
myocardial infarction. To avoid using zero values for few ages, data sources were 
consulted to find out the correct prevalence rates and tables were reconstructed. Same 
utility and costs values reported in Flack et al. (2007a) were used in the replicated 
model. 
The prevalence rate for Lung Cancer, Coronary Heart Disease and Myocardial 
Infarction for the first age intervals was reported as 0 due to the large number of 
decimals (five decimals). This was assumed to be zero to obtain closer results to Flack 
et al (2007a). 
 
4.2.4 Interventions 
The replication modelled the same interventions as Flack et al. (2007a) and used 
effectiveness data contained in the report. However, there was some unclear information 
on adjustment of six-month quitting rate by the relapse rate. Although intervention quit 
rates were supposed to be adjusted by relapse rate, there was no information available in 
the report about whether these rates were finally transformed to transition probabilities. 
Therefore, no transformation was adopted in the replication exercise. 
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4.2.5 Economic evaluation 
Cost-effectiveness analysis was conducted to assess the costs and benefits from the 
smoking cessation programmes. The comparator was ‘no intervention’ as in Flack et al. 
(2007a), Moreover, the results referred to the ‘average’ smoker included in the model in 
terms of costs per person and QALY gained by the replication model. 
 
4.2.6 Results of replication 
Average lifetime costs in £2006, QALYs gained per person and ICER per intervention 
are shown in Table 4.6 for M2. 
Table 4.6 Model estimates (M2) of average lifetime costs per smoker and QALYs lifetime gained per 
smoker (cohort of 1000 smokers; > 16 years; lifetime period reaching 100 years; starting distribution: 
100% smokers; health states: smokers; former smokers; death) 
 
Interventions Average cost 
(£ 2006) 
QALYs 
gained 
ICER for 
M2  
NMB M2 
NI 6849.15 11.8842 -  
BA 6833.95 11.8964 Dominant 259,79 
BAS 6818.05 11.9079 Dominant 505,10 
BASNRT 6828.09 11.9309 Dominant 953,86 
BASNRTS 6669.18 12.0341 Dominant 3177,38 
LICB 6497.65 12.1327 Dominant 5321,77 
MICB 6369.08 12.2222 Dominant 7239,67 
NPGC 6575.18 12.0976 Dominant 4541,68 
NPIC 6643.89 12.0433 Dominant 3386,20 
NPNC 6694.63 11.9980 Dominant 2429,32 
NPPC 6548.89 12.1429 Dominant 5474,70 
NPPCBP 6378.01 12.2607 Dominant 8001,53 
 
In concordance with Flack et al (2007a), NPPCBP was the most cost-effective strategy 
compared with no intervention, followed by MICB. However, there were two important 
differences that need comment and questioning. First, the BASNRT, in the replication 
model (M2), appears to be dominant, but not in the original model (M1). Second, all 
interventions seem to have different expected costs, compared with those obtained in 
the original model. As part of the validation process, the results obtained in the 
replication model (M2) were shown to York authors for them to comment on. After 
Matthew Taylor checkboth spreadsheets (M1 and M2 spreadsheets), both differences 
were attributed to the cost of myocardial infarction. Details to follow in section 4.3.1. 
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Graph 4.2 shows the expected cost and QALYs for different smoking cessation 
interventions in M2.  
Graph 4.2 Expected costs and effects for M2 
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Regarding sensitivity analysis, reducing the background cessation rate to 1.2% in M2, 
but keeping everything else the same, led to similar results. All interventions dominate 
‘no intervention’. When the costs of the interventions were assumed to be zero all the 
interventions were dominant when compared with ‘no intervention’. 
 
 
4.2.6.1 Quality assessment of replication and recommendations to facilitate 
replication of models  
 
Table 4.7 shows the differences in lifetime costs and QALYs gained between M1 and 
M2. The differences in lifetime costs were calculated using the cost of myocardial 
infarction reported in Flack et al (2007a) report (£2175) and the cost used in the 
spreadsheet model to calculate results (£2750). 
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Table 4.7 Differences in lifetime costs and QALYs gained between M1 and M2 
Interventions % differences in lifetime costs 
(M1 vs M2) 
% differences in 
lifetime QALYs 
gained (M1 vs M2) costs MI=2175  costs MI=2750 
NI 5,59% -1,20% 0,13% 
BA 5,66% -1,13% 0,11% 
BAS 5,69% -1,10% 0,10% 
BASNRT 6,44% -0,35% 0,08% 
BASNRTS 6,73% -0,07% -0,12% 
LICB 6,50% -0,28% -0,27% 
MICB 7,05% 0,25% -0,43% 
NPGC 7,02% 0,22% -0,23% 
NPIC 6,50% -0,29% -0,11% 
NPNC 6,03% -0,76% -0,07% 
NPPC 8,42% 1,58% -0,35% 
NPPCBP 9,91% 3,01% -0,50% 
Average 6,80% -0,01% -0,14% 
 
There 0.14% difference between lifetime QALYs reported in Flack et al (2007a) and 
those in found in the current analysis. In terms of lifetime costs, the difference between 
my model and Flack et al (2007a) results amounted to 6.80%. Due to the magnitude of 
the difference, the replicated model was checked with, Matthew Taylor, one of the 
authors from Flack et al (2007a) report. It was then realised that a different figure for 
the cost of myocardial infarction in Flack et al (2007a) was used. Therefore, the report 
used a figure of £2175 for myocardial infarction, whereas the results reported in the 
published report (Flack et al (2007a) were obtained from using a figure of £2750 for 
that particular disease. Having changed the figure of £2175 to £2750 the actual 
difference between obtained costs in the model reduced to 0.01%. Analysis in this thesis 
from M2 onwards assumed the cost of myocardial infarction to be £2175 because this 
was the figure that Matthew Taylor confirmed Flack et al (2007a) used, and also give 
the closest results to Flack et al (2007a). Overall, given the small differences (less than 
1%) between both studies in terms of the lifetime costs and QALYs gained, for costs 
(using cost of £2750) and QALYs gained, M2 was considered a good quality replication 
of M1.  
There are no established rules for the replication of economic evaluation models. 
However, some could be established from the process followed in this chapter. First, it 
is important to follow the diagram reported in any economic evaluation to build the 
structure of the model and to make sure this follows the explanation detailed in the text. 
In Flack et al (2007a), the diagram was not the best representation of the model because 
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the health states described in the text were not fully represented in the diagram. 
Reporting the structure of the model must be accurate in terms of transmitting the 
correct scheme of analysis. In this case, the Markov model structure should only have 
reported health states actually modelled to avoid confusion. Second, it is also of 
importance to understand whether a population or a cohort model was modelled, and the 
time horizon of the model. Finally, it is important to verify all data reported with 
epidemiological sources, to make sure the data is fully understood and the correct data 
is used in the model.  
Findings from this chapter outline the importance of reporting methods of economic 
evaluation analyses in a transparent way to allow replication. Some problems with 
adjustments of transition probabilities were encountered because of the lack of clear 
steps by Flack et al (2007a). It is also important to reference all data sources and to 
report tables with a sensible number of decimals for costs (at least two decimals) and 
QALYs (at least four decimals).  
Some time could have been saved asking for the model spreadsheet to Flack et al 
(2007a) authors, but the replication of the model was considered a good practice in 
order to fully understand the spreadsheet, and allow the subsequent incorporation of 
external effects into the model. 
 
4.2.6.2 Critique of Flack et al (2007a) model (M1) 
Decision analytic models are necessary to inform decision making by bringing together 
existing evidence to assess the likely cost-effectiveness of competing forms of smoking 
cessation programs. The replicated model presented in this thesis incorporated the full 
range of assumptions used to assess the cost-effectiveness over the lifetime of the cohort 
by Flack et al (2007a). However, this implies that a number of limitations in Flack et al 
(2007a) model may also apply here. 
First, due to the lack of data on the relative risk of having each condition by smoking 
status it was not possible to ‘split’ former smokers into ‘recent’ and ‘long-term’ 
categories. It is unclear what the impact of this simplification would have on the 
model’s results. If the probability of developing some or all of the conditions returns to 
the level found in non-smokers after a certain period of time, the model have 
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overestimated the number of people with each condition. This in-turn may have resulted 
in an overestimation of the associated costs and an underestimation of the associated 
QALYs. Second, within the model it is assumed that smokers attempt one type of 
cessation intervention and only try it once. In real life, smokers who fail to quit smoking 
with one intervention may be more likely to repeat the same intervention or try a 
number of different interventions (Hajek et al., 2009). Third, the effectiveness of the 
interventions was taken from published studies and may not be generalisable to the 
population older than 16 years modelled in this economic evaluation. In relation to that, 
Parrot et al (1998), which described the interventions related to the NHS or primary care 
setting and workplaces, highlighted an issue of the generalisability of the interventions 
arguing that those interventions provided within the workplace were not specifically 
delivered within the workplace, though they were assumed to be provided in the 
workplace. 
Regarding cost data, it is unclear whether lung cancer costs obtained from Sanderson 
and Spiro (2006) took account of gender differences in the number of people. Stabile 
and Siegfried (2003) raised the importance of accounting for these differences, which 
accrue in terms of different costs for lung cancer.  In any case,   all the issues bordering 
on all lack of data summarised in section 4.3.1 could be considered as a critique of the 
model. 
 
4.2.6.3 Changes to Flack et al (2007a) replication model (M2) 
The exercise of replicating Flack et al (2007a) model (M2) and knowing the details of 
the M1 model generated some uncertainty regarding the appropriate use of some data 
and correct methods of some parameters’ calculation. Therefore, some changes were 
applied to M2 to improve the model in terms of using appropriate data and calculating 
some parameters correctly. These changes led to model 3 (M3). 
Flack et al (2007a) reported the current smokers’ mortality rate for people aged 75-84 as 
106, whereas Doll et al (1994) reported in their paper a 106.4 annual mortality per 1000 
men. Evidence reported in papers should be used in model 3 (M3). 
The assumption about running the model for 100 years, not accounting for the real life 
expectancy, is considered unrealistic though it did not have much impact on the results. 
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Therefore, when any person in the model reached the age of 100 years he/she exits the 
model. 
Regarding the intervention cessation rates, it seemed that Flack et al (2007a) were 
directly using the annual rates reported in their report in the Markov model instead of 
accounting for the rate/probability conversion. According to Briggs et al (2006) it is 
necessary to transform all rates into transition probabilities for use in a Markov model. 
Transformed rates (i.e. transition probabilities) were therefore used  
The prevalence rate for Lung Cancer, Coronary Heart Disease and Myocardial 
Infarction for the first age intervals was reported as 0 due to the large number of 
decimals. In some cases this resulted in no difference in lung cancer cases according to 
being a smoker, former smoker or a never smoker. As the authors reported the data 
sources, it would have been appropriate to re-calculate all these prevalence rates and 
achieve a small distinction for the different smoking health status habits. Forman et al 
(2003) and Allender et al (2006) were consulted to extract the evidence needed to 
replace those zero values. 
All costs and prices were updated to £ 2010 using the GDP deflactor, from the World 
Economic Outlook Database, and the exchange rates for 2010 from the European 
Central Bank. 
To estimate incremental cost-effectiveness ratios (ICERs), the smoking cessation 
interventions in each patient group should be ranked according to effectiveness and, 
therefore, the ICERs calculated by dividing the incremental cost by the incremental 
effect for each successively more effective treatment (Karlsson and Johannesson, 1996; 
Glick et al, 2007). Flack et al (2007a) compared all interventions to ‘No Intervention’. 
Although it was the costless and least effective option, not all the ICERs should be 
calculated using the no intervention as the comparator. The NICE Report ‘Methods for 
the development of NICE public health guidance (2008)’ states that “the cost per QALY 
gained should be calculated as the difference in mean cost divided by the difference in 
mean QALYs for one intervention compared with the next most effective alternative. 
Therefore, results should have been calculated using this alternative and appropriate 
way but, because of consistency reasons and to facilitate the comparison with published 
and reported results by the replicated economic evaluation in this thesis (Flack et al, 
2007), the used procedure of using “No Intervention” in all cases as the comparator was 
70 
 
kept. The ICER for each smoking cessation intervention was compared with a threshold 
value of £20K to establish whether the intervention represents an efficient use of limited 
NHS resources (Devlin and Parkin, 2004). 
Net monetary benefit was also constructed from model M3 onwards as a validation of 
the results, though it was not reported till model 4 (M4) to keep comprehensive 
comparisons with M1 and M2. According to the criteria for interventions choice by 
using cost-effectiveness ratios, to select therapies that have not quantified sampling 
uncertainty, the net monetary benefit was calculated when a therapy has a significantly 
larger cost and effect than the alternative. In this case, the intervention recommended 
was the one with the greatest Net Monetary Benefit (NMB). 
Concluding, the incorporation of all these changes resulted in a new version of the 
model labelled model 3 (M3). Table 4.8 shows results from M3, where all the changes 
previously detailed in this section has been incorporated in M2. 
 
Table 4.8 Model estimates (M3) of average lifetime costs per smoker and QALYs lifetime gained per 
smoker (cohort of 1000 smokers; > 16 years; lifetime period reaching 100 years; starting distribution: 
100% smokers; health states: smokers; former smokers; death) 
 
Interventions Average cost 
(£ 2006) 
QALYs 
gained 
ICER for 
M3  
NMB M3 % 
differences 
in lifetime 
costs (M2 vs 
M3) 
% 
differences 
in lifetime 
QALYs 
gained (M2 
vs M3) 
NI 6839,91 11,8783 -  0,14% 0,05% 
BA 6851,34 11,8731 Dominant -114,93 -0,25% 0,20% 
BAS 6844,45 11,8787 11269,24 3,52 -0,39% 0,25% 
BASNRT 6874,69 11,8897 3033,09 194,55 -0,68% 0,35% 
BASNRTS 6803,42 11,9380 Dominant 1231,67 -1,97% 0,80% 
LICB 6715,24 11,9820 Dominant 2198,73 -3,24% 1,26% 
MICB 6671,75 12,0200 Dominant 3003,85 -4,54% 1,68% 
NPGC 6532,11 12,1130 Dominant 5003,33 0,66% -0,13% 
NPIC 6598,33 12,0602 Dominant 3879,66 0,69% -0,14% 
NPNC 6651,66 12,0133 Dominant 2889,66 0,65% -0,13% 
NPPC 6513,23 12,1545 Dominant 5851,14 0,55% -0,10% 
NPPCBP 6379,66 12,2521 Dominant 7936,37 -0,03% 0,07% 
Average - - - - -0,70% 0,35% 
 
Even though that all these changes are relevant to get more appropriate results, no much 
impact, in terms of lifetime costs and QALYs gained, was observed (i.e. average 
71 
 
difference on lifetime costs of -0.70%, and average difference on lifetime QALYs 
gained of 0.35%).  
Smoking cessation interventions have been shown to result in greater benefits at lower 
or marginally higher costs than ‘no intervention’, though some changes considered 
appropiate have been incorporated into M2. Therefore, M3 was taken forward in 
subsequent chapters to incorporate external effects. The next modellling exercise in this 
thesis involved the incorporation of the external effects of passive smoking on adults 
and children in an economic evaluation of smoking cessation interventions. The three 
external effects (i.e. passive smoking, smoking during pregnancy, and transmission of 
smoking behaviour) were not incorporated at the same time because there exist different 
interventions for smokers and for pregnant smokers. In addition,  the incorporation of 
external effects and their impact would be easier to understand incorporating one 
external effect after the other one. This procedure also allows comparison of the 
magnitude of the impact of each external effect in order toassess the relative importance 
of each external effect.  
 
4.3 Changes to allow incorporation of external effects  
Whilst the Flack et al (2007a), model (M1), reported all data for never smokers, this 
information was never included in the Markov model. Since this thesis intends to 
include external effects of passive smoking and smoking transmission behaviour, it is 
important to include the never smokers population group. The reason is that passive 
smokers are part of the never smokers. Therefore, to include passive smokers in the 
model we would need to distinguish between ‘passive never smokers’ and ‘non passive 
never smokers’ in the model. Therefore, a key difference between the M3 and the 
models used to account for external effects (M4 to M11) is the incorporation of these 
two new groups of population in the latter models. In light of these, the next chapter 
will be based on M3. Keeping M3 separate from M4 allowed a comparison of models 
that did not include these two new groups of population, which were added because of 
the incorporation of external effects. 
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CHAPTER 5 Economic Evaluation of Smoking Cessation 
Interventions: accounting for passive smoking in 
adults and children 
 
5.1 Introduction 
Chapter 4 replicated an economic evaluation of smoking cessation interventions using 
no intervention as a comparator. In line with current practice, that model did not account 
for external effects. This chapter incorporates passive smoking (in both adults and 
children) in an economic evaluation of smoking cessation interventions, as this external 
effect has been extensively studied in the UK (SCOTH, 2004; RCP, 2010) and 
worldwide (WHO, 2007; Oberg et al., 2010; Wipfli and Samet, 2010) and relevant 
empirical evidence gathered. The approach taken in this thesis is to measure costs and 
health outcomes arising from external effects and to incorporate them into the economic 
evaluation tool, with the ultimate aim of influencing policy. The chapter is structured as 
follows. First, there is a discussion of the methodology through which passive smoking-
related health effects can be incorporated into the economic evaluation of smoking 
cessation interventions. It is necessary to identify the health consequences and costs of 
passive smoking in order to decide which health outcomes, costs and extended impacts 
of passive smoking should be included in the economic evaluation model. Second, 
therefore, the health consequences of passive smoking for adults and children are 
presented prior to inclusion in the model. Third, a review is conducted of the literature 
relating to prevalence, costs, and utilities of the health effects of passive smoking for 
children and adults. In this way, the data required for the model is identified. The 
remaining part of this chapter presents and discusses the methods and results of 
incorporating passive smoking in an economic evaluation of smoking cessation 
interventions. The purpose of this is to measure the impact of the incorporation of 
passive smoking into the economic evaluation, and to identify any potential policy 
recommendations. The chapter also investigates whether there is any difference in the 
incremental cost effectiveness analysis (ICER) and decision making, and assesses the 
magnitude of this difference.  
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5.2 Methods 
This section discusses the development of the economic model and how the two 
literature reviews were conducted, including the search strategy and selection criteria. It 
explains how the health effects of passive smoking were incorporated in the Markov 
model, and how data was gathered relating to prevalence, costs and QALYs to measure 
these effects. 
 
5.2.1 Model parameters 
In order to build the model, a number of key input parameters were required: health 
effects caused by passive smoking among adults and children; mortality due to passive 
smoking; and prevalence, costs and utilities related to passive smoking. Also required 
was information relating to incidence; prevalence of different smoking states; mortality; 
quit and relapse rates; and effectiveness. The data values for these parameters have been 
obtained from a variety of sources which are described in the following sections. 
Regarding data on mortality and illness prevalence caused by passive smoking, same 
adjustments than previous models were needed (see Sections 4.1.4.1 and 4.1.4.2, in 
chapter 4, for further details).  
 
Health effects and mortality associated with passive smoking according to age: 
systematic literature review 
This question was addressed by systematically identifying and assessing all those papers 
describing health effects and mortality associated with passive smoking, and then 
summarising the evidence from the review of these studies. The search methods adopted 
are described in Appendix 5.1. Selected papers were then examined to check if they 
covered any of the data on health effects and mortality which were required for the 
model. Where potentially relevant data was identified in more than one source, 
preference was given to those studies which offered meta-analyses or pooled estimates 
for health effects and mortality data associated with passive smoking. This was done 
because meta-analyses offer a quantitative synthesis approach, combining results from a 
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number of studies to present the average effect. Meta-analysis carried out in the UK 
setting was prioritised above other settings because this is the context of our analysis.  
The key methodological features of the reviewed studies are presented below, along 
with a summary of their empirical findings. The search strategy for epidemiological 
studies yielded 1619 papers. A review of their titles and abstracts indicated that 205 
potentially met the review’s inclusion criteria. A more detailed review of these papers 
revealed that only six met the inclusion criteria. Six more papers were produced by a 
review of references, and incorporated into the search results. Details of this systematic 
literature review are shown in Appendices 5.2 to 5.3. 
The main findings of the studies are summarised in three parts: the clinical implications 
of passive smoking for adults; the implications for children; and the mortality risk for 
passive smokers.  
 
Clinical implications of passive smoking for adults 
The findings indicated that among adults, lung cancer and coronary heart disease are the 
medical side effects from passive smoking with the strongest supporting evidence (see 
Table 5.1 below for findings). In this context, the effect on coronary heart disease and 
ischemic heart disease were assumed to be the same. 
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Table 5.1 Summary of characteristics and data from included studies for adults 
Author, year Health effect N studies Type of 
data12 
Estimated 
value 
Adjusted13  
estimate 
95% CI 
Studies identified       
Barnoya and Glantz 
2005 
Coronary heart 
disease 
29 RR 1.31 not stated 1.21 to 1.41 
He et al. 1999 Coronary heart 
disease 
18 RR 1.25 not stated 1.17 to 1.32 
Law et al. 1997 Ischemic heart 
disease 
19 RR 1.3 not stated 1.22 to 1.38 
Thun et al. 1999 
 
Ischemic heart 
disease 
17 RR 1.25 not stated 1.17 to 1.33 
SCOTH14 2004 
 
Lung cancer - RR 1.24 not stated - 
Ischemic heart 
disease 
- RR 1.25  - 
Hackshaw et al.1997 Lung cancer 37 RR 1.24 unadjusted 1.13 to 1.36 
Parameter value used in model 
SCOTH15 2004 
 
Lung cancer - RR 1.24 not stated - 
RR: relative risk of health effect associated with exposure to environmental tobacco smoke due to living with a smoker compared to 
living with a lifelong non-smoker 
 
Data relating to risk for adults in all six studies was reported in terms of relative risk. As 
shown in Table 5.1, five of the studies report 95% confidence intervals, but none of the 
five states whether or not their estimates were adjusted for potential confounding 
variables. In order to assess the relative risk of lung cancer and coronary heart disease, 
the estimates given by the Smoking Committee on Tobacco and Health (SCOTH, 2004) 
were used, as these represent pooled estimates for the UK. To assess the passive 
smoking relative risk for lung cancer, the SCOTH report (RR 1.24) adopted values from 
Hackshaw et al. (1997). Taylor et al. (2007) also calculated the relative risk for lung 
cancer, but as this was a pooled estimate for Europe, it was felt to be less suitable than 
SCOTH`s UK-specific data. The same criterion was applied for the ischemic or 
coronary heart disease estimate; although some of the literature points to a higher 
estimate (RR 1.30) than the one used (RR 1.25), the pooled estimate for the UK was 
preferred.  
 
                                                 
12
 RR: relative risk (defined as the ratio of the chance of a disease developing among members of a population exposed to a factor 
compared with a similar population not exposed to the factor (medical dictionary, 2011 <http://medical-
dictionary.thefreedictionary.com>); OR: odds ratio  (this ratio estimates the chances of a particular event occurring in one 
population in relation to its rate of occurrence in another population (medical dictionary, 2011 <http://medical-
dictionary.thefreedictionary.com>). 
13
 Adjustment for potential confounding variables 
14
 Scientific Committee on Tobacco and Health 
15
 Scientific Committee on Tobacco and Health 
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Clinical implications of passive smoking for children 
The most relevant medical side effects of passive smoking on children reported in the 
literature were asthma, wheezing, coughing, phlegm, breathlessness, acute otitis media, 
recurrent otitis media, middle ear effusion, glue ear, sudden infant death, and low birth 
weight (refer to Table 5.2 for findings). For babies, increased risk of low birth weight 
and sudden infant death were also reported as clinical consequences of a parent’s 
smoking. 
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Table 5.2 Summary of characteristics and data from included studies for children older than five years  
Author, year Health effect N 
studies 
Type of 
data16 
Estimated 
value 
Adjusted17 
estimate 
95% CI 
Studies identified 
Uhari et al. 1996 Acute otitis media 22 RR 1.66 not stated 1.33 to 2.06 
Leonardi-Bee et al. 
2008 
Birth weight 26 OR18 
OR19 
1.32 
1.22 
not stated 1.07 to 1.63 
1.08 to 1.37 
Cook and Strachan 
199920 
Wheeze 
Cough 
Phlegm 
Breathlessness 
Asthma (cross sectional 
studies) 
Acute otitis media 
Recurrent otitis media 
Middle ear effusion 
Glue ear 
Sudden infant death 
30 
30 
6 
6 
21 
 
13 
9 
5 
9 
18 
OR 
OR 
OR 
OR 
OR 
 
OR 
OR 
OR 
OR 
OR 
1.24 
1.40 
1.35 
1.31 
1.21 
 
1.0 to 1.6 
1.48 
1.38 
1.21 
2.13 
unadjusted 
unadjusted 
unadjusted 
unadjusted 
unadjusted 
 
unadjusted 
unadjusted 
unadjusted 
unadjusted 
adjusted 
1.17 to 1.31 
1.27 to 1.53 
1.13 to 1.62 
1.08 to 1.59 
1.10 to 1.34 
 
 
1.08 to 2.04 
1.23 to 1.55 
0.95 to 1.53 
1.86 to 2.43 
Li et al. 1999 Lower respiratory tract 
infection 
13 OR 1.2521 unadjusted 0.88 to 1.78 
Pattenden et al. 
2006 
Smoking in pregnancy 
Wheeze 
Asthma 
Nocturnal dry cough 
Morning cough 
 
Smoking in first 2 years 
Wheeze 
Asthma 
Nocturnal dry cough 
Morning cough 
 
12 
12 
12 
12 
 
 
12 
12 
12 
12 
 
OR 
OR 
OR 
OR 
 
 
OR 
OR 
OR 
OR 
 
1.12 
1.17 
1.15 
1.14 
 
 
1.06 
1.04 
1.03 
1.05 
 
adjusted 
adjusted 
adjusted 
adjusted 
 
 
adjusted 
adjusted 
adjusted 
adjusted 
 
1.04 to 1.22 
1.04 to 1.31 
1.00 to 1.32 
0.94 to 1.39 
 
 
0.95 to 1.19 
0.94 to 1.14 
0.94 to 1.18 
0.96 to 1.25 
Parameter value used in model 
Cook and Strachan 
199922 
Wheeze 
Cough 
Asthma (cross sectional 
studies) 
Acute otitis media 
Middle ear effusion 
30 
30 
21 
 
13 
5 
OR 
OR 
OR 
 
OR 
OR 
1.24 
1.40 
1.21 
 
1.0 to 1.6 
1.38 
unadjusted 
unadjusted 
unadjusted 
 
unadjusted 
unadjusted 
1.17 to 1.31 
1.27 to 1.53 
1.10 to 1.34 
 
- 
1.23 to 1.55 
RR/OR: relative risk/odds ratio of health effect associated with exposure to environmental tobacco smoke due to parental smoking 
compared to having non-smoking parents. 
 
Children’s risk is generally reported in the studies in terms of odds ratio measures, with 
the exception of Unhari et al. (1996), who use the relative risk measure. All of the 
studies report 95% confidence intervals; only two papers do not say whether their 
estimates were adjusted for potential confounding (see Table 5.2). 
                                                 
16
 RR: relative risk (defined as the ratio of the chance of a disease developing among members of a population exposed to a factor 
compared with a similar population not exposed to the factor (medical dictionary, 2011 <http://medical-
dictionary.thefreedictionary.com>); OR: odds ratio (this ratio estimates the chances of a particular event occurring in one population 
in relation to its rate of occurrence in another population (medical dictionary, 2011 <http://medical-
dictionary.thefreedictionary.com>). 
17
 Adjustment for potential confounding variables 
18
 Maternal exposure to ETS during pregnancy (birth weight <2500g; prospective studies). 
19
 Maternal exposure to ETS during pregnancy (birth weight <2500g; retrospective studies). 
20
 The ORs reported in this paper are calculated on the assumption that either parent smokes at home, except in the case of sudden 
infant death, when only the mother`s smoking is considered. 
21
 Four figures were reported in the paper; only the most conservative is given here.  
 
22
 The ORs reported in this paper are calculated on the assumption that either parent smokes at home, except in the case of sudden 
infant death, when only the mother`s smoking is considered. 
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Although there are more recent estimates regarding the clinical implications of passive 
smoking for children at home, the figures reported by Cook and Strachan (1999) were 
used in the model because they represent pooled estimates for children younger than 16 
years old. Using these estimates also allows us to differentiate between the side effects 
of passive smoking on babies and children. Three experts23 in the field were contacted 
by email, and they recommended that the effects of passive smoking on babies ought to 
be studied for the first five years after birth. Care has been taken to avoid an overlap 
between this chapter (which focuses on passive smoking-related health effects on 
children aged 0 to 15) and Chapter Six (which focuses on health effects on 0 to 1 year 
old of maternal smoking during pregnancy). Thus, sudden infant death and low birth 
weight are considered to be the clinical implications of smoking during pregnancy, and 
are discussed in Chapter 6, while this chapter follows Cook and Strachan (1999) and 
focuses on wheezing, asthma, morning and nocturnal cough among children aged 0 to 
15. Two studies report the relative risk of acute otitis media, with the value estimated by 
Cook and Strachan (1999) lying at the highest edge of the 95% confidence interval. The 
pooled estimates of Cook and Strachan (1999) are therefore used in the model. These 
estimates have also been used in other studies to calculate health effects on children 
from passive smoking (Rushton et al., 2003). 
 
Mortality risk for passive smokers 
The systematic literature review found no articles giving passive smoking-related 
mortality data, so advice was sought from those with the relevant knowledge in the UK. 
These experts directed the researcher to Jamrozik’s UK-based study (2005); however, 
when reporting by cause the deaths attributable to passive smoking, this study does not 
compare passive and non-passive never-smokers groups. Only one other data source 
was recommended (Hill et al., 2004). This study examined the association between 
passive smoking and mortality from all causes in New Zealand. The clinical trial was 
conducted among adults aged 45-74 who had responded to the 1981 and 1996 censuses 
identifying themselves as “non-smokers” and providing data on the smoking status of 
all household members. The data used in the model came from the most recent census 
(1996-1999). The adjusted relative risk for men who were passive compared to those 
who were non-passive was 1.16, with a 95% confidence interval between 1.04 and 1.30. 
                                                 
23
 Professor S Petrou, of NICE, Lesley Owen, and Hema Mistry. 
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For women, this relative risk was 1.28, with a 95% confidence interval between 1.16-
1.42. Although these estimates were not pooled, lack of evidence meant that this was 
the only data we could use in the model. 
The death rate for smokers, former smokers, passive and non-passive never smokers 
was calculated by age and gender, converted to a transition probability, and considered 
in the Markov model. Refer to Appendix 5.4 for further details. 
 
Prevalence, costs and utilities of health effects associated with passive smoking 
among children aged 0 to 15: systematic literature review  
The aim of this systematic review was to identify and critically appraise all published 
material relating to the prevalence, costs and utilities of the health effects associated 
with passive smoking among children. Refer to Appendix 5.5 for the search methods. 
Once again, where relevant data was identified in more than one source, preference was 
given to meta-analyses or pooled estimates relating to the health effects and mortality 
data associated with passive smoking. Meta-analysis carried out in the UK was 
prioritised as this setting is the context of the current analysis. Estimates used in HTA or 
NICE reports, which inform NICE policy making, were also favoured, followed by 
estimates from credible sources such as national statistics institutions. Estimates 
calculated from populations with the widest possible age interval were favoured. Where 
age intervals were comparable, the study offering the most conservative estimate was 
preferred.   
The search strategy for prevalence studies yielded 1649 papers. Following a review of 
their titles and abstracts, only 233 were felt to meet the inclusion criteria. Of these, only 
37 reported data of interest (see Appendices 5.6 and 5.7 for more details). The findings 
are summarised below according to type of data. 
  
Prevalence 
19 out of 37 studies reported data on the prevalence of passive smoking-related 
illnesses. See Table 5.3 for more details. 
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Table 5.3 Summary of characteristics and data relating to prevalence of health effects caused by living 
with a smoking parent among children younger than 15 years 
Author, year Health effect Sample Children`s 
age 
Country Estimated 
annual 
prevalence 
95% CI 
Studies identified 
SIGN 2003 Acute otitis media 
Otitis media with 
effusion 
- 
- 
< 10 
< 4 
UK 25% 
80% 
- 
- 
Asher et al. 2006 Asthma 1843 6-7 
13-14 
UK 20.9% 
24.7% 
- 
- 
Kwong GNM et al. 
2001 
Asthma 4806 
4810 
8-9 UK 29.7% 
35.8% 
- 
- 
Soriano et al. 2003 Asthma 15751 5-14 UK 9.08% - 
Anderson et al. 
2004 
Asthma24 
Wheeze25 
15755 12-14 UK 25.9% 
27.5% 
- 
- 
Burr et al. 2006 Asthma 
Wheeze26 
Breathless 
Wheeze27 
1148 12 UK 27.3% 
28% 
 
19.9% 
- 
- 
 
- 
Butland et al. 2006 Asthma or Wheeze 4246 7-8 UK 17.8%  
Kurukulaaratchy et 
al. 2002 
Asthma 
Wheeze 
1456 10 UK 14.4% 
18.9% 
- 
- 
McCann et al. 2002 Asthma 
Wheeze28 
1732 
328 
7-9 UK 24.3% 
18.9% 
- 
- 
ONS 2004 Asthma 
Wheeze 
25507 
 
12-14 
 
UK 21.08% 
33.73% 
- 
- 
Pearce et al. 2007 Asthma 
 
Wheeze 
 
- 
- 
- 
- 
6-7 
13-14 
6-7 
13-14 
UK 24.8% 
22.9% 
19.6% 
27.1% 
- 
- 
- 
- 
Rizwan et al. 2004 Asthma 
Wheeze 
Breathlessness 
1964 5-11 UK 29.8% 
29.4% 
19.8% 
- 
- 
- 
Shamssain and 
Shamsian 1999 
Asthma 
Wheeze 
3000 6-7 UK 22.7% 
29.6% 
- 
- 
Kuehni et al. 2001 Wheeze 2600 1-5 UK 26%29 
29%30 
 
Kuehni et al. 2000 Wheeze 1422 8-13 UK 20.5%31  
Patel et al. 2008 Wheeze 35485 13-14 UK 32.2%32  
Duran-Tauleria and 
Rona 1999 
Asthma 
Wheeze 
Cough 
1028 
2196 
1047 
5-11 UK 6.6% 
14.1% 
6.8% 
- 
- 
- 
Linehan et al. 2009 Asthma 
Wheeze 
Cough (night) 
2377 
2408 
2387 
6-11 UK 9.3% 
20.3% 
33.5% 
- 
- 
Shamssain 2007 Asthma 
 
Wheeze 
 
Cough 
1843 
2195 
1843 
2195 
1843 
2195 
6-7 
13-14 
6-7 
13-14 
6-7 
13-14y 
UK 26.95% 
25.8% 
35.6% 
30.55% 
27.2% 
19.1% 
- 
- 
- 
- 
- 
- 
Parameter value used in model 
ONS 2004 Asthma 
Wheeze 
25507 
 
12-14 
 
UK 21.08% 
33.73% 
- 
- 
Shamssain 2007 Cough 1843 
2195 
6-7 
13-14y 
UK 27.2% 
19.1% 
- 
- 
                                                 
24
 lifetime prevalence 
25
 12 month prevalence 
26
 have ever wheezed  
27
 have ever been breathless or wheezed 
28
 last 12 months 
29
 wheezing in 1998  
30
 wheezing in 1998 
31
  wheezing in 1998 
32
 This estimate taken from the International Study of Asthma and Allergies in Childhood (ISAAC) conducted in 1994-1995. 
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Author, year Health effect Sample Children`s 
age 
Country Estimated 
annual 
prevalence 
95% CI 
SIGN 2003 Acute otitis media 
Otitis media with 
effusion 
- 
- 
< 10 
< 4 
UK 25% 
80% 
- 
- 
 
With regard to asthma and wheezing, the prevalence data selected for the model was 
that reported by the Office for National Statistics (ONS) (2004). This was the best 
evidence source for this data as it met the criterion of coming from an established 
source – the National Statistics Institution. For cough, the estimate used was that 
provided by Shamssain (2007). Although Linehan’s estimate is more recent (2009), a 
comparison of those papers containing estimates for cough shows that the prevalence 
rates for asthma and wheeze also reported by the studies were closest the ones reported 
by Shamssain than the others (Duran-Tauleria and Rona, 1999; Linehan et al. 2009). An 
average prevalence rate was calculated where two separate rates were reported for the 6-
7 and 13-14 age groups. The unique estimates for acute otitis media and otitis media 
with effusion were used. 
 
Costs 
Only nine studies out of 40 reported data on costs related to passive smoking illnesses. 
Table 5.4 shows details of this data. 
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Table 5.4 Summary of characteristics and data relating to costs associated with passive smoking-related 
illnesses among children aged 0 to 15 years who live with smoking parents 
Author, year Health effect Sample Children`s 
age (years) 
Coun
try 
Estimated 
annual cost 
95% CI Currency
/year 
Studies identified 
Alsarraf et al. 1999 Acute otitis 
media 
25 1-3 US 137.94 133.74-
142.14 
$ 1996 
Koskinen et al. 2006 Acute otitis 
media 
369 0-6 Finland 123.55 - € 2002 
Main et al. 2008 Asthma 3416 0-12 UK 79.83 - £2006 
Ungar et al. 2001 Asthma 339 4-14 Canada 663 630-701 $1995 
Van der Akker-van 
Marle et al. 2005 
Asthma 2000 6-7 and 13-14 UK 189 - £2004 
Wang et al. 2005 Asthma 2.52 
million 
5-17 USA 401  $2003 
Weinmann et al. 2003 Asthma 145 0-8 German
y 
627 157-1918 $1996 
Stevens et al. 2003 Asthma or 
wheeze 
90 1-5y UK 428.51 34.07-
1781.89 
£1999 
Hollinghurst et al. 
2008 
Cough 121 3-5 UK 27.43 24.38-30.49 £2006 
Hartman et al. 2001 Otitis media 
with effusion 
187 1.6 Netherla
nds 
286 - $ 1998 
Plaza and de los Santos 
2003 
Otitis media 
with effusion 
1000 2-6 Spain 146 - €2003 
Parameter value used in model 
Koskinen et al.2006 Acute otitis 
media 
369 0-6 Finla
nd 
123.55 - € 2002 
Plaza and de los Santos 
2003 
Otitis media 
with effusion 
1000 2-6 Spain 146 - €2003 
Main et al. 2008 Asthma 3416 0-12 UK 79.83 - £2006 
Stevens et al. 2003 Asthma or 
wheeze 
90 1-5y UK 428.51 34.07-
1781.89 
£1999 
Hollinghurst et al. 
2008 
Cough 121 3-5 UK 27.43 24.38-30.49 £2006 
 
For acute otitis media (Koshinen et al., 2006) and otitis media with effusion (Plaza and 
de los Santos, 2003), the estimates were taken from those studies with the largest age 
intervals.  Main et al’s estimate of the cost of an asthma episode (2008) was taken for 
the model as it was derived from a recent HTA report. Only one paper supplied 
estimates for wheeze and cough. To aid comparability, cost values were converted to 
sterling using country-specific gross domestic product deflators (World Bank, 2009) 
and euro-pound sterling exchange rates (European Central Bank, 2009).    
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Utility 
Twelve out of 40 studies reported utilities (see Table 5.5 for more details). Only one 
study reported utility estimates for cough and otitis media with effusion, while several 
gave estimates for asthma and wheezing. Main et al’s (2008) utility estimate for asthma 
was taken for the model because it was used in an HTA report. Regarding acute otitis 
media, although Brouwer et al. (2005) supplied the most recent estimate, the age 
interval in Oh et al’s (1999) study was larger; the latters’ estimate was therefore 
considered more appropriate for the model. Mohangoo et al’s (2007) utility estimate for 
wheezing was taken for the model was the most conservative estimate. 
 
Table 5.5 Summary of characteristics and data relating to utilities of health effects caused by living with 
smoking parents among children aged 0 to 15 years 
Author, year Health effect Sample Children`s 
age 
(years) 
Estimat
ed 
utility 
95% CI Instrument 
Studies identified 
Oh et al. 1996 Acute otitis 
media 
10 
physicians 
2 months-
18years 
0.7933 0.713-0.867 Physician 
interviews 
(utilities)34 
Brouwer et al. 
2005 
Acute otitis 
media 
384 
children 
1-7 0.87 - Dutch instrument 
on generic HRQoL 
Main et al. 2008 Asthma 3416 0-12 0.85 - HRQoL 
Van der Akker-
van Marle et 
al. 2005 
Asthma 2000 6-7 and 
13-14 
0.73 - HRQoL 
Goldbeck et al. 
2007 
Asthma 81 7-18 0.77 - Quality of life 
 
Norrby et al. 
2006 
Asthma 53 9-16 0.82 - CHQ-HRQoL 
Sawyer et al. 
2004 
Asthma 123 10-14 0.69 - PAQLQ-HRQoL35 
Polley et al. 
2008 
Chronic cough 147 40-67 0.76 - LCQ-CQLQ-
HRQoL36 
Tengs and 
Wallance 
2000 
Otitis media 
with effusion 
- children 0.7 - Quality of life 
Mohangoo et al. 
2007 
Wheeze 1071 15 0.75 - CHQ-HRQoL37 
Oostenbrink et 
al. 2006 
Wheeze 500 0-4 0.76 - ITQOL-HRQoL38 
Mohangoo et al. 
2005 
Wheeze 500 0-3.3 0.86 - TAPQOL-
HRQoL39 
                                                 
33
 The value reported by the authors was 0.79 (utility per day) of AOM. This was transformed to a utility value according to the 6 
months cycle of my model. The treatment length was assumed to be the same as the length of an AOM episode. 
34
 A utility analysis was performed based on the physicians’ responses to the AOM and adverse-event scenarios presented in the 
mail survey. Utility was defined as a preference for each given health state, rated on a scale of severity from 0 to 1. 
35
 The Paediatric Asthma Quality of Life Questionnaire (PAQLQ) was utilised as the disease-specific HRQoL measure. 
36
 The researchers undertook a cross-sectional comparison of scores from two cough-specific, health-related quality of life (HRQoL) 
questionnaires, the Leicester Cough Questionnaire (LCQ), and the Cough Quality of Life Questionnaire (CQLQ), together with a 
generic HRQoL measure, the EuroQol. 
37
 The Child Health Questionnaire (CHQ) is a generic self-report questionnaire for measuring and comparing HRQoL. 
38
 The Infant/Toddler Quality of Life Questionnaire (ITQOL) is a generic “profile measure” for HRQoL among children. 
39
 This study evaluated the HRQoL using the TNOZAL Preschool Children Quality of Life (TAPQOL) questionnaire. 
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Author, year Health effect Sample Children`s 
age 
(years) 
Estimat
ed 
utility 
95% CI Instrument 
Parameter value used in model 
Polley et al. 
2008 
Chronic cough 147 40-67 0.76 - LCQ-CQLQ-
HRQoL40 
Tengs and 
Wallance 
2000 
Otitis media 
with effusion 
- children 0.7 - Quality of life 
Main et al. 2008 Asthma 3416 0-12 0.85 - HRQoL 
Oh et al. 1996 Acute otitis 
media 
10 
physicians 
2 months-
18years 
0.7941 0.713-0.867 Physician 
interviews 
(utilities)42 
Mohangoo et al. 
2007 
Wheeze 1071 15 0.75 - CHQ-HRQoL43 
HRQoL: Health-related quality-of-life 
 
Uptake of smoking (incidence) 
At the start of the modelling process, age and gender-specific incidence rates were 
calculated for each of the two never-smoking categories (non-passive and passive).   
The data for the analysis was taken from the General Household Survey (GHS) of 2006 
(see Appendix 5.8 for how this survey was selected). In each cycle, until reaching the 
age of 100 the transition from non-passive never-smoker, to passive smoker to smoking 
status was modelled. To calculate the incidence (uptake) of smoking from non-passive 
and passive never smokers two types of information were needed: (a) the incidence rate 
(new smokers/population) of smoking and the increase in the relative oddsof uptake of 
smoking if any household member was smoking in the household, which was 
calculated, from the Health Survey for England (HSE) (2006), as the quotient of odds of 
passive never-smokers and odds of non-passive never-smokers. It was assumed that this 
household data was representative of total passive smoking exposure. This data was 
adjusted by age, and gender. 
 
                                                 
40
 The researchers undertook a cross-sectional comparison of scores from two cough-specific, health-related quality of life (HRQoL) 
questionnaires, the Leicester Cough Questionnaire (LCQ), and the Cough Quality of Life Questionnaire (CQLQ), together with a 
generic HRQoL measure, the EuroQol. 
41
 The value reported by the authors was 0.79 (utility per day) of AOM. This was transformed to a utility value according to the 6 
months cycle of my model. The treatment length was assumed to be the same as the length of an AOM episode. 
42
 A utility analysis was performed based on the physicians’ responses to the AOM and adverse-event scenarios presented in the 
mail survey. Utility was defined as a preference for each given health state, rated on a scale of severity from 0 to 1. 
43
 The Child Health Questionnaire (CHQ) is a generic self-report questionnaire for measuring and comparing HRQoL. 
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The incidence rate of smoking (rate at which never smokers start smoking) was adjusted 
using the (respective) increase  in the odds ratio(s) of uptake of smoking if any 
household member was smoking, and therefore, increasing the risk of smoking if the 
household members were passive never smokers. This increased risk was also published 
by Leonardi-Bee et al (2011) for children, though not for adults. Therefore, this odds 
ratio was finally proxied using data from the HSE (2006). . Finally, this rate was 
converted to a transition probability value for use in the Markov model.  
Detailed data on the incidence transition probability values used in the model is given in 
Appendix 5.9. 
 
Quit and relapse rates 
These were modelled exactly as in the M2 and M3 models (see Section 4.1.6, Chapter 
4). 
 
Prevalence 
At the start of the modelling process, for each of the four smoking categories, the age 
and gender-specific prevalence of smoking status was applied to mirror the known 
prevalence of these states in the English population. The prevalence rates for adults and 
children were taken from the Health Survey for England (2006) (see Appendix 5.10 for 
how the survey was selected). This survey represents the most up to date information 
we have about people`s smoking at home, but the fact that it also includes non-
household members (i.e. visitors) who smoke makes it impossible to calculate exactly 
how many passive smokers there are in a given household. Separate information was 
calculated for adults (defined as anyone over16) and children in the HSE survey. The 
variable used to derive the adult number of passive smokers was generated by asking 
household members if they were often near people who smoke at home; this data was 
broken down according to cigarette smoking status, age and sex. It was assumed that 
smokers smoke inside and not outside of the house/flat in the HSE survey. This variable 
was used to calculate the number of passive smokers inside the Markov model. This 
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cohort of people was used to measure the impact of passive smoking in the cost-utility 
analysis of smoking cessation interventions. 
Those whose cigarette smoking status was: “never smoked cigarettes at all” were 
considered non-smokers, whereas those who said they “used to smoke cigarettes 
occasionally” and “used to smoke cigarettes regularly” were classified as former 
smokers.  
The data relating to adults which was used in the model is reported in Table 5.7. More 
detailed data extracted from the HSE 2006 can be seen in Appendix 5.11. 
 
Table 5.7 Prevalence of smoking status among the adult population (aged 16 onwards) 
Age Current smoker 
(S) 
Former (F) Non-passive never-
smokers 
Passive never-
smokers 
men women men women men women men women 
16-24 0.28 0.28 0.10 0.10 0.51 0.52 0.12 0.09 
25-34 0.34 0.25 0.22 0.25 0.41 0.47 0.03 0.03 
35-44 0.28 0.23 0.24 0.24 0.46 0.48 0.02 0.04 
45-54 0.24 0.24 0.30 0.27 0.43 0.46 0.03 0.03 
55-64 0.19 0.20 0.46 0.34 0.33 0.44 0.02 0.02 
65-74 0.14 0.13 0.55 0.34 0.30 0.51 0.01 0.02 
75 and over 0.09 0.08 0.60 0.41 0.30 0.47 0.01 0.03 
All ages 0.23 0.21 0.35 0.28 0.39 0.47 0.03 0.04 
 
Because passive smokers are assumed to be generated by adult smokers, the prevalence 
of passive smokers was adjusted to account for this. The steps followed were: (a) take 
prevalence rates among current smokers by age and sex (from the HSE 2006) and 
multiply them by the average prevalence of passive smokers; and (b) divide the 
resulting numbers by the average prevalence of current smokers (i.e. for men of 16-24 
years: 0.28 * (0.035/0.22)). To capture an average for female and male passive smokers 
combined, the average figure for passive smokers of all ages (0.035) was calculated. 
This proxy was necessary because of the lack of data on the number of passive smokers 
caused by the current number of smokers. It was the only possibility with the available 
data. 
The impact on child passive smokers was also considered. In order to keep the structure 
of the model comparable with previous versions, the effect of passive smoking on 
children was calculated outside the Markov model, but using the output for smokers 
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generated in the model. The population used in the model was a cohort of 1000 adults 
aged 16 upwards; introducing children would have changed the whole structure of the 
model cohort. 
The only available data relating to the prevalence of passive smoking among children is 
in the HSE 2006, but this is limited to children aged between 8 and 15. It was assumed 
that rates among children aged 0 to 7 would be similar to those among 8 to 15 year olds. 
With this assumption, it was possible to calculate the prevalence of smoking status 
among children aged 0 to 15 (see Table 5.8 for details).  
 
Table 5.8 Prevalence of smoking status among children aged 0 to 15 
Age  Ever smoked Non-passive 
never-smoker  
Passive never-
smoker  
0-15 0,15 0,63 0,22 
 
Although, children who ever smoke may have tried once, and refused to try again, and 
therefore they could have been affected by passive smoking, the 15% of children who 
had ever tried cigarettes were not included in the model. The figures used in the model 
may therefore be conservative. The same method as was used for adults – multiplying 
by the average prevalence of passive smokers and dividing by the average prevalence of 
current smokers – was adopted for children. The prevalence rate for child passive 
smokers (0.22 according to Table 5.8) was divided by the overall average smoking 
prevalence rate for adults (i.e. the average of 0.23 and 0.21 from Table 5.7) to obtain the 
rate of passive smoking children generated by smokers. The result accords with the 
findings of Jarvis et al. (2000) on the prevalence of passive smoking as reported by 
schoolchildren aged 11-15 in England. Jarvis`s study was a cross-sectional survey of 
data from nationally representative samples of secondary school children, collected by 
the Office for National Statistics between 1988 and 1998. Although offering similar 
results, the more recent data has been taken for use in the model. It suggests that 96.5% 
of children living with a smoker are passive smokers. 
The average number of children living in a household was calculated by dividing the 
total population under 15 years by the total population aged between 15 and 59. (Further 
details are given in Appendix 5.12.) The model assumes a maximum age of 59 for 
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parents of children aged 15 or under (taking 45 as the maximum age for getting 
pregnant). An average number of 0.63 dependent children is assumed for every two 
adult members in each household. Although recent evidence from Smallwood and 
Wilson (2007) claimed that the average number of dependent children per family was 
1.8 in 2006, this estimate has not been used here because it only covers families with 
dependent children, and does not take into account families with any dependants. 
Multiplying the number of adult smokers (aged 16-100) in each model cycle by the 
average number of children by person, the average number of children living with each 
smoker was obtained. This number was then multiplied by the prevalence of passive 
smoking children in the total child population to arrive at the average number of 
children passive smokers per existing number of smokers in the population. 
 
Sources of effectiveness  
The same effectiveness studies were used in this economic model as before (see Section 
4.1.6, Chapter 4). However, because Model M3 incorporated the transformation of these 
effectiveness rates to transition probabilities, Brief Advice resulted in a lower 
effectiveness rate than the comparator. Therefore, to ensure “face validity” the 
intervention was assumed to be minimally more effective (0.05) than non-intervention. 
This figure (0.05) was chosen to ensure that this assumption did not affect the cost-
effectiveness of this intervention.  
 
5.2.2 Economic model 
The aim of this analysis is to determine, using a Markov decision model, the relative 
cost-utility of the different smoking cessation interventions identified in NICE`s report 
(Flack et al., 2007a) on the health effects of passive smoking. The population examined 
is a cohort of 1000 adults, who, as in M2 and M3, are divided according to their 
smoking status. When passive smoking among children is incorporated into the model 
(M5), the cohort of 1000 adults increases by the number of passive children generated 
by smokers in the population (96.5% of adult smokers’ children). In this way, the 
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population of M4 and M5 (the models being developed in this chapter) differs from that 
of M3. 
A Markov (state transition) model was developed in Microsoft EXCEL (Microsoft 
Corporation). The structure of the model was adapted from that of M3. The models used 
in this chapter (M4 and M5) differ from M3 in the addition of two new groups to the 
population: non-passive never-smokers and passive never-smokers (M3 considered 
smokers, former smokers and death health states only). M4 and M5 differ in their 
incorporation of external effects: M4 does not consider the effects of passive smoking, 
while M5 does. See Table 5.9 for details. 
 
Table 5.9 Summary of differences between M3, M4 and M5 
Model Starting population in Markov Model Incorporation 
of passive 
smoking on 
adults and 
children 
Smokers Former 
smokers 
Non-
passive 
never- 
smokers 
Passive  
never-
smokers 
Death 
M3 √ x x x x x 
M4 √ √ √ √ x x 
M5 √ √ √ √ x √ 
√≡ included in the model 
x≡ not included in the model 
 
To assess the impact of passive smoking, the number of passive smokers was calculated 
from the number of smokers by age and gender from the Markov model. As in M2 and 
M3, the analysis adopts the National Health Service`s preferred cycle length of six 
months.  
The model estimates44: (a) impact on average lifetime costs due to passive smoking (£ 
2010); and (b) quality-adjusted life-years (QALYs) lost to adults and children due to 
passive smoking. The effectiveness outputs differ from those calculated and obtained in 
M2 and M3, which were lifetime QALYs gained. This change was made because it 
seems to be conceptually easier to understand the impact of negative external effects 
                                                 
44
 To facilitate the presentation and interpretation of results, only those lifetime costs and QALYs lost associated with the least and 
most cost-effective smoking cessation programmes are presented. 
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introduced in the model when the effects are calculated as QALYs lost. However, it 
would also have been possible to calculate QALYs gained.   
 
Model structure 
Within the Markov state transition model, adults reside in one of five discrete health 
states. The model starts with a fixed distribution of the population according to their 
smoking habits. At regular time intervals (the model cycle), adults make at most one 
transition between states. During each cycle, all adults must be in one of the health 
states in the model. The probabilities attached to each transition between model cycles 
were based on the data used in the Flack et al (2007) report and, when new data was 
needed (e.g. regarding costs or utilities of the health effects of passive smoking on 
adults and children), systematic literature reviews were carried out. Some of the model 
states therefore have an associated utility and cost, and some of the model transitions 
have a cost. Transition probabilities were assigned to each of the transitions (indicated 
by the arrows in Figure 5.1). The model was run for the lifetime of the population 
modelled (with a convenience cut off at 100 years). 
The structure of the model is shown in Figure 5.1. 
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Figure 5.1 Structure of the smoking cessation model accounting for passive smoking 
  
* Children who are passive smokers generated by the smokers in the adult population modelled 
 
The passive smokers’ cohort is a function of the smokers’ cohort. Smokers and former 
smokers are linked through their quit and relapse rates, as are passive and non-passive 
never-smokers. Adults might remain in a given state at the end of each cycle or could 
transition to death. The model assumes that passive smoking is irrelevant to smokers 
and former smokers; it does not materially increase the already high risk faced by these 
groups. This assumption also enables a clearer distinction to be made between active 
(smokers and former smokers) and passive smoking (never smokers). Passive smoking 
does increase the risk faced by non-smokers, however. Although the model is built 
separately by gender, female smokers generate female and male passive smokers of any 
age, and male smokers generate male and female passive smokers of any age, and then 
results are adjusted according to the population weights. 
 
Non-passive 
never-
smokers 
Passive  
never-
smokers 
Smokers 
Death 
Former 
smokers 
quit 
quit 
relapse 
Children * 
(passive 
smokers) 
relapse 
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5.2.3 Time horizon 
The time horizon of the model was set for a maximum lifespan of 100 years, as before. 
 
5.2.4 Discount rate 
Both costs and benefits (QALYS) in the model have been discounted at an annual rate 
of 3.5%, as before.  
 
5.2.5 Cost-effectiveness ratios and net monetary benefit 
Mutually exclusive treatment options were adopted as for M2 and M3. Net monetary 
benefit (NMB) was constructed following the same criteria as before, adopting a 
threshold value of £20,000.  
 
5.2.6 Uncertainty 
Uncertainty about estimates of costs, effectiveness, and the cost-effectiveness ratio or 
NMB can arise in a number of ways. There are two major sources of uncertainty: 
parameter and model uncertainty (Manning et al., 1996). Only parameter uncertainty 
has been studied in this case. In an attempt to deal with parameter uncertainty in the 
input parameters of the decision model, univariate and probabilistic sensitivity analyses 
were conducted after the economic evaluation. Univariate sensitivity analysis only was 
conducted by Flack et al. (2007a) in M1 (see Section 4.1.10, Chapter 4). Their analysis 
addressed the background cessation rate and the cost of interventions. For consistency`s 
sake, therefore, univariate sensitivity analysis was also conducted here. 
Although univariate sensitivity analysis remains the most popular technique to account 
for uncertainty, the analysis of M4 and M5 demonstrates that it gives insufficient insight 
into the scale of decision uncertainty (Claxton et al., 2005). Probabilistic sensitivity 
analysis (PSA) is an alternative approach that involves specifying distributions for input 
parameters in the model and employing Monte Carlo simulation to sample from these 
distributions, allowing the joint effect of parameter uncertainty to be assessed (Briggs et 
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al., 2002). Probabilistic sensitivity analysis involves specifying distributions for model 
parameters to represent parameter uncertainty in their estimation and employing Monte 
Carlo simulation to select values at random from those distributions (Briggs et al., 
2002). Variables can take a range of values described by the specified distribution 
(Briggs et al., 2002). This type of sensitivity analysis was also employed in M4 and M5. 
There was uncertainty about the true numerical variables of the parameters used as 
inputs in the model, such as the incidence rates of starting smoking, effectiveness of 
smoking cessation programmes, relative risk of getting a particular disease due to 
passive smoking, utility values and costs. Therefore, having specified distributions for 
all these parameters of the model, probabilistic analysis was undertaken by randomly 
sampling from each of the parameter distributions and calculating the expected costs 
and expected QALYs for that combination of parameter values. This process formed a 
single replication of the model results, and a total of 1000 iterations were performed in 
order to examine the distribution of the resulting cost and outcomes for each smoking 
intervention. The cumulative NMB for the most cost-effective intervention was 
calculated to see whether the number of iterations was enough to produce stable results. 
 
5.2.6.1 Choosing distributions for the parameters 
Care was taken to choose the distribution which was most appropriate to the nature of 
the data; different distributions were deployed for the four different types of parameters 
employed in this cost-effectiveness model. Distributions for estimation of parameters 
were selected according to the recommendations of Briggs et al. (2002; 2006, pp108). 
For probability parameters such as quit and relapse rates and smoking incidence rates, 
the beta distribution was selected. The utilities parameters was also based  on a beta 
distribution. Gamma distribution was considered more appropriate for the unit cost 
parameters. Finally, for the relative risk parameters regarding the five different diseases 
(LC, CHD, COPD, MI, ST) and diseases associated with passive smoking, and the 
relative risk of mortality for passive and non-passive never-smokers, the lognormal 
distrubution was considered. Beta and gamma parameters were calculated differently 
depending on the distribution. The formulas for making these calculations have been 
fully described by Briggs et al. (2006, pp.87, 91,90). There was little data available to 
provide information on 95% Confident Intervals (CI) and standard deviation of all 
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parameters to use in the PSA. Therefore, when reported, 95% CI and standard deviation, 
was used. However, in cases where only the CI was reported, the standard deviation was 
calculated from the difference range from the interval estimates divided by 2 * 1.96. 
This formula should theoretically be used only for normal distributions, but it has also 
been applied here for non-normal distributions (Briggs et al., 2006). Where data on 
standard deviations or confidence intervals is not available, the common practice in 
regard to the standard deviation is to substitute 1/10th of the mean value for any missing 
value (Fox et al., 2007). Refer to Appendix 5.13 for more details.  
 
5.2.6.2 Cost-effectiveness acceptability curves  
In the updated NICE methods guidance, the use of cost-effectiveness acceptability 
curves (CEACs) is recommended (Claxton, 2005). Therefore, cost-effectiveness 
acceptability curves (CEACs) were derived from the joint distribution of incremental 
costs and incremental effects resulting from comparing each intervention with the base 
case (no intervention). The most common technique for estimating these joint 
distributions is nonparametric bootstrapping of the observed data, although other 
methods are available (Fenwick and Byforf, 2005). In this case, we used the 
bootstrapping technique. CEACs were constructed by recording the number of times 
each alternative was cost effective or calculating the highest Net Benefit from the 
simulated output of a model (Claxton, 2008) for M4 and M5. They show the probability 
that an intervention is likely to be cost-effective compared with the alternative, given 
the observed data, for a range of maximum monetary values that a decision-maker 
might be willing to pay for a particular unit change in outcome (Fenwick and Byforf, 
2005). For each specified value of this “acceptable” cost-effectiveness ratio (a point on 
the x-axis), the CEAC shows the probability that the data is consistent with a true cost-
effectiveness ratio falling below that value (read off the y-axis) (Fenwick and Byforf, 
2005). However, it is important to note that the alternative with the highest probability 
of being cost-effective may not be the most cost-effective alternative (having the highest 
expected net-benefit) (Claxton, 2008). To facilitate the presentation and interpretation of 
the results, only CEACs of the least and most cost-effective smoking cessation 
programmes are presented. In order to facilitate comparison with the results of Flack et 
al. (2007a), the CEACs need to be calculated comparing each alternative with no 
intervention. If the same intervention comes out on top for any simulation, the CEACs 
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will be meaningful. Therefore, to study the probability of NMB having a point estimate 
below a threshold was studied through histograms of NMB. 
                                                                                                                
5.3 Results 
The Markov model outlined in this chapter was evaluated to estimate average lifetime 
costs and QALYs lost. The results are first presented for an adult passive population 
only, and then for a population including both passive adults and children. Table 5.10 
distinguishes between the results generated by M4 (excluding external effects) and M5 
(including external effects). Because the inclusion of external effects does not alter 
policy decisions in regard to the ranking of cost-effectiveness of interventions, the 
results are only presented for no intervention (NI), for an intervention falling in the 
middle of the cost-effectiveness scale (LICB), and for the most cost-effective 
intervention (NPPCBP). The initial intention was to present the results for the least cost-
effective intervention (BA), but because these results were so similar to those for no 
intervention, it was decided that selecting an intervention which fell in the middle of the 
cost-effectiveness ranking (LICB) would better facilitate the presentation of the results.  
 
 Table 5.10  M4 and M5 estimates of average lifetime costs and QALYs lost per adult (cohort of 1000 
adults; > 16 years; lifetime period reaching 100 years; starting distribution: according to prevalence; 
health states: smokers; former smokers; non-passive never-smokers; passive smokers; and death)  
 
M4=M3 incorporating non-smokers in the Markov model, but excluding passive smoking 
M5=M3 incorporating non-smokers in the Markov model, but including passive smoking 
 
In both M4 and M5, NPPCBP, with the highest NMB, is the most cost-effective 
intervention. It is therefore the recommended intervention, whether or not passive 
smoking is included. Model M5 (which includes adult passive smokers) shows that 
external effects are responsible for an extra lifetime cost of £20.19 per adult and 0.0004 
extra lifetime QALYs lost. When external effects are excluded, the NMB value of the 
Interventions Discounted 
average COST 
per adult 
(M4) 
Discounted 
average 
COST per  
adult (M5) 
Discounted 
QALYs lost  
per adult 
(M4) 
Discounted 
QALYs lost  
per adult 
(M5) 
NMB  per 
adult  
(M4) 
NMB  per  
adult (M5) 
NI  3676.48 3708.68 3.3159 3.3165   
LICB 3640.46 3669.19 3.3118 3.3123 117.79 122.49 
NPPCBP  3549.00 3569.19 3.3018 3.3021 409.76 426.04 
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most cost-effective intervention is £409.76; when external effects (i.e. passive smoking) 
are included, this figure rises to £426.04 – a difference of £16.28. Graph 5.1 compares 
the differences in lifetime costs and QALYs when external effects are included and 
excluded. To facilitate the interpretation of the graphical results, QALYs lost were 
converted to lifetime QALYs adjusting for the negative sign.  
 
Graph 5.1 Lifetime costs and lifetime QALYs per adult (M4) and per adult including adult passive 
smokers (M5) 
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When child passive smokers are included, the most cost-effective smoking cessation 
intervention remains unchanged (refer to Table 5.11). Comparing the results from M4 
and M5 (and including both adult and children passive smokers), it emerges that 
external effects are responsible for an extra lifetime cost of £154.08 per adult and 
0.0999 extra lifetime QALYs lost. In this case, when passive smoking among both 
adults and children is taken into account, the NMB of NPPCBP is £2460.12. When 
passive smoking is not accounted for, the NMB for the most cost-effective intervention 
(NPPCBP) drops by £1192.46.  
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Table 5.11  M4 and M5 estimates of average lifetime costs and QALYs lost per adult (cohort of 1000 
adults which includes 96.5% of adult smokers’ children considered as passive smokers; > 16 years + 0-15 
years; lifetime period reaching 100 years; starting distribution: according to prevalence; health states: 
smokers; former smokers; non-passive never-smokers; passive smokers; and death) 
 
M4=M3 incorporating non-smokers in the Markov model, but excluding passive smoking 
M5=M3 incorporating non-smokers in the Markov model, but including passive smoking 
 
The impact of incorporating child passive smokers is seen by comparing Graph 5.1 with 
Graph 5.2. The difference between the least and the most cost-effective interventions is 
much greater when external effects are included.  
 
Graph 5.2 Lifetime costs and lifetime QALYs per adult (M4) and per adult including adult and children 
passive smokers (M5) 
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Interventions Discounted 
average COST 
per  adult 
(M4) 
Discounted 
average 
COST per  
adult (M5) 
Discounted 
QALYs lost  
per  adult 
(M4) 
Discounte
d QALYs 
lost  per  
adult 
(M5) 
NMB  per 
adult 
(M4) 
NMB  per  
adult (M5) 
NI  3713.13 3949.41 3.4592 3.6146   
LICB 3676.16 3892.08 3.4427 3.5820 366.65 708.43 
NPPCBP  3582.76 3736.83 3.4024 3.5022 1267.66 2460.12 
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A univariate sensitivity analysis, consisting on a decrease of background cessation rate 
to 1.2% and costs of interventions equal to zero, was conducted for coherence with the 
sensitivity analysis carried forward by Flack et al. (2007a). In both M4 and M5, these 
assumptions led to the same conclusions as were obtained by the main analysis in both 
adult-only and adult and child scenarios – NPPCBP remained the dominant strategy in 
both cases. Having specified distributions for all the relevant parameters of the model, 
probabilistic analysis was undertaken by randomly sampling from each of the 
parameters` distributions and calculating the expected costs and expected QALYs for 
that combination of parameter values. This process formed a single replication of the 
model results; a total of 1000 replications from the model are presented on the cost-
effectiveness plane in Graph 5.3 (for the model excluding external effects) and Graph 
5.4 (for the model including adult and child passive smokers).  Both graphs indicate that 
higher uncertainty exists around the most cost-effective interventions. 
Graph 5.3 shows the net incremental costs and net incremental effectiveness of LICB 
and NPPCBP compared to no intervention when external effects are included and not 
included. The graph suggests no significant uncertainty associated with the incremental 
cost-effectiveness ratio for LICB (M4), the middle ranking cost-effective intervention, 
whereas for NPPCBP (M4), the most cost-effective intervention, it appears to suggest 
more uncertainty around the cost-effectiveness ratio. This higher uncertainty might be 
explained by the higher effectiveness rate from NPPCBP (M4) and, therefore, higher 
uncertainty introduced in the model, because the standard deviation for the PSA is 
calculated from 10% of the estimated value. For the most cost-effective intervention 
(NPPCBP (M4)), the 95% confident interval (CI) in terms of costs is (-132.70,-128.12), 
whereas for QALYs lost, the 95% CI is (0.0048, 0.1022). 
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Graph 5.3 Monte Carlo simulation results on the cost-effectiveness plane for M4 and M5 
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When adult and children passive smokers are included, the scatter plot of net 
incremental costs and net incremental effectiveness compared to no intervention shows 
a similar level of uncertainty, though the uncertainty around costs slightly increases. 
This might be explained as the result of the incorporation of external effects. Not much 
uncertainty is suggested for LICB EE (M5), but it is for NPPCBP EE (M5) (see Graph 
5.3 for details). In this case, for the most cost-effective intervention, the 95% CI for 
costs is (-215.82, -209.28) and the 95% CI for QALYs lost is (0.0602, 0.1577). The 
pattern of uncertainty around the incremental costs and effects and the level of 
uncertainty seem to be similar whether external effects are included or not, though there 
are differences in terms of both costs and QALYs. The findings suggest that uncertainty 
does not increase massively with the inclusion of external effects. 
Graph 5.4 shows the uncertainty around the NMB of the most cost-effective 
intervention (NPPCBP) with and without passive smoking. Higher uncertainty around 
the NMB estimates is observed in the simulations calculated by the PSA. 
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Graph 5.4 Uncertainty surrounding the NMB of the most cost-effective intervention when impact of 
passive smoking on adults and children is taken into account (NPPCBP EE; M5) and when it is not 
(NPPCBP; M4) 
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Cost-effectiveness acceptability curves (CEAC) were calculated for M4 – excluding 
external effects – and M5 – including them (see Appendix 5.14 for details). However, as 
NPPCBP is so cost-effective and the dominant strategy, these CEACs did not tell us 
much information, so the decision was made to present histograms showing the NMB 
for the most cost-effective intervention instead. Graph 5.5 presents a histogram of the 
distribution of predicted NMB results.  The median (IQ range) NMB was estimated at 
around £1250 per QALY. Overall, 90% of the NMB estimates have a point estimate 
below £2000. 
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Graph 5.5 Distribution of predicted NMB for NPPCBP at M4 
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However, when the impact of passive smoking on adults and children is incorporated 
into the economic evaluation (see Graph 5.6), the median (IQ range) NMB increases to 
approximately £2500.  90% of the estimates were estimated to have a point estimate of 
NMB below £3250. Thus, the NMB rises when external effects are included.  
 
Graph 5.6 Distribution of predicted NMB for NPPCBP EE at M5 
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Graph 5.7 shows that, as far as the most cost-effective intervention was concerned, 
around 250 iterations were required to achieve stable results from the model when 
external effects were excluded. When external effects were included, results became 
stable after about same iterations. The results in both scenarios may therefore be 
considered robust. 
 
Graph 5.7 Cumulative average NMB for LICB and NPPCBP in M4 and M5 
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5.4 Discussion  
This chapter incorporates passive smoking into the economic evaluation of smoking 
cessation interventions. Attempts in previous studies have been made to value passive 
smoking, but none of this work has so far been incorporated into economic evaluation 
modelling (Sloan et al., 2004). The findings of this chapter, apart from the methods to 
incorporate of external effects, are of value - assessing whether the incorporation of 
external effects into cost-effectiveness of interventions might change policy decisions. 
This chapter also provides insights into the uncertainty which surrounds the parameters 
driving the model, and the difficulty of estimating the impact of passive smoking on 
society. 
The systematic literature reviews show that passive smoking can be measured in adults 
by the occurrence of episodes of lung cancer and coronary heart disease, and in children 
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by episodes of asthma, wheeze, cough, otitis media with effusion, and acute otitis 
media.  Other health effects caused by passive smoking which are cited in the literature, 
such as increased risk among children of pulmonary tuberculosis, are not yet supported 
by epidemiological evidence. 
In terms of results, the changes made to the model (see Chapter 4, Section 3) mean a 
straightforward comparison with Flack’s results (2007) is not possible. However, 
notwithstanding these changes, the results do accord with those of Flack et al.: the 
intervention composed of nicotine patch, pharmacist consultation and comprehensive 
behavioural programme (NPPCBP) is the most cost-effective smoking cessation 
intervention. Other barriers to direct comparison are the change in result unit from total 
lifetime QALYs to total QALYs lost; and the change in population (the addition of 
96.5% of adult smokers’ children to account for child passive smokers in the model). 
When the economic evaluations of the chosen public smoking interventions were 
compared, the inclusion or otherwise of external effects made no difference to the cost-
effectiveness rankings. This was to be expected, since the incorporation of external 
effects introduces a multiplicative effect on costs and QALYs. Although a difference 
exists in terms of the magnitude of the ICER, the incremental cost-effectiveness ratios 
generated by smoking cessation interventions are typically well below the sort of 
thresholds used by NICE for technology appraisals. It is thus almost axiomatic that all 
the interventions people consider are cost-effective. 
Adult passive smokers are responsible for an extra lifetime cost of £20.19 per adult and 
0.0004 extra lifetime QALYs lost in the model, whereas adult and child passive 
smokers combined are responsible for an extra lifetime cost of £154.08 and 0.0999 extra 
lifetime QALYs lost per adult. In other words, the biggest impact into economic 
evaluation, in terms of costs and QALYs lost, relies on children passive smoking. 
Univariate and probabilistic sensitivity analyses were conducted to study the robustness 
of the results. The areas of uncertainty in this assessment were background cessation 
rates and the cost of interventions; for consistency`s sake, these were examined 
according to Flack’s (2007a) criteria. No differences were noted when the uncertainty 
around these parameters was studied. Other uncertainties noted in relation to the model 
presented in this chapter were: intervention quit rate; relative risk of different illnesses 
for passive smokers; incidence of smoking; and cost and utilities of illness episodes. 
Although uncertainty was present, the probabilistic sensitivity analysis strongly 
104 
 
supports the results derived from the base model, although the level of uncertainty 
appears to be wider, the more cost-effective the intervention. This seems to be coherent, 
because the probabilistic analysis is based on the standard deviations calculated from a 
10% of the effectiveness rate. It appears that the more effective the intervention, the 
higher the effectiveness rate and the higher the standard deviation, leading to higher 
variability in the model. When external effects are incorporated, costs and health effects 
shift down and to the right on the graph as additional costs and QALYs lost are 
incurred. Therefore there is a movement in costs and QALYs lost across the graph. The 
size of these differences could be due to the uncertainty surrounding the incidence rate. 
This is an important parameter as it significantly influences the number of smokers in 
the model. Additional checks were conducted on the variability of this parameter, and 
results were highly sensible to its variability. Cost-effectiveness acceptability curves 
show that when external effects are incorporated into the economic evaluation, the least 
cost-effective interventions become even less so, while the most cost-effective 
programmes seem to become more cost-effective. In smoking cessation programmes 
does not change policy making decision, but in other scenarios, with less cost-effective 
programmes, this could potentially change all policy decisions taken so far.  
Regarding the data on prevalence used in the model, self reported measures of second-
hand exposure have several important limitations – i.e living with a smoker captures 
less than half of the variation in nicotine concentration in never-smokers (Breteler et al., 
1994) and does not take into account exposure in workplaces and public places 
(Llewellyn et al., 2009). 
One of the most relevant parameters of this model, as discussed, is the incidence or 
uptake rate of smoking. This parameter was a proxy, constructed from data drawn from 
the General Household Survey (2006). The most important assumption made was that 
this database was based on a consistent population and that across the years the smoking 
uptake rates have not varied. In the survey, people were asked at what age they started 
smoking. The problem, however, is that uptake rates and patterns are likely to have 
changed since NHS smoking cessation interventions began. Moreover, the population 
itself may have changed over time: the number of missing observations may have gone 
up or down, and the starting age for smoking may have altered. It was intended to track 
individuals across time, but no data was available for doing so. Household identification 
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codes were different for each survey wave. The validity and generalisability of the 
quitting and relapse rate in the model are also a limitation. 
Changes in effectiveness rates could be discussed in terms of the different nature of the 
trials, related to the different structure of the randomised controlled trials or on the 
design of the trial, in calculating varying effectiveness for each different intervention. 
But this is outside the scope of this thesis. 
Indirect benefits to the family members of successful quitters, especially children, are 
widely accepted as probable outcomes of individuals quitting. However, these potential 
benefits are somewhat difficult to quantify (Wang et al., 2008). Similarly, potential 
benefits for society in general through avoidance of passive smoking and unwelcome 
exposure to cigarette smoke may also accrue (Wang et al., 2008), but this is out of the 
scope of this thesis. 
An additional question to better explore uncertainty would be whether further evidence 
is required to support decision-making about smoking interventions in the future. 
Decisions based on existing information will be uncertain, and there will always be a 
chance of making the “wrong” decision (Briggs et al., 2006). Although we may make 
the correct decision now based on our current estimate of expected net-benefit, there is a 
chance that another alternative might have higher net-benefit once our current 
uncertainties are resolved (Briggs et al., 2006). If a decision based on current 
information turns out to be “wrong”, there will be costs in terms of health benefits and 
resources forgone (Briggs et al., 2006). Although this is beyond the scope of this thesis, 
further research into the Value of Information would be useful; such analysis might 
make it possible to calculate the maximum that the health care system should be willing 
to pay for additional evidence to inform decisions about smoking interventions in the 
future, and it would place an upper bound on the value of conducting further research.  
However, my figures suggest that the Value of Information (VOI) may in practice be 
low; uncertainty does not significantly alter policy as most smoking cessation 
programmes are recognised as generally cost-effective. 
One important limitation of this analysis is that current smokers and former smokers 
who also consider themselves to be passive smokers are not considered. On the other 
hand, this avoids the misclassification of current smokers as non-smokers; only those 
who have never smoked are classified as passive smokers. This avoids any confusion 
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between active and passive smoking. Further research could explore the impact of 
incorporating into the model all those people who consider themselves passive smokers. 
The study only counts those children exposed to ETS at home as passive smokers. This 
seems to be an appropriate assumption in current times, given that it has been forbidden 
to smoke in public places since July 1st 2007, and the home is the site where young 
children are most exposed to ETS (Brown, 2001). However, as the data source is the 
HSE of 2006, the burden of passive smokers may have been underestimated. 
The next chapter incorporates into the model the effects on babies of smoking during 
pregnancy. It will illustrate the importance of including a second external effect in the 
economic evaluation of smoking cessation programmes.   
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CHAPTER 6 Economic Evaluation of Smoking Cessation 
 Interventions: accounting for smoking during 
 pregnancy 
 
6.1 Introduction 
Chapter 5 evaluated the introduction of passive smoking into an economic evaluation of 
smoking cessation interventions. The aim of this chapter is to incorporate the impact of 
smoking during pregnancy on babies’ first year of life. The specific objectives are: (a) 
by means of a systematic literature review, to identify the main health effects in babies’ 
first year of life caused by mothers smoking during pregnancy; (b) by means of a 
systematic literature review, to explore the prevalence, costs, and utilities for babies’ 
first year of life; (c) to explore the incidence, mortality, prevalence and sources of 
effectiveness used in this particular model; (d) to take an existing economic evaluation 
tool, designed to assess the cost effectiveness of interventions for reducing smoking 
during pregnancy, and adapt it to calculate the average extra lifetime costs and QALYs 
lost in babies’ first year of life as a result of smoking during pregnancy; (e) to present 
and discuss the results produced by the model; and (f) to demonstrate the differences in 
lifetime costs and QALYs lost when this external effect is incorporated, considering the 
reasons for these differences. 
 
6.2 Methods 
This section discusses: (a) how the two literature reviews on health effects and 
prevalence, costs and utilities were conducted, including the search strategy, selection 
criteria, and data extraction strategy; (b) the parameters used in the model; and (c) how 
the structure of the existing economic evaluation tool (assessing smoking cessation 
programmes for pregnant women) was adapted to incorporate the health effects of 
smoking during pregnancy. 
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6.2.1 Model parameters 
In order to run the model a number of key input parameters were required: incidence; 
mortality; quit and relapse rates; prevalence of different smoking states; effectiveness; 
and prevalence, costs and QALYs associated with passive smoking. These relate 
primarily to the transition probabilities, and the costs and utilities required to calculate 
the model cost-utility outputs. Some of the model states (smokers, former smokers, non-
passive never-smokers and passive smokers) have an associated utility and cost, and 
some of the model transitions have a cost. Transition probabilities were assigned to each 
of the transitions (indicated by the arrows in Figure 6.1). The data values for these 
parameters were obtained from a variety of sources which are described in the following 
sections. 
 
Systematic reviews investigating health effects due to smoking during pregnancy 
The aim of these systematic literature reviews was to ascertain from the perspective of 
the UK NHS which health effects experienced by pregnant women and babies in their 
first year are most likely to be associated with smoking during pregnancy. This question 
was addressed by systematically identifying those papers which describe the health 
effects on pregnant women and babies in their first year associated with smoking during 
pregnancy, assessing the quality of these papers and reviewing and summarising the 
relevant evidence. Two discrete reviews were undertaken; one focused on health effects 
on babies in their first year, and the other focused on health effects on women.  
The first literature review formed part of the systematic literature review which 
investigated the health effects of passive smoking on children (see Clinical implications 
of passive smoking for children, Section 5.2.1; Chapter 5). The literature review 
indicated that, according to existing evidence, the only health effects of smoking during 
pregnancy on babies’ first year of life are low birth weight and sudden infant death (see 
Table 6.1 below for findings). For the odds ratio of low birth weight, the lowest 
differential effect (i.e. estimate with lower confident interval) was adopted, introducing 
in the model the estimate with lower uncertainty. 
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Table 6.1 Summary of characteristics, data and odds ratios presented in included studies investigating 
health effects for babies in their first year of life associated with smoking during pregnancy  
Author, year Health effect N studies Type of 
data45 
Estimated 
value 
Adjusted 
estimate 
95% CI 
Studies identified       
Leonardi-Bee et al. 2008 Low birth weight 26 OR46 
OR47 
1.32 
1.22 
not stated 1.07 to 1.63 
1.08 to 1.37 
Cook and Strachan 199948 Sudden infant death 18 OR 2.13 adjusted 1.86 to 2.43 
Parameter value used in 
model 
      
Leonardi-Bee et al. 2008 Low birth weight 26 OR49 1.22 not stated 1.08 to 1.37 
Cook and Strachan 199950 Sudden infant death 18 OR 2.13 adjusted 1.86 to 2.43 
OR: odds ratio of health effect associated with exposure to environmental tobacco smoke due to maternal smoking during 
pregnancy compared to having non-smoking mother. 
 
The second literature review, exploring the clinical implications of smoking during 
pregnancy for women, yielded 4051 “hits”. Details of this systematic literature review 
are shown in Appendices 6.1 and 6.2. Two studies were excluded for reasons of 
duplication. After a detailed review of titles and abstracts, only one paper met the 
inclusion criteria (US Department of Health, 2004).  
The aim of this report, from the Surgeon General’s Advisory Committee on Smoking 
and Health in the USA, was to evaluate all available scientific evidence to determine 
whether smoking causes disease. The report identified all the relevant data, evaluated 
and summarised the evidence and applied the criteria for causal inference to determine 
whether the weight of the evidence supported a definitive conclusion. Chapter 5 of the 
report reviews the evidence for a relationship between smoking and adverse 
reproductive effects. In particular, it examines the associations between smoking and 
fertility, smoking and pregnancy complications, and the health of children born to 
smokers. The 1978 Surgeon General’s report (US Department of Health and Human 
Services, 1978) introduced new findings concerning smoking and pregnancy 
complications including placental abruption, placenta praevia, and the premature 
                                                 
45
 RR: relative risk (defined as the ratio of the chance of a disease developing among members of a population exposed to a factor 
compared with a similar population not exposed to the factor (medical dictionary, 2011 <http://medical-
dictionary.thefreedictionary.com>); OR: odds ratio (this ratio estimates the chances of a particular event occurring in one population 
in relation to its rate of occurrence in another population (medical dictionary, 2011 <http://medical-
dictionary.thefreedictionary.com>). 
46
 Maternal exposure to ETS during pregnancy (birth weight <2500g; prospective studies). 
47
 Maternal exposure to ETS during pregnancy (birth weight <2500g; retrospective studies). 
48
 The ORs reported in this paper are calculated on the assumption that either parent smokes at home, except in the case of sudden 
infant death, when only the mother`s smoking is considered. 
49
 Maternal exposure to ETS during pregnancy (birth weight <2500g; retrospective studies). 
50
 The ORs reported in this paper are calculated on the assumption that either parent smokes at home, except in the case of sudden 
infant death, when only the mother`s smoking is considered. 
 
110 
 
rupture of membranes. The 1980 report on the health consequences of smoking for 
women (US Department of Health and Human Services, 1980) went further in its 
assertion of the effects of smoking on the placenta. This report also introduced new 
information on smoking risks. It found the evidence to be suggestive but not sufficient 
to infer a causal relationship between maternal active smoking and ectopic pregnancy. 
However, for placenta praevia51, placental abruption52 and pre-eclampsia53 it found 
there was sufficient evidence to infer a causal relationship (see Table 6.2). Flack et al. 
(2007a) did additional analysis to investigate the impact of smoking cessation 
interventions on pregnant women in terms of the costs and QALY implications, using 
the economic model in Flack et al. (2007). In their report (2007a), they identified the 
same clinical implications for women of smoking during pregnancy, apart from ectopic 
pregnancy.  
 
Table 6.2 Summary of risk data for pregnant women who smoke 
Author (year) 
 
Health effect N studies Type of 
data54 
Estimated 
value 
Adjusted 
estimate 
95% CI 
Studies identified       
US Department of 
Health (2004) 
Placenta praevia 
 
- OR 2.3 - 1.3 to 4.4 
US Department of 
Health (2004) 
Placenta 
abruption 
- OR  - 1.4 to 2.4 
US Department of 
Health (2004) 
Pre-eclampsia - OR  - 0.45 to 0.71 
Parameter value used in model  
- - - - - - - 
 
Placenta praevia has been consistently found to occur more frequently in smokers than 
in non-smokers, with one report estimating an odds ratio value of around 2.3. Only a 
pooled estimate value was encountered for placenta praevia. The other health effects 
were reported by means of adjusted odds ratios. Although this made it possible to 
calculate a mid-point estimate which would have enabled these health effects to be 
                                                 
51
 Placenta praevia occurs when the maturing placenta is close to the cervical os or completely obstructs the os (US Department of 
Health, 2004). 
52
 Placental abruption occurs when the normally implanted placenta prematurely separates from the wall of the uterus. It is 
associated with high rates of preterm deliveries, stillbirths, and early infant deaths. 
53
 Pre-eclampsia is a hypertensive disorder developed during pregnancy with proteinuria and edema. 
54
 RR: relative risk (defined as the ratio of the chance of a disease developing among members of a population exposed to a factor 
compared with a similar population not exposed to the factor (medical dictionary, 2011 <http://medical-
dictionary.thefreedictionary.com>); OR: odds ratio (this ratio estimates the chances of a particular event occurring in one population 
in relation to its rate of occurrence in another population (medical dictionary, 2011 <http://medical-
dictionary.thefreedictionary.com>). 
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incorporated into the model, they were ultimately excluded because of the lack of data 
on the costs and utilities of these health effects on women. 
 
Systematic review investigating prevalence, costs and utilities of health effects 
associated with passive smoking on infants in their first year of life  
In order to incorporate the external effect smoking during pregnancy into the model, 
prevalence, cost and utility data were required. Each disease associated with women and 
first year babies (i.e. ectopic pregnancy, low birth weight, etc.) has an associated utility, 
cost and prevalence. The prevalence data was adjusted according to the procedure 
detailed in Sections 4.1.4.1 and 4.1.4.2, in chapter 4, of this thesis.  
A number of criteria were applied where potentially useful data was identified in 
multiple sources. First, consistent with the previous systematic literature reviews, meta-
analyses or pooled estimates for health effects and mortality data associated with 
passive smoking were given preference. Meta-analysis carried out in the UK setting was 
prioritised over other settings as this is the context of the current analysis. Second, 
priority was given to estimates used in HTA or NICE reports, as these inform NICE 
policy making. Third, estimates from credible sources such as national statistics 
institutions were preferred, followed by estimates calculated for the UK setting. 
However, for data on the costs associated with low birth weight, the most important 
consideration was to find estimates which were appropriate to child weight. Mrs Hema 
Mistry, author of one of the papers on the costs associated with low birth weight first 
year babies, suggested that it was appropriate to look for cost estimates from the 
European context55 for first year babies weighing between 2250 and 2500 grams. 
Anything below this is now considered extremely low weight, and cost estimates in this 
bracket are generally less realistic than those calculated for average cases of low birth 
weight. Finally, preference was given to the most conservative estimate.  
The search strategy for prevalence studies yielded 300 citations. Following a review of 
the titles and abstracts, 281 potentially met the review’s inclusion criteria. Of these, 21 
reported data of interest (see Appendices 6.3, 6.4 and 6.5 for more details on the study 
selection process and included references). The findings are summarised below. 
                                                 
55
 All US estimates are in a very different context. 
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Prevalence 
Six studies out of 21 reported data on the prevalence of illnesses related to smoking 
during pregnancy (see Table 6.3). 
 
Table 6.3 Summary of characteristics and data related to prevalence of health effects caused by smoking 
during pregnancy on the health of women and infants in their first year 
Author, year Health effect Sample Country Estimated 
annual 
prevalence56 
95% 
CI 
Studies identified  
Petrou (2003) LBW (<2500grams) - UK 7.28% - 
Walker (2000) Pre-eclampsia - UK 40%57 - 
Meads et al. 
(2008) 
Pre-eclampsia - - 4.7%58 4.3-5.3 
Simon et al. 
(2005) 
Pre-eclampsia - - 2-8% - 
Dattani and 
Cooper (2000) 
SIDS - UK 3.7% - 
Messer (2009) SIDS (under one year after 
live birth) 
- UK 2.8%59 - 
Parameter value used in the model 
Petrou (2003) LBW (<2500grams) - UK 7.28% - 
Messer (2009) SIDS (under one year after 
live birth) 
- UK 2.8% - 
 
No data was found on placenta praevia or placental abruption. There was only one 
estimate for prevalence of low birth weight. For SIDS, the estimate of 2.8% was 
selected because, in accordance with the selection criteria, it was the most conservative 
estimate. Also in line with the selection criteria, the estimate chosen for prevalence of 
pre-eclampsia was the one from the UK (Walker, 2000).  
                                                 
56
 Estimated annual prevalence of liveborn babies 
57
 This estimate is reported by the author referencing one study from 1982. 
58
 Considering medium risk women. 
59
 In terms of infants deaths, the estimate includes both  neonatal and post-neonatal deaths. 
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Costs 
Fifteen studies out of 21 reported data on the costs of treatment of illnesses related to 
smoking during pregnancy. Table 6.4 shows details of this data.  
 
Table 6.4 Summary of characteristics and data related to costs of treatment of pregnant women and first 
year babies 
Author, year Health effect Sample Country Annual 
cost 
95% CI Currency/ 
year 
Studies identified       
Boyle et al. (1983) LBW 
(500-999 grams) 
(1000-1499 
grams) 
 
265 
98 
 
Canada 
 
13600 
14200 
- Canadian 
$/1978 
Gorsky and Colby 
(1984) 
LBW  
(1500-
2499grams) 
- US 1967160 - $/1984 
Herdman et al. 
(1987) 
LBW 
(<2500grams) 
- US 31000-
71000 
- $/198761 
Lewit  et al. (1995) LBW 
(1000-
2500grams) 
- US 11900 - $/1988 
McCormick et al. 
(1991) 
LBW 
(< 1500 grams) 
 
32 
US 10139 - $/1984 
Mistry et al. (2009) LBW 
(1000-
1499grams) 
(<1000grams) 
199 UK  
18817 
2681562 
- £/2004- 
2005 
Orme et al. (2000) LBW - UK 14790.52
63
 
- £/1999 
Petrou (2003) LBW 
(<1500 grams) 
(1000-1499 
grams) 
(<1000 grams) 
 
- 
- 
- 
UK  
9207 
22541 
39483 
 
4295-
14119 
14780-
30302 
30466-
48500 
£/1998 
Ringborg et al. 
(2006) 
LBW 
(2250-2499 
grams) 
(2000-2249 
grams) 
(1750-1999 
grams) 
(1500-1749 
grams) 
(1250-1499 
grams) 
(1000-1249 
grams) 
(750-999 grams) 
(500-749 grams) 
(<500 grams) 
 
 
1529 
1247 
790 
577 
459 
338 
303 
140 
13 
Sweden  
12900 
14463 
17330 
21501 
25838 
38190 
58959 
74264 
77677 
 
- 
- 
- 
- 
- 
- 
- 
- 
- 
€/2000 
Rogowski (1998) LBW  US  - $/1987 
                                                 
60
 This cost comprised: initial hospitalisation costs, rehospitalisation costs and long-term morbidity costs. 
61
 Publication year 
62
 Both costs are calculated for Level 3 care, including ambulance transfers. Excluding ambulance transfers, the cost would be 
£12325 for first year babies 1000-1400grams, and £19558 for first year babies <1000grams. 
63
 Total cost of treating smoking-related disease in the first year (health care cost). 
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Author, year Health effect Sample Country Annual 
cost 
95% CI Currency/ 
year 
(<1000 grams) 
(1000-1249 
grams) 
(1250-1499 
grams) 
 
887 58900 
55800 
44100 
Russell et al. (2007a) LBW 384200 US 1510064 13300-
16800 
$/2001 
Schmitt et al. (2006) LBW 
 (2000-2499 
grams) 
(1750-1999 
grams) 
(1500-1749 
grams) 
(1250-1499 
grams) 
(1000-1249 
grams) 
(750-999 grams) 
(500-749 grams) 
(<500 grams) 
 
 
16806 
3117 
1974 
1352 
1050 
913 
667 
107 
US  
8987 
27545 
44992 
69799 
118816 
193833 
220802 
127785 
 
- 
- 
- 
- 
- 
- 
- 
- 
$/2000 
Walker et al. (1985) LBW 
(<1500 grams) 
 
273 
Rhode 
Island 
 
4092 
- $/1982 
Wu et al. (2006) placental 
abruption 
- - 659.24 - £/2002 
 
Meads et al. (2008) pre-eclampsia - - 9009 - £/200565 
Wu et al. (2006) pre-eclampsia66 - - 2211 - £/2002 
Parameter value used in the model 
Ringborg et al. 
(2006) 
LBW 
(2250-2499 
grams) 
1529 Sweden 12900 - €/2000 
 
There were a number of estimates for LBW, most of them using different weights as 
benchmarks. Low birth weight is defined by the World Health Organisation as anything 
less than 2500 grams (NHS, 2008). As specified in the selection criteria discussed 
earlier, first year babies weighing less than 2250 grams are now generally considered 
severely low weight. As cost estimates calculated for children between 2250 grams and 
2500 grams are more reliable than those for babies at the extreme low end of the weight 
scale, the decision was made to adopt the estimate given by Ringborg et al. (2006). No 
estimates for placenta praevia were found. Only one estimate for placental abruption 
was found, which was the one used. The most conservative estimate for pre-eclampsia 
was used, according to the selection criteria established. The annual cost assigned to 
SIDS was assumed to be zero, as the cost of an infant death to the NHS is very low. 
                                                 
64
 Preterm infant hospitalisation costs. 
65
 This cost from Simon et al. (2006) was converted from US$ 2001 to UK£ inflated to 2004-5 costs.  
66
 This cost includes all costs related to management of severe pre-eclampsia (inpatient stay, consultant visits, drugs, etc). The 
estimate for management costs for mild pre-eclampsia is taken as the lower limit for the confident interval. 
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This assumption is consistent with no NHS costs assumed for any death occurring in the 
Markov model due to smoking habits. 
 
Utility 
Of the 21 studies, three reported data on utilities (see Table 6.5 for details). In 
accordance with the selection criteria, the most conservative estimate for low birth 
weight was used (Moya and Goldberg, 2002). Table 6.5 shows that no estimates exist 
for health effects on pregnant smokers (i.e. placenta praevia, placental abruption and 
pre-eclampsia). Flack et al. (2007a) also found this. A value of full life (utility equal to 
one) was used when SIDS occurred, to calculate QALYs lost. 
 
Table 6.5 Summary of characteristics and data relating to utilities of health effects on pregnant women 
and babies in their first year of life 
Author, year Health effect Sample Estimated 
value 
95% CI Instrument 
Studies identified 
Tengs and 
Wallace (2000) 
LWB - 0.75 - - 
Petrou et al. 
2009 
LBW 190 0.789  Health Utilities Index 
Mark III 
Moya and 
Goldberg 
(2002) 
LBW 
(<1500grams) 
- 0.85 - Expert judgement 
Parameter value used in the model 
Moya and 
Goldberg 
(2002) 
LBW 
(<1500grams) 
- 0.85 - Expert judgement 
 
In summary, the model could not ultimately include any health effect on pregnant 
women, given the lack of data on prevalence, costs or utilities. Only the external effects 
of maternal smoking on babies’ first year of life were measured and included. The life 
expectancy of an infant under one year, 71.99 years, was used to estimate the lost 
lifetime from deaths of babies during the first year of life from smokers during 
pregnancy (ONS, 2010). This lost lifetime was discounted according to the six-month 
cycle used in the model. 
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Uptake of smoking (incidence) 
Data on the incidence of smoking was assumed to be the same as that reported and 
calculated in M4 and M5 for women aged 16 to 44.5 years (see Section 5.2.1 in Chapter 
5 for details). 
 
Mortality 
Mortality was handled as reported in Section 5.2.1 in Chapter 5 for women from 16 to 
44.5 years.   
 
Prevalence 
At the start of the model, for each of the four smoking categories, the age and gender-
specific prevalence of smoking status was applied to mirror the known prevalence of 
these states in the English population. The prevalence rates for smoking pregnant 
women were taken from the Health Survey for England (2006), as described in Chapter 
5. From the survey it was possible directly to obtain data describing pregnant women by 
age group and smoking status.  
Those whose cigarette smoking status was “never smoked cigarettes at all” were classed 
as non-smokers, whereas those who said they “used to smoke cigarettes occasionally” 
or “used to smoke cigarettes regularly” were classified as former smokers. 11.21% 
(n=2) of answers in the HSE were missing and therefore not considered. 
The prevalence data on pregnant smokers used in the model is reported in Table 6.6, 
which shows that pregnant women under 24 years had the highest prevalence smoking 
rate. More detailed data from the HSE 2006 is available at Appendix 6.6. 
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      Table 6.6 Prevalence of smoking status among pregnant women (aged 16 to 44.5 years) 
Age  Current 
smoker (S) 
Former (F) Non-passivenon-
never smokers 
(NPNS) 
Passive never-
smokers (PNS) 
16-24 0.37 0.16 0.41 0.06 
25-34 0.10 0.31 0.55 0.04 
35-44 0.11 0.21 0.65 0.04 
 
To calculate the average number of babies delivered per pregnancy in the UK setting, 
the Office for National Statistics, the Northern Ireland Statistics and Research Agency, 
and the National Services Scotland were consulted to obtain separate data for England, 
Ireland and Scotland, before calculating a total average for the UK. The most recent 
data was from 2007, and it was assumed to have remained unchanged in 2010. The 
results from this data are shown in Appendix 6.7.  
 
Sources of effectiveness: quit and relapse rates 
Table 6.7 shows differences in sources of effectiveness between models M1 to M5 and 
M6 and M7, the models introduced in this chapter. 
 
Table 6.7 Summary of differences between M1-M5 and M6-M7 
Models Parameters related to effectiveness 
Background quit rate Relapse rate Interventions 
M1-M5 2% 21% General population interventions 
M6-M7 Overall weighted mean background 
quit rate (first two cycles) and 2% 
(rest of cycles) 
70%  Specific interventions for pregnant women 
 
Each estimate for the quit rate of a particular intervention was calculated and compared 
to the particular background cessation rate in the trial where the intervention was taking 
place. Calculation of an overall weighted mean relapse rate was carried out using the 
methods developed by Bland and Kerry (1998). Initially, the background cessation rate 
118 
 
calculated for each individual trial was used, but after the intervention had occurred, the 
general background cessation rate of 2% was applied. In the first cycle, the last six 
months of the pregnancy, the during-pregnancy quitting rates were used, whereas in the 
second cycle, cessation rates immediately after pregnancy were considered. This data 
was adapted from Flack et al. (2007a), who did a specific literature review to obtain it. 
No relapse was assumed where there was no intervention – the background quit rate was 
applied here – while between months six and twelve it was assumed that all 
interventions had a 70% relapse rate. According to Flack et al. (2007a), their 
communication with Peter Hajek suggested that 70% of pregnant women who stop 
smoking will relapse within a year. A review of the NHS database was conducted to 
corroborate this estimate, and the findings indicate that the relapse rates range from 70% 
to 85% among women who smoke but quit at some time during their pregnancy (Fang 
et al., 2004). Thus, the 70% used in the model is a conservative estimate. After 12 
months everything reverted back to background cessation rates.  
Public health interventions to stop smoking among pregnant women differ from general 
population smoking cessation programmes. The interventions modelled for pregnant 
women were: midwife brief advice (MBA); computer counselling (CC); health 
education methods (HEM); proactive calls worst case (PCW); proactive calls best case 
(PCB); nicotine replacement therapy (NRT); peer counselling (PC); proactive calls, 
educational booklet, counselling and education interventions concerning nicotine 
fading, relaxation and social support at delivery (BD); and proactive calls, educational 
booklet, counselling and education interventions concerning nicotine fading, relaxation 
and social support two weeks after delivery (BAD). See Table 6.8 for further details. 
These interventions, which particularly focus on reducing smoking among pregnant 
women, are different from those evaluated so far in M2, M3, M4 and M5, which focus 
on the adult general population (see Section 4.1.6, Chapter 4). 
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Table 6.8 Background and intervention pregnancy and post-pregnancy quit rates 
Intervention Cessation rate during 
pregnancy 
Cessation rate immediately 
after pregnancy 
Source 
Background 
rate 
Intervention 
rate 
Background 
rate 
Intervention 
rate 
Studies identified and parameter values used in model 
MBA 11.40% 11.60% 11.40% 11.60% Hajek et al. (2001) 
CC 1.70% 5.70% 3.50% 8.10% Lawrence et al. 
(2003) 
HEM 2.00% 16.00% 6.00% 13.00% Walsh et al. (1997) 
PCW 14.90% 18.20% 14.90% 18.20% Solomon et al. 
(2000) 
PCB 14.90% 18.20% 14.90% 18.20% Solomon et al. 
(2000) 
NRT 25.00% 28.00% 18.00% 21.00% Kapur et al. (2001) 
and Wisborg et al. 
(2000) 
PC 21.00% 24.00% 21.00% 24.00% Malchodi et al. 
(2003) 
BD 90.00% 61.00% 90.00% 61.00% Buchanan 2002 
BAD 80.00% 52.00% 80.00% 52.00% Buchanan 2002 
      
      Note: There was no need to temporarily adjust these cessation rates because they occurred during the pregnancy, that is, in a 6 
month cycle. 
 
6.2.2 Economic model 
The aim of this analysis was to determine, using a Markov decision model, the relative 
cost-utility of different smoking cessation interventions identified by the NICE report 
(Flack et al., 2007a) on the health effects of smoking during pregnancy. The population 
examined here is a cohort of 1000 pregnant women, who were classified according to 
their smoking status. The impact of maternal smoking during pregnancy on first year 
babies was measured, as were the health effects of smoking on pregnant women. 
Therefore, when the external effect was incorporated in the model the population of the 
model increased in average number of babies per delivery per smoker.  
A Markov (state transition) model was developed in Microsoft EXCEL (Microsoft 
Corporation). The structure of the model was adapted from that of the model detailed in 
Chapter 5 of this thesis, and informed by current research literature and expert opinion. 
Apart from the population, which differs from that used in M1-M5, the models used in 
this chapter (M6 and M7) also differ from M3 in the addition of two new health states to 
the model structure: like M4 and M5, the models in this chapter also include non-
passive never-smokers and passive smokers (M3 only considered smokers, former 
smokers and death health states). The difference between M6 and M7 lies in the 
incorporation of external effects. M6 does not incorporate smoking during pregnancy, 
whereas M7 does. See Table 6.9 for details. 
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Table 6.9 Summary of differences between M3, M6 and M7 
Models Starting population in Markov model Incorporation of 
health effects of 
smoking during 
pregnancy on women 
and babies’ first year 
of life 
Pregnant 
smokers 
Pregnant 
former 
smokers 
Pregnant 
non-
passive 
never- 
smokers 
Pregnant 
passive  
never-
smokers 
Death 
M3 x x x x √ x 
M6 √ √ √ √ √ x 
M7 √ √ √ √ √ √ 
√≡ included in the model 
x≡ not included in the model 
 
To value the impact of smoking during pregnancy on babies’ first year of life, the 
number of babies’ first year of life depended on the number of pregnant smokers by age 
from the Markov model. The analysis adopted the same perspective and cycle length as 
M4 and M5 (see Section 5.2.2 in Chapter 5 for details). 
The model estimates67: (a) the impact on average lifetime costs due to smoking during 
pregnancy (£ 2010); and (b) quality-adjusted life-years (QALYs) lost to pregnant 
women and first year babies due to smoking during pregnancy. The estimates were 
finally adjusted according to the distribution of probability of being pregnant according 
to age (ONS, 2009). As stated earlier (see Section 6.2.1), the effectiveness outputs again 
differ from those calculated and obtained in M2 and M3 (see Section 5.2.2, Chapter 5 
for discussion of how they differ in M4 to M11). 
 
Model structure 
Within the Markov state transition model, pregnant women reside in one of five discrete 
health states. At regular time intervals (the model cycle) pregnant women make at most 
one transition between states. During each cycle, all pregnant women must be in one of 
the health states in the model. The probabilities attached to each transition between 
model cycles are based on the data used in Flack et al’s (2007a) report and, where new 
                                                 
67
 To facilitate presentation and interpretation, only the results for the least and most cost-effective smoking cessation programmes 
are presented. 
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data was needed (i.e. costs or utilities of health effects of smoking during pregnancy on 
women and first year babies), systematic literature reviews were carried out. 
A structure diagram of the model is shown in Figure 6.1.  
 
Figure 6.1 Structure diagram of smoking cessation interventions aimed at pregnant women aged 16 to 
44.5 
 
 
Passive smoking and non-passive never-smoking pregnant women68 were included in 
the model, along with pregnant smokers, pregnant former smokers and the death state. 
This was done in order to introduce the health effects of smoking during pregnancy into 
the model. Women entered the model in their third month of pregnancy. In the first 
cycle of the model, women were pregnant; when they started the second cycle they were 
post-partum. From the second cycle onwards, women were deemed to have exited 
pregnancy and they were treated as female adults (see M4 and M5). The health effects 
on babies in their first year of life are a function of the pregnant smokers’ cohort. 
                                                 
68
 The starting distribution of the cohort of pregnant women was calculated using prevalence data. The model covers pregnant 
smokers, pregnant former smokers, pregnant passive smokers and pregnant non-exposed non- smokers in order to maintain the same 
structure as previous models (M4 and M5). 
Pregnant 
NPNS 
Pregnant PS 
Pregnant S 
Death 
Pregnant 
Former 
Smokers 
Average 
babies 
delivered per 
pregnancy 
quit 
quit 
relapse 
relapse 
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Although Flack et al. (2007a) argued that the impact on babies of smoking during 
pregnancy should be studied over the first five years of life69, no evidence could be 
found regarding the costs and utilities associated with low birth weight and SIDS for 
such a period. For this reason, only the utility and of life-years lost from SIDS occurring 
in the first year were taken into account.  
 
6.2.3 Time horizon 
The time horizon of the model comprised a cohort of pregnant women aged from 16 to 
44.5 years followed for the lifetime period. 
 
6.2.4 Discount rate 
Both costs and benefits (QALYS) in the model have been discounted at the same annual 
rate as in M2, M3, M4 and M5. 
 
6.2.5 Cost-effectiveness ratios and net monetary benefit 
The same methodology as was used in M4 and M5 was applied to calculate ICERs and 
NMB for each intervention (see Section 5.2.5 of Chapter 5 for details). NMB was 
calculated considering a threshold of £20,000.  
 
6.2.6 Uncertainty 
Parameter uncertainty in this cost-effectiveness model was addressed by conducting 
univariate and probabilistic sensitivity analysis, as in M4 and M5 (see Section 5.2.6 in 
Chapter 5). The variables selected for univariate analysis (background cessation rate, 
cost of interventions and relapse rate) were the same as in Chapter 5 (see Section 5.2.6). 
However, for the probabilistic sensitivity analysis, only the relative risk of getting a 
particular disease due to smoking during pregnancy, the utility values and costs 
                                                 
69
 Mrs Lesley Owen, NICE smoking specialist, recommended the inclusion of the impact on babies’ first five years of life.  
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remained constant; the incidence rates for starting smoking during pregnancy and the 
effectiveness of smoking cessation programmes among pregnant smokers were 
parameters specific to this model. The differences in effects and costs arising from the 
inclusion in the model of health effects on babies` first year of life were derived using 
Montecarlo simulations (n=1000). A cumulative average of NMB iterations was 
presented to study the number of iterations needed to reach stability on the NMB 
threshold. 
 
6.2.6.1 Choosing distributions for the parameters 
The same distributions were chosen for parameters as were used in M4 and M5 (see 
Appendix 6.8 for details), and the same number of replications was performed 
(n=1000).    
 
6.2.6.2 Cost-effectiveness acceptability curves  
As reported for M4 and M5, cost-effectiveness acceptability curves were deployed for 
the least and most cost-effective interventions (see Section 5.2.6.2). Cost-effectiveness 
acceptability curves (CEACs) were derived from the joint distribution of incremental 
costs and incremental effects resulting from comparing each intervention with the base 
case, as in M4 and M5. CEACs were constructed by recording the number of times each 
alternative generated the highest Net Benefit in the simulations run using M6 and M7 
(Claxton, 2008). Histograms of net monetary benefit results are presented to study the 
heterogeneity in the NMB predicted estimates. 
 
6.3 Results 
The impact of smoking during pregnancy on first year babies will be presented in terms 
of average lifetime costs and average lifetime QALYs lost per pregnant adult and per 
pregnant adult and baby. The results obtained from the Markov model are shown in 
Table 6.10, which differentiates between M6 (the model excluding health effects on first 
year babies) and M7 (which includes them). 
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Table 6.10 M6 and M7 estimates of average costs and QALYs lost per pregnant woman (cohort of 1000 
pregnant women aged 16 - 44.5) + average babies delivered by pregnancy (0-1 years); starting 
distribution: according to prevalence; health states: smokers; former smokers; non-passive never-
smokers; passive smokers; and death 
 
M6=M3+incorporation of non-smokers in the Markov model, but excluding health effects on first year babies 
from smoking during pregnancy 
M7=M3+incorporation of non-smokers in the Markov model, but including health effects on first year babies  
from smoking during pregnancy 
 
 
Cost-effectiveness and NMB analyses reached the conclusion that BAD was the most 
cost-effective intervention, compared with no intervention, both when external effects 
were excluded (M6) and included (M7). This is therefore the recommended 
intervention, whether or not smoking during pregnancy is included. When the results 
from M6 and M7 are compared, i.e. when the health effects on babies’ first year of life 
are taken into account, external effects are seen to be responsible for an extra lifetime 
cost of £109.94 per pregnant adult and baby and 0.2244 extra lifetime QALYs lost per 
pregnant adult and baby. The NMB value for the most cost-effective intervention was 
£645.20 when the external effect smoking during pregnancy was excluded, and 
£2989.97 when it was included – a difference of £2344.77 in absolute NMB. Graph 6.1 
compares the differences in costs and QALYs lost when external effects are excluded 
and included. To facilitate the interpretation of the graphical results, QALYs lost were 
converted to QALYs gained adjusting the negative sign.  
 
 
Pregnant 
women 
interventions 
Discounted 
average COST 
per pregnant 
woman 
(M6) 
Discounted 
average 
COST per 
pregnant 
woman  
(M7) 
Discounted 
QALYs lost 
per pregnant 
woman (M6) 
Discounted 
QALYs lost 
per pregnant 
woman (M7) 
NMB  per 
pregnant 
woman  
(M6) 
NMB  per  
pregnant 
woman  
(M7) 
NI 1477.07 1642.95 4.1296 4.4685   
MBA 1461.58 1608.77 4.1152 4.4158 304.40 1087.65 
BAD 1433.82 1543.76 4.0995 4.3239 645.20 2989.97 
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Graph 6.1 Costs and QALYs lost per pregnant woman when external effect on babies’ first year of life is 
excluded (M6) and included (M7) 
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The effects on the estimates of three inputs (decrease of background cessation rate to 
1.2%, cost of interventions equal to zero, and 10% variation in relapse rate) were 
studied to preserve consistency with Flack et al. (2007a), as in Chapter 5. Neither the 
deterministic sensitivity analysis on background quit rate, nor intervention costs equal 
to zero, nor the 10% variation in relapse rate had any impact on the ICER and NMB 
ranking, though the results for costs and QALYs changed slightly when external effects 
were included. Having specified distributions for all the relevant parameters of the 
model, probabilistic analysis was undertaken. This process formed a single replication 
of the model results; a total of 1000 replications from the model are presented on the 
cost-effectiveness plane in Graph 6.2, including results from both M6 (health effects on 
first year babies of maternal smoking in pregnancy excluded) and M7 (health effects 
included). The graph indicates that higher uncertainty exists around the most cost-
effective interventions. Graph 6.2 shows the incremental cost plotted against 
incremental effectiveness for the results of the Markov simulation when external effects 
are not included. The graph suggests much uncertainty around the cost-effectiveness 
ratio, and indicates that BAD is the most cost-effective intervention. The fact that BAD 
demonstrates the highest variability and widest 95% confident interval (CI) in terms of 
cost savings (-45.03, -41.54) and QALYs gained (-0.1354, 0.1790) could be explained 
as the consequence of this intervention exhibiting the highest rate of effectiveness, and 
therefore the highest standard deviation (standard deviation is assumed to be 10% of the 
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effectiveness rate). Ultimately, however, compared to the no intervention option, all the 
interventions seem to be cost-effective.  
 
Graph 6.2 Monte Carlo simulation results on the cost-effectiveness plane for MBA and BAD in M6 and 
M7 (including health effects on first year babies from adults smoking during pregnancy) 
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When external effects are included (MBA EE and BAD EE), all interventions compared 
to no intervention are dominant rather than cost-effective. In this case, the uncertainty 
diminishes in terms of QALYs gained (95% CI (-0.0208, 0.2942)), but it increases in 
terms of cost savings (95% CI (-102.62, -95.97)). The change in terms of effects could 
be explained by the clear reduction in QALYs due to the incorporation of SIDS and 
LWB into the model. However, the increase in cost variability could be due to the 
introduction of LBW effects on first year babies. There is a clear shift from the first 
quadrant to the third quadrant of the cost-effectiveness plane. In other words, when 
external effects are included, this has a clear impact on decision-making.  When the 
external impact on babies` first year is included in the model, the change in the 95% CI 
for costs and QALYs for the most cost-effective intervention show there is a higher 
level of uncertainty. 
Graph 6.3 presents the uncertainty surrounding the NMB of the most cost-effective 
intervention, when the health impact of maternal smoking in pregnancy on babies` first 
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year is included and when it is excluded. Higher uncertainty is clearly observed around 
the NMB when the external effect is taken into account. 
 
Graph 6.3 NMB of the most cost-effective intervention when the impact on babies’ first year of life is 
included (BAD EE; M7) and when it is excluded (BAD; M6) 
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Cost-effectiveness acceptability curves were calculated for models not incorporating 
(M6) and incorporating (M7) external effects (see Appendix 6.9 for details). However, 
because, when external effects are introduced, the BAD programme has 100% 
probability of being cost-effective, these graphs are not very informative. For this 
reason, histograms showing the NMB for the most cost-effective intervention are 
presented instead. As the cost-effectiveness model is able to predict NMB as a function 
of the prediction pattern, it was used to generate a prediction of the NMB based on a 
comparison of BAD versus no intervention. A histogram of the distribution of predicted 
NMB results (in terms of incremental cost per QALY gained from BAD) is presented in 
Graph 6.4.  It is important to recognise that this distribution represents the estimated 
heterogeneity with regard to NMB. The median (IQ range) NMB across the 
heterogeneous population was estimated as approximately £750 per QALY. Overall, 
90% of the estimates were estimated to have a point estimate of NMB below £3000. 
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Graph 6.4 Distribution of predicted NMB for BAD in M6 
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However, when the impact on babies’ first year of life is included (see Graph 6.5), the 
median (IQ range) NMB increases to £3000 per QALY. Overall, around 90% of the 
estimates were estimated to have a point estimate of NMB below £5250. It is thus 
evident that when the external effect is included, the NMB of the most cost-effective 
intervention rises. 
 
Graph 6.5 Distribution of predicted NMB for BAD in M7 
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Graph 6.6 shows that the results for the most cost-effective intervention (external effects 
excluded) become stable at around 700 iterations. The results derived from the 1000 
iterations here therefore seem to be robust. When external effects are included, same 
iterations (around 700) are needed to achieve robust results. 
 
Graph 6.6 Cumulative average NMB for BAD in M6 and M7 
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6.4 Discussion 
This chapter attempts to incorporate the impact of smoking during pregnancy on babies’ 
first year of life in an economic evaluation of smoking cessation interventions. It takes a 
completely different perspective from Flack et al. (2007a), who calculated the additional 
costs associated with first year babies born to smoking mothers, but did not incorporate 
them into the economic evaluation of smoking cessation programmes for pregnant 
women. The value of this chapter lies not just in the methods it outlines for 
incorporating external effects, but also in its discussion of how incorporating these 
effects into cost-effectiveness assessments might impact upon policy decisions. This 
chapter also provides insights into the uncertainty which surrounds the parameters 
driving the model. The main question is whether the cost-effectiveness of the smoking 
interventions recommended for pregnant women changes when external effects are 
taken into account, and if so, what the magnitude of that change is.  
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Data on maternal smoking and resource utilisation from the Oxford Record Linkage 
Study, published by Petrou et al. (2005), was used to calculate the additional costs 
associated with children whose mothers smoked during pregnancy. It specifies exactly 
where these costs come from (low birth weight and sudden infant death burden).  
The static Markov model was used to incorporate external effects into the economic 
evaluation and calculate the extra lifetime costs and QALYs lost per pregnant woman 
and baby due to smoking during pregnancy. This chapter also suggests that the 
taxonomy of the models used in economic evaluation so far is incomplete (see Section 
5.4 for details). Looking at the results, the inclusion of external effects on first year 
babies caused by maternal smoking during pregnancy led to no changes in ICER 
ranking, as expected. Results from both deterministic and probabilistic models led to a 
similar conclusion. However, as discussed in Chapter 5, there was an impact on the 
magnitude of the ICER. BAD was revealed to be the most cost-effective intervention in 
both scenarios.   
Weaknesses in the model are the widely varying sample sizes cited and some 
questionable relapse rate data. These introduced additional uncertainty in both models 
M6 and M7. For instance, the disparity in sample size (30 women in Hackman`s trial as 
opposed to 1120 women in Hajek, West & Lee) suggests that effectiveness rates may 
not be comparable or robust across smoking cessation programmes for pregnant 
women. The relapse rate for smoking during pregnancy is quite high, and assumptions 
were made about going back to the background quit rate after pregnancy, as the adult 
population did in M4 and M5. According to Flack et al. (2007a), Peter Hajek (2001) 
suggested that 70% of pregnant women who stop smoking will relapse within a year. 
Fang et al. (2004) and Lopez et al. (2008) supported this estimate, establishing an 
interval for the relapse rate of 70% to 85% and 70% to 80% respectively. Bolling et al. 
(2007a) suggested that 30% of mothers who stopped smoking during pregnancy 
resumed smoking within a year of giving birth, while Secker-Walker et al. (1998) 
reported a relapse rate during pregnancy of 15% to 30%. Given these widely varying 
statistics, we should be conservative about the conclusions we draw from the results 
obtained, though the sensitivity analysis applied to this parameter showed no change in 
terms of cost-effectiveness ranking.  
It should be noted that models M6 and M7 are basically driven by the weighted 
background quit rate, effectiveness of interventions and relapse rates. For instance, 
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although the three highest ranking smoking cessation interventions among pregnant 
women reported close to 100% success rates, these included self-reported unaided 
quitters rather than just smokers actually treated. Although the variability of 
effectiveness rates (quit rates) used in our model was scrutinised by means of 
probabilistic sensitivity analysis, it is nevertheless advisable to be cautious in our 
treatment of the results. The estimates for cessation rates after pregnancy are the 
weakest in the model, because in many interventions these rates were not reported. 
Moreover, there is no commonly agreed cut-off point: studies variously take three, five 
or eight weeks after delivery. Probabilistic analysis was run establishing, and not, a 
distribution to each parameter, and studying their impact. Although there was no impact 
in terms of cost-effectiveness or NMB ranking, better data is needed on these 
parameters to properly establish confidence intervals and study the uncertainty they 
introduce. 
 Prevalence rates for smoking during pregnancy in the United Kingdom provided by the 
Infant Feeding Survey (IFS) 2005 (Bolling et al., 2007) were in accordance with those 
used in the models M6 and M7 calculated from the Health Survey for England (HSE) 
2006 data. In the IFS, smoking prevalence among pregnant women aged 20 and under 
and 20-24 was 45% and 29% respectively, whereas in the model, a 37% smoking 
prevalence rate was adopted for pregnant women aged 16 to 24. Between 25 and 39 
years, and 30 and 34 years, the prevalence rates calculated by the IFS were 15% and 
10% respectively. The HSE reports an 11% prevalence rate in this age group. Finally, 
the IFS calculated a prevalence rate of 9% among pregnant smoking women aged 35 
and over, while the HSE`s figure was 11%. Had these values been used in models M6 
and M7, it would have made no difference either to the results or the ICER ranking. 
One potential limitation of the external effect as it is incorporated into the model is that 
it does not take into account maternal deaths (death while pregnant or within 42 days of 
the end of pregnancy, from any cause related to or aggravated by the pregnancy), direct 
deaths (deaths resulting from obstetric complications of the pregnant state) or indirect 
deaths (deaths resulting from previous existing disease but aggravated by the 
physiologic effects of pregnancy (Fisher, 2008)). General female mortality rates during 
pregnancy by age interval (rather than gestation-specific infant illnesses and neonatal 
and post-neonatal mortality rates) could be adopted as a proxy for mortality in the 
model. Although this may introduce bias in terms of the effectiveness of interventions, 
132 
 
it should have no impact on cost-effectiveness or NMB ranking of programmes. This 
proxy was not considered in order to keep the model simple, though some data on 
deaths during the pregnancy period has been published (Moser et al., 2007). According 
to Blair et al. (2006), most SIDS deaths happen within the first eight months of life, 
though this economic evaluation considers the RR of SIDS for smokers` children during 
the first year of life. In other words, this assumption introduces further parameter 
uncertainty. The analysis includes information regarding smoking in pregnant women 
up to 44.5 years old, but does not take into account smoking by any other household 
members. This may also introduce bias into the results in terms of costs and QALYs, 
though smoking patterns among other family members will presumably not be changed 
by interventions focused on pregnant women. 
In general, future research should rely on better relapse estimates, and clinical trials 
studying the health effects of smoking during pregnancy on women. The next chapter of 
this thesis will introduce transmission of smoking behaviour to the other two external 
effects already studied, passive smoking and smoking during pregnancy, to study the 
impact of the incorporation of this last external effect into economic evaluation of 
smoking cessation programmes. 
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CHAPTER 7 Economic Evaluation of Smoking Cessation 
 Interventions: considering smoking dynamics and  
 passive smoking  
 
7.1 Introduction 
Chapters 5 and 6 examined the impact of passive smoking and smoking during 
pregnancy respectively, in an economic evaluation of alternative smoking cessation 
programmes using a static Markov model.  Chapter 7 aims to assess the impact of the 
third external effect, transmission of smoking behaviour, in an economic evaluation of 
smoking cessation. Brennan et al (2006) suggested that static models, such as decision 
trees or Markov models are the main approaches adopted by health economists in 
conducting economic evaluation. Static models unlike dynamic models, however, 
cannot accommodate the ‘interactions between individuals’, necessary for transmitting 
an infectious disease, or smoking behaviour in this particular case (Barton et al., 2004; 
Brennan et al., 2006). There is therefore a need for a dynamic model because the 
external effect considered in this chapter (i.e. transmission of smoking behaviour) 
involves a transmission mechanism. Castillo-Garsow et al (1997) and Sharomi and 
Gumel (2007) emphasised the need of a dynamic model to account for transmission of 
smoking behaviour. 
There is a large body of literature on both the theoretical and empirical aspects of the 
transmission dynamics of infectious diseases (Keeling and Rohani, 2008; Anderson and 
May, 1991; Nokes and Anderson, 1988; Fine, 1993) which is aimed at explaining 
observed epidemiological patterns and predicting the consequences of the introduction 
of public health interventions to control infection and disease. Edmunds et al (1999) and 
Beuthe et al., (2002) noted that specific economic evaluation guidelines are needed to 
accommodate those health benefits (herd-immunity effects). Transmission dynamic 
models are mainly used to incorporate the health benefits in a cost-effectiveness 
analysis of vaccination programmes (Beuthe et al, 2002) given the positive external 
effects accruable from such programmes. Vaccination gives indirect protection to non-
vaccinated people.  
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Transmission of smoking behaviour appears to be a negative external effect generated 
via contact with smokers. Smoking cessation programs would result in fewer smokers in 
the population and the number would decline, at least partly, as more individuals attend 
those programs. While a dynamic framework could account for the declining rate at 
which ‘never smokers’ become ‘smokers’, in a static model framework this rate would 
remain unaltered ignoring the fact there will be fewer and fewer never smokers who risk 
start smoking. The declining rate is important to consider because it may have an effect 
on the cost-effectiveness of a smoking intervention. Therefore, the static model may not 
provide the correct picture of the cost-effectiveness analysis. Therefore, a dynamic 
approach seems to be the adequate model framework to incorporate the external effects 
of transmission of smoking behaviour (Sharomi and Gumel, 2007; though as it will be 
pointed in the discussion of this chapter, this thesis cannot claim that the model built in 
this chapter is a true dynamic model because though captures some of the population 
dynamics, it does not capture the second and higher order effects). 
In this chapter, the incorporation of the transmission of smoking behaviour in an 
economic evaluation of smoking cessation interventions is undertaken, singly or in 
combination with passive smoking. The inclusion of more than one external effect at a 
time is because the analysis focuses on a cohort of smokers from the general population 
and another cohort of their contacts and group of interventions that are common to the 
external effects being considered. The objectives of the chapter are to: (a) conduct a 
literature search on smoking dynamic models to identify an appropriate framework to 
incorporate the transmission of smoking behaviour; (b) apply dynamic modelling 
techniques to allow the incorporation of external effects to capture the disease dynamics 
(c) estimate the impact of  incorporating the transmission of smoking behaviour into 
economic evaluation of smoking cessation programs; and, (d) to compare, in terms of 
relative impact on economic evaluation, the incorporation of the transmission of 
smoking behaviour with passive smoking previously incorporated, in chapters 5. 
This chapter first presents a mathematical model of the long-term dynamics of smoking 
transmission behaviour among general adult population between 16 and 69 years (M8). 
This is followed by a modification of the model to incorporate the external effects of 
passive smoking (M9) while accounting for transmission of smoking behaviour. Third, 
an economic evaluation of the cost-effectiveness of smoking cessation interventions, 
based on data used in a previous chapter (Chapters 5) of this thesis is presented.  
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7.2 Methods 
The methods include how the literature review on smoking dynamic models was 
conducted, including the search strategy, selection criteria and findings. It also details 
the economic model used to incorporate the transmission of smoking behaviour. This 
section also shows how to incorporate the transmission of smoking behaviour using a 
cohort dynamic model, and the addition of passive smoking external effect in this 
model. Model parameters are also described, concentrating on the concept of “force of 
infection”.   
 
7.2.1 Systematic review of smoking dynamic models 
The aim of this systematic review was to examine literature on smoking dynamic 
models to inform the incorporation of the transmission of smoking behaviour into 
economic evaluation.  
 
Search strategy 
Comprehensive literature searches were undertaken in July 2008 and involved 6 
bibliographic databases (Web of Knowledge, Econlit, Mathscinet, NHS EED, HEED 
and Cochrane Library) as well as bibliographies of relevant reviews on smoking. The 
search was restricted to smoking, English Language and human subjects, with no time 
restrictions. The free text search terms were “smoking”, “cost benefit”, “cost 
effectiveness”, “economic evaluation”, “cost”, “valuation”, “critical appraisal”, “model, 
pecuniary”, “technological”, “knowledge”, “network”, “external effects”, “externalities” 
and “spillovers”. Search terms were contrived to retrieve papers on dynamic models 
related to smoking. These terms were modified to suit individual databases, given the 
nature of search engines. Appendix 7.1 gives further details. 
 
 
Selection criteria 
A selected paper had to satisfy all the following criteria: (a) present a dynamic model 
focussed on smoking behaviour; (b) the structure of the model should be fully detailed; 
and, (c) written in English language as there were no resources for translation. This 
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review differed from an earlier literature review that concentrated on economic models 
of smoking cessation interventions (see Appendix 4.2 for details) in that the previous 
review aimed to find only empirically tested models, whereas in this chapter, that is not 
an important requirement.  
 
 Results 
Appendix 7.2 shows that titles or/and abstracts of 18 papers produced by the search 
were screened leading retrieval of 15 papers. The excluded papers were duplicates (see 
Appendix 7.3 for included references). A total of 11 papers did not merit inclusion: (a) 
one paper was not smoking related (James and Venn, 2006); and (b) ten papers (Collins 
and Lapsley, 1999; Ahmad and Franz, 2008; Van Baal et al, 2007; Ahmad, 2005a; 
Leffondré et al, 2006; Liu and Powers, 2007; Mannan and Koval, 2003; Wang et al, 
2006; Chan and Kapadia, 2006; Feenstra et al, 2005) were not presenting dynamic 
model structures according to the different smoking habits. Overall, 4 papers were 
selected for review. However, two more papers were obtained from references and 
therefore included in the review (Castillo-Garsow et al 1997; Tengs et al, 2001b).  
 
The findings of this literature review indicated that only six (Castillo-Garsow et al 1997; 
Sharomi and Gumel, 2007; Tengs et al, 2001a; van Genugten et al, 2003; Tengs et al, 
2001b; Ahmad, 2005b) of the eighteen papers found had used dynamic models of 
smoking. However, only two papers presented full details on the dynamic models 
(Castillo Garsow et al, 1997; Sharomi and Gumel, 2007). Castillo-Garsow et al (1997) 
using a general epidemiological model to describe the dynamics of tobacco use among 
adolescents. A general model for drug abuse adaptable to study the dynamics of tobacco 
use was specified using three classes of individuals: S (individuals susceptible to 
become regular users); D (individuals who are regular drug users) and R (individuals 
recovered from habitual drug use). The rate of transmission (frequently defined in the 
infectious disease area as the ‘force of infection’) depended on the regular drug users at 
a specific time in the population. A recovery rate per habitual drug user and a relapse 
rate per recovered individual were a function of D and incorporated in this model. This 
general mathematical model was extended to include demographic factors in the 
population considered; to make relapse dependent on the presence of drug users, and to 
assess effectiveness of rehabilitations programs. The model showed the endemic 
character of tobacco use. Sharomi and Gumel (2007) adapted the mathematical model 
based on Castillo-Garsow et al (1997) to assess the dynamics of smoking and its public 
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health impact in the community. This model incorporated different classes of smokers 
according to the frequency of smoking, the transition dynamics between these 
subclasses, and, the public health impact of smoking-related illnesses. The transmission 
dynamic model used differential equations to define each health state in the model, as 
frequently transmission dynamic models do (Edmunds et al, 1999; Brisson et al, 2000; 
Trotter et al, 2006; Sufton et al, 2006; Bauch et al, 2007). Although Tengs et al (2001a), 
van Genugten et al (2003), Tengs et al (2001b) and Ahmad (2005b) presented 
empirically tested dynamic model structures, the parameters of the model estimations 
were not fully reported. Apart from that, the model structure presented in all these 
papers was in concordance with that presented by Sharomi and Gumel (2007), which is 
fully detailed below. 
 
To establish my model structure incorporating transmission of smoking behaviour, I 
analysed the conventional dynamic model used by Sharomi and Gumel (2007). In this 
paper, the authors specified that the number of potential smokers (term used to refer to 
non-smokers) is increased by the recruitment of individuals into the non-smoking class 
(at a rate: µN, where µ is the natural rate of people increasing the population modelled, 
and N the total population). For simplication, Sharomi and Gumel (2007) assumed that 
the natural rate of people increasing the population modelled was the same as the 
natural death rate to keep the population size constant. It is assumed that never-smokers 
can acquire smoking habits (and become smokers) via effective “contacts” with 
smokers (at a rate β=c*q, where c is the average number of contacts per unit time; and q 
is the probability of becoming a smoker for a member of the potential smokers class 
following contact with a smoker). In other words, it is assumed that the acquisition of 
smoking habit is analogous to acquiring disease infection; the more “contact” a 
potential smoker has, the higher the likelihood of such an individual acquiring smoking 
habit. This acquisition of smoking habits, and therefore the transmission of smoking 
behaviour, is referenced as force of infection in a conventional dynamic approach (i.e. 
infectious diseases). Sharomi and Gumel (2007) did not try to estimate neither beta nor 
any other parameter. It was a paper concentrated in providing a rigorous mathematical 
study to assess the dynamics of smoking, but no application was carried forward at any 
stage. 
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A flow diagram for a basic SIR (Susceptible-Infected-Recovered) health states dynamic 
model was created by Sharomi and Gumel (2007). This example of a SIR model 
represents graphically the transmission of smoking behaviour (see Box 7.1 for details).  
 
 
 
 
Box 7.1 Structure of a smoking SIR health states model (adapted from Sharomi and Gumel, 2007) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To mathematically represent the relationships among the different health states 
represented in Box 7.1, differential equations are extensively used. Differential 
equations in Box 7.2 are simply reporting what Sharomi and Gumel did. 
 
µQp 
 
Potencial 
Smokers (P) 
Temporary 
Quitters (Qt) 
Permanent 
Quitters (Qp) 
µP 
 
µN 
 
Smokers (S) 
µS 
βPS/N 
ΨS 
ΨσS 
αQt 
µQt 
Definition of parameters and variables: 
 
 
P  ≡Non-smokers (potential smokers) 
S  ≡Smokers 
Qt  ≡Smokers who temporary quit smoking 
Qp  ≡Smokers who permanently quit smoking 
N  ≡Total population 
β ≡rate at which non-smokers can acquire smoking habits (and become smokers) via 
“effective” contacts with smokers 
Ψ  ≡
 
quit rate  
α  ≡rate of revert to smoking when smokers temporarily quit smoking (relapse rate) 
σ  ≡fraction of temporarily smokers who permanently quit smoking 
µ  ≡
 
rate of recruitment and mortality  
 
Source: Sharomi and Gumel (2007) 
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Box 7.2 Differential equations of a smoking SIR model 
 
 
Models of infectious disease transmission need to represent the population level effect 
of processes that occur at the individual level (Keeling and Rohani 2008). An 
uninfected individual’s risk of becoming infected (referred to as the force of infection) 
depends on the prevalence of infectious individuals, which is a population level 
characteristic. Therefore, translating this concept into the smoking context, a never 
smoker’ risk of becoming a smoker depends on the prevalence of smoking in the 
population. It also depends on the rate of contact, direct or indirect, between smokers 
and never smokers in the household. Therefore, the transmission of smoking behaviour 
in a population is a dynamic process and the individual risk of smoking can change over 
time depending on the number of infectious individuals in the population. The 
population rate of infection in each time period depends upon the number of never 
smokers and the number of smokers of that time period. To incorporate the external 
effect of transmission of smoking behaviour, the change in the force of infection (FOI) 
needs to be accounted for.  
The transmission of smoking behaviour modelled using a conventional transmission 
dynamic (compartment) approach would be calculated using the risk that a never 
Rate of change in the number of potential smokers over time 
dP/dt= µN – (βPS/N) - µP 
 
Rate of change in the number of smokers over time 
dS/dt= (βPS/N) + αQt – (µ + Ψ)S 
 
Rate of change in the number of temporary quitters over time 
dQt/dt= Ψ (1- σ )S – (µ + α)Qt  
 
Rate of change in the number of permanent quitters over time 
dQp/dt= Ψ σS - µQp 
 
Source: Sharomi and Gumel (2007) 
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smoker becomes a smoker during a given time (FOI). The never smoker category 
should be split in two different categories non-passive and passive never smokers. The 
reason is because the transmission of smoking behaviour is likely to be higher in the 
latter, because by definition their contact with smokers is greater. This is what my 
model adds to Sharomi and Gumel’s work, the idea of modelling smoking transmission 
distinguishing between non-passive and passive never smokers. The risk of never 
smokers depends on two factors: (a) the number of smokers present in the population at 
that time (S); and, (b) the probability that a non-passive or passive never smoker comes 
into effective direct or indirect contact with a smoker (β). According to Abbey (1952), 
an effective contact is defined as a contact sufficient to lead to smoking if it occurs 
between a non-passive never smoker and a smoker (see equation E7.1)  
FOINPNS = βNPNS * S      (E7.1) 
and, a passive never smoker and a smoker (see equation E7.2) 
FOIPNS = βPNS * S      (E7.2) 
where betaNPNS is likely to be lower than betaPNS. For large populations, the number 
of smokers present in the population (S) will be divided (adjusted) by the total 
population (N). 
See further details in Appendix 7.4. The probability that a specific smoker and never 
smoker individual comes into effective contact between time t and t+1 (β) is needed for 
calculating the transmission of smoking behaviour with that approach. A literature 
review using the google scholar engine was conducted and also the papers obtained 
from the systematic review of smoking dynamic models (see section 7.2.1) were 
reviewed to check the existence of this required parameter and Professor John 
Edmunds, as an expert in the transmission dynamic models, was also consulted. 
However, there was no available data to calculate this parameter. In infectious diseases, 
where transmission dynamic models are widely used and studied, there is a particular 
area of research that focuses just on the calculation of transmission rates of diseases and 
their probability of effective contact (Goeyvaerts et al, 2010; Björnstad et al, 2002; 
Heptonstall, 1996). Therefore, because an accurate calculation of this parameter is out 
of the scope of this thesis and there is an interest of keeping same Markov model 
structure for comparability reasons with previous models, the beta parameter was not 
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specifically calculated, but proxied using two cohorts in the model. The contact between 
never-smokers and smokers (β) was modelled by inter-relations between two cohorts: 
cohort of smokers (cohort a) and cohort of passive smokers (cohort b). Cohort b is 
driven by: (a) the number of existing smokers in cohort a in each particular time period, 
and (b) the number of smokers and former smokers who quit and relapse respectively in 
cohort a. This movement between number of smokers and former smokers in cohort a 
will affect the number of non-passive never smokers and passive never smokers.    
The impact of smoking cessation interventions will affect the smoking cohort (cohort a) 
and therefore the number of passive smokers generated by each smoker at cohort b. It 
will also affect the number of people quitting and relapsing in cohort a. Because the 
number of passive smokers in cohort b will also depend on number of smokers quitting 
smoking and former smokers relapsing smoking in cohort a, the smoking cessation 
interventions will also impact costs and QALYs lost on cohort b. In every time period 
that smokers quit smoking in cohort a, passive smokers become non-passive never 
smokers in cohort b at quit plus mortality rate of smokers. For instance, the movement 
from passive never smokers to non-passive never smokers is due to a smoker who they 
live with has quit or died. And conversely, non-passive never smokers may become 
passive never smokers if someone they live with takes up smoking (or relapses). As 
more effective is the intervention and more smokers quit smoking in the smoking 
cohort, higher number of people is leaving the state of passive smoker to become a non-
passive never smoker again in passive never-smoker cohort. 
Something else to consider is that for an infectious disease, the only way you can get the 
disease is if the pathogen is transmitted to you. But, it seems that this is not true for 
behaviours like smoking. There are other factors out of our control that make people 
start smoking for other reasons (i.e marketing influence from tobacco companies, 
psychosocial reasons). In this thesis, because of data limitations, the transmission of 
smoking behaviour was restricted to live with a smoker, but this is not entirely true, 
though it is probably the highest influencial factor. 
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7.2.2 Economic model 
One model containing two cohorts were developed in Microsoft EXCEL (Microsoft 
Corporation) to account for the transmission of smoking behaviour, one for a general 
smoking cohort and, the other for a cohort of passive smokers generated by the smokers 
cohort. The structure of the two cohorts composed model used the model structure of 
the replicated model M3 (see section 4.1.2, Chapter 4) and M4 and M5 (see section 
5.2.2, Chapter 5), and is described below. 
The model estimates: (a) impact on average lifetime costs per adult (£ 2010); and (b) 
quality-adjusted life-years (QALYs) lost per adult due to transmission of smoking 
behaviours and passive smoking. This chapter introduces four new models: M8, which 
includes cohorts a and b but does not include transmission of smoking behaviour; M9, 
which includes cohorts a and b and passive smoking; M10, which includes cohort a and 
b and transmission of smoking behaviour; and M11, which contemplates cohorts a and 
b, passive smoking and transmission of smoking behaviour. These models are compared 
by pairs (M8 versus M10 and M9 versus M11) to study the magnitude of the effect of 
incorporating this third external effect (i.e. transmission of smoking behaviour). The 
additive impact of two external effects is studied in this chapter (M8 versus M11). The 
population is simulated over time, as in chapters 5 and 6. To capture the transmission of 
smoking behaviour two cohorts are modelled in parallel. The first cohort, cohort a, is a 
cohort of 1000 smokers at whom the smoking cessation interventions are targeted. This 
model structure is the one used for M3 in chapter 4. Whereas, the second cohort, cohort 
b, is a cohort of never-smokers who are living with members of cohort a, and are thus 
susceptible to the effects of and transmission of smoking behaviour. Cohort b is of 
mixed ages between 16 to 25 years because this is the age range when most smokers 
start smoking. A wide range of literature suggests that the transmission of smoking 
behaviour is more likely to occur within age bands or peer groups (Thomas et al, 2006; 
Thomas et al, 2008; Harris and Lopez-Valcarcel, 2008). However, for simplication 
purposes no different influences were assumed to occur by different age clusters of 
people. Therefore, it is assumed that in the age interval of 16 to 25 years, the never-
smokers are susceptible to be influenced by the smoker population, and therefore, the 
transmission of smoking behaviour could occur. Therefore, there is a need to calculate 
thr number of passive never smokers, aged between 16 and 25 years, generated by a 
smoker. This will vary with the age of the smokers. In the first cycle of the model, the 
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number of passive smokers generated by a smoker was calculated using data from the 
Household Survey for England, which takes place in a household context. Because of 
the calculation difficulties of this number, the proxy used was the division of the 
number of never smokers divided by the number of smokers in the whole population 
interviewed. Therefore, every smoker in cohort a generate 0.42 passive smokers in 
cohort b aged between 16 and 25 years. From second cycle onwards, the number of 
passive smokers generated by a smoker is calculated from the existent number of 
passive smokers in previous cycle in cohort b divided by the number of smokers in 
previous cycle in cohort a. Cohort a is supposed to live with never-smokers who are 
between 16 and 25 years to have the chance to transmit the smoking behaviour. 
However, it does not seem sensible to assume that people at any age in cohort a could 
live with a young adult between 16 to 25 years. Therefore, there is a need to establish a 
boundary around wich is the age at which people would not live with young people 
between 16 to 25 years. Because the upper age limit boundary assumed to get pregnant 
is 44 years (see chapter 6), the smokers cohort, cohort a, living with never smokers, 
cohort b, will be adults between 16 and 69 years (i.e 44 years is the latest age to deliver 
a baby and he/she will reach the age of 25 years when the smoker parent is 69 years). 
Refer to Table 7.1 for details on population and external effects differences between M8 
M9, M10 and M11, and models previously presented in chapters 5 and 6. 
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Table7.1 Summary of differences among M4, M5, M6, M7, M8, M9, M10 and M11 
Models Population Incorporation of 
health effects of 
passive smoking on 
adults and children 
Incorporation of 
health effects of 
smoking during 
pregnancy on 
women and 
babies 
Incorporation of 
transmission of 
smoking behaviour 
1000 
adults 
1000 adults 
+ 96.5% of 
adult 
smokers’ 
children 
1000 
pregnant 
woman 
1000 
pregnant 
woman + 
average 
babies 
delivered 
by 
pregnanc
y 
Number 
of passive 
smokers 
generated 
by 1000 
smokers  
M4 √ x x x x x x x 
M5 x √ x x x √ x x 
M6 x x √ x x x x x 
M7 x x x √ x x √ x 
M8 √ * x x x √ x x x 
M9 √ * √* x x √ √ x x 
M10 √ * x x x √ x x √ 
M11 √ * √* x x √ √ x √ 
√≡ included in the model 
x≡ not included in the model 
*≡ In these models, the starting population in cohort a are 1000 smokers adults, whereas in M4, M5, M6 and M7 the starting 
population are distributed according to smoking habits. 
 
There is a need to compare the impact of including the transmission of smoking 
behaviour with not including it. However, as detailed in Table 7.1, starting population 
across models (M4, M5, M6, M7, and M8 or M9 or M10 or M11) are different. 
Therefore, there is a need to create four new models to value the incorporation of the 
transmission of smoking behaviour. M8 will be same as M10, and M9 same as M11 but 
with no transmission between cohorts a and b (i.e. X and Y from Figure 7.1 will be set 
to zero). 
The models used in this chapter (M8, M9, M10 and M11) differ from M4, M5, M6 and 
M7 in the incorporation of the transmission of smoking behaviour and the starting 
population considered. M4, M6, and M8 did not consider any external effect but has 
different starting population groups, whereas M10 incorporated the transmission of 
smoking behaviour. M5 and M9 incorporated passive smoking, but M9 has a different 
starting population group. M11 apart from passive smoking also incorporates the 
transmission of smoking behaviour (Table 7.1). M8, M9, M10 and M11, apart from 
considering a 1000 smokers as the starting population, it also includes a second cohort 
145 
 
of never smokers living with smokers (passive smokers) generated by the thousand 
smokers cohort. The proportion of passive smokers between 16 and 25, assumed to be 
the age interval when transmission of smoking behaviour happen, generated by a 
smoker was calculated using the Health Survey for England (2006). This survey takes 
place in a household context. The number of passive smokers per smoker is calculated 
dividing the total number of never-smokers between 16 and 25, in the population 
interviewed, from the total number of smokers between 16 and 69 years in the 
population. The model stops when the smoking cohort reaches the age of 69 because is 
considered that after that age there is no chance to live with a young adult between 16 
and 25 years old. The analysis takes the perspective of the National Health System and 
uses a cycle length of six months, similar to models in previous chapters (section 5.2.1, 
Chapter 5; and, section 6.2.1, Chapter 6). 
 
Model structure to calculate transmission of smoking behaviour 
This dynamic model (Sharomi and Gumel, 2007) was useful in terms of establishing a 
model structure to incorporate transmission of smoking behaviour into an economic 
evaluation model, but the model was not populated. Therefore, gaps existed as to how to 
populate this model structure, and to adapt the model structure to incorporate the 
external effects under consideration in this thesis. Therefore, the static Markov model 
structure I replicated from Flack et al (2007) and used to evaluate the different smoking 
cessation interventions in Chapter 4, and the one I used to incorporate passive smoking, 
in chapter 5, were linked and adapted to reflect the transmission dynamic model of 
smoking. The only difference from the Markov model used to incorporate passive 
smoking in chapter 5 with the dynamic model I built in this chapter is that the Markov 
model assumes a constant force of infection and, therefore, the uptake of smoking does 
not depend on the number of smokers in the population. There is a need to 
accommodate a force of infection dependant on the number of smokers in the 
population to account for the transmission of smoking behaviour. The author also 
consulted with an expert on the transmission dynamic model, Professor John Edmunds, 
to confirm suspicions about the unique difference between a static and dynamic model, 
dependence on number of current infectious individuals in the population (i.e. smokers). 
Therefore, to accommodate the transmission of smoking behaviour and allow the 
comparison of the model structures of economic evaluation models in this chapter with 
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those of previous chapters, the static Markov model was transformed to a transmission 
cohort dynamic model. In this occasion, the model contains two cohort of people, a 
smokers cohort (cohort a) and a passive smokers cohort (cohort b). The cohort of 
passive smokers (cohort b) depends on the number of smokers (cohort a). In cohort a, 
when smokers quit or former smokers relapse smoking this influences the number of 
passive never smokers becoming non-passive never smokers in the population and 
otherwise. Therefore, the number of never-smokers who are living with smokers 
accounts for the influence of a cohort of current smokers in the population. 
 
 
Markov-type approach 
To develop the two-cohort dynamic model using a Markov-type approach, explicit 
assumptions about the smoking transmission route are made. Transmission of smoking 
behaviour (new cases of smokers) is build using two cohorts model: (a) a first cohort of 
1000 smokers between 16 and 69 years (cohort a), who cohabitates with (b) a never-
smokers cohort between 16 and 25 years (cohort b). The never smokers cohort is 
derived from multiplying the smokers cohort (1000 smokers) by 0.42 passive smokers 
(number of passive smokers generated by a smoker), obtaining the never smokers who 
are at risk of transmission. The model structure for cohort b used in this chapter is based 
on a slightly modified version of the model presented in Chapter 5. The transmission is 
captured by calculating the transition probability from non-passive never smoker to 
passive never smoker (red arrow Y in Figure 7.1) and viceversa (red arrow X in Figure 
7.1), which changes over time, accounting by age and sex differences. See Figure 7.1 
for details of the new dynamic model built using a Markov-type approach.  
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Figure 7.1 Structure of Markov models used to capture transmission of smoking behaviour  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The two new transition probabilities (X and Y) incorporated in the model are needed to 
capture the transmission of smoking behaviour, concept described in Castillo-Garsow 
(2000), and Sharomi and Gumel (2007) and, to allow individual risk of smoking to 
change over time. These two new transitions capture the interaction between the two 
Definition of parameters and variables: 
 
INPNSt ≡
  
Incidence rate for non-passive non-smokers (proportion of NPNSt who start smoking 
during period) 
iPNSt   ≡  Incidence rate for passive non-smokers (proportion of PNSt who start smoking during              
period) 
qt    ≡  Quit rate for cohort a smokers (proportion of St who give up smoking during period) 
rt    ≡  Relapse rate for cohort a ex-smokers (proportion of FSt who start smoking during period) 
mSat   ≡ Mortality rate for cohort a smokers (proportion of Sat who die during period) 
mSbt   ≡ Mortality rate for cohort b smokers (proportion of Sbt who die during period) 
mFSat   ≡ Mortality rate for cohort a ex-smokers (proportion of FSat who die during period) 
mFSbt   ≡ Mortality rate for cohort b ex-smokers (proportion of FSbt who die during period) 
mNPNSt   ≡ Mortality rate for non-passive non-smokers (proportion of NPNSt who die during period) 
mPNSt   ≡ Mortality rate for passive non-smokers (proportion of PNSt who die during period) 
 
Xt  ≡ Proportion of PNS moving to NPNS during time period 
Yt  ≡ Proportion of NPNS moving to PNS during time period 
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cohorts, smokers (cohort a) and passive smokers (cohort b, adults between 16 and 25 
years susceptible to be influenced to become a smoker because of living with a smoker). 
 
The two health states, non-passive and passive never smokers, interact via variables X 
and Y. For further details, see equation 7.3 for the transition probability from passive 
never-smoker to non-passive never smoker and, equation 7.4 for the transition 
probability from non-passive never smokers to passive never-smokers.  
 
(Equation 7.3) 
 
 
 
where Xt is the proportion of passive never-smoking cohort b people, between 16 and 
25 years, living with a smoker who quit or died last year.  This has two components, 
one for the smokers cohort a people and one for the passive never-smokers cohort b 
people; u is defined as the number of never-smokers living with each smokers (i.e 
passive smokers), and w as the number of never-smokers living with each never smoker. 
 
 
(Equation 7.4) 
 
 
 
Similarly, Yt is the proportion of non-passive non-smoking cohort b living with 
somebody who took up smoking last year, and therefore, considering a component for 
cohort a people, and for cohort b people. 
 
The starting population has a u fixed, as detailed previously in this section (u=0.42). 
When cohort a starts aging, u is recalculated for each time period in cohort b dividing 
the number of passive smokers in cohort a from previous time period by the current 
number of smokers in cohort a from previous time period. 
 
For simplicity reasons, the number of never-smokers living with each never-smoker 
could assumed to be equal to zero (w=0), and therefore, no transmission of smoking 
behaviour occur between never-smokers living with never-smokers. 
( ) ( )bttbtattatt mSqSwmSqSuX 111111 ** −−−−−− +++=
)***(*** 11111111 −−−−−−−− +++= tttttbttatt iPNSPNSiNPNSNPNSrFSwrFSuY
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Therefore, the transmission of smoking behaviour has been modelled indirectly by 
assuming that as smokers quit, this shifts never-smokers from the PNS to the NPNS 
categories, and as the latter have a lower rate of smoking uptake this reduces the number 
of new smokers in the future. But, this is again assuming that transmission of smoking 
behaviour only works thorugh people living in the same house. This is an illustrative 
approach used in this thesis, but others ways to model the transmission exist. This will 
be discussed in section 7.4. 
 
Death rates in cohorts a and b are all cause mortality rates, same as in previous models 
(from M1 to M7). However, the death and incidence rates of cohort b are particular 
from a group of people aged between 16 and 25 years.  
 
Each cycle in these equations, likewise previous models (described in Chapters 4, 5 and 
6) is a function of one or more of the state variables NPNS, PNS, S and FS meaning that 
the value of the terms change as the state variable changes. Transition probabilities 
among different health states were calculated, same as in chapters 5 and 6. 
 
 
 7.2.3 Model parameters 
In order to run the model, a number of key input parameters, as with models detailed in 
chapters 5 and 6, were required: uptake of smoking; prevalence of smoking habits; 
mortality; quit and relapse rates; effectiveness rates; and, prevalence, costs and QALYs 
associated with passive smoking. In order to allow for comparisons among models, 
parameters of both static and dynamic cohort models were the same as in chapter 5 and 
chapter 6. This is also the case for uptake rate of smoking. Therefore, data values for 
these parameters were obtained from a variety of sources which are described in 
Chapter 5 and 6 (section 5.2.2, Chapter 5; and section 6.2.2, Chapter 6). The only 
difference between parameters used in cohort b and previous models (M4, M5, M6 and 
M7) is that because this is a cohort of adult people in a particular age interval, the 
transition probabilities used for all parameters has been calculated from the averaged 
different rates from 16 to 25 years old. 
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7.2.4 Time horizon 
The time horizon of the models accounting for smoking transmission behaviour (M8 
and M9) and not accounting for it (M10 and M11) is set to the lifetime period. 
 
7.2.5 Discount rate 
Both costs and benefits (QALYS) in the model have been discounted at an annual rate 
of 3.5%, according to NICE guidelines (National Institute for Health and Clinical 
Excellence, 2004) and as for previous models in chapters 5 and 6. 
 
7.2.6 Cost-effectiveness ratios and net monetary benefit 
The same methods used in M4 and M5 were applied to calculate ICERs and NMB for 
each intervention (see for details section 5.2.5, Chapter 5). NMB estimates were 
calculated using a £20 000 threshold.  
 
7.2.7 Uncertainty 
Deterministic and stochastic sensitivity analysis was carried out as in chapters 5 and 6 
to study parameter uncertainty.  
 
7.2.7.1 Choosing distributions for the parameters 
The same distributions used in chapters 5 and 6 were chosen for parameters. Moreover, 
the same number of replications performed in M4, M5, M6 and M7 were calculated for 
M8, M9, M10 and M11.  The probabilistic sensitivity analysis accounted for variability 
in the smoking incidence (same as in chapter 5 and 6). 
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7.2.7.2 Cost-effectiveness acceptability curves  
As reported for M4 and M5, and M6 and M7 cost-effectiveness acceptability curves of 
different interventions were provided for M8, M9, M10 and M11 (see for more details 
section 5.2.6.2, Chapter 5; and, 6.2.6.2, Chapter 6). 
 
7.3 Results 
The dynamic models outlined in this chapter were evaluated to estimate lifetime costs 
and QALYs lost of: (a) incorporation of transmission of smoking behaviour itself (M8 
versus M10), and (b) transmission of smoking behaviour and passive smoking using a 
dynamic cohort model (M9 versus M11). The results reported in this section are 
including results for cohorts a and b. 
 
 
7.3.1 Accounting or not for transmission of smoking behaviour (M8 versus M10) 
The transmission dynamic model for adults outlined in this chapter was evaluated to 
estimate average lifetime costs and QALYs lost for lifetime period. Results are shown 
in Table 7.2, differentiating between the model not including transmission of smoking 
behaviour itself (M8) and the model including transmission of smoking behaviour 
(M10) for cohorts a and b.   
 
Table 7.2 M8 and M10 estimates of average lifetime costs per smoker and QALYs lost per passive 
smoker smoker where transmission of smoking behaviour may and may not occur (cohort of 417 adult 
passive smokers; between  16 and 25  years old ; lifetime period reaching 100 years; starting distribution: 
passive never smokers) 
 
 
When including transmission of smoking behaviour there is an extra saving on cost per 
passive smoker for the most cost-effectiveness intervention of £1736.28, and an 
Interventions Discounted 
average COST 
per adult 
(M8) 
Discounted 
average 
COST per 
adult (M10) 
Discounted 
QALYs lost 
per adult 
(M8) 
Discounted 
QALYs lost  
per adult 
(M10) 
NMB  per 
adult  
(M8) 
NMB  per 
adult 
(M10) 
NI  16849.21 16427.10 8.3498 8.2710   
LICB 16705.27 15878.60 8.3430 8.1881 280.67 2205.76 
NPPCBP 16341.05 14604.77 8.3262 8.0003 979.86 7235.80 
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additional QALY lost reduced per passive smoker of 0.3259 (See graph 7.1). This is due 
to the benefits of the smoking cessation intervention on the never-smokers population 
living with smokers in the same household. 
 
 
Graph 7.1 Lifetime costs and lifetime QALYs lost per passive smoker not accounting (M8) and 
accounting for transmission of smoking behaviour (M10) 
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In summary, the impact of acconting for the transmission of smoking behaviour into an 
economic evaluation of smoking cessation programs lies in a cost saving of £1736.28 
per passive smoker and less QALYs lost reduced per passive smoker of 0.3259.  
 
7.3.2 Accounting or not for transmission of smoking behaviour and passive 
smoking (M9 versus M10) 
This particular dynamic model was evaluated to estimate average costs and QALYs lost 
for lifetime period accounting and not for transmission of smoking behaviour and 
incorporating passive smoking. Results are shown in Table 7.3, differentiating between 
M9 (model including passive smoking) and M11 (model including transmission of 
smoking behaviour and passive smoking) for cohorts a and b.  
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Table 7.3 M9 and M11 estimates of average lifetime costs and QALYs lost per passive smoker where 
passive smoking in adults and children is incorporated and transmission of smoking behaviour may and 
may not occur (cohort of 427 adult passive smokers + (96.5% of adult smokers children); between 16 and 
25 years  (+ 0-15 years); lifetime period reaching 100 years; starting distribution: passive never smokers) 
 
 
When adding transmission of smoking behaviour to passive smoking, adults, and 
children passive smoking, there is an extra saving on cost per passive smoker for the 
most cost-effectiveness intervention of £1874.91, and an additional QALY lost reduced 
per passive smoker of 0.4199. (See graph 7.2). 
 
 
Graph 7.2 Lifetime costs and lifetime QALYs lost per passive smoker adult accounting for passive 
smoking in adults and children (M9) and passive smoking and transmission of smoking behaviour (M11) 
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In summary, the impact of introducing one or two external effects into an economic 
evaluation of smoking cessation programs lies in an extra saving cost of £138.63 per 
passive smoker and less QALYs lost reduced per adult and adult smoker’s children of 
0.094.  
Interventions Discounted 
average COST 
per adult 
(M9) 
Discounted 
average 
COST per 
adult (M11) 
Discounted 
QALYs lost 
per adult 
(M9) 
Discounted 
QALYs lost  
per adult 
(M11) 
NMB  per 
adult  
(M9) 
NMB  per 
adult 
(M11) 
NI  17275.08 16819.34 8.7430 8.6475   
LICB 17131.15 16238.52 8.7362 8.5408 280.67 2713.61 
NPPCBP 16766.93 14892.02 8.7194 8.2995 979.86 8885.90 
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7.3.2.1 Parameter uncertainty 
Although the deterministic sensitivity analysis on background quit rate and intervention 
costs were not uncertainties particularly related to the transmission of smoking 
behaviour, this sensitivity analysis was calculated for consistency with Flack et al 
(2007) and, previous chapters of this thesis. Neither the deterministic sensitivity 
analysis on background quit rate nor intervention costs equal to zero had an impact on 
the ranking of ICER and NMB in M8, M9, M10 and M11, as expected, though the 
estimates changed.  
Having specified distributions for all the relevant parameters of the models M8, M9, 
M10 and M11 (same distributions as for M4, M5, M6 and M7), the probabilistic 
analysis was undertaken. First, results for M8 and M10 are presented, and later on for 
M9 and M11.  
Including transmission of smoking behaviour (M8 versus M10)  
A total of 1000 replications from the model are presented on the cost-effectiveness 
plane in Graph 7.3 for the model including including transmission of smoking 
behaviour. Graph 7.3 shows that the majority of simulations lie in the third quadrant 
from the cost-effectiveness plane. For M8, the 95% CI on costs is (-518.06, -497.36) 
whereas for QALYs lost is (95%CI (0.1515, 0.2221) for the most cost-effective 
intervention (NPPCBP).Whereas for M10, the 95% CI on costs is (-1845.39, -1800.78) 
whereas for QALYs lost is (95%CI (0.0915, 0.4473) for the most cost-effective 
intervention (NPPCBP). 
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Graph 7.3 Monte Carlo simulation results on the cost-effectiveness plane for M8 and M10 (including 
transmission of smoking behaviour)  
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A graphical representation of the uncertainty around NMB, when including (M10) or 
not (M8) the impact of transmission of smoking behaviour in the most cost-effective 
intervention is presented in Graph 7.4.  
 
Graph 7.4 NMB when including transmission of smoking behaviour in the most cost-effective 
intervention (NPPCBP EE; M10) or not (NPPCBP; M8) 
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Cost-effectiveness acceptability curves were calculated for incorporating external 
effects. However, because when external effects are introduced the NPPCBP 
programme is most cost-effective intervention with a 100% probability, cost-
effectiveness acceptability curves are not considered much explanatory, and therefore 
histograms of NMB for the most cost-effective intervention are presented instead, as in 
previous chapters 5 and 6. Graph 7.5 presents the histogram of NMB when transmission 
of smoking behaviour is not accounted for and Graph 7.6 when it is. Graph 7.5 shows 
that the median (IQR) NMB was estimated approximately £1000 per QALY. Overall, 
90% of estimates were estimated to have a point estimate of NMB below £3500. 
Whereas is Graph 7.6, when transmission of smoking behaviour is accounted for, the 
median (IQR) NMB was estimated approximately £7250 per QALY. Overall, 90% of 
estimates were estimated to have a point estimate of NMB below £9500. 
Graph 7.5 Distribution of predicted NMB for NPPCBP at M8 
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Graph 7.6 Distribution of predicted NMB for NPPCBP at M10 
0
10
20
30
40
50
60
70
£0
£1
00
0
£2
00
0
£3
00
0
£4
00
0
£5
00
0
£6
00
0
£7
00
0
£8
00
0
£9
00
0
£1
00
00
£1
10
00
£1
20
00
NMB
Fr
eq
u
en
cy
0%
20%
40%
60%
80%
100%
120%
Frequency
% acumulated
 
157 
 
Graph 7.7 shows that around 100 iterations, the results for the most cost-effective 
intervention when not incorporating transmission of smoking behaviour (M8), are 
stable, therefore, the results from these thousand iterations seems to be robust. 
However, around 650 iterations are needed when the transmission of smoking 
behaviour is incorporated. 
 
Graph 7.7 Cumulative NMB average for LICB and NPPCBP in M8 and M10 
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Including transmission of smoking behaviour and passive smoking (M9 versus M11) 
A total of 1000 replications from the model are presented on the cost-effectiveness 
plane in Graph 7.8 for the model including passive smoking and transmission of 
smoking behaviour. Graph 7.8 shows that the majority of the 1000 simulations lie in the 
third quadrant from the cost-effectiveness plane. When passive smoking is introduced in 
the model the 95% CI on costs is (-518.06, -497.36) and the 95%CI on QALYs lost is 
(0.1515, 0.2221). However, when transmission of smoking behaviour and passive 
smoking are introduced the 95% CI on costs is (-1951.82, -1904.53) and the 95%CI on 
QALYs lost is (0.1688, 0.5243).  
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Graph 7.8 Monte Carlo simulation results on the cost-effectiveness plane for M9 and M11 (including 
transmission of smoking behaviour)  
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A graphical representation of the uncertainty around NMB, when including the impact 
of passive smoking and transmission of smoking behaviour (or not) in the most cost-
effective intervention is presented in Graph 7.9. Higher NMB is observed when 
transmission of smoking behaviour is added to passive smoking. 
 
Graph 7.9 NMB when including passive smoking in the most cost-effective intervention (NPPCBP EE; 
M11) and including passive smoking and transmission of smoking behaviour (NPPCBP; M9) 
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Cost-effectiveness acceptability curves were also calculated for not incorporating (M9) 
and incorporating (M11) transmission of smoking behaviour, but they were again not 
considered much explanatory, and therefore histograms of NMB for the most cost-
effective intervention are presented instead, as in previous chapters 5 and 6. Graph 7.10 
presents the histogram of NMB when passive smoking is introduced and Graph 7.11 
when passive smoking and transmission of smoking behaviour. Graph 7.10 shows that 
the median (IQR) NMB was estimated approximately £1000 per QALY. Overall, 90% 
of estimates were estimated to have a point estimate of NMB below £3250. However, 
graph 7.11 shows that the median (IQR) NMB was estimated approximately £9000 per 
QALY. Overall, 90% of estimates were estimated to have a point estimate of NMB 
below £11250. 
Graph 7.10 Distribution of predicted NMB for NPPCBP at M9 
0
50
100
150
200
250
300
350
£0
£1
00
0
£2
00
0
£3
00
0
£4
00
0
£5
00
0
£6
00
0
£7
00
0
£8
00
0
£9
00
0
£1
00
00
£1
10
00
£1
20
00
NMB
Fr
eq
u
en
cy
0%
20%
40%
60%
80%
100%
120%
Frecuency
% acumulated
 
 
Graph 7.11 Distribution of predicted NMB for NPPCBP at M11 
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Graph 7.12 shows that around 100 iterations, the results for the most cost-effective 
intervention when not incorporating transmission of smoking behaviour but 
incorporating passive smoking, are stable, therefore, the results from these thousand 
iterations seems to be robust. However, when passive smoking and transmission 
smoking behaviour are accounted for, up to 650 iterations are needed to reach results 
stability. 
Graph 7.12 Cumulative NMB average for LICB and NPPCBP in M9 and M11 
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
10000
100 200 300 400 500 600 700 800 900 1000
Iterations
N
M
B Cumulative NMB
average
NPPCBP EE
(M11)
Cumulative NMB
average
NPPCBP (M9)
 
 
7.4 Discussion 
 
This model incorporates an important aspect associated with tobacco smoking, smoking 
transmission behaviour, which had not been accounted in the two previous models 
described in this thesis. This investigation could inform the current policy debate 
regarding the most cost-effective smoking cessation programs. To my knowledge, 
published economic evaluation of smoking cessation interventions to date has not 
addressed dynamics of smoking behaviour.  
To incorporate transmission of smoking behaviour, two cohorts of people were needed, 
trying to capture the influence of a cohort smokers over a passive never smokers cohort. 
This was the main difference between models from previous chapter 5 and 6. The 
starting population of the model is different, though the structure of the model is 
preserved. According to the results, the transmission of smoking behaviour has more 
impact on lifetime costs and QALYs lost estimates than passive smoking and smoking 
161 
 
during pregnancy. However, difficulties in terms of lack of data were encountered in 
trying to capture the transmission of smoking behaviour, and therefore results need to 
be carefully interpreted. Lifetime costs and QALYs were also significantly different 
when passive smoking was also incorporated in the dynamic model. As expected, 
changes of the cost-effectiveness ranking were not detected. When passive smoking is 
already incorporated in the economic evaluation and a second external effect, 
transmission of smoking behaviour is added, a greater impact in terms of extra lifetime 
costs and QALYs lost is observed. The impact of transmission of smoking behaviour is 
shown by the difference, in terms of extra lifetime costs and QALYs lost per passive 
smoker when comparing M8 to M10 (£1736.28 and 0.3259 QALYs lost per passive 
smoker) model. Moreover, in the model including passive smoking, the impact of 
transmisison of smoking behaviour is shown by the comparison between M9 and M11 
(£1874.91 and 0.4199 QALYs lost per passive smoker). 
 
Although mathematical modelling has been extensively used to address questions of 
public health importance, not much has been done in terms of the mathematical 
modelling of human social behaviour (Brisson et al, 2000; Brisson and Edmunds, 2003; 
Trotter et al, 2005). In particular, with the exception of the basic model in Brauer and 
Castillo-Chavez (2000) and Castillo et al (2000), and the extended model in Sharomi 
and Gumel (2007), the author is not aware of any mathematical study for fully 
examining the impact of smoking in human population. In addition, none of the existing 
models has incorporated external effects such as passive smoking or smoking during 
pregnancy. This chapter demonstrates the possibility of transforming a static model 
currently informing decision making (ie Flack et al, 2007) into a “dynamic” model. 
 
However, it might be that I can not claim that this is a true “dynamic model”. The 
cohort of passive never smokers declines as the model runs.  This is because i) I am not 
replacing them with new susceptible contacts of the initial smoking cohort (e.g. as 
cohort a’s children move into the 16-25 age group), but also ii) there is no onward 
transmission from cohort b (e.g. to their children).  Therefore, my “dynamic model” is 
missing second and higher order transmission. How much this matters depends on the 
circumstances (the force of infection, mixing patterns, etc).  If transmission is weak, the 
second and higher order effects will not make much of a difference to the overall costs 
and effects.  But if transmission is strong, they could outweigh the immediate costs and 
effects for cohorts a and b (as with an epidemic of an infectious disease).   
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This unconventional approach undertaken has advantages and limitations in relation to a 
more conventional transmission dynamic model. The main advantage is to use a 
common decision analytic tool, such as Markov model, to capture the transmission of 
smoking behaviour. Therefore, it encourages the incorporation of relevant but 
complicated external effects, such as the transmission of smoking behaviour, in simple 
model structures which are used to inform policy making. This fact implies that not 
extended changes need to be done to the existing economic evaluation models to try to 
capture broader costs and benefits, and to incorporate the societal perspective into the 
analysis. However, these advantages also need to be weighted by some limitations. 
Some assumptions as the household context; number of passive smokers generated by 
the smokers living in a household are generated; not capturing the transmission of 
smoking behaviour from adult smokers to other non-adults members of the family, such 
as children; or not chance to capture different influence on transmission of smoking 
behaviour according to the particular age of the population need to be considered and 
recognised when unconventional transmission dynamic approaches are used. Whereas 
the transmission of smoking behaviour is mainly captured by the probability that a non-
passive or passive never smoker comes into effective direct or indirect contact with a 
smoker (β), unconventional approaches need to try to capture this transmission through 
modelling different inter-relations into the model, through many times the steps to do so 
are more transparent and understandable for those who are responsible for taking 
decisions. 
 
There is not necessarily a conceptual difference between the conventional dynamic 
model and a Markov-type approach. The later is just a simplified implementation of the 
former. In both the number of people in a given state at a given time is just the number 
of people in that state at the previous time point, plus people who entered between the 
two time points, and minus those who left between the two time points. The main 
difference regarding the transition probabilities between the health states represented in 
the dynamic model detailed in Appendix 7.4 and the static model structure used so far 
(for M4, M5, M6 and M7) is that the number of potential smokers (i.e never smokers) 
depends on the number of smokers in the population. So far, this has not been 
considered and incorporated into the cohort model. However, an important difference 
between a cohort model as the one presented in this chapter and a population dynamic 
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model is that in a conventional population model I would model a whole population 
with replacement, whereas in here I have modelled a cohort of 1000 smokers. 
 
Regarding the model structure, there is also a difference around the never smokers 
health state. Although from chapter 5 onwards, never smokers’ health state (i.e potential 
smokers) has been considered in the model, this had been divided in two different health 
states: non-passive and passive never smokers. However, Sharomi and Gumel (2007) 
did not differentiate between non-passive and passive never smokers health state, where 
it is assumed that both health states are included in the non-smokers group. Therefore, 
the graphical representation of Box 7.1 and the differential equations from Box 7.2 
should be adapted to contemplate the division of the non-smokers health state (see 
Appendix 7.4 for further details). The only difference between Box 7.1 and Figure 7.1 is 
that the transmisison of smoking behaviour (coloured in red in Box 7.1) needs to be 
captured and built into the Markov Model structure (arrows in red in Figure 7.1), 
making that rate dependant on the number of smokers in the population. 
 
Recruitment of new individuals into the non-smokers health state was considered and 
included in the basic dynamic model approach by Sharomi and Gumel (2007), whereas 
no groups of people entering in the model were allowed in previous models built in 
Chapter 5 and 6 from this thesis. For simplication for the purposes of the PhD, it was 
decided to stick to that decision and to not incorporate new people entering in the 
model. 
 
Unlike Sharomi and Gumel (2007) in the Markov model approach: (a) no distinction is 
made according to frequency of smoking among individuals, and between those 
smokers who quit smoking either temporarily or permanently because there was no time 
for this within the scope of this PhD; and, (b) transmission of smoking behaviour is only 
considering the household context due to data limitations. This last limitation should be 
considered reasonable regarding the recent smoke-free law which does not allow 
smoking neither at work or public places. Thus, the household is assumed to be the 
place where passive smoking more intensively occurs. 
 
Although not considered in this thesis, other factors such as tobacco advertising and 
mass consumption of tobacco in the community could influence this process (and, 
164 
 
hence, should be included in the function governing the generation of new smokers in 
the community). 
 
The degree, or frequency, of smoking, where some smokers do so in a mild manner 
(categorised as mild smokers) while others may smoke more frequently (defined as 
chain smokers) per unit time should be further explored in the model. The transition 
dynamics (back-and-forth movement) between these subclasses of varying smoking 
frequencies is recommended for incorporation into a model to further explore its 
influence. However, to do so, would require good epidemiological data regarding the 
frequency of smoking, as of starting smoking, and number of cigarettes smoked every 
day. There is no quality data on rate of number of new smokers, as detailed in section 
5.2.1 in Chapter 5, by age and the number of cigarettes you smoke. This particular data 
is key for dynamic models of smoking, because this is one of the variables used to 
calculate the force of infection. Panel data could be really useful to calculate the trend of 
the probability of uptake of smoking by age. It would, however, be preferable to have 
such data classified by whether current smokers were passive smokers prior to the 
uptake of smoking in order to capture the transmission of smoking behaviour estimate. 
 
Further research could be carried out in order to study the transmissibility of smoking 
behaviour. The basic reproduction number (Ro, which is a composite measure of the 
transmissibility, is the main component of the force of infection), can be defined as the 
average number of people who start smoking produced by one smoker introduced into a 
never smoker population, should be explored. This basic reproduction number has not 
been calculated in this model because it is out of the scope of this thesis, but it is 
assumed to be captured in the force of infection concept. To calculate a better estimate 
of the force of infection, there is a need to explore and calculate the basic reproduction 
number of smoking. It would also be interesting to know the epidemic feature of 
smoking (Gomes et al, 2005), how the force of infection evolves with times passes and, 
how the smoking cessation interventions are influencing the trend of that parameter. 
With a more complete understanding of lifetime smoking dynamics, it would be 
possible to forecast how overall population smoking rates would vary in the short and 
long run 
 
According to Bantle and Haisken-DeNew (2002), youths living in families with both 
parents smoking are 3.3 times more likely to smoke themselves, while a ‘smoking’ 
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father raises the probability by the factor 2.8 and a ‘smoking’ mother by the factor 2.1. 
Therefore, further research should be done in the future trying to distinguish these 
grades of influence according to sex.  
 
Apart from passive smokers, data was extrapolated from a household context (see 
section 5.2.2, Chapter 5). This is intuitive as the closer you are to a smoker, and 
therefore you are considered a passive smoker, the more you are likely to be influenced 
by the smoking behaviour. However, this feature could be further explored (i.e. 
transmission of smoking behaviour when you are a never smoker by media or other 
forms of influencing people). 
 
The dynamic model built in this chapter incorporates a proxy for a heterogeneous 
mixing pattern of population to describe the transmission dynamics of smoking 
behaviour. This indicates that transmission of smoking behaviour exists with people 
between 16 and 25 years old. However, Flay et al (1994) shows the existence of 
differential influence of parental smoking and friend’s smoking on adolescent smoking. 
Also, peer effects have also been widely studied. Therefore, future ‘smoking’ dynamic 
models could account for the different relationship of smoking by age to smoking 
uptake and cessation by different age groups. Social interactions play a prominent role 
in determining behavioural and economic outcomes on smoking. These issues 
concerning interactions effects are sure to remain a fertile ground for future research. 
Moreover, in the future, this type of model taxonomy could be transferred to study the 
impact of dynamics on public health interventions of other behavioural problems, such 
as obesity (Christakis and Fowler, 2007) or alcohol (Mortimer and Segal, 2006). 
 
The person-to-person spread of smoking cessation appears to have been a factor in the 
population-level decline in smoking in recent decades (Christakis and Fowler, 2008). 
Moreover, there appear to be different clusters in the society (age groups, people with 
same social activities, receiving same type of education and attending same institution, 
etc) within the social network which could lead to different transmission of smoking 
behaviour patterns (Christakis and Fowler, 2008). This suggest a potential further 
research step to create a network of analytic methods to study the extent of the person-
to-person spread of smoking behaviour and the extent to which groups of widely 
connected people quit together, though it seems that not much data is available to do it 
reliably.  
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This chapter shows that including dynamic effects seems to be worthy. Although there 
is a need to recognise that there is no good data available on the contact rate between 
smokers and never smokers, which drives the impact of transmission of smoking 
behaviour, the numerical impact seems not to be important. Therefore, the conclusions 
of this chapter seem to point that developing a dynamic model seem to be worthy to 
incorporate transmission of smoking behaviour in economic evaluation of smoking 
cessation interventions. Further research on getting a better estimate on the beat 
parameter could be plausible; however, policy making regarding smoking cessation 
programmes is likely not to be affected by the findings. 
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CHAPTER 8 Comparison of all models including and not external 
effects 
 
8.1 Introduction 
Chapter 8 compares the models used in chapters 5 to 7 (M4 to M11) to explore the 
potential impact of incorporating external effects into decision-making for public health 
programmes. It considers the size of the various external effects valued in this thesis and 
their relative importance in terms of costs and QALYs. The comparison also provides a 
natural point for reflection on the methods by which to incorporate external effects into 
the economic evaluation of public health programmes. In so doing, this chapter: (a) 
compares the incorporation of the impact of passive smoking, smoking during 
pregnancy and transmission of smoking behaviour into the economic evaluation of 
smoking cessation programmes and (b) examines the methods used to incorporate 
external effects into economic evaluation of those interventions. 
Although the results of all eleven smoking cessation programmes have been calculated, 
this chapter focuses mainly on the most cost-effective intervention because the ranking 
of cost-effectiveness did not vary between interventions. 
 
8.2 Value of incorporating passive smoking, smoking during pregnancy and 
transmission of smoking behaviour in the economic evaluation of smoking 
cessation programmes  
 
The main purpose of this section is to compare and contrast the eight models presented 
in chapters 5 to 7 some of which include external effects and others that do not. 
 
Table 8.1 shows the differences across models in terms of costs and QALYs lost 
according to the population group modelled. This table presents results separately for 
those models dealing with the general population, those focusing on pregnant women, 
and those focused on a cohort of smokers (cohort a) generating a cohort of passive 
smokers (cohort b). Cost and QALYs in M5 represent the burden on the 3.5% of adult 
passive smokers and the 96.5% of child passive smokers in the population that is 
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generated by the 22% of the population modelled who are smokers. The starting 
population in this case was 1000 adults categorised according to their smoking status. 
However, in M6 where the population (n=1000) is pregnant women the effects of 
smoking during pregnancy are accounted for in the ‘burden’ identified as the average 
number of babies delivered by pregnant woman (M7). Costs and QALYs from the 
general and pregnant population are difficult to compare because these groups 
experienced different smoking cessation programmes and varying levels of 
effectiveness’ (NPPCBP for general population and BAD for pregnant women). For 
instance, the interventions for pregnant women are specifically designed for this 
particular group of the population. Moreover, from M8 to M11, the starting population 
is a cohort of 1000 smokers and a cohort of 417 passive smokers. This also adds 
difficulties on the comparisons among models. The table below presents the standard 
error of the difference between the two means, which was calculated using the methods 
of unequal variance (Armitage et al, 2002):  
 
SE (avg1 – avg2) = √ ((s1^2/n1)+(s2^2/n2));  (E8.1) 
 
where “avg” is average, ‘s’' the standard deviation of each mean, and ‘n’ the sample 
size. 
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Table 8.1 Comparison of incremental lifetime costs, QALYs lost and NMB differences per person between models for the most cost-effective intervention (from M4 to M11) 
 
                                                 
70
 The NMB is calculated when a QALY (lost or gained) is valued at £20 000. 
Models Description of models Most cost-
effective 
intervention 
Discounted 
average 
COST per 
adult or 
pregnant  
Incremental 
cost (mean 
and SE) 
Differences 
in COST 
Discounted 
average 
QALYs lost  
per adult or 
pregnant  
Incremental 
QALY lost 
(mean and 
SE) 
% 
Differences 
in QALYs 
lost  
NMB70 Incremental 
NMB (mean 
and SE) 
% 
Differences 
in NMB 
Units 
General adult population 
M4 
Replication of Flack et al (2007) model with 
relevant changes considered and changes to 
the starting distribution of population 
NPPCBP 
 
3582.76 
 
 
base case base case 
 
3.4024 
 
 
base case 
 
base case 
 
1267.66 
 
base case 
 
base case 
 
per adult  
lifetime 
M5 
 
M4 including passive smoking 
 
NPPCBP 
 
3736.83 
 
 
154.07 
(79.98) 
4.30% 
 
3.5022 
 
 
0.0998 
(0.0673) 
 
2.93% 
 
2460.12 
 
1192.46 
(85.20) 
 
94.06% 
 
per adult  
lifetime 
Pregnant women population 
M6 
 
 
Replication of Flack et al (2007) model, for 
females only, with relevant changes 
considered, including changes to the starting 
distribution of population 
BAD 
 
 
1433.82 
 
 
 
base case base case 
 
 
4.0995 
 
 
 
base case 
 
base case 
 
645.20 
 
base case 
 
base case 
per pregnant 
woman during 
pregnancy 
M7 
 
 
M6  including impact of newborn babies 
from smokers mothers 
 
BAD 
 
 
1543.76 
 
 
109.94 
(8.94) 
7.66% 
 
 
4.3239 
 
 
0.2244 
(0.0285) 
5.47% 2989.97 2344.77 
(136.06) 
363.42% per pregnant 
woman during 
pregnancy 
Smokers (cohort a) and passive smokers (cohort b) 
M8 
 
 
M3 used to model a cohort of 1000 smokers, 
and M4 used to model a cohort of 417 
passive smokers generated by a smoker. Not 
including transmission of smoking behaviour 
NPPCBP 
 
16341.05 
 
base case 
 
base case 
 
8.3262 
 
 
base case 
 
 
base case 
 
 
979.86 
 
base case 
 
 
base case 
 
 
per adult  
lifetime 
M10 
 
 
M8 including transmission of smoking 
behaviour 
NPPCBP 
 
14604.77 
 
-1736.28 
(280.34) -11.88% 
 
8.0003 
 
-0.3259 
(0.0777) 
-4.07% 7235.80 6255.94 
(193.74) 
638.45%  
per adult  
lifetime 
M9 
M3 used to model a cohort of 1000 smokers, 
and M4 used to model a cohort of 417 
passive smokers generated by a smoker. Not 
including transmission of smoking behaviour 
but including passive smoking 
NPPCBP 
 
 
16766.93 
 
 
 
 
base case 
 
base case 
 
 
8.7194 
 
 
 
 
base case 
 
 
 
base case 
 
 
 
979.86 
 
 
base case 
 
 
 
base case 
 
 
per adult  
lifetime 
M11 
M9 including transmission of smoking 
behaviour and passive smoking 
NPPCBP 
 
14892.02 
 
 
-1874.91 
(280.87) 
-12.59% 
 
8.2995 
 
 
-0.4199 
(0.0908) 
 
-5.06% 
 
8805.90 
 
7826.04 
(216.94) 
 
798.69% 
 
per adult  
lifetime 
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The lifetime discounted average cost and lifetime discounted QALYs lost from an adult 
population (M4) are compared with results obtained when passive smoking of adults 
and children (M5 for adult and child passive smokers. The biggest impact in terms of 
NMB is for transmission of smoking behaviour (see Table 8.1). When M5 (adult 
population including adult and child passive smokers) is compared with M4 (adult 
population) lifetime costs per adult increase by 4.30%, lifetime QALYs lost by 2.93% 
and NMB by 94.06%.  
For the population of pregnant women, discounted lifetime average cost and discounted 
lifetime QALYs lost (M6) are compared with results obtained when health impacts on 
babies’ first year of life (M7) are incorporated. When M7 (pregnant women, including 
average number of babies delivered per pregnancy) is compared with M6 (pregnant 
women) lifetime costs increases by 7.66%, lifetime QALYs lost by 5.47% and NMB by 
363.42%.  
For the smokers and passive smokers cohorts discounted lifetime average cost and 
discounted lifetime QALYs lost are compared. The first comparison tries to isolate the 
transmission of smoking behaviour (M8 versus M10) and the second comparison adds 
the impact of transmission of smoking behaviour on top of passive smoking 
consequences.  In both cases, the transmission of smoking behaviour when a smoker 
cohort is receiving smoking cessation interventions highlights a positive external effect 
in terms of savings costs and QALYs lost to the population. This external effect seems 
to be the most relevance in terms of costs and QALYs gained. 
No prior comparison of the importance of these external effects exists in economic 
evaluations of smoking cessation programmes and there is scant awareness of the 
impact of external effects on economic evaluation outside smoking cessation 
programmes.  Fortunately, however, the Department of Health recognises the effects on 
babies health due to smoking during pregnancy as the principal impact of tobacco on 
others’ health (SCOTH, 2004) and reflects this view in policy its making (for example, 
smoke-free law introduced in public places in UK). The findings of this thesis as to 
which are the most important external effects therefore match both empirical evidence 
and policy direction.    
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The uncertainty of parameters surrounding incremental NMB increases with the higher 
lifetime costs and QALYs lost differences. For instance, there is higher parameter 
uncertainty in the area of costs and QALYs for the general adult population than for 
pregnant women. Therefore, the incorporation of external effects into economic 
evaluation adds bias around the ICER or average NMB, and more uncertainty, but this 
has to be balance against the fact that bias is reduced as more relevant costs and health 
effects are accounted for.  
 
NICE’s ‘Methods for the development of NICE public health guidance’ (2009) 
recommends using ‘reference-case’ assumptions as a basis for cost-effectiveness 
analysis: (a) the perspective on costs should be public sector, including NHS and PSS 
and (b) the perspective on outcomes should include all health effects on individuals. 
This implies that all costs generated by smoking should be included in economic the 
evaluation of smoking cessation programmes. Failing to incorporate external effects, 
therefore, is inconsistent with the advice on the appropriate reference for public health, 
and decision making based on this position involves a degree of bias, because of 
missing costs and health effects generated by smoking, around the ICERs presented in 
the cost-effectiveness analysis of smoking cessation programmes. (i.e. NHS costs and 
health effects of passive smoking including effects on baby health caused by smoking 
during pregnancy are not included in the economic evaluation of smoking cessation 
programmes).  NICE also argues that the guidance development process must ensure 
that all important health effects and resource costs are included in an economic 
evaluation but when external effects are excluded, this does not happen.  
 
The findings of this thesis suggest that transmission of smoking behaviour is the 
external effect with the largest impact. This should, therefore, be considered the most 
important external effect to be incorporated in economic evaluations of smoking 
cessation programs. Interestingly, this external effect also happens to generate the most 
inappropriate and weak data with which to measure and value it. Although much 
research in the last 20 years has focused on the transmission of smoking behaviour 
(Bantle and Haisken-De New, 2002; Harris et al, 2008; Ditre et al, 2008; Alexander et 
al, 2001; Christakis and Fowler, 2008; Simons-Morton et al, 2001; Gilleskie and 
Strumpf, 2000), there is little data on transmission parameters. Chapter 7 highlighted the 
lack of data of the beta parameter which drives the whole model. The beta parameter 
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has been studied for longer in vaccination than other programmes, so better proxies are 
available in that area (Farrington, 1990; Scott et al, 2004). Future research should, 
therefore, encourage better estimates of the beta for the transmission of smoking 
behaviour to improve study of the impact of this external effect.  
The incorporation of external effects produced no difference in the ranking of the cost-
effectiveness of the different public health interventions but this was expected because 
smoking cessation programmes are highly cost-effective.  It follows, therefore, that no 
impact on decision-making could have occurred between competing programmes. Nor 
would the inclusion of these external effects have changed a decision about whether the 
best or worst intervention would be cost-effective, because the evidence already showed 
that the smoking cessation interventions were very efficient uses of public expenditure. 
Adding these external effects would simply further improve their existing levels of 
efficiency.  However, when considering less cost-effective public health programmes 
(i.e. if the ICER were closer to £20,000 or £30,000) this may well have had an effect on 
decision making. To answer this question, future research could focus on the 
incorporation of external effects into less cost-effective interventions than smoking 
cessation programmes. 
There is evidence (Brisson and Edmunds, 2003; Ford et al, 2004; McIntosh et al, 2005) 
that incorporating positive external effects, such as the herd-immunity effect, into 
economic evaluation makes a difference in terms of costs and QALYs. Research for this 
thesis identified a similar pattern for negative external effects. The main positive 
external effect that has been studied so far (herd-immunity effect) and the negative 
external effects assessed in the health area, have been on the consumption side. Findings 
in chapter 3 highlight that in sectors other than health, such as transport or environment, 
external effects on the consumption side have been the most studied part of the market. 
However, external effects do exist on the production side (see Chapter 3), so future 
research could incorporate external effects on the production side and compare both 
their absolute and relative importance with those on the consumption side.  
 
As may be seen in chapter 4, in the areas with a long tradition of measuring and valuing 
external effects, there is no specific criterion as to which external effect to choose. The 
general criterion used by these sectors was the availability of epidemiological data to 
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justify the importance of that particular external effect. Chapter 5, 6 and 7 also highlight 
the importance of considering the availability of data when deciding whether or not to 
incorporate a particular external effect.  In order to sharpen choice when deciding which 
of several different external effects to incorporate into an evaluation when all have 
enough available data on their epidemiological relevance, future research should 
attempt to establish a criterion which will rank the importance of external effects. 
 
 
8.3 Methods for incorporating external effects into the economic evaluation of 
public health interventions 
 
Although it might be assumed that when two different external effects are incorporated 
in an evaluation model, (e.g. transmission of smoking behaviour and passive smoking) 
the impacts on extra lifetime costs and lifetime QALYs lost will be a simple summary 
of individual external effects (i.e. transmission of smoking behaviour plus passive 
smoking or smoking during pregnancy), this may not be the case. This is because the 
populations included in each model are different and therefore the number of total costs 
and QALYs do not lend themselves to simple summitry. For instance, M5 (which 
included the external effect of passive smoking), and M11 (which included transmission 
of smoking behaviour and passive smoking) included a different starting population, 
according to smoking habits and a smokers cohort respectively. The inclusion of 
children increased the population of these two models (M5 and M11) when compared 
with the other models. However, smoking during pregnancy is accounted for by falls in 
the average number of babies delivered at the end of the pregnancy. The populations of 
M6 and M7 were pregnant females, including a group of three month pregnant smokers 
who remained pregnant for the first six-month cycle. M7 (which included smoking 
during pregnancy) included the average number of births per pregnant smoker in 
addition of the cohort of pregnant smokers during the fertile period assumed to be from 
16 years to 44.5 years old. All differences in population across all models suggests that 
ideally, the model best able to incorporate external effects appropriately would be a 
general whole population model rather than one for a cohort. Including everyone in the 
model facilitates the interpretation of results for lifetime costs and QALYs lost, and 
eases comparisons across models with comparable populations.  
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Table 8.3 compares the population characteristics for each model developed in this 
thesis. Appendix 8.1 provides details of the full set of population characteristics and the 
analytic horizon of all models used. 
 
 
Table8.3 Population characteristics from M1 to M11 
 
Models 
Population 
Adults 
 
Passive adults and 
children 
Pregnant 
women 
Average babies from pregnancy 
delivery 
M1 √ x x x 
M2 √ x x x 
M3 √ x x x 
M4 √ x x x 
M5 √ √ x x 
M6 x x √ x 
M7 x x √ √ 
M8* √ x x x 
M9* √ √ x x 
M10* √ x x x 
M11* √ √ x √ 
     √≡ included in the model 
     x≡ not included in the model 
 *≡ different starting population. Model composed by two cohorts: cohort of 1000 smokers (cohort a) and 417 passive smokers   
generated 1000 smokers (cohort b). 
 
 
M1, M2 and M3 considered everyone starting as a smoker, whereas in the other models, 
the cohort was distributed according to smoking habit prevalence by age and sex. This 
was needed in order to incorporate the external effects of passive smoking into the 
model. Therefore, two extra population groups were included from M4 onwards (i.e. 
never smokers who are non passive and never smokers who are passive) to account for 
passive smoking. 
Apart from differences of populations across models, other parameters and assumptions 
had to be adjusted to enable the incorporation of external effects. A summary of 
relevant parameters and assumptions used alongside models may be found in Appendix 
8.2. Incidence rates were needed from M4 to M11, when ‘never smokers’ who were 
either non passive or passive were incorporated into the model to account for adult 
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passive smoking (see section 5.2.1, Chapter 5).  Conversion from being a passive ‘never 
smoker’ or on passive to a smoker was expressed as a transition probability.  
When passive smokers were accounted for in M5 and M11, extra costs were 
incorporated into the cost-effectiveness analyses to cover QALYs lost, and the 
incidence of asthma, wheeziness, cough, acute otitis media and otitis media with 
effusion episodes, generated among passive child smokers between the ages of 0 and 15 
years, When adult passive smokers were accounted for using the same models (for both 
M5 and M11) extra costs were introduced for QALYs lost because of lung cancer and 
coronary heart disease. However, when the external effect of smoking during pregnancy 
was accounted for in M7 extra costs were incorporated in the economic evaluation for 
QALYs lost lifetime for SIDS and QALYs lost for first year of life for LBW. 
In Chapters 5 and 7, one assumption adopted was that passive smoking is irrelevant if 
you are a smoker or former smoker. Another was that it does matter if you are a never 
smoker. The justification for this position is that most evidence concerning the risks of 
passive smoking involves never smokers not smokers or former smokers who were 
passive smokers in the same population. In order to ensure strict coherence with the 
data, this assumption was adopted in the model.  
 
Data on passive smoking was derived from the Health Survey for England (HSE) 
(2006), which assumed a household context. At the time, that assumption was 
reasonable.   Today of course, it is forbidden by law to smoke in public places (e.g. at 
work) but in the past this was not the case. Sloan et al (2004) provided a detailed 
analysis of the price of smoking, which explained both the burden imposed on the 
smoker and his/her family and that placed on other unwilling members of society. The 
health effects of smoking on others were proxied by valuing the effects of 
environmental tobacco smoke defined simply as being married to a smoker and 
therefore, also a proxy in a household context. Ignoring other sources of exposure to 
secondary smoke on which they had no information, such as other persons in the 
household, the workplace and in other public areas, was one of their main assumptions 
Therefore, this chapter supports the findings of Sloan et al (2004) who examined the 
impact of external effects on the household and attempted to incorporate this valuation 
into economic evaluation - the UK tool of decision makers. According to the HSE 
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(2006), passive smokers are created by those who smoke inside and not outside the 
house/flat. Therefore, this assumption could slightly mislead the actual rate of 
prevalence of passive smokers. 
No robust trials and epidemiological studies have been conducted to confirm the link 
between the illnesses outlined in Chapters 5 and 7 and passive smoking. There appears 
to be enough evidence to conclude that smoking is causally associated with tuberculosis 
[TB] (Chiang and Enarson, 2007), but the relative incidence of risk for passive and non 
passive smokers is not possible to calculate at the moment. Little data on the effect of 
ETS on disease of the eye (Lois et al, 2008) exist in the literature. 
A static model such as the Markov was used in this thesis to incorporate passive 
smoking and smoking during pregnancy into economic evaluations. This suggests that a 
taxonomy of models of economic evaluation is so far, incomplete. Barton et al (2004) 
provided an overview of alternative approaches to modelling in economic evaluation 
and highlighted situations where each of the alternative modelling techniques could be 
employed. The authors recommend that the selection of the appropriate model for the 
evaluation of a health care intervention should be based on the independence of 
individuals in the model. If there is interaction between individuals and therefore 
feedback on external effects (i.e. transmission of smoking behaviour), then discrete 
event simulation and dynamic models should be used. The authors recommend decision 
trees and Markov models when there are no external effects. However, no modelling 
approach is recommended when external effects exist but there is no feedback (i.e. 
passive smoking or smoking during pregnancy). Therefore, findings from this thesis 
indicate that when that is the case, a decision tree and Markov model could be used to 
incorporate external effects which have no feedback. The taxonomy established by 
Barton et al (2004) does not specify which is the most adequate model for incorporating 
external effects into economic evaluation, when interaction between individuals does 
not occur. The expanded taxonomy in the paper by Brennan et al (2006) does not 
resolve this issue either.    
Static Markov models are, therefore, able to account for some external effects - at least 
those (passive smoking and smoking during pregnancy) which appear to have a higher 
impact on costs, QALYs lost and NMB, as demonstrated in this thesis. However, this 
opens the debate as to whether or not it is sensible to move to dynamic models in order 
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to capture transmission of behaviour. According to findings in Chapter 7, transmission 
of smoking behaviour has the highest impact on costs and effects when used in the 
economic evaluation of smoking cessation programmes. However, it needs to be 
recognised that results of the dynamic model are driven by the contact between smokers 
made with never smokers (beta), and no sound evidence was found for this parameter. It 
was proxied with the data available but better quality data is needed, in order to 
ascertain the true impact of transmission of smoking behaviour. There will always be a 
trade-off between understandable and intuitive models and the complicated new 
generation of models.  The findings of this thesis indicate that one should use static 
Markov models to incorporate widely recognised external effects supported by available 
epidemiological data and be conservative in the use of dynamic models, unless sound 
and reliable data is available. This might be explored further in the future research 
agenda. 
 
Chapter 3 shows that contingent valuation approaches to cost-benefit analysis, have 
been used extensively to measure and value health and non-health related external 
effects in other sectors. However, only those studies which incorporated health effects 
were examined here:  non-health effects were not calculated.  One of the strengths of 
this thesis is that it demonstrates that cost-effectiveness analysis is an appropriate way 
to incorporate external effects under the NICE approach.  Chapter 3 confirms that cost-
benefit analysis has been extensively used in other sectors to incorporate non-health 
effects. It is possible, therefore, that a broader measure than QALYs would incorporate 
non-health effects more successfully. For example, environmental impact is a non-
health effect attributable to smoking because there is some evidence of the social 
damage caused by cigarette butts in roadways (Novotny et al, 2009) or, more seriously, 
of fires (ODPM, 2006). Further research into the incorporation of non-health effects 
could strengthen the debate about whether NICE should reconsider the CBA as the 
primary rather than secondary analysis, especially now that health technologies have 
been added to its portfolio of public health programmes to be assessed.  
 
8.4 Summary 
This chapter summarise average lifetime costs and QALY gained or lost differences 
alongside models that include and others that exclude external effects (from M4 to 
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M11). These comparisons provide a clear picture of the magnitude of costs and QALYs 
lost for each external effect, their differences and the uncertainty around the estimates 
currently being used. Methods by which external effects may be incorporated into 
public health interventions are also discussed.   
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CHAPTER 9 Conclusion 
 
9.1 Introduction 
In the context of health policy, consideration of passive smoking and smoking during 
pregnancy has played a central role in the provision of public health programs. There 
was therefore, a need to incorporate the valuation of these external effects into 
economic evaluation to improve its relevance as a decision making tool.  Of particular 
importance in the empirical studies of this thesis was the need to demonstrate how 
external effects could be accounted for in the economic evaluation of smoking cessation 
interventions and to study the impact of external effects on guidance based on cost-
effectiveness analyses given to decision makers. The findings suggest that when 
external effects are introduced into the economic evaluation of smoking cessation 
interventions, lifetime costs and QALYs lost change, though the ranking of 
interventions is not modified, as might have been expected. The subsequent sections of 
this chapter offer: (a) an overview of the contributions of the thesis to the literature; (b) 
the limitations of the thesis; (c) the policy implications of the findings; (d) 
recommendations for future research; and, (e) and concluding remarks. 
This thesis has been structured in nine chapters. Chapter 2 explains the economic theory 
of external effects and its application to health care markets. It specifies types (positive 
and negative) and categories (technological and pecuniary) of external effects, reviews 
private and public solutions for the use of these effects and sets the context for provision 
of public health programmes. It also explores the importance of accounting for the 
external effects of health care in economic evaluations in the context of NICE.  In 
conclusion, it explains the need to review the measurement and value methods used to 
incorporate external effects into the economic evaluation of public health programmes. 
Chapter 3 explores measures and approaches to the valuation of external effects and 
conducts a systematic literature review of nine different sectors with a tradition of using 
external effects. Negative technological external effects were the most commonly 
studied in those nine sectors and they were concentrated on the consumption side of the 
market. The most studied aspect of external effects was their impact on health and the 
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environment using a wide range of different measures, and the most frequently used 
approach to the evaluation of external effects was contingent valuation which was used 
to inform cost-benefit analyses. However, NICE recommends the use of cost-
effectiveness analysis as the first approach for economic evaluation of public health 
interventions. Therefore, this was the approach used to value and incorporate external 
effects into economic evaluation of a public health programme.  
Chapter 4 reviews economic evaluations of smoking cessation programmes which have 
incorporated external effects. As no previous economic evaluation was found a new 
form of economic evaluation is suggested for smoking cessation programmes to inform 
NICE guidance (Flack et al, 2007a), and this replicates the model which incorporates 
the external effects of smoking. This chapter evaluates the accuracy of replication 
methods; discusses the model and its replication; and, incorporates changes in the model 
to overcome its deficiencies or modelling limitations and incorporate external effects. 
The main change in the model is the addition of two new population groups (non-
passive and passive never smokers) to facilitate the incorporation of external effects.  
The first external effect to be incorporated in the economic evaluation of smoking 
cessation interventions is passive smoking in adults and children, and it is detailed in 
Chapter 5. The population models the smoking status of a thousand adults, by age and 
sex. To account for passive smokers between the age of 0 and 16 years, the external 
health effects of 96.5% of these young passive smokers generated from the smoker 
population modelled are factored into the process. The health effects caused by passive 
smoking in adults are lung cancer and coronary heart disease, and those for children are 
asthma, wheezing, cough, acute otitis media, and otitis media with effusion. The 
smoking cessation programmes are focused on a general adult population. Although 
there is no impact on the ICER and NMB ranking, as predicted, there is an impact on 
the proportion of extra costs (£154.07) per adult and QALYs lost (0.0998) per adult 
when passive smoking in both adults and children, is incorporated into the economic 
evaluation. The increment on NMB of £1192.46 is due to the incorporation of passive 
smoking into the model. 
Chapter 6 incorporates the impact on the first year of babies’ lives caused by their 
mothers’ smoking during pregnancy. The population modelled in this case is one 
thousand pregnant women, categorised by age and smoking status during the pregnancy 
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period. To account for health effects on the first year of babies’ lives, the average 
number of babies delivered per pregnancy was incorporated into the model. The health 
effects identified are low birth weight and infant sudden death syndrome. In this 
chapter, the smoking cessation programmes are focused on pregnant women. Although 
there is no impact on the ICER and NMB ranking, as expected, there is an impact on the 
proportion of extra costs (£109.74) and QALYs lost (0.2244) per pregnant woman when 
smoking during pregnancy is incorporated into the economic evaluation. The increase in 
NMB of £2344.77 is due to the inclusion in the model of health effects on the first year 
of babies’ lives. 
In chapter 7, transmission of smoking behaviour is incorporated into the economic 
evaluation of smoking cessation interventions as a single external effect and in 
combination with passive smoking. The same static Markov model used in Chapters 5 
and 6, but two different cohorts are modelled in here, one depending one the other. As 
in chapters 5 and 6, there is no impact on the ICER and NMB ranking.  When 
transmission of smoking behaviour alone is incorporated into the economic evaluation, 
it has an impact on savings costs (-£1737.81) per adult, QALYs lost reduced (0.3218) 
per adult. When transmission of smoking behaviour is incorporated in previously 
passive smoking model, it has a greater impact on savings costs (-£1876.42) per adult, 
QALYs lost reduced (0.4161). The highest positive impact on costs, QALYs lost and 
NMB occurs where external effects appear in combination with transmission of 
smoking behaviour. 
Chapter 8 compares the varying impacts on costs, QALYs lost and NMB of the 
incorporation of transmission of smoking behaviour itself or together with passive 
smoking into the economic evaluation of smoking cessation programmes. It also 
discusses the methods used to incorporate external effects into economic evaluation of 
public health interventions. The incorporation of the transmission of smoking behaviour 
on its own has a higher impact on costs and QALYs lost, than incorporation of either 
passive smoking or smoking during pregnancy alone. Because of its high impact, there 
seems great benefit in building dynamic models of the economic evaluation of smoking 
cessation programmes simply to introduce transmission of smoking behaviour. This 
thesis also shows how static models might be used in cost-effectiveness analysis to 
incorporate health related external effects. However, non health related effects are not 
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considered in this thesis and broader measures than QALYs may well be needed to 
value them. CBA could be used to incorporate these non health external effects, as other 
sectors traditionally use them. 
  
9.2 Contributions of the thesis 
The relevance of incorporating external effects into public sector decision-making is 
well documented. However, to date, they have rarely been incorporated into economic 
evaluations of public health programmes. This thesis has filled a gap in the literature by 
including health related external effects in an economic evaluation, using smoking 
cessation programmes as a case study.  
The most important contribution which this thesis makes to research on health related 
external effects is to detail the methods by which  these effects may be incorporated into 
the economic evaluation of costs and QALYs, and to compare the relative importance of 
different types of external effects and their impact on the evaluation. It has 
demonstrated that static Markov models might be used to incorporate non-dynamic 
external effects and dynamic models may be used to incorporate external effects with 
dynamicity or transmission. 
For first time, passive smoking, smoking during pregnancy and transmission of smoking 
behaviour is quantified in terms of cost and QALYs as a result of incorporating these 
external effects into cost-effectiveness analyses. This thesis explicitly incorporates the 
societal impact of certain external effects to aid the public health decision making 
process, thus improving the quality of economic evaluation by enabling the social costs 
of smoking behaviour to be measured. 
Economic evaluation of other public health interventions could be helped by this 
research in four different ways. First, as it has proved possible to use cost-effectiveness 
analyses to incorporate negative external effects on the consumption side, the same 
methodology could be used for other type of public health interventions, particularly 
behavioural programs, because of the possibility of including dynamics effects (e.g. 
transmission of eating habits in the context of obesity or alcohol consumption in homes 
where parents regularly abuse this substance). Secondly, prior to incorporating external 
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effects in economic evaluation, it is important to think about the availability of 
epidemiological data as this will determine the extent to which external effects can be 
incorporated into an economic valuation of public health programmes. Thirdly, findings 
from chapter 3 shows that contingent valuation is the approach most frequently used in 
other sectors with a long tradition of measuring and valuing non-health external effects 
and this suggests that broader measures than QALYs might be needed it to incorporate 
non-health related effects. This opens the debate as to whether cost-benefit analysis is 
the most appropriate way of incorporating non-health effects. 
This thesis is the only health study that has adapted the categorization of external effects 
from non-health related disciplines. No other study has attempted such a cross-
disciplinary approach.  
 
9.3 Limitations of the thesis 
Notwithstanding its contributions, this thesis has its limitations and these are detailed 
below in order of importance. 
The main limitation is that it has not found a criterion that can be used consistently to 
distinguish the most relevant external effects, impacts and measurements to guide 
decision making. Some studies chose to concentrate on a particular external effect in 
order to establish the full social costs and benefits as a basis for efficient pricing and 
allocation of resources, or to study the implications for economic evaluation.  However, 
no established criteria exist to rank the importance of external effects and their inclusion 
depends currently on epidemiological evidence and the size of costs and QALYs. 
Non-health effects were not considered. Chapter 3 indicates that a broader measure will 
be needed to capture this type of external effects. Findings from this research suggest 
that cost-benefit analysis is the most appropriate way of including those effects that are 
not in cost-effectiveness analyses. The incorporation of non-health effects might 
challenge the primary analysis used by NICE (cost-effectiveness analysis).  
Only external effects on the consumption side generated by smoking are incorporated in 
this thesis. However, external effects on the production side generated by smoking (e.g. 
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tobacco companies and the economy of countries which produce tobacco) have not been 
incorporated. These external effects on the production side might have the opposite 
impact, in terms of ICER or NMB, to external effects originated on the consumption 
side by smoking and affect policy decision regarding economic evaluation of smoking 
cessation programmes. 
There are also data weaknesses in the economic evaluation of smoking cessation 
programmes and the valuation of external effects, as for example, the validity and 
generalisability of the quitting and relapse rate in the economic evaluation of smoking 
cessation programmes. In general, further research should rely on better estimates on the 
relapse rate. In addition, the evidence of effectiveness provided by Flack et al (2007a) 
and Flack et al (2007b) is taken from very diverse sources and trials with a significant 
disparity of sizes. This suggests that effectiveness rates may not be comparable in the 
same robust way across smoking cessation programmes for adult and pregnant women 
populations. 
Some data weaknesses relate to external effects. Firstly, economic valuation of pregnant 
women accounts only for general female mortality rates in the pregnancy age interval. 
No burden of gestation-specific infant illnesses and neonatal and post-neonatal 
mortality rates has been considered in order to keep the model simple, though some data 
on mortality has been published (Moser et al, 2007). Moreover, according to Blair et al 
(2006) most SIDS deaths happen within the first 8 months of life, though this economic 
evaluation assumed the RR of smokers for SIDS to be constant for the first 5 years of 
life Secondly, the modelling has been limited by a reliance on self report data for 
passive smoking prevalence. In particular, the use of  the definition ‘living with a 
smoker’ captures less than half the variation in cotinine concentration in non-smokers 
(Breteler et al, 1994) and does not take into account exposure in workplaces and public 
areas (Llewellyn et al, 2009). Measurement of cotinine by medical appliances or staff 
would have provided more robust estimates. In addition, the model only considers 
passive smokers who have never smoked, which precludes those smokers and former 
smokers who also rationalise themselves as passive smokers. 
The quality of the studies used to identify data may also be questioned. All study 
designs used were vulnerable to potentially important confounders, yet many of these 
were not recorded or, if recorded, could not be adjusted for in any analysis. 
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Furthermore, studies did not describe measures taken to prevent bias, and no intervals 
recommending values for further use in policy decisions (Eshet et al, 2005) were 
reported. 
Finally, there are differences between costs on the original model (M1) and the 
replication (M2). M2 was peer-reviewed by health economists from the Health 
Economics Research Group and by Matthew Taylor from the York Health Economics 
Consortium, one of the authors of M1. The cost detailed in the NICE report for an 
episode of myocardial infarction was not the one used in the model 1 (M1). The cost 
they used was higher than it should have been which could explain the higher costs they 
obtained in the ICER compared with those from this research.  The results for QALYS 
are similar, the trend in costs and QALYs among different interventions following the 
same direction in both models. Therefore, one could accept the replication of the M1 as 
correct and add the external effects.  There are also limitations inherent within the basic 
model that has already been noted by Flack et al (2007a). First, due to the lack of data 
on the relative risk of contracting each condition by smoking status’ it was not possible 
to split former smokers into ‘recent’ and ‘long-term’ categories. It is unclear what the 
impact of this simplification will have on the models’ results. If the probability of 
developing some or all of the conditions returns to the level found in non-smokers after 
a certain period of time, the model will have overestimated the number of people with 
each condition. This in-turn may have resulted in an overestimation of the associated 
costs and an underestimation of the associated QALYs. Moreover, models should have 
been accounted for by different smoking frequency levels and adjusted for that.  
 
9.4 Policy implications of the findings from the thesis 
The findings of this thesis generally suggest that although the ranking of cost-effective 
interventions does not change with the addition of external effects, there is a clear 
impact on costs and QALYs. This has implications for public health interventions 
generally and smoking cessation in particular. 
To date, most smoking cessation therapies and programmes that have been shown to 
offer effective treatment have also been highly cost-effective (Parrot and Godfrey, 2004; 
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Lazzaro and Nardini, 2008). Incorporating passive smoking, smoking during pregnancy 
and transmission of smoking behaviour does not change the ICER or NMB ranking and 
would not, lead NICE to change its recommendations on smoking cessation in respect 
of those effects. However, other public health interventions with ICERs closer to the 
£20,000 threshold should be evaluated to see if the incorporation of external effects 
would change policy guidance. 
Incorporation of negative external effects on the production side (e.g. productivity 
losses in tobacco producer companies) might be the only factor capable of changing 
policy making for smoking cessation because it reduces the gain in cost per QALY lost. 
Accounting for these external effects would imply the need to study the impact of non-
health benefits and move towards the use of CBA. 
The findings of this thesis suggest that discrete population models would be a more 
appropriate means of incorporating external effects because they can be used to 
compare the impact of incorporation without the need for complex and difficult 
comparisons that stem from populations with a multiplicity of sub-sections. 
 
9.5 Research agenda 
Future research could now be taking forward by: (a) incorporating and modelling 
external effects in economic evaluation; and, (b) improving the smoking cessation 
research agenda. 
The research agenda for modelling external effects could include: 
a) Developing methods to account for non-health related external effects. This would 
imply moving to CBA which would challenge the primary analysis used by the 
NICE approach (cost-effectiveness analysis); 
b) Exploring the impact of incorporating external effects on the production side (i.e. 
tobacco companies) of the economic evaluation of smoking cessation interventions. 
Potential changes in the ICERs or NMB ranking could be observed with the 
incorporation of these external effects;  
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c) Considering whether guidance on public health interventions closer to the £20,000 
or £30,000 threshold might change if external effects were accounted for in 
economic evaluation; 
d) Developing general population models for the evaluation of public health 
programmes in order to incorporate and assess the differences between various 
external effects and and avoid problem of  multiple populations. 
This research would also suggest that the smoking cessation agenda could benefit from 
the following research: 
e) Further study of the impact of transmission of smoking behaviour, with better data 
evidence, especially for the force of infection; 
f) One of the most important parameters of this model is the uptake rate for smoking. 
This parameter was proxied regarding the data available on the Health Survey for 
England (2006). In that study, people were asked at what age they started smoking. 
The problem is that the current tendency to start smoking would almost certainly 
have varied during the recently extended National Health Service smoking cessation 
interventions. The intention was to track individual over time but this was precluded 
because household identification codes were different for each survey wave. Better 
data is needed if one is to make reliable estimates of the incidence of smoking; 
g) However, the validity and generalisability of the effectiveness (i.e. quit and relapse 
rate) rates of the smoking cessation programmes used in the model are limited. 
Meta-analyses during effectiveness trials would be needed to ensure the 
appropriateness of trials and the validity of comparisons made by them; 
h) There is a lack of up-to-date evidence meta-analysis on the health effects of passive 
smoking by children. There is, for example, some evidence to the effect that 
smoking is causally associated with tuberculosis (Chiang and Enarson, 2007) and 
diseases of the eye (Lois et al, 2008) but it was not possible to obtain meta-analyses 
of the relative risk to passive and non-passive smokers. Meta-analyses of the health 
effects of passive smoking by children would greately help future estimates of these 
factors. 
 
 188
9.6 Concluding remarks 
This thesis contributes to knowledge in a variety of ways. Firstly, it provides the first 
empirical analysis in the UK of the effects of incorporating the external effects of public 
health smoking interventions into the decision making process for economic evaluation. 
The analysis shows that incorporating external effects into economic evaluation makes a 
clear difference, to costs and QALYs, in the cost-effectiveness analysis of public health 
interventions. 
 
Secondly, it has contributed to the setting of a research agenda for the incorporation and 
modelling of external effects in economic evaluation and the smoking cessation agenda. 
 
Thirdly, it suggests improvements that need to be considered when making economic 
evaluations of smoking cessation interventions, by replicating an existing model from 
NICE. It has also demonstrated that static models can be used to incorporate non-
dynamic external effects. However, when compared with the external effects of passive 
smoking and smoking during pregnancy, transmission of smoking behaviour has a 
greater impact on costs and QALYs in economic evaluation. This suggests that there is 
probably need to develop further dynamic models in smoking cessation interventions. 
 
Fourthly, it identifies different categories of external effects by applying definitions 
from other disciplines to the area of public health. It also identifies methods for the 
measurement and evaluation of external effects in nine different areas and attempts to 
extrapolate these methods to the health field. 
The overarching purpose of this thesis has been to incorporate external effects into 
economic evaluation using smoking cessation interventions as a case study. The 
substantive contribution has been to estimate the size of passive smoking, smoking 
during pregnancy, and transmission of smoking behaviour. Comparison of the size of 
different types of external effects and their impact on economic evaluations indicated 
that transmission of smoking behaviour has the biggest impact on costs and QALYs in 
the economic evaluation of smoking cessation programs, whereas for a population of 
pregnant women, the external health effects on babies’ is has the lowest impact on costs 
and QALYs. This thesis is the only study that has estimated the size of these external 
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effects, and incorporated them into economic evaluation of a public health programme. 
It therefore contributes to an improvement in the potential quality of future economic 
evaluations and decision making.  
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Appendix 2.1 Review of external effects on different disciplines 
Aim 
The aim of this preliminary review was to identify which disciplines conduct research 
related to external effects. The objectives were to detect types and categories of external 
effects used in the literature. 
 
Methods 
This section highlights how the search was conducted.  
Search strategy and search terms 
A search for textbooks was conducted from October to December 2006 through Brunel 
University and London School of Economics Library. In addition, some 
recommendations from experts on the field were given. 
Search terms at Brunel University Library: “Externalities”; “Externalities Economics”; 
“Spillovers”; “Economics of Environment”; “Economics of transports”; “Economics of 
education”; “Economics of Energy”; “Economics of Agriculture”; “Economics of 
telecommunications”; and, “Crime prevention economic aspects”. 
Search terms used at London School of Economics Library: “Externalities”. 
Search terms used to search in google scholar (http://scholar.google.com/): 
“Externalities”; “Externalities Economics”; “Spillovers”; “Economics of Environment”; 
“Economics of transports”; “Economics of education”; “Economics of Energy”; 
“Economics of Agriculture”; “Economics of telecommunications”; “Crime prevention 
economic aspects”; “types of externalities”; “externalities, environment”; “externalities, 
transports”; “externalities, education”; “externalities, energy”; “externalities, 
agriculture”; “externalities, telecommunications”; and, “externalities, crime prevention 
economic aspects”. 
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Selection criteria 
Books that satisfied the following criteria were selected for review: (a) related to 
external effects, spillovers or externalities; or (b) focused on economics of some 
particular areas with good evidence of external effects; and, (c) dataset having smoking 
specific indicators. 
 
Results 
Nine areas were detected to have conducted research about external effects. These areas 
comprised: agriculture, environment, innovation, technology, telecommunications, 
network, transport, education and health. Moreover, two types of external effects were 
identified: positive, related to social benefits, and negative, related to social costs. 
Finally, external effects were grouped into two main categories: technological and 
pecuniary external effects 
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Appendix 2.2 Vaccination programme 
 
Consumption Production 
Positive effects Negative effects Positive effects Negative effects 
Herd-immunity 
effect: whole 
population 
coverage due to 
an individuals’ 
vaccine 
Opposite to herd-
immunity effect: 
bacteria spread across 
population affecting 
people’s health  
GPs not related with the 
vaccination programme 
would be attending less 
patients and increasing 
their quality of work 
Lower ‘quality of work’ 
from reception 
personnel because of 
attending more new 
patients for vaccination 
program 
Increases 
awareness for 
other vaccines 
Higher risk to get an 
imported disease 
(from immigration) 
Increasing capacity to 
deal with other patients 
and increasing the 
quality of life from rest 
of patients 
Monopoly pricing could 
increase prices and 
leave poor patients out 
of the vaccination 
program 
Satisfaction from 
colleagues due to 
you are taking 
part of a societal 
decision 
Moral hazard Vaccination 
programmes are 
contributing to change  
national priorities on 
health 
Differences on quality 
of care provided by 
hospitals personnel due 
to some of them are 
participating in 
vaccination 
programmes and some 
are not 
Less traffic jams 
and less air 
pollution near the 
hospital due to 
less people 
travelling there 
Contraindications of 
the vaccine due to 
over-vaccination of 
the population 
Increase in the vans or 
lorries manufacture and 
work due to higher 
demand to carry the 
vaccines to the hospitals 
Higher vaccines’ 
prescription increase the 
use of computers and 
therefore computer 
systems workers have 
more work to do 
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Appendix 2.3 Hospital infections 
 
Consumption Production 
Positive effects Negative effects Positive effects Negative effects 
Infection-control 
initiatives (such 
as asking 
healthcare 
professionals who 
were in contact 
with, or whether 
they washed their 
hands, etc) 
Collaborating to 
develop cross-
infections 
Screening programs of 
high-risk patients to 
transmit germs 
Higher exposure to 
hazards from surgeons 
 
 
 
Help to prevent 
the spread 
infection due to 
an improvement 
on the 
immunization 
system 
Higher morbidity and 
mortality risk of other 
people attending the 
hospital 
Infection surveillance 
program (infection 
control; prevention and 
early detection of 
outbreak and the 
assessment of infection 
rates over time) 
Multi-resistant 
infections 
Health seeking 
behaviour instead 
of risk taking 
behaviour 
Increasing resistances 
to antibiotics 
Hospital Infection 
Control Network 
(establishment of an 
infection control 
network within a group 
of community hospitals 
associated with 
decreasing in infection 
rates) 
Lower quality in 
hospital resources due 
to extra expenses in 
adequate 
supplies/equipment to 
live with an hospital 
infection 
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Appendix 2.4 Addictive behaviour interventions 
 
Consumption Production 
Positive effects Negative effects Positive effects Negative effects 
Alcohol campaigns 
Reducing crime 
rates (mortality 
rate) 
Increasing number of 
aggressions due to 
anxiety 
GPs not related with the 
campaign attend less 
patients and increase 
their quality of work 
Cost of opportunity to 
invest hospital money 
in alcohol campaigns 
and not into other 
programmes is affecting 
other’s people health 
Improve quality 
of life of other 
people due to a 
decrease number 
of aggressions 
related to alcohol 
consumption 
Increasing risk of 
Adverse Drug 
Reactions 
Decreasing on suicide 
rate 
Lower research on 
health because of lower 
benefits on statins 
production 
Lower risky 
behaviour 
(unprotected sex) 
Lower QALYS for 
relatives because of 
higher risk of 
participants 
osteoporosis and bone 
loss 
Better quality of health 
services due to lower 
intoxication cases 
 
 
- 
Smoking 
? Passive smoking 
 
 
 
 
tobacco companies and 
the economy of 
countries which 
produce tobacco 
 
? 
? Smoking during 
pregnancy 
 
 
? 
? Smoking behaviour 
transmission 
 
? 
Food habits 
Higher QALYs 
for the family due 
to making a 
personal change 
on others health 
Increase number of 
aggressions due to 
anxiety 
GPS not related with 
the campaign are 
attending less patients 
and increasing their 
quality of work 
Cost of opportunity to 
invest hospital money 
in behaviour changes 
and not to other 
programs is damaging 
health of other ill 
people 
Reduced risk for 
disease 
Lower QALYS to 
other people due to 
his/her no satisfaction 
Decrease on mortality 
and morbidity of the 
country (implementing 
use of condoms) 
? 
Benefit to others 
due to adherence 
to long term 
medications 
Lower QALYs due to 
the discontinuation on 
the behaviour change 
Better quality of care 
due to lower number of 
ill people 
 
? 
Food habits 
Lower rates of 
premature death 
Increase in the 
anorexic and bulimic 
rate 
GPS not related with 
the campaign are 
attending less patients 
and increasing their 
Cost of opportunity to 
invest hospital money 
in improve food habits 
and not to other 
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Consumption Production 
Positive effects Negative effects Positive effects Negative effects 
quality of work programs is damaging 
health of other ill 
people 
Lower drugs 
intake, so 
avoiding 
interactions 
between drugs 
due to healthy 
food habits 
Consequences of 
psychological 
problems due to 
instability of changing 
food habits 
? ? 
Better QALYs for 
participants and 
their families due 
to increment 
physical activity 
Lower QALYS to 
other people due to 
his/her no satisfaction 
with food 
? ? 
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Appendix 3.1 Selected books in the review 
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Grafe,F. and Mauleon,A. (2000) ‘Externalities and free Trade Agreements’. Annales 
d’Economie et de Statistique, 59: 63-88. 
 
Heady,E.O. and Whiting,L.R. (1975) Externalities in the transformation of Agriculture: 
Distribution of benefits and costs from development. The Iowa State University Press.  
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Appendix 3.2 Search strategy and search terms of systematic review of  
 external effects valuation methods 
 
 
 
 
  
                                                 
71
 ‘health*’ for health field, ‘education*’ for education field, ‘transport*’ for transport field, ‘network*’ for network field, 
‘telecomm*’ for telecommunications field, ‘technolog*’ for technology field, ‘innovati*’ for innovation field, ‘environm*’ for 
environment field, ‘agricultur*’ for agriculture field; 
 
Database Search terms Hits Selected 
papers 
Web of 
Knowledge 
TI=((field search term)71 and ("cost-benefit" 
or "costbenefit" or "cost benefit" or "cost-
effectiveness" or "costeffectiveness" or 
"cost effectiveness" or "economic* 
valuation" or cost* or valu* or "critical 
appraisal") and ("pecuniary external*" or 
"technological external*" or "knowledge 
external*" or "network external*" or 
"external*" or "spillover*" or "spill-over*")) 
47 29 
Econlit TI= (field search term) AND "cost-benefit" 
or "costbenefit" or "cost benefit" or "cost-
effectiveness" or "costeffectiveness" or 
"cost effectiveness" or "economic* 
valuation" or cost* or valu* or "critical 
appraisal" AND "pecuniary external*" or 
"technological external*" or "knowledge 
external*" or "network external*" or 
"external*" or "spillover*" or "spill-over*" 
49 23 
 
Other sources  7 7 
TOTAL  103 59 
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Appendix 3.3 Review questions 
 
Headings Review questions 
Specification 
and 
categorisation 
of external 
effects 
1. PIC (personal identification code) 
2. LSIC (literature search identification code) 
3. Title 
4. Authors 
5. Year of publication 
6. Year of study 
7. Source  
8. If question number 7=4, specify 
9. Field 
10. Paper’s objective 
11. Why is important to study the external effects in this study? 
12. Categorization of external effects according to the author/s’ criterion (open 
text). (i.e. Congestion) 
13. If 12=6, specify 
14. Description of external effects according to author/s of paper  
15. Type of externality/ies valuated 
16. Consumption or Production side 
17. Why is important to focus on external effects on this side of the market in this 
study? 
18. Categorization of externality/es valuated (according to my own definition) 
19. If question number 15≠5, How well do they fit in my definitions? 
20. Does the paper cite other authors for the same external effect? 
Impact and 
measures 
21. Is this paper identifying and/or measuring impact/s of external effects?  
22. Identification of impact/s 
23. Measurement of impact/s 
Valuation 
approach 
24. Is this paper assigning monetary values to the impact/s of external effects? 
25. If 22=1, describe methods to assign monetary values to impacts (according to 
Eshet et al., 2005) 
26. If question number 23=8, specify 
27. Valuation methods’ description 
28. Do they specify a formula to quantify the monetary valuation of impacts? 
29. If question number 26=1, specify formula 
30. If question number 26=1, description of formula’s variables 
31. Data source for the formula’s variables 
32. Type of data of the study 
33. If question number 31=1, cite references from this extra estimates 
34. Are the valuations of external effects used to do a cost-benefit analysis 
according to this paper? 
35. If question number 33=1, which country? 
Main 
findings and 
given critics 
36. Paper’s strengths stated by the author 
37. Paper’s limitations stated by the author 
38. Main conclusions of the paper 
Application 
to health 
39. What interesting ideas I can get from this paper? 
40. Paper’s gradation for containing useful ideas for application to health 
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Appendix 3.4 Study selection process for systematic review of external  
 effects valuation methods  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* 53 articles were included from the literature review and 6 papers were added from experts’ recommendations 
103 titles and/or abstracts identified 
Web of Science             47 
Econlit                  49 
Other sources     7 
37 excluded for duplication: 
Web of Science  9 
Econlit                      28             
7 excluded because: 
Papers containing comments on technical and 
general descriptive aspects of any valuation 
method; 
Review papers; 
 
66 Potentially relevant titles & 
abstracts identified 
Web of Science   38          
Econlit                           21 
Other sources                               7 
59*  articles included 
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Appendix 3.6 Summary of external effects papers reviewed 
 
Authors Year Consequences 
Type Identification Measurement (physical effect) Valuation72 Type of 
data 
Tegtmeier,
E.M.; 
Duffy,M.D. 
(Rw 38) 
2004 negative Value lost of water, 
soil and air resources, 
wildlife and 
ecosystem 
biodiversity and, 
human health 
Water resources: a)treatment of surface water for microbial 
pathogens (microorganisms in livestock); b)facility infrastructure 
needs for nitrate treatment; c)facility infrastructure needs for 
pesticide treatment; 
Soil resources:  a)cost to water resources; b)cost to replace lost 
capacity of reservoirs; c)water conveyance costs; d)flood damages; 
e)damages to recreational activities; f)cost to 
navigation:shipping,dredging; g)Instream impacts:commercial 
fisheries,preservation; h)off-stream impacts:industrial users, steam 
power plants; 
Air resources: a)cost of greenhouse gas emissions from cropland; 
b)cost of greenhouse gas emissions from livestock production; 
Wildlife and ecosystem biodiversity: a)honey bee and pollination 
losses from pesticide use; b)loss of beneficial predators by pesticide 
applications; c)fish kills due to pesticides; d)fish kills due to manure 
spills; e)bird kills due to pesticides; 
Human health 
• (pathogens): a)cost of illnesses caused by common foodborne 
pathogens; b)cost to industry to comply with HACCP rule; 
• (pesticides): a)pesticide poisonings and related illnesses; 
Water (costs of treatment to control major pollutants): 
• Pathogens: annualised national cost of implementing 
surface water treatment rule*% of damage associated to 
these pathogens; 
• Nitrate: cost for water treatment facilities to meet federal 
nitrate standards* % of nitrate pollution is due to 
agriculture; 
• Pesticide: cost for treatment facilities to meet Safe 
Drinking Water Act*% of pesticides (something in 
between the % of existing pesticides and % of 
conventional pesticide usage); 
Soil resources:  
• Water industry: % that cropland contributes o total 
suspended solids*water withdrawn for public supply from 
surface water sources (litres per day)*treatment costs (per 
million litres); 
• Reservoirs: %loss of total national capacity (between % 
of the nation´s water storage capacity lost annually and 
the average storage loss from sediment depletion)*per 
thousand cubic metres replacement value*% of sediment 
from cropland; 
• Conveyance: cost for sediment removal and maintenance 
to prevent local flooding*% for the contribution of 
sediment from cropland; 
• Flood damages ,recreational activities, navigation, 
commercial fisheries and preservation and, off-stream 
costs: total erosion effects*% damage due to cropland; 
Air resources: net emissions of carbon dioxide 
equivalents*market price carbon dioxide equivalents*% of this 
cost from crop production or livestock sources; 
Wildlife and ecosystem biodiversity:  
• Honey bee and pollination losses: colony losses, reduced 
honey production and crop pollination and the cost of bee 
rentals; 
• Loss of beneficial predators: cost of additional 
secondary 
                                                 
72
 Valuation approaches: CV (Contingent Valuation); CHM (Choice Modelling Methods); HP (Hedonic Price Method); AB (Averting Behaviour Method); CI (Cost of Illness); HP (Health Production Function); TC 
(Travel Cost Method). 
 247
 
Authors Year Consequences 
Type Identification Measurement (physical effect) Valuation72 Type of 
data 
applications of pesticide due to drops in the population of 
beneficial insects and crop losses associated with 
secondary pests; 
• Fish kills due to pesticides: fish deaths per year due to 
pesticides and values of freshwater fish, reflecting 
commercial hatchery production costs of various fish 
species*cost in $ per fish; 
• Fish kills due to manure spills: (info on feedlot spills and 
associated fish kills in 10 states for 3 years=rough proxy 
for a national estimate)*cost in $ per fish; 
• Bird kills due to pesticides: number of birds exposed to 
pesticides*% of birds dying*value of bird’s life (using 
lowest value from cost per bird watching, hunting costs 
per bird felled and the cost of rearing and releasing a bird 
to the wild); 
Human health:  
• Pathogens 
o Foodborne illnesses: annual costs for 
bacteria damage estimates*% of health 
costs attributable to agricultural 
production; 
o Cost to industry to comply with HACCP: 
industry costs for meat and poultry plants 
to comply with HACCP regulations*% 
of health costs attributable to agricultural 
production; 
• Pesticides 
o Pesticide poisonings: costs of pesticide 
poisonings and deaths based on 
hospitalizations, outpatient treatment, 
loss of work and fatalities due to 
accidental poisonings and treatment costs 
for pesticide-induced cancers (based in 
part on speculation regarding the 
incidence of illness and death); 
Brisson,M.; 
Edmunds,
W.J. (Rw 
39) 
2004 positive Value created on 
altruism due to 
varicella vaccination 
The vaccine may derive benefit from knowledge that by being 
vaccinated they will not infect other children; they estimated whether 
individuals derive benefit from not infecting others because they are 
immunised; 
• CV and standard gamble questionnaire:  
o CV: the respondents were given a description of a child with 
chickenpox; initially respondents were asked to assume that 
their child has chickenpox and that a drug exists which can cure 
their child immediately; They then elicited the maximum the 
respondent is willing to pay for the drug using a bidding 
algorithm. In the second section of the CV questionnaire, 
primary 
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Authors Year Consequences 
Type Identification Measurement (physical effect) Valuation72 Type of 
data 
respondents were asked the maximum they were willing to pay 
to vaccinate their child against chickenpox; Respondents were 
given randomly one of 4 different contingent valuation 
questionnaires; The value parent’s put on preventing their child 
infecting others (altruism) was measured by comparing the 
WTP from questionnaires stressing this effect to those in which 
the effect was not mentioned; 
o SG: a separate group of respondents were asked to imagine 
that their child is in an imaginary health state for 15 years; the 
duration of disease was chosen so that parents would trade risks 
of death for intervention and it is the time-span of childhood. 
Apart from the duration of disease, the health profile is 
identical to the description of chickenpox; the only attribute 
varied in the SG questionnaire was altruism: in half of the 
questionnaires altruism was included by stressing that treatment 
will prevent the child from giving the disease to other children. 
In the remainder there were no mention of knock-on effects; 
Van de 
Vijver,M.; 
Vos,B. (Rw 
40) 
2006 positive Benefit created by 
the additional 
activities that result 
from the JSF 
programme within 
and outside the Dutch 
aerospace industry  
Knowledge creation and innovation (and use of this knowledge in 
other settings); from the consumer electronics industry (electric 
shaving) to the aerospace industry. The improved and adjusted 
production technology is now used for machining of blisks in the JSF 
project and can also be used in the future in automotive and medical 
systems industries; Urenco Aerospace developed technology on 
extreme loading of thermoplastics. This technology can also be used 
in other industries. The material that is used for these applications is 
Carbon Fibre Reinforced Plastics (CFRP); TNO, the Netherlands 
organizations for applied scientific research, developed specific 
knowledge in the JSF programme to improve video resolution 
techniques. They can also use this knowledge in security purposes. 
TNO also developed new knowledge in the field of noise nuisances, 
which can be used in the development of industrial zones and the 
design of airports. 
Employment effects (how many more people are contracted?);  
Estimated total revenues related to the JSF programme; 
Knowledge expanded= valuation method not specified but 
monetary valuated; 
Employment=not monetary valuated; 
Revenue (revenue for the aerospace industry=(number of hours 
needed for one shipset*total number of shipsets)/annual 
workable hours per employee; (Maintenance, Repair and 
Overhaul activities are not included in the estimates); 
primary 
(through 
interviews) 
Jaffe,A.B. 
(Rw 41) 
1986 positive Value created on 
R&D due to the 
proximity of the 
firms technology 
space 
Weighted sum of other firms’ R&D, with weights proportional to the 
proximity of the firms in technology space; This measure spillovers 
using a cost function approach and time-series data for the chemical 
industry; 
Not monetary valuated; secondary 
Castronova,
E. (Rw 42) 
2006 negative Value of real-money 
trade (RMT) lost 
within the current 
Consumer and surplus loss as the change in demand and supply times 
the current subscriber base (marginal effects) 
Total Marginal external costs: consumer and surplus loss 
(as the change in demand and supply) 
Consumer surplus: n subscribers*(RMT elasticity of 
secondary 
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Authors Year Consequences 
Type Identification Measurement (physical effect) Valuation72 Type of 
data 
online game market subscriptions*subscription fee)*12 months (because we want 
annual data) 
Producer surplus: n subscribers*(RMT elasticity of 
subscriptions*subscription fee)*12 months (because we want 
annual data) 
Total external cost= total marginal external costs*RMT 
elasticity total external costs 
Beuthe,M.; 
Degrandsart
,F.; 
Geerts,J-F.; 
Jourquin,B. 
(Rw 43) 
2002 negative 73Value lost due to air 
pollution, accidents, 
noise and road 
damages 
74Effects of: Air pollution (millionECU per gram); 
Congestion (source of inefficiency of the transport system): cost 
function expressed in millionECU per t-km; ; 
Accidents (social cost for accidents between vehicles=between 
vehicles and pedestrians or cyclists; expressed in millionECU per t-
km; 
Noise (estimated either through a statistical analysis linking the rents 
paid with different characteristics of housing or by costing the 
reparative expenditures);expressed in millionECU per t-km; 
Air pollution=concentration per gram of 
pollutant*population*mortality rate*value of life75 
Congestion=loss of time for trucks travelling along the road 
during peak hours*truck flows* value of time; 
• Loss of time=speeds on road during peak hours and 
outside peak hours are computed using a flow speed 
relation. The difference between these speeds 
translates into a loss of time for trucks travelling along 
this road during peak hours; 
• Value of time=all the costs linked to the operation of a 
truck (labour, fuel, insurance, maintenance and 
vehicle cost)=inventory cost of the goods transported 
which varies with the value of the commodities and 
the loading of the vehicles; 
Accidents: 
• Between vehicles=(WTP for cancelling the risk of an 
accident for the user=WTP for cancelling the risk of 
an accident for the closest relations=cost per vehicle 
made of the costs of police, ambulance (cold blood 
cost))*traffic flow*risk of accidents; 
• Between vehicles and pedestrians or cyclists=(WTP 
for cancelling the risk of an accident for the 
user=WTP for cancelling the risk of an accident for 
the closest relations=cost per vehicle made of the 
costs of police, ambulance (cold blood cost))*total 
number of km by pedestrians and cyclists*risk of 
accidents; 
Noise: estimates which are averages of various studies relying 
secondary 
                                                 
73
 Many of these cost estimates are based on market prices and costs rather than on WTP; 
74
 In general, a static methodology is applied in this paper (this means that  not analyse the flows’ impact on the costs of a link use and the resulting spread of the traffic over different routes like in a spatial equilibrium 
model; 
75
 All the computed costs of illnesses not inducing death are based on market prices and costs: cost of medicines, ambulance, hospital, and medical services. A WTP estimate is only used for the value of life in case of 
death. 
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Authors Year Consequences 
Type Identification Measurement (physical effect) Valuation72 Type of 
data 
on either of linking the rents paid with different characteristics 
of housing or costing the reparative expenditures; 
de Dios 
Ortuzar,J.; 
Cifuentes,L.
A.; 
Williams,H.
C.W.L. (Rw 
44) 
2000 negative Value lost due to 
road accidents and air 
pollution 
Effect of road fatality risks (health effects) and pollution-related 
mortality risks (health effects); 
Road accidents: CHM (respondents were invited to choose 
between two alternative states of the highway on the basis of 
three attributes: travel time, accident risk and toll charge); 
Air pollution: CV (WTP for small reductions in the risk of 
death); 
primary 
Snowball,J.
D.; 
Antrobus,G.
G. (Rw 45) 
2001 benefit Value created by arts 
to the lower income 
and education groups 
in South Africa 
Effect of Standard Bank National Arts Festival in Grahamstown CV(after being given certain basic information about the cost of 
the Festival and the level of government sponsorship, 
Grahamstown respondents were  asked in a closed-ended, yes 
or no, question whether they would be willing to pay an extra 
R5 in taxes per month to support the Festival, first non-liable 
and then liable) 
primary 
Gray,R.; 
Malla,S. 
(Rw 46) 
1998 benefit Value of health costs 
saved due to reduce 
saturated fat acid 
consumption (SFA) 
External portion of the CHD costs reported associated with 
consumption of butterfat to calculate a per-unit externality 
(kilograms of fat reduced); 
External cost savings=costs of annual CHD reduction  due to a 
reduction in SFA (from literature)*(% of costs being external to 
the individual (assumption)); 
Kilograms of SFA consumed by the 
population=population*SFA per individual; 
Per-unit externality=External cost savings/kilograms of SFA 
consumed by population; 
External cost saved=per-unit externality*reduced kilograms of 
SFA consumed by the population; 
secondary 
Pretty,J.N.; 
Brett,C.; 
Gee,D.; 
Hine,R.E.; 
Mason,C.F.
; Morison, 
J.I.L.; 
Raven,H.; 
Rayment,M
.D.; van der 
Bijl,G. (Rw 
47) 
2000 negative Value of agricultural 
lost due to 
environmental and 
health effects 
Effects on the treatment  or prevention costs (those incurred to clean 
up the environment and restore human health to comply with 
legislation or to return these to an undamaged state); 
Administration and monitoring costs (those incurred by public 
authorities and agencies for monitoring environmental, food and 
health parameters); 
Environment: water, air, soil and biodiversity and landscape76; 
• Water: Cost of remove pathogens from water 
(pesticides, nitrate, phosphate and 
zoonoses)=annual operating costs*% assumed to be 
agricultural treatment cost; 
Cost to pay for restoring water courses 
(eutrophication and pollution incidents)=costs 
incurred to restore rivers to their pre-incident 
condition; 
Monitoring and advice on pesticides=pesticide 
monitoring in food and livestock and on surface 
and groundwater sites=costs in providing advice; 
• Air:  
marginal external costs from methane, nitrous 
oxide and carbon dioxide (adopted from ExternE 
secondary 
                                                 
76
 All this data is adopted from the literature; 
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Authors Year Consequences 
Type Identification Measurement (physical effect) Valuation72 Type of 
data 
project:CV (WTP)); 
External costs of ammonia: CV (WTP) using the 
more conservative value of life year (from 
literature); 
• Soil:  
Damage caused by soil erosion: costs estimated 
from soil carried off farms by water or wind blocks 
ditches and roads, damages property, induces 
traffic accidents, increases the risk of floods, and 
pollutes water through sediments and associated 
nitrate, phosphate and pesticides;  
Organic matter and carbon dioxide losses; 
• Biodiversity and landscape:  
Costs of wildlife and habitat losses=costs or 
restoring species and habitats under the 
Biodiversity Action Plans (BAPs) as a proxy; 
Costs of hedgerows and drystone walls=amount 
that farmers receive for replacing hedgerows and 
drystone walls under agri-environment schemes 
used as a proxy; 
Cost of agricultural biodiversity=not possible to put 
a cost on these losses; 
• Human health:  
Pesticides (acute effects)=(value of a symptom-
day*(number of farmers are off work for one 
day=those are off half a day))*GP consultation 
cost; 
Pesticides (chronic effects)=not included; 
Nitrate=assumed zero; 
Cost of food poisoning=(lost wages=consultations 
with doctors=hospital beds)*% poisoned people 
from UK farming; 
Antibiotic resistance=impossible to estimate; 
BSE and CJD(transmissible disease occurring in 
animals and humans)=total costs BSE*% belonging 
to farming; 
Gulli,F. 
(Rw 48) 
2006 negative Value of gas-fired 
distributed generation 
(decentralized 
supply) lost due to 
non-greenhouse 
emissions 
Environmental damage: pollution concentration*population*dose-
response function; 
Using the ExternE methodology (bottom-up approach): 
a)determining  the emissions for each stage of the fuel cycle (from 
the production of primary input to the output production); 
b)simulating the dispersion of the pollutants both on a local and 
CV (WTP or WTA) Secondary 
(ExternE 
data) 
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Authors Year Consequences 
Type Identification Measurement (physical effect) Valuation72 Type of 
data 
regional scale; c)identifying all the receptors; d)calculating the 
impact (by applying the “dose-response” functions); 
The pollutants taken into consideration are solid, liquid and gaseous 
residues. The main impact is due to the emissions of CO2,SOx,NOx 
and particulate (PM10); 
The damage taken into consideration includes the effects on public 
health, agriculture, forests (acid rain), the ecosystem in general, 
materials (deterioration of buildings and monuments) and the damage 
related to global warming due to greenhouse gas emissions; 
Dose-response functions provide the marginal damage caused by 
increment of concentration due to plant emissions (USD/Kg); 
Rey,F.J.; 
Martin-
Gil,J.; 
Velasco,E.; 
Pérez,D.; 
Varela,F.; 
Palomar,J.
M.; 
Dorado,M.P
. (Rw 49) 
2004 negative Value lost due to 
environmental 
damage of a heat 
pump 
Eco-indicator methodology: evaluate the environmental damage 
weighting human health, ecosystem and resources. 
• Human health: expressed as DALY (Disability Adjusted 
Life Years). It links health effects to DALYs, using 
estimates of the number of Years Lived Disabled, and 
Years of Life Lost; 
Inorganic substances (respiratory effects): emissions to 
the air; 
• Ecosystem: quality are expressed  in relation to the 
species that have disappeared in a certain area and 
period, mainly vascular plants and simple organisms; 
Damages to ecosystems needs to introduce the following 
impact categories: ecotoxicity, 
acidification/eutrophication, and land use. For 
ecotoxicity, they use the unit PAFm2yr, meaning the 
Potentially Affected Fraction (PAF)of species in relation 
to the concentration of toxic substances per area and 
year. For acidification and eutrophication we use the unit 
PDFm2yr, meaning the Potentially Disappeared Fraction 
of plant species (PDF) per area and year. For land use, 
we also use the PDFm2yr as unit; 
Carcinogenesis (emissions to the air); 
Climatic change (emissions to the air); 
• Resources: Waste heat  per Kg of extracted material 
(surplus energy); 
Combustibles (mining:petroleum, coal and natural gas); 
 
EPS2000 methodology: this method evaluates the impact over the 
environment via its impact on one or several safe guard subjects, that 
is, human health; 
 
Eco-indicator methodology: Unit named Eco-indicator point 
(the absolute value of the points is not very relevant, as the 
main purpose is to compare relative differences between 
products or components); 
 
EPS2000 methodology: is expressed in environmental load 
units (ELU), equivalent to the Euro; 
secondary 
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Authors Year Consequences 
Type Identification Measurement (physical effect) Valuation72 Type of 
data 
The impact categories identified are: human health (including human 
diseases), ecosystem production capacity (including information 
relative to crop, fish/meat, and wood yield decrease), abiotic stock 
resources, and biodiversity (including the extinction of species); 
Damage categories: 
• Resources (mining); 
• Life expectancy (emission to the air); 
• Severe unhealthy conditions (emission to the air); 
• Moderate discomfort (emissions to the air); 
• Moderate unhealthy conditions (emissions to the air); 
Wattage,P.; 
Soussan,J. 
(Rw 50) 
2003 positive 
and 
negative 
Value created by the 
System 
Rehabilitation 
Project, a water 
control structure, to 
the environmental 
development projects 
Not specified Net present value (NPV): the result of discounting  and 
summing of annual net benefits stream overtime over the 
lifetime of the project; 
NPV=(NDB-DBP=ENB)*e^rt; 
 
NDB=net development benefits (difference between benefits 
and costs of development over time); 
DBP=disbenefits as a result of the project (estimated using the 
survey information); 
ENB=environmental benefits (CV method); 
secondary 
Hamacher,
T.; 
Sáez,R.M.; 
Aquilonius,
K.; 
Cabal,H.; 
Hallberg,B.; 
Korhonen,R
.; 
Lechón,Y.; 
Lepicard,S.; 
Schleisner,
L.; 
Schneider,T
.; Ward,D. 
(Rw 51) 
2001 negative Value of environment 
lost due to a fusion 
power plant 
• The external effects due to energy consumption for the 
production and transportation of the materials, the traffic 
accidents and the occupational accidents during the production 
processes; 
• Plant construction: 
o External costs of SO2,NOx and CO2 emissions (Euro/t 
CO2); 
o Increase in traffic during the construction phase; 
o Increase in road accidents, due to increase in traffic, 
leads to deaths and injuries of the public involved in the 
accidents. The number and severity of the accidents are 
estimated using  an estimation of the total amount of 
materials necessary to be transported together with the 
national road and rail accident statistics; 
o Occupational accidents during the construction of the 
plant and components are based on the expected 
investment cost, which lead to an estimation of the value 
for the person years, and the accident statistics for the 
different branches involve; 
• Normal operation: 
o Impacts due to the emissions and the effluents of 
radioactive isotopes, the impacts due to the occupational 
* Methods not specified; 
• Construction: 
o Emissions of the transport; 
o Road accidents; 
o Occupational accidents; 
• Power plant operation: 
o Routine releases; 
o Occupational exposure; 
o Other occupational impacts; 
• Power generation; 
• Decommissioning: 
o Emissions of the transport; 
o Traffic accidents; 
o Occupational accidents; 
• Recycling: 
o Emissions of the transport; 
o Traffic accidents; 
o Non radioactive dust emissions; 
o Radioactive emissions; 
o 14C emissions; 
• Site restoration: 
secondary  
(ExternE 
data) 
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Authors Year Consequences 
Type Identification Measurement (physical effect) Valuation72 Type of 
data 
radioactive exposure and other ‘normal’ occupational 
accidents; 
• Decommissioning77 and recycling: 
o Human health impacts due to release of dust and 
radioactivity from the recycling plant; 
o Death and health impacts of the decommissioning 
workers (number of person-years was based on estimated 
decommissioning years; and the number of expected 
accidents were based on experience from fission plants); 
o Road and rail accidents; 
• Waste disposal: 
o 14C releases from final repositories; 
o 94NB releases from final repositories; 
• Intense fusion economy: 
o Radioactive emissions in normal operation and from the 
final repository; 
• Accidents (input/output analysis): 
o Acute and chronic health effects on different 
geographical scales; 
o Economic losses due to food bans; 
o Economic disturbances due to relocation of the 
population; 
o General risk aversion of the population; 
o Emissions; 
o Traffic accidents; 
• Waste disposal; 
 
Human life is assessed by CV (WTP/WTA): 
• WTP for a reduction in the risk of death. The ‘value of 
statistical life’ is calculated by dividing the cost of the 
measure to reduce the risk  by the reduction in the risk 
of death; 
• WTA compensation for a higher risk; 
• WTP or WTA a higher risk as evaluated from interviews 
or questionnaires; 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nishi,J.; 
Tanaka,T.;S
eiki,T.;Ito,
H.;Okuyam
a,K. (Rw 
52) 
2000 positive Value created on 
exterior environment 
• Stop a development that would obscure or make unsightly their 
favorite view; 
• Emailed questionnaires where respondents were asked 
how much money they would pay to stop a development 
that would obscure or make unsightly their favorite view; 
primary 
Niskanen,A
. (Rw 54) 
1998 positive 
and 
Value created of 
reforestation (carbon 
• Benefits in erosion control: the amount of soil erosion was 
estimated with the modified universal soil loss equation 
• Benefits in erosion control: replacement cost method 
(used to estimate the on-site costs of soil erosion; This 
secondary 
                                                 
77
 Decommissioning includes all activities starting with the decontamination and demolition of the plant, waste treatment, including recycling, and transport of radioactive waste to final repositories; 
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Authors Year Consequences 
Type Identification Measurement (physical effect) Valuation72 Type of 
data 
negative sequestration and 
increased erosion 
control) and value 
lost of reforestation 
(water consumption 
and nutrition loss in 
harvesting) in 
Thailand 
(MUSLE) (Thai baht ha^-1); 
• Costs of nutrient loss in harvesting: nutrients accumulated in 
and removed with felled trees (teak, eucalypt and cassava: Thai 
baht ha^-1); 
• Costs of transpiration: depends on climatic factors (radiation, 
relative humidity, temperature, wind speed); physiological 
response mechanisms; canopy structure; and the availability of 
soil water to roots (Thai baht ha^-1); 
• Benefits in carbon sequestration (Thai baht ha^-1); 
involved pricing the amount of commercial fertilizers that 
were needed to replace lost nutrients in eroded material); 
• Costs of nutrient loss in harvesting: replacement cost 
technique; 
• Cost of transpiration: transpiration ratio (basal area of the 
tree at breast height) and water use efficiency approaches 
(describe the volume of water in liters that is consumed 
by a plant during the growing season per kilogram of dry 
matter produced; 
• Benefits in carbon sequestration: method used by Nabuurs 
and Mohren (1993) based on the assumption that the 
estimation of carbon sequestration of the trees’ different 
structures is possible when the annual stem volume 
increment in known; 
Parfomak, 
P.W. (Rw 
55) 
1997 negative Value of environment 
lost due to power 
plant emissions 
• Coal uncontrolled emissions (lbs k Wh^-1); 
• Coal SO2 controlled emissions (lbs k Wh^-1); 
• Natural gas steam (lbs k Wh^-1); 
• Natural gas combined cycle (lbs k Wh^-1); 
Externality cost (1994¢ kWh^-1)=Cost of emissions (1994$ 
lb^-1)*emissions (lbs kWh^-1); 
secondary  
Torfs,R. 
(Rw 56) 
2007 negative Value of 
environmental health 
lost due to air 
pollution and noise 
• PM10 acute effects (10µg/m3): 
o Non accidental mortality; 
o Respiratory hospital admissions; 
o Cardiovascular hospital admissions; 
o Use of bronchodilators against asthma; 
o Prevalence of acute bronchitis; 
• PM2.5 chronic effects (10µg/m3): 
o Cardio-respiratory mortality; 
o Mortality due to lung cancer; 
• PM10 chronic effects (10µg/m3): 
o Incidence of chronic bronchitis; 
• Oxone (50µg/m3): 
o Non accidental death; 
o Days with restricted activity; 
o Respiratory hospital admissions (15-64) (65=); 
o Exacerbation of extreme asthma; 
o Symptom days; 
• UV radiation/stratospheric ozone: 
o Death due to melanoma cancers; 
• Benzene: 
o Death due to leukaemia; 
o Non fatal leukaemia; 
• PAHs: 
• Concentration response function or unit risk factor=CV 
(WTP) 
• Results: External cost per DALY; 
secondary 
(ExternE 
data) 
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Authors Year Consequences 
Type Identification Measurement (physical effect) Valuation72 Type of 
data 
o Mortality due to lung cancer; 
• As: 
o Mortality due to lung cancer; 
• Ni: 
o Inhalation and decrease of IQ; 
o Ingestion and decrease of IQ (µg/year); 
• Noise: 
o IHD Mortality; 
o Cardiovascular hospital admissions (IHD); 
o Serious nuisance; 
o Sleep disturbance; 
• Exposure: health changes and mortality risks: 
o DALYs: YLL = YLD 
 YLL=number of deaths *disability weight*standard life 
expectancy at age of death in years L; 
 YLD=number of incident cases*disability 
weight*average duration of disability in years L; 
 The number of cases (N) attributable to outdoor air 
pollution or noise is estimated by using the ‘at least’ 
approach. The required data components are the 
exposure-response function, the frequency of the health 
outcome and the level of exposure; 
Godoy,R.; 
Contreras,
M. (Rw 57) 
2001 positive Value created on 
tropical forest due to 
schooling 
• Annual value of lower tropical deforestation due to one 
additional year of a household head’s schooling ($); 
• $ that households should receive each year for saving the forest 
so the rest of the world can enjoy its benefits; 
• Annual value of externality=average area of old-growth 
forest cleared by a household each year*mean total value 
of a rain forest excluding food, raw materials, and 
recreation ($)*annual value of the positive externality 
produced by education (%); 
• Additional environmental externality from not cutting the 
fallow forest= average area of old-growth forest cleared 
by a household each year*mean total value of a rain forest 
excluding food, raw materials, and recreation ($)*% of 
area reduction of cut fallow forest of one more year of 
schooling; 
primary 
(household 
survey) 
Viswanatha
n,S. (Rw 
59) 
2005 positive Consumers' utility 
derived from the 
bundle, and 
consumers' utility 
derived from the 
network of 
consumers who 
purchase from the 
same firm; 
• Two period model (in which a firms' consumer base (demand) 
in Period I confers utility to the firm's consumers in Period II - 
the value to a consumer being directly proportional to the 
number of consumers her firm has in Period I; 
Not specified Not 
specified 
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data 
Lechón,Y.; 
Cabal,H.; 
Sáez,R.M.; 
Hallberg,B.; 
Aquilonius,
K.; 
Schneider,T
.; 
Lepicard,S.; 
Ward,D.; 
Hamacher,
T.; 
Korhonen,R
. (Rw 60) 
2003 Negative Value lost due to 
electricity generation 
by different fuel 
cycles; 
Emissions of the transport; 
o Road accidents; 
o Occupational accidents; 
• Recycling: 
o Emissions of the transport; 
o Road accidents; 
o Non radioactive dust emissions;Non radioactive dust emissions; 
o Radioactive emissions; 
o C-14;  
• Site restoration : 
o Emissions; 
o Traffic accidents; 
• Waste disposal; 
• Accidents; 
Not specified secondary 
Park,G.; 
Park,Y. 
(Rw 61) 
2003 positive 
and 
negative 
Value created and 
lost on productivity 
and labour due to 
information and 
communications (IC) 
technology on other 
industrial sectors 
• Positive and negative impact are specified in terms of 
productivity and employment; 
• They divide the IC industry into IC-machinery sector and IC-
service sector, assuming that these two sub-sectors are 
considerably different to each other in terms of knowledge 
contents and flow pattern. In order to measure the inter-
industrial spillover effect, other industries are classified into 17 
different sectors; 
• They identify specific effects of IC technology on individual 
industries; 
• They measure the spillover effect of  IC technology on 
production cost (cost function) and labour demand (labour price 
function) of other industrial sectors; 
• Not specified; secondary 
Saelensmin
de,K. (Rw 
62) 
2004 positive 
and 
negative 
Value created and 
lost of insecurity and 
health effects due to 
changes from travel 
by car to cycling or 
walking 
• Benefits: 
o Traffic accidents resulting in injury: will remain 
unchanged; 
o Travel time: travel times for pedestrians and cyclists 
remain unchanged because of the walking and cycle tracks. 
They assume that travel times for car drivers who do not  
substitute walking or cycling for driving are reduced in 
cities with traffic congestion; 
o Insecurity: included as a cost of NOK 2 per kilometre; 
o Less severe diseases and aliments and long-term 
absence/disability; 
o External costs of road transport: CO2 emissions, local 
emissions to air, noise, congestion, and infrastructure costs; 
• Methods not specified. Unit: NOK million(NOK 1=USD 
0.14) 
o Accidents (assumed no change); 
o Travel time (assumed no change); 
o Reduced insecurity for current pedestrians; 
o Reduced insecurity for current cyclists; 
o Reduced insecurity for new future pedestrians; 
o Reduced insecurity for new future cyclists; 
o Reduced costs for transporting school children; 
o Reduced costs related to less severe diseases and 
aliments and less short-term absence; 
o Reduced costs related to severe diseases and 
aliments ; 
o Reduced external costs of motorized road transport; 
secondary 
Baublys,A.; 2005 negative Value lost on • External and infraestrucutre costs of a heavy vehicle moving on • Methods not specified: secondary 
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Authors Year Consequences 
Type Identification Measurement (physical effect) Valuation72 Type of 
data 
Isoraité,M. 
(Rw 63) 
transport sector due 
to air pollution, 
climate changes, 
infrastructure and 
noise emission costs 
a motorway at 100km/h under the conditions of non-intensive 
traffic (€): 
o Air pollution: costs related to health and harvest 
damages; 
o Climate changes: floods and harvest damages; 
o Infraestructure; 
o Noise emission costs; 
o Air pollution; 
o Climate changes; 
o Infrastructure; 
o Noise emission; 
o Road accidents; 
o Congestion; 
o General; 
Gibbons,E.; 
O'Mahony,
M. (Rw 64) 
2002 negative Value lost on 
environment due to 
transport activities 
• Congestion: longer journey times, increased fuel consumption 
and greater wear and tear on vehicles. Congestion function to 
describe how average speed is influenced by traffic flow. The 
congestion function allows the time loss suffered by other roads 
users to be computed if an additional passenger car unit (PCU) 
joins the traffic flow; 
• Air pollution: take into account the impact of pollutant 
emissions on local concentration levels and refer to the external 
costs of air pollution on human health, materials, crops and 
global warming. The values are calculated for car, bus and 
train. The values shown for the car are in EURO per vkm, 
while the values for the public transport modes are in EURO 
per passenger km; 
• Accidents: what society would be prepared to pay to reduce the 
risk of an accident; 
• Noise: cost of noise generated by road traffic; 
• Marginal external congestion cost= the congestion 
function is combined with information on the value of 
time (cost of an additional PCU kilometre); 
• Air pollution=CV (WTP/WTA); obtained by ExternE 
project; 
• Accidents=CV (WTP/WTA); The WTP of relatives and 
friends of the victim to avoid the accident was not 
included in the cot estimate; 
• Noise=it is calculated through an algorithm. The total 
external noise cost was calculated by multiplying the 
monetary value per dB by the noise level above the 
threshold of 50 dB(A) by the length of road where a noise 
externality is generated. The monetary value of noise was 
calculated at 0.6 EURO per 1dB(A) per kilometre; 
secondary 
Forkenbroc
k,D .J. (Rw 
65) 
2001 negative Value lost of freight 
train transportation 
due to accidents, 
emissions and noise 
• Accidents:  
3 primary categories of accidents=collisions at highway-rail 
grade crossing, persons struck by a train at other locations, and 
mishaps involving the train alone; 
o Fatalities: 
o Injuries: 
o Property damage: estimate of the value of property damage 
to other vehicles involved in crashes with trains at 
highway-rail grade crossings 
• Emissions: 
Air pollution: volatile organic compounds (VOC), nitrogen 
oxides (NOx), sulphur oxides (SOx) and particulate matter 
under 10 µm in aerodynamic diameter (PM10) (emission 
rates per ton-mile);  
Emission costs (cents per ton-mile); 
o Greenhouse gases: CO2 (cents per ton-mile); 
• Noise: 
o social cost of noise per ton-mile of transportation service in 
rural areas; 
• External cost of accidents=numbers of fatal, personal 
injury, and property damage accidents*the appropriate 
per-event cost-the amount of compensation paid by the 
particular mode; 
o Per-ton-mile external cost=external cost of accidents/ 
number of ton-miles; 
o Property damage=pProperty damage for non-
crossing rail accidents (other than to trains) is 
comparatively minor and ignore the costs of such 
damage; 
• Emissions: emission rates*emission costs; 
• Noise: same value as applied for trucks; adopted from the 
literature; 
 
secondary 
 259
 
Authors Year Consequences 
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data 
Spadaro,J.V
.; Rabl,A.; 
Jourdain,E.; 
Coussy,P. 
(Rw 67) 
1998 negative Value lost due to air 
pollution of road 
transport 
• Source: gasoline cars with and without three-way catalytic 
converter and diesel cars; 
• Emission factors: benzo-a-pyrene (BaP) (in g/km); The 
calculation of emissions has been done by dividing the journey 
into six sections representing different traffic conditions, 
driving cycles and meteorological conditions; 
• Impacts (Impact Pathway approach: exposure-response 
function): 
Health: restricted activity days, chronic bronchitis, 
respiratory problems, cough, chronic bronchitis in children, 
chronic sore throat, respiratory hospital admissions, 
cerebrovascular hospital admissions, cancers and chronic 
mortality; 
o Agricultural crops: SO2; 
o Forests: Acid rain; 
o Materials: Acid rain; 
CV (WTP to avoid the impacts): ECU per case; Secondary 
(ExternE 
project) 
Mayeres,I.; 
Ochelen,S.; 
Proost,S. 
(Rw 68) 
1996 negative Value lost due to 
cars, trucks and urban 
public transport 
modes 
• Congestion:  
o Congestion function: expresses the minutes needed to drive 
1km in a certain period as a function of the million 
passenger car units (PCU) per hour at that moment in the 
city; 
o Time costs: time loss suffered by the other road users if an 
additional PCU joins the traffic flow; 
• Pollution: effects on 
o Health: mECU/g VOC(volatile organics compound); 
o Vegetation: SO2 and NOx (mECU/g); 
o Materials; 
o Aquatic ecosystems; 
o Visibility; 
o Climate: global warming (mECU/g); 
• Accidents: marginal social accident cost (MSAC) of a car is the 
derivative of the total accident cost (TAC) with respect to the 
number of car km; A distinction is made between fatal 
accidents, accidents with serious injuries, accidents with light 
injuries and accidents with only material damage; (ECU or 
million ECU); 
• Noise: effect on the noise level of an additional car km; They 
assume that the average street in Brussels has a U-shape; 
(mECU per vehicle km); Index for noise used is the energy 
mean sound level over a given period=53.9 = 10log (flow of 
light vehicles in veh/h = flow of heavy vehicles in veh/h) – 
10log of width between the facades (in metres) =  correction 
• Congestion: not described; 
• Pollution: 
o Health (CV): mortality; morbidity (respiratory 
hospital asmission; emergency room visit; symptoms 
of chronic bronchitis; symptoms of chronic cough; 
restricted activity day; minor restricted activity day; 
asthma attack; and symptom days; 
o Vegetation: direct effect of SO2 on wheat, barley rye 
and oats (national and transnational); effect of NOx 
on O3 on wheat (national); 
o Global warming: coastal defence; dryland loss; 
wetland loss; ecosystem loss; agriculture; forestry 
and fishery losses; gains and losses in the energy and 
water supply; life and morbidity effects; air pollution 
damages; migration costs and an estimate of natural 
hazard damages; 
• Accidents: CV 
o MSAC=(WTP to avoid an accident of type n = WTP 
of the relatives and friends of the victim to avoid an 
accident of type n = pure economic costs (net output 
losses, ambulance costs, medical costs, 
etc))*probability that an accident of severity n occurs 
between transport modes I and j and in which i is the 
victim*number of vehicle km travelled by transport 
mode; 
• Noise: Hedonic housing market method 
secondary 
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Type Identification Measurement (physical effect) Valuation72 Type of 
data 
factor for speed, which means that 1dB is added for each 
10km/h above a speed of 60km/h; 
o Total external noise cost for Brussels=monetary 
value * noise level above the threshold of 50 * 
number of road km where a noise externality is 
generated (we assumed 500km supra); 
o To compute the resulting marginal external noise 
cost (MENC) in the reference equilibrium, we derive 
the total external noise cost function with respect to 
the number of vehicle km; 
de Dios 
Ortuzar,J.; 
Rizzi,L.I. 
(Rw 69) 
2007 negative Value placed for 
improving urban road 
safety, better air 
quality and 
increasing levels of 
quietness due to the 
provision of urban 
transport 
• Urban road accidents: human capital approach (value of a life 
saved given by the present value of the expected income flow 
the individual would have earned, had she not died); Linear 
indirect utility functions; 
• Local air pollution: a realistic way of ‘offering’ distinct 
atmospheric conditions consisted in presenting different 
residential locations associated with different air quality levels; 
Although there are many factors influencing housing choice 
behaviour, it was considered reasonable to include only 
accessibility to work and accessibility to study (expressed in 
minutes of travel time for each individual in the household) and 
the rent paid (CH$); 
• Quietness: to value reductions in urban noise levels;  attributes 
chosen for the experiment were the rent or mortgage paid, noise 
level, travel time to work and sun orientation; The authors 
tested presenting the noise variable in relation to recalled levels 
at different intersections in Santiago (e.g. some objectively 
louder than others); Using a 10-point scale; 
• Urban road accidents: CHM (stated choice experiment; 
Discrete Choice Modelling); Through a multinomial logit 
and mixed logit it is possible to obtain value of travel time 
and the subjective value of accident reduction; 
• Local air pollution: SP; Through a multinomial logit and 
mixed logit it is possible to obtain WTP values for travel 
time to work  by individual h from location I and, travel 
time to study by individual h from location i; 
• Quietness: CHM (Discrete Choice Modelling); Through a 
multinomial logit and mixed logit it is possible to obtain 
WTP values for noise level and travel time to work; 
Primary 
data (first 
senior 
manageme
nt staff of 
private and 
public 
institutions
) 
Friedrich,R.
; Bickel,P. 
(Rw 70) 
2001 negative Value lost of 
environment due to 
transports 
• Health impacts: exposure-response for acute and for chronic 
effects of air pollution; Gaseous pollutants: Ozone, SO2, CO 
and NO2; chronic mortality effects: the years of life lost  
(YOLL) attributable to air pollution were estimated by linking 
the regression estimates from literature with the populations-at-
risk and age-specific death rates in four European countries 
(Germany, Italy, Netherlands, UK), using life table methods; 
• Impacts on building materials: loss of mechanical strength, 
leakage and failure of protective coatings due to degradation of 
materials; A dose-response function links the dose of pollution, 
measured in ambient concentration and/or deposition, to the 
rate of material corrosion 
• Impacts on terrestrial ecosystems: effects on the physical 
structure of the landscape (such as direct loss of land and 
habitat fragmentation, of the land used solely for transport), 
effects of management of the transport route and adjacent land 
• CV: WTP for environmental benefit or WTA payment in 
lieu of environmental harm; 
• Health impacts:  
o Ashmatics: bronchodilator usage, cough and lower 
respiratory symptoms (wheeze); 
o Elderly 65=: congestive heart failure; 
o Children: chronic cough; 
o Adults: restricted activity days, minor restricted 
activity days and chronic bronchitis; 
o Entire population: chronic mortality, respiratory 
hospital admissions, cerebrovascular hospital 
admissions, symptom days, cancer risk estimates 
and acute mortality; 
• Building materials:  in order to be able to calculate costs a 
damage function needs to be obtained. A physical damage 
function links the rate of material corrosion (due to the 
Secondary 
(ExternE 
project) 
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data 
(including cutting and clearing vegetation, salting and drainage) 
and, effects produced by use of the transport system (for 
example the impacts of atmospheric emissions from the 
transport vehicles and dispersal of organisms); Only the 
localised are studied, where the impacts are concentrated by the 
use of fixed routes such as roads; 
• Global warming: three uniformly-mixed gases – carbon 
dioxide, methane, nitrous oxide – and two region-specific 
gases-nitrogen (from aircraft) and sulphur, which influence 
ozone and sulphate aerosol concentrations, respectively; 
pollution exposure given by the dose-response function); 
• Global warming: damage costs; morbidity risks are 
valued based on the value of a life year lost; 
Forkenbroc
k,D.J. (Rw 
71) 
1999 negative Value lost of truck 
freight transportation 
due to accidents, 
emissions, noise and, 
unrecovered costs 
associated with the 
provision, operation, 
and maintenance of 
public facilities 
• Accidents (fatalities, injuries, and property damage): costs of 
deaths, injuries and property damage;  
• Emissions (air pollution and greenhouse gases):  
o Air pollution: is needed the amount of air pollution 
associated with a unit of travel by different types of 
vehicles operating under different conditions and, 
the dollar value of damage to human health and 
other things of value – animals, crop, yields, 
building and structures, and scenic views; 
o Greenhouse gases: CO2 emission; 
• Noise: to associate the noise level in decibels above an 
established noise threshold with average changes in property 
values. Average property value changes per decibel increase 
can then be tied to the noise generated by a particular type of 
vehicle operating at various distances from the property; 
• Unrecovered costs associated with the provision, operation, and 
maintenance of public facilities (primarily roads and bridges): 
assess which vehicle  classes, on balance, overpay and which 
underpay relative to other classes; 
• Accidents:  WTP for risk reduction;  
Per ton-mile external cost of general freight 
trucking=amount of compensation paid by affected 
trucking companies; 
External cost=total cost of society- Per ton-mile external 
cost of general freight trucking; 
• Emissions:  
o Air pollution: emission factors (g per mile)*costs 
(dollars)=costs of air pollution per vehicle-
mile; Damage cost function to value damage 
to materials; 
o Greenhouse gases: quantity of diesel fuel burned 
(CO2 emissions)*cost per ton=cost to society 
of CO2 emissions per ton-mile shipped by 
truck; 
• Noise: not specified; 
• User charge underpayment: estimates of the magnitude of 
government subsidies to freight trucks are based on the 
equity ratios (user charges paid / cost responsibilities) 
produced by the Federal Highway Cost Allocation Study 
(Federal HCAS); 
secondary 
Turtós 
Carbonell,L
.; Meneses 
Ruiz,E.; 
Sánchez 
Gácita,M.; 
Rivero 
Oliva,J.; 
Díaz 
Rivero,N. 
(Rw 72) 
2007 negative Value lost on health 
due to atmospheric 
emissions of 
electricity generation 
• Health impacts: Year of Life Lost (YOLL) approach; the loss 
of life expectancy is a meaningful indicator; 
o Mortality impact: acute and chronic impact; specific 
exposure-response functions; proxies used: chronic 
mortality in adults and acute mortality; 
o Morbidity impact: cost of an acute crisis of asthma; 
proxies used: chronic bronchitis in adults, hospital 
admissions for respiratory causes, restricted activity 
days in adults, emergency room visits, and acute 
asthma crisis (asthmatic population); 
• Mortality and morbidity costs: not specified; unit costs in 
EU (USD 2002 per case or YOLL); 
secondary 
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data 
Houndekon,
V.A.; De 
Groote,H.; 
Lomer,C. 
(Rw 73) 
2006 negative health costs to non-
farming members of 
the community, costs 
covered by 
communal health 
centres, health costs 
to farmers' children 
and, externalities of 
livestock losses 
• livestock losses: farmers and pastoralists were asked to recall 
the number of animals with pesticide intoxication thay had 
observed in their herds over the last five years, and how many 
of those animals died; 
• Losses were valued at market price, and divided by the 
average number of hectares treated by the farmers 
(multiplying the mortality by the number of animals per 
farm and by their average values); 
Mixed 
(primary 
and 
secondary) 
Houndekon,
V.A.; De 
Groote,H.;  
(Rw 74) 
1998 negative Value lost on health, 
animals and 
environment due to 
chemical pesticides 
• Human health: impact on respiratory system, neurological 
system, skin, eye and the gastro-intestinal system; studied  by a 
statistical model (logit model); The independent variables are 
individual characteristics, indicators of exposure to pesticides, 
and other factors that might influence health;  
• Livestock losses: number of animals with pesticide intoxication 
they had observed in their herd over the last five years, and how 
many of those animals died; 
• Destruction of obsolete pesticides: cost of cleaning up obsolete 
pesticides; 
• Human health: 
o Health costs=expenses of medical services 
(medications or consultation fees)=loss of 
productive work time; 
• Livestock losses: (total number of animals intoxicated and 
how many of those died*market price of those 
animals)/number of hectares treated during that year in 
that region; 
• Obsolete pesticides: average cost of destroying obsolete 
pesticides per litre (obtained from a destruction project 
already existing) / hectare treated; 
primary 
and 
secondary 
Brisson,M.; 
Edmunds,
W.J. (Rw 
76) 
2004 positive Value created on 
altruism due to 
varicella vaccination 
• The vaccine may derive benefit from knowledge that by being 
vaccinated they will not infect other children; they estimated 
whether individuals derive benefit from not infecting others 
because they are immunised; 
• CV and standard gamble questionnaire:  
o CV: the respondents were given a description of a 
child with chickenpox; initially respondents 
were asked to assume that their child has 
chickenpox and that a drug exists which can 
cure their child immediately; They then 
elicited the maximum the respondent is willing 
to pay for the drug using a bidding algorithm. 
In the second section of the CV questionnaire, 
respondents were asked the maximum they 
were willing to pay to vaccinate their child 
against chickenpox; Respondents were given 
randomly one of 4 different contingent 
valuation questionnaires; The value parent’s 
put on preventing their child infecting others 
(altruism) was measured by comparing the 
WTP from questionnaires stressing this effect 
to those in which the effect was not 
mentioned; 
o SG: a separate group of respondents were asked to 
imagine that their child is in an imaginary 
health state for 15 years; the duration of 
primary 
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disease was chosen so that parents would trade 
risks of death for intervention and it is the 
time-span of childhood. Apart from the 
duration of disease, the health profile is 
identical to the description of chickenpox; the 
only attribute varied in the SG questionnaire 
was altruism: in half of the questionnaires 
altruism was included by stressing that 
treatment will prevent the child from giving 
the disease to other children. In the remainder 
there were no mention of knock-on effects; 
Henderson,
V(Rw 77) 
1997 positive Value created on 
employment levels 
due to increased 
concentrations of 
own industry activity 
• To estimate the nature, magnitude and timing of dynamic 
externalities, and presents industry specific estimates for five 
industries: through a model of local individual industry 
employment, using variables such as: 
o Concentration of own industry country employment; 
o Non diversity index; 
o Market variables: 
 Wages; 
 Metro area employment, excluding 
county own industry employment; 
• Not calculated; secondary 
European 
Comission, 
DG 
Environmen
t (Rw 80) 
2000 positive 
and 
negative 
Value created and 
lost  on environment 
due to landfill 
disposal and 
incineration of waste 
• Incineration: 
o Air emissions: 
o Particulates: mortality and morbidity; ecosystem; 
and, damage to buildings;  
o NO2: forest dieback and damage to buildings; 
aerosols (mortality and morbidity); O3(mortality, 
morbidity, forest die-back and lower agricultural 
yield); ecosystem; 
o SO2: mortality and morbidity; lower agricultural 
yield; forest die-back; damage to buildings; 
ecosystem;  
o CO: climate effect; mortality and morbidity; 
o VOCs: mortality and morbidity; effects of O3; 
o CO2: climate effect; 
o HCI and HF: morbidity; acidification;  
o Dioxins: mortality and morbidity; ecosystem; 
o Heavy metals: mortality and morbidity; ecosystem; 
o Wastewater emissions: ecosystem and mortality and 
morbidity; 
o Solid waste residues from incineration plants: bottom ash; 
flue gas cleaning residues; composition of solid waste 
*Reporting several studies with different methods each to 
valuate external effects 
• Incineration: 
o External costs of air emissions; 
o External costs of emissions to water and soil; 
o External benefits; 
o External costs of disamenity effects; 
• Landfill disposal: 
o External costs of air emissions; 
o External costs of emissions to water and soil; 
o External benefits; 
o External costs of disamenity effects; 
secondary 
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residues; emission to air; 
o Energy recovery: in the form of electricity and/or heat; 
o Disamenity impacts: nuisance caused as a result of the 
presence of an incineration plant including noise, 
dust, odours, visual pollution (particularly the 
smoke stack), and the national presence of vermin; 
o Risk of accidents: contact with auxiliary materials; fire in 
the silo; fire in the dioxin filter; leaks from high 
pressure feed-water and steam system; overheating; 
explosive matter in the waste; leak of ammonia; 
contact with flue gas residues; 
• Landfill disposal: 
o Timing of emissions from landfills: landfill strategy; final 
storage quality; and timeframe; 
o Air emissions: CO2 climate effects; CH4 climate effects; 
CO2 and CH4 ecosystem; VOCs mortality and morbidity; 
dust and emissions resulting from using landfill gas; 
o Emissions to soil and water: leachate; 
o Land use: externality per se; 
o Displaced impacts: net energy recovered; 
o Disamenity impacts; 
o Risk of accidents: explosions and leachate emissions; 
Rabl,A.; 
Spadaro,J.V
.; 
Desaigues,
B. (Rw 81) 
1998 negative Value lost of 
environment and 
health due to 
municipal solid waste 
incinerators 
• Air pollution: Particles, NO2, SO2 (kg/person-year); 
• Health impacts: 
o morbidity: acute and chronic effects; Number of asthma 
attacks due to this O3, using dose-response functions; 
o mortality; 
CV  
• PM10 rural; 
• PM10, typical urban; 
• PM10, Paris 
• SO2 via sulfates; 
• NO2 via nitrates; 
• NO2 via ozone; 
secondary 
Jacobsson,F
.; 
Carstensen,
J.; 
Borgquist,L
. (Rw 82 
(22)) 
2005 positive Value created for 
someone’s health due 
to an altruistic 
behaviour 
• respondents willingness to pay for someone else’s possibility to 
be cured from each health state: seven hypothetical  health 
states with different severity levels; 
• The respondents drew a line from each box representing a 
health state to a box representing the amount of money 
the respondent was willing to pay for someone else’s 
possibility to be cured from each health state. The method 
was similar to payment cards. This type of open-ended 
question was also used to get as much information as 
possible from each respondent; 
primary 
Krewitt,W.; 
Friedrich,R.
; Heck,T.; 
Mayerhofer
,P. (Rw 
1998 positive Value created on 
environment and 
health due to a 
reduction of SO2 and 
NOx emissions 
• Human health: impact on 
o Mortality 
o Morbidity (respiratory symptom days, asthma attacks, or 
respiratory hospital admissions; 
• Materials: impact on replacement frequency of zinc, galvanised 
• Human health:  
o Mortality: Value of Statistical Life (VSL), 
indicating WTP for a reduction of (a small) risk; 
o Morbidity: WTP and cost of illness of the overall 
health related damage costs; 
secondary 
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84(25)) steel, limestone, mortar, sandstone, paint, and rendering for 
utilitarian buildings; 
• Crop production: impact on wheat, barley, potato, rye, oats, and 
sugar beets; 
• Agriculture: direct effects of SO2 on crop yield; The costs 
of changing the amount of lime needed to deal with 
acidification of agricultural soils, and the benefits of N 
deposition as fertiliser has been estimated; The estimated 
yield cross is valued with world market prices to obtain 
resulting damage costs. Costs of liming and benefits of 
oxidised N deposition are calculated from market prices 
for lime and ferlitiser; 
• Building materials: effect of SO2 and wet acid deposition 
on corrosion valued using market prices; the material 
inventories are quantified in terms of the exposed material 
area from representative buildings; 
Brisson,M.; 
Edmunds,
W.J (Rw 
85(7)) 
2003 positive Value created on 
health due to routine 
mass vaccination 
• Effect of Herd-immunity on the dynamics of infection using 
routine varicella vaccination: the rate at which susceptible 
become infected is assumed to be a function of the number of 
infectious individuals in the population at a given point in time, 
multiplied by the effective contact rate between susceptible and 
infectious individuals; The impact of herd-immunity effect on 
the incidence of infection can be visualized as the difference 
between the static model (that containing the herd-immunity 
effect) and the static one (where the force of infection or pre-
susceptible rate of infection remains constant through time); 
• Not calculated; secondary 
Pillet,G., 
Zingg,N., 
Maradan,D. 
(Rw 86) 
2001 positive 
and 
negative 
Value lost and 
created on 
environment, societal 
and spatial structures 
of a region or 
country, welfare of 
people due to actions 
of agricultural 
business 
• Landscape image: landscape unkeep and structuring; 
• Recreation: rural sightseeing, recreation and sports; 
• Education: education (values); 
• Well-being health: noise; 
• Animal well-being: detention condition; 
• Human environment: infrastructure damages (roads, railways, 
etc); 
• Resources: soil (landslide and erosion), water (pollution and 
eutrophication) and air (pollution, contamination); 
• Natural patrimony: fauna, flora and habitats, diversity and 
environmental domains (soil and water protection); 
• Climate: micro-climate, CO; 
• Natural hazards: avalanches; 
• CV, TC or HP; 
• Benefits and costs 
o Amenities (landscape upkeep and structuring, rural 
sightseeing); 
o Costs (pollution correction) – only costs; 
o Natural patrimony (recreational areas, water 
pollution and distribution, fauna and flora); 
o Climate, health, hazards (diversity and CO2 
production/absorption); 
• Examples of values used for appraising external costs and 
benefits of agriculture: 
o Landscape: WTP in Germany for landscape upkeep; 
o Recreation: TCM estimating relation between 
recreation and agriculture in Italy; 
o Soil protection: expenses in CH to maintain soil 
fertility; 
o Diversity: WTP for biodiversity in Swiss Jura 
Mountains; 
• Costs: 
o Nitrates: Cost to equip STEPs for denitrification; 
secondary 
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o Phosphates: Cost of chemicals used to precipitate in 
STEPs; 
Hyojin 
Jeong,M.A. 
(Rw 87) 
2004 negative Value lost on water 
quality due to 
agricultural practices 
(pesticide application 
and tillage practice)  
• Water quality aspect: pesticide contamination level is measured 
as micrograms per litre in finished public surface water; It is 
derived by summing contamination levels of seven commonly 
applied pesticides; 
 
 
 
• External cost of Pesticide contamination= average annual 
pesticide contamination level* annual chemical cost per 
million gallons of water treated; 
• Water quality aspect=average annual pesticide 
contamination level in finished surface water as a measure 
of water quality; 
• Water treatment cost effect=annual chemical cost per 
million gallons of water treated as a measure of water 
treatment costs; 
primary 
and 
secondary 
Gulli,F. 
(Rw 91) 
2002 negative Value lost on 
environment due to 
CO2 emissions 
• Based on dose-response approach: pollution * concentration * 
population * dose-response function; 
• Civil sector: fuel oil, diesel and, methane; 
• Industrial sector: fuel oil, and methane; 
• Transport: petrol and diesel oil; 
• Thermoelectric generation: Carbone, fuel oil and methane; 
• Not specified; secondary 
Matthews,H
.S. (Rw 95) 
1999 negative Value lost on 
environment due to 
air pollution 
• Carbon Monoxide; 
• Nitrogen oxides; 
• Particulate matter; 
• Sulphur Dioxide; 
• Volatile Organic Compounds; 
• Global Warming Potential (in CO2) equivalent; 
(all in metric tons) 
• Estimated external cost ($ / metric ton of air emissions)= 
emissions * median estimate of dollar damage; 
secondary 
dey 
Chaudhury,
P. (Rw 98) 
2006 negative Value lost on 
environment and 
health due to 
transport emissions 
• Accidents  
o Risk that he/she himself/herself may be killed or severely 
disabled in which case his/her family and friends will 
experience the costs of grief and suffering; 
o Risk that the operator may kill or injure someone else, such 
as pedestrian or cause damage to someone else’s vehicle or 
property; 
• Fatalities; 
• Injuries; 
(on the rail and road modes for the three of them) 
• Human health: noxious pollutants, noise pollution, climate 
change, ecological damage, etc. 
• Accidents, fatalities and injuries (in rupees) ‘gross output’ 
(or ‘human capital’) approach. The major component of 
the cost of an accident involving a fatality is the 
discounted present value of the victim’s future output (or 
income) foregone as a result of his premature death. In the 
case of individuals whose services are not marketed 
imputations are typically made for such services. An 
allowance is then made for various other economic effects, 
such as vehicle damage, police and medical costs. The 
gross output approach can thus be seen as an attempt to 
measure the impact of death or injury on current and 
future levels of national output, broadly construed to 
include various non-marketed services; 
• Human health: not specified; 
secondary 
de 
Nocker,L., 
Vergote,S., 
1998 negative Value lost on 
environment due to 
airborne pollutants 
• Air pollution; 
• Human health; 
o Chronic mortality: KECU per year of life lost; 
• Air pollution (including global warming)= 
emission*monetary value; 
• Human health (market prices or WTP): takes into account 
secondary 
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Vinckx,L., 
Wouters,G. 
(Rw 99) 
from passenger cars 
and public transport 
• Agriculture; 
• Materials; 
• Ecosystems; 
o Ecological impacts; 
o Global warming; 
the loss of income and the value people attach toa  
reduced mortality risk; The estimation takes into account 
the estimated number of years lost; 
Bickel,P., 
Friedrich,R. 
(Rw 100) 
1997 negative Value lost due to 
road and rail 
transport 
• Accidents: impairment of life and health; Only personal injury 
is considered; 
• Air pollution: health effects and impairment of materials and 
vegetation; 
• Noise: human well-being on the psychological and on the 
physical level;  
• Land use: use of the surface and functions of the ground; 
• Barrier effects: human communication and biodiversity; 
• Accidents:  
o human capital approach (monetary valuation oh 
health impairment includes rehabilitation costs as 
well as the costs of lost production due to injuries 
and fatalities; rehabilitation costs comprise average 
costs of medical treatment, emergency service, 
police and legal activity per killed or inured person; 
Costs of lost production are estimated based on the 
national income per person of employable age and 
year); 
o WTP (provides an indicator for the subjective value 
which individuals put on the risk of losing their life 
in an accident); 
o Damage costs like costs of medical treatment, 
emergency service, police, and legal activity have to 
be taken into account as well as the net losses for 
society due to lost production; 
• Air pollution: WTP from ExternE project; 
• Noise: 
o WTP which can be  subdivided into two categories: 
one using results of studies based on the HP, the 
other using the CV; 
o Quantifying health effects by means of dose-
response relationships; 
• Land use: opportunity costs are calculated for the case 
that the land used for traffic would be used for farming, 
housing, or recreation; 
• Barrier effects: only time losses of pedestrians are taken 
into account (use subways or traffic lights and waiting for 
a possibility to cross lead to time losses; 
secondary 
 
Mayeres,I., 
van 
Dender,K. 
(Rw 101) 
 
2001 negative Value lost on 
transport due to 
congestion, air 
pollution (including 
global warming), 
noise, accident and 
road damage costs; 
• Congestion:  
o Change in resource  costs of other vehicles due to the 
decrease in speed caused by the additional vehicle; 
o The time losses of all other road users due to the decrease 
in speed caused by the additional vehicle; 
o Air pollution (including global warming): Damage to the 
rest of society and to future generations; effects on health, 
• Congestion: time and operation costs of the road users; 
o Marginal external congestion cost=time losses 
suffered by other road users*number of km in a 
period by mode j of transport*value of marginal time 
saving per passenger or per tonne per hour; 
o Value of marginal time savings=stated preference 
method; 
secondary 
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vegetation, materials, visibility, ecosystems, etc. 
(exposure-response relationships); The impacts considered 
are: health, materials soiling, materials, visibility, crops, 
forests, ecosystems, fisheries, climate change; 
• Accident costs: Cost of the increased accident risk = direct 
economic costs associated with average accident risk; 
• Noise: Damage to the neighbourhood; effect  on the noise level 
of an additional vehicle-km; index used is the energy mean 
sound level; 
• Road damage costs: increased repair cost of the road borne by 
the government; They arise when the passage of trucks causes 
damage to the road surface; Two types distinguished: the 
increased repair cost of the road, borne by the government and 
the increased vehicle operating costs for the other road users; 
• Air pollution: 
o The impacts valued are: health, materials soiling, 
materials, crops, and climate change; 
o Marginal external air pollution costs=emission 
factors*damage cost per g of pollutant emitted; 
o Damage cost per g of pollutant emitted from ExternE 
project data; 
• Accident costs: 
o Marginal external accident costs=pure economic 
costs (net output loss, ambulance costs, police and 
medical costs) borne by the rest of 
society*probability that an accident of severity n 
occurs between transport modes j and v and in which 
j is the victim (accident risks); 
o Pure economic costs=output loss=police and medical 
costs-discounted consumption; 
• Noise: function that relates the noise level in a street to 
the traffic flow; 
o Monetary valuation: hedonic housing market 
method; 
o Total external noise cost=monetary value for 
dB*noise level above the threshold 
established*number of road km where a noise 
externality is generated; 
• Road damage costs: 
o increased repair cost of the road=fraction of the 
average repair cost allocated over the total number of 
equivalent standard axles; 
o the increased vehicle operating costs for the other 
road users=are negligible; 
Roebeling,P
. (Rw 102) 
2006 Positive 
and 
negative 
Value created from 
terrestrial sediment 
water pollution and 
value lost on 
marginal marine 
costs from water 
pollution; 
• Terrestrial benefits: Marginal benefits from water pollution are 
obtained by computing the shadow value for sediment loads at the 
margin; 
• Marine costs: The effects of water pollution in the GBR-lagoon on 
reef quality and fish stocks are estimated using results from research 
performed by AIMS, GBRMPA, the Reef-CRC and results from 
research performed in other parts of the world; 
• not specified - 
Fernandez,
L. (Rw 103) 
2006 negative Value lost on forest 
and soil resources 
due to changes on 
property rights; 
• impact on future generations of current use, thereby 
internalizing the social externality of individual household use 
of a rotating common property forest resource; 
• not specified - 
LeClair,M. 2006 Positive Value lost on • Negative (agricultural or mineral in nature): land degradation • (8) The most common is to utilize some measure of the secondary 
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S.; 
Franceschi,
D. (Rw 
104) 
and 
negative 
environment and 
value created on 
preservation of 
indigenous and 
cultural goods; 
and species extinction (timber, sugar), excess use of a critical 
resource (rice), or outright pollution/poisoning of the 
environment (gold); Positive: usually involve preservation of 
indigenous culture or techniques of production (handicrafts); 
premium consumers would be willing to pay for a substitute 
product that does not have the negative externality attached to it 
(or, in the case of positive externalities, does have the benefit 
imbedded. For negative spillovers, such as environmental 
damage, this is likely to produce, at best, a lower boundary for 
the valuation placed upon elimination of the externality; 
• (8) A value can also be placed upon externalities by 
measuring the cost of undoing a negative, or achieving a 
positive, spillover; 
• (8) A third means of measuring external costs and benefits is 
to examine the magnitude of public expenditures that are 
undertaken to achieve the same outcome, as this may best 
reflect the public's valuation of these goals; 
• (9) Estimates of what consumers would be willing to pay to 
purchase Green Products that reduce pollution; 
Janic,M. 
(Rw 105) 
2007 negative Value lost on 
environment due to a 
road transport 
network 
• Air pollution: 
• Congestion: delays imposed on other vehicles; 
• Noise pollution: decline productivity and adverse health effects; 
• Traffic accidents: damage and property loss the network 
operators and third parties, in addition to the loss of life and 
injuries to the affected people; 
• External cost (road network)= 
o frequency*external cost per frequency; 
o demand / (load factor*vehicle capacity) * external 
cost per frequency; 
 
secondary 
Owen,A.D.; 
(Rw 108) 
2006 negative Value lost due to 
electric power 
generation 
• Damage caused to health and the environment by emissions 
other than those associated with climate change:  
o damage from acid rain and health damage from oxides of 
sulphur and nitrogen from coal-fired power stations; 
o power industry accidents (whether they occur in coal 
mines, on offshore oil or gas rigs, in nuclear plant, on wind 
farms or at hydro plants); 
o visual pollution; 
o noise; 
• Net costs of climate change attributable to greenhouse gas (and 
particularly CO2) emissions: 
o Flooding; 
o Changes in agriculture pattern; 
o Other effects; 
• WTP to avoid damage arising from the emissions secondary 
de Beer,P.; 
Friend,F. 
(Rw 109) 
2006 negative Value lost on 
environment and 
human beings, their 
property and their 
welfare due to 
operations and 
products by 
• Environmental degradation for which firms are not legally liable; 
• Adverse impacts on human beings, their property and their welfare 
that cannot always be compensated for through legal systems; 
• Not specified primary 
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industries; 
Blottnitz,H.
V.; Rabl,A.; 
Boiadjiev,D
.; Taylor,T.; 
Arnold,S. 
(Rw 110) 
2006 negative Value lost of 
environment due to 
synthetic nitrogen 
fertilizer 
• Impacts due to fertilizer production (€/kg of pollutant) : 
o Emission of greenhouse gases; 
o Other air pollutants (NOx and NH4NO3); 
• Global warming due to N fertilizer use (€/kg of pollutant); 
• Health impacts (€/kg of pollutant): methemoglobinemia, a 
serious and often fatal illness in infants due to conversion of 
nitrate to nitrite by the body, which can reduce the oxygen-
carrying capacity of blood;  
• Eutrophication (€/kg of pollutant): concentration of the 
phosphorus, nitrogen and other plant nutrients in an aging 
aquatic ecosystem, leading to excessive growth of certain 
species, especially blooms of algae, and creating conditions that 
interfere with the recreational use of lakes and estuaries, and 
the health and diversity of indigenous fish, plant and animal 
populations; 
• CV (WTP to avoid damage) 
Fertilizer: emission value* damage costs of fertilizer; 
Global warming: emission per kg of fertilizer*damage cost of 
fertilizer; 
o Greenhouse gases from fertilizer production; 
o NOx from fertilizer production; 
o NH4NO3 from fertilizer production; 
o N2O from fertilizer in soil; 
o NH3 emissions from fertilizer in fields; 
o Eutrophication; 
o Health (infant mortality due to nitrates in drinking 
water); 
secondary 
(ExternE 
project) 
Pongthanap
anich,T. 
(Rw 111) 
2006 negative Value lost on 
environment due to 
shrimp farming; 
• Eutrophication  
•  Abandonend farms: 
o Abandoned ponds are unsuitabe for raising shrimp or growing 
economic crops due to high salinity; 
o Without soil reclamation, salt accumulation will be a point source 
of surface water and groundwater contamination; 
o The abandoned pond cannot purify itself without remediation; 
• Marginal external costs= Supply - rate of 
discharge*shadow price of the stock; 
Mixed 
(primary 
and 
secondary) 
Bond,E.W. 
(Rw 112) 
2006 positive Value created on 
cooperation on 
infraestructure 
investments due to 
infraestructure 
investments 
• Changes in world prices: changes in the terms of trade that results 
from reductions in the transport cost per unit between countries; 
•  Technological spillover from the transport cost function:  which 
allows the level of investments in one country to affect the 
productivity of investments in the other country; 
• Not specified  
Riddel,M.; 
Schwer,R.K
. (Rw 113) 
2006 positive Value created on 
perceived risks due to 
nuclear-waste 
transport; 
• Welfare values of reducing nuclear-waste transport risk; • WTP: to avoid health and safety risks from transport by 
conducting a conjoint experiment where respondents rank 
housing choices based on various attributes including the 
distance from the transport route; WTA: with a contingent 
valuation model that analyzes household-relocation 
preferences for an increase in the level of neighborhood 
health risks from nuclear-waste transport. By using the 
same sample of households and the same good (housing) 
under different property-right assignments, they hope to 
offer estimates that are free of bias arising from 
uncertainty about the good; 
primary 
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Appendix 3.7 Impact, measures and valuation methods: negative external effects on the consumption side 
 
Impact area External 
effect 
Measurement Paper context Valuation method 
Environment Air pollution Concentration per gram of pollutant and value of life Freight transport (Rw 43) Concentration per gram of pollutant*population*mortality rate*value 
of life (All the computed costs of illnesses not inducing death are 
based on market prices and costs: cost of medicines, ambulance, 
hospital, and medical services. A WTP estimate is only used for the 
value of life in case of death); 
  pollution-related mortality risks (health effects); Transport in less developed 
countries (Rw 44) 
CV (WTP for small reductions in the risk of death); 
  PM10 acute effects (10µg/m3): 
o Non accidental mortality; 
o Respiratory hospital admissions; 
o Cardiovascular hospital admissions; 
o Use of bronchodilators against asthma; 
o Prevalence of acute bronchitis; 
• PM2.5 chronic effects (10µg/m3): 
o Cardio-respiratory mortality; 
o Mortality due to lung cancer; 
• PM10 chronic effects (10µg/m3): 
o Incidence of chronic bronchitis; 
• Oxone (50µg/m3): 
o Non accidental death; 
o Days with restricted activity; 
o Respiratory hospital admissions (15-64) (65=); 
o Exacerbation of extreme asthma; 
o Symptom days; 
• UV radiation/stratospheric ozone: 
o Death due to melanoma cancers; 
• Benzene: 
o Death due to leukaemia; 
o Non fatal leukaemia; 
• PAHs: 
o Mortality due to lung cancer; 
• As: 
o Mortality due to lung cancer; 
• Ni: 
o Inhalation and decrease of IQ; 
o Ingestion and decrease of IQ (µg/year); 
Environmental health 
decision making (Rw 56) 
Concentration response function or unit risk factor=CV (WTP) 
  costs related to health and harvest damages; Transport sector (Rw 63) Not specified 
  take into account the impact of pollutant emissions on local 
concentration levels and refer to the external costs of air pollution 
Urban transport (Rw 64) CV (WTP/WTA); obtained by ExternE project; 
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Impact area External 
effect 
Measurement Paper context Valuation method 
on human health, materials, crops and global warming. The values 
are calculated for car, bus and train. The values shown for the car 
are in EURO per vkm, while the values for the public transport 
modes are in EURO per passenger km; 
  • Source: gasoline cars with and without three-way catalytic 
converter and diesel cars; 
• Emission factors: benzo-a-pyrene (BaP) (in g/km); The 
calculation of emissions has been done by dividing the journey into 
six sections representing different traffic conditions, driving cycles 
and meteorological conditions; 
• Impacts (Impact Pathway approach: exposure-response function): 
o Health: restricted activity days, chronic bronchitis, respiratory 
problems, cough, chronic bronchitis in children, chronic sore 
throat, respiratory hospital admissions, cerebrovascular hospital 
admissions, cancers and chronic mortality; 
o Agricultural crops: SO2; 
o Forests: Acid rain; 
o Materials: Acid rain; 
Road transports (Rw 67) CV (WTP to avoid the impacts): ECU per case; 
  effects on 
o Health: mECU/g VOC(volatile organics compound); 
o Vegetation: SO2 and NOx (mECU/g); 
o Materials; 
o Aquatic ecosystems; 
o Visibility; 
o Climate: global warming (mECU/g); 
Cars, trucks and urban public 
transports (Rw 68) 
o Health (CV): mortality; morbidity (respiratory hospital asmission; 
emergency room visit; symptoms of chronic bronchitis; symptoms of 
chronic cough; restricted activity day; minor restricted activity day; 
asthma attack; and symptom days; 
o Vegetation: direct effect of SO2 on wheat, barley rye and oats 
(national and transnational); effect of NOx on O3 on wheat 
(national); 
o Global warming: coastal defence; dryland loss; wetland loss; 
ecosystem loss; agriculture; forestry and fishery losses; gains 
and losses in the energy and water supply; life and morbidity 
effects; air pollution damages; migration costs and an estimate 
of natural hazard damages; 
  Not specified Urban transport (Rw 
99) 
(including global warming)= emission*monetary value; 
  health effects and impairment of materials and vegetation; Transport (Rw 100) WTP from ExternE project; 
  (including global warming): Damage to the rest of society and to 
future generations; effects on health, vegetation, materials, 
visibility, ecosystems, etc. (exposure-response relationships); 
The impacts considered are: health, materials soiling, materials, 
visibility, crops, forests, ecosystems, fisheries, climate change; 
Transport (Rw 101) o The impacts valued are: health, materials soiling, materials, 
crops, and climate change; 
o Marginal external air pollution costs=emission 
factors*damage cost per g of pollutant emitted; 
o Damage cost per g of pollutant emitted from ExternE project 
data; 
  Not described Road freight transport 
(Rw 105) 
Not valued 
 Noise Estimated either through a statistical analysis linking the rents Freight transport (Rw estimates which are averages of various studies relying on 
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Impact area External 
effect 
Measurement Paper context Valuation method 
paid with different characteristics of housing or by costing the 
reparative expenditures 
43) either of linking the rents paid with different characteristics of 
housing or costing the reparative expenditures; 
  IHD Mortality; 
o Cardiovascular hospital admissions (IHD); 
o Serious nuisance; 
o Sleep disturbance; 
• Exposure: health changes and mortality risks: 
o DALYs: YLL = YLD 
o YLL=number of deaths *disability weight*standard life 
expectancy at age of death in years L; 
o YLD=number of incident cases*disability weight*average 
duration of disability in years L; 
o The number of cases (N) attributable to outdoor air pollution or 
noise is estimated by using the ‘at least’ approach. The required 
data components are the exposure-response function, the 
frequency of the health outcome and the level of exposure; 
Environmental health 
decision making (Rw 
56) 
Concentration response function or unit risk factor=CV (WTP) 
  Emission costs Transport sector (Rw 63) Not specified 
  cost of noise generated by road traffic; Urban transport (Rw 64) it is calculated through an algorithm. The total external noise cost was 
calculated by multiplying the monetary value per dB by the noise level 
above the threshold of 50 dB(A) by the length of road where a noise 
externality is generated. The monetary value of noise was calculated at 
0.6 EURO per 1dB(A) per kilometre; 
  social cost of noise per ton-mile of transportation service in rural 
areas; 
rail freight transportation (Rw 
65) 
same value as applied for trucks; adopted from the literature; HP 
  effect on the noise level of an additional car km; They assume 
that the average street in Brussels has a U-shape; (mECU per 
vehicle km); Index for noise used is the energy mean sound level 
over a given period=53.9 = 10log (flow of light vehicles in veh/h 
= flow of heavy vehicles in veh/h) – 10log of width between the 
facades (in metres) =  correction factor for speed, which means 
that 1dB is added for each 10km/h above a speed of 60km/h; 
Cars, trucks and urban public 
transports (Rw 68) 
Hedonic housing market method 
o Total external noise cost for Brussels=monetary value * noise level 
above the threshold of 50 * number of road km where a noise 
externality is generated (we assumed 500km supra); 
o To compute the resulting marginal external noise cost (MENC) in 
the reference equilibrium, we derive the total external noise cost 
function with respect to the number of vehicle km; 
 
  to associate the noise level in decibels above an established noise 
threshold with average changes in property values. Average 
property value changes per decibel increase can then be tied to 
the noise generated by a particular type of vehicle operating at 
various distances from the property; 
Truck Freight Transport (Rw 
71) 
HP 
  human well-being on the psychological and on the 
physical level; 
Transport (Rw 100) o WTP which can be  subdivided into two categories: one using results 
of studies based on the HP, the other using the CV; 
o Quantifying health effects by means of dose-response relationships; 
  Damage to the neighbourhood; effect  on the noise Transport (Rw 101) function that relates the noise level in a street to the traffic flow; 
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Impact area External 
effect 
Measurement Paper context Valuation method 
level of an additional vehicle-km; index used is the energy mean 
sound level; 
o Monetary valuation: hedonic housing market method; 
o Total external noise cost=monetary value for dB*noise level above 
the threshold established*number of road km where a noise externality 
is generated; 
   decline productivity and adverse health effects; Road freight transport (Rw 
105) 
 o frequency*external cost per frequency; 
o demand / (load factor*vehicle capacity) * external cost per 
frequency; 
 Congestion Cost function expressed in million ECU per t-km Freight transport (Rw 43) loss of time for trucks travelling along the road during peak 
hours*truck flows* value of time; 
• Loss of time=speeds on road during peak hours and outside peak 
hours are computed using a flow speed relation. The difference 
between these speeds translates into a loss of time for trucks travelling 
along this road during peak hours; 
• Value of time=all the costs linked to the operation of a truck (labour, 
fuel, insurance, maintenance and vehicle cost)=inventory cost of the 
goods transported which varies with the value of the commodities and 
the loading of the vehicles; 
  longer journey times, increased fuel consumption and greater 
wear and tear on vehicles. Congestion function to describe how 
average speed is influenced by traffic flow. The congestion 
function allows the time loss suffered by other roads users to be 
computed if an additional passenger car unit (PCU) joins the 
traffic flow; 
Urban transport (Rw 
64) 
the congestion function is combined with information on the value of 
time (cost of an additional PCU kilometre); 
  o Congestion function: expresses the minutes needed to drive 
1km in a certain period as a function of the million passenger car 
units (PCU) per hour at that moment in the city; 
o Time costs: time loss suffered by the other road users if an 
additional PCU joins the traffic flow; 
Cars, trucks and urban 
public transports (Rw 
68) 
Not described 
  o Change in resource  costs of other vehicles due to the decrease 
in speed caused by the additional vehicle; 
o The time losses of all other road users due to the decrease in 
speed caused by the additional vehicle; 
Transport (Rw 101) o Marginal external congestion cost=time losses suffered by other road 
users*number of km in a period by mode j of transport*value of 
marginal time saving per passenger or per tonne per hour; 
  delays imposed on other vehicles; Road freight transport 
(Rw 105) 
 o frequency*external cost per frequency; 
o demand / (load factor*vehicle capacity) * external cost per 
frequency; the external cost in the collection step in zone k is 
proportional to the frequency of trips dependent on the quantity of 
loads units, the vehicle capacity and load factor, and the aggregate 
external cost per trip; 
 Emissions o Air pollution: volatile organic compounds (VOC), nitrogen 
oxides (NOx), sulphur oxides (SOx) and particulate matter under 
10 µm in aerodynamic diameter (PM10) (emission rates per ton-
mile);  
rail freight 
transportation (Rw 
65) 
emission rates*emission costs; 
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Impact area External 
effect 
Measurement Paper context Valuation method 
o Emission costs (cents per ton-mile); 
o Greenhouse gases: CO2 (cents per ton-mile); 
  o Air pollution: is needed the amount of air pollution associated 
with a unit of travel by different types of vehicles operating under 
different conditions and, the dollar value of damage to human 
health and other things of value – animals, crop, yields, building 
and structures, and scenic views; 
o Greenhouse gases: CO2 emission; 
Truck Freight 
Transport (Rw 71) 
o Air pollution: emission factors (g per mile)*costs (dollars)=costs of 
air pollution per vehicle-mile; Damage cost function to value damage 
to materials; 
o Greenhouse gases: quantity of diesel fuel burned (CO2 
emissions)*cost per ton=cost to society of CO2 emissions per ton-mile 
shipped by truck; 
 Climate 
changes 
floods and harvest damages; Transport sector (Rw 63) Not specified 
 Ecosystem quality are expressed  in relation to the species that have 
disappeared in a certain area and period, mainly vascular plants 
and simple organisms; Damages to ecosystems needs to introduce 
the following impact categories: ecotoxicity, 
acidification/eutrophication, and land use. For ecotoxicity, they use 
the unit PAFm2yr, meaning the Potentially Affected Fraction 
(PAF)of species in relation to the concentration of toxic substances 
per area and year. For acidification and eutrophication we use the 
unit PDFm2yr, meaning the Potentially Disappeared Fraction of 
plant species (PDF) per area and year. For land use, we also use 
the PDFm2yr as unit; 
Carcinogenesis (emissions to the air); 
Climatic change (emissions to the air); 
Manufacturing and 
functioning of a heat pump 
(Rw 49) 
Eco-indicator methodology and, EPS2000 methodology; 
  Ecological impacts and global warming Urban transport (Rw 99) Not valued 
 Resour
ces 
Waste heat  per Kg of extracted material (surplus energy); 
  
Manufacturing and 
functioning of a heat pump 
(Rw 49) 
Eco-indicator methodology and, EPS2000 methodology; 
 Livest
ock 
farmers and pastoralists were asked to recall the number of animals 
with pesticide intoxication thay had observed in their herds over 
the last five years, and how many of those animals died 
Pesticide use (Rw 73) Losses were valued at market price, and divided by the average 
number of hectares treated by the farmers (multiplying the mortality by 
the number of animals per farm and by their average values); 
  number of animals with pesticide intoxication they had observed in 
their herd over the last five years, and how many of those animals 
died; 
Pesticide use (Rw 74) (total number of animals intoxicated and how many of those 
died*market price of those animals)/number of hectares treated 
during that year in that region; 
 Agricu
lture 
Not specified Urban transport (Rw 99) Not valued 
 Materi
als 
Not specified Urban transport (Rw 99) Not valued 
 Destru
ction 
of 
obsolet
cost of cleaning up obsolete pesticides; Pesticide use (Rw 74) average cost of destroying obsolete pesticides per litre 
(obtained from a destruction project already existing) / hectare 
treated; 
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Impact area External 
effect 
Measurement Paper context Valuation method 
e 
pestici
des 
 Land 
use 
use of the surface and functions of the ground; Transport (Rw 100) opportunity costs are calculated for the case that the land used 
for traffic would be used for farming, housing, or recreation; 
 Barrier 
effects 
human communication and biodiversity Transport (Rw 100) only time losses of pedestrians are taken into account (use 
subways or traffic lights and waiting for a possibility to cross 
lead to time losses; 
Health Accide
nts 
Social cost for accidents between vehicles = between vehicles and 
pedestrians or cyclists; expressed in million ECU per t-km 
Freight transport (Rw 43) • Between vehicles=(WTP for cancelling the risk of an accident 
for the user=WTP for cancelling the risk of an accident for the 
closest relations=cost per vehicle made of the costs of police, 
ambulance (cold blood cost))*traffic flow*risk of accidents; 
• Between vehicles and pedestrians or cyclists=(WTP for 
cancelling the risk of an accident for the user=WTP for 
cancelling the risk of an accident for the closest relations=cost 
per vehicle made of the costs of police, ambulance (cold blood 
cost))*total number of km by pedestrians and cyclists*risk of 
accidents; 
  Effect of road fatality risks (health effects) Transport in less developed 
countries (Rw 44) 
 
CHM (respondents were invited to choose between two 
alternative states of the highway on the basis of three attributes: 
travel time, accident risk and toll charge); 
  what society would be prepared to pay to reduce the risk of an 
accident; 
Urban transport (Rw 64) CV (WTP/WTA); The WTP of relatives and friends of the victim to 
avoid the accident was not included in the cot estimate; 
  3 primary categories of accidents=collisions at highway-rail grade 
crossing, persons struck by a train at other locations, and mishaps 
involving the train alone; 
o Fatalities: 
o Injuries: 
o Property damage: estimate of the value of property damage to 
other vehicles involved in crashes with trains at highway-rail grade 
crossings 
rail freight transportation (Rw 
65) 
numbers of fatal, personal injury, and property damage accidents*the 
appropriate per-event cost-the amount of compensation paid by the 
particular mode; 
o Per-ton-mile external cost=external cost of accidents/ number of ton-
miles; 
o Property damage=pProperty damage for non-crossing rail accidents 
(other than to trains) is comparatively minor and ignore the costs of 
such damage; 
  marginal social accident cost (MSAC) of a car is the derivative of 
the total accident cost (TAC) with respect to the number of car km; 
A distinction is made between fatal accidents, accidents with 
serious injuries, accidents with light injuries and accidents with 
only material damage; (ECU or million ECU); 
Cars, trucks and urban public 
transports (Rw 68) 
CV 
o MSAC=(WTP to avoid an accident of type n = WTP of the relatives 
and friends of the victim to avoid an accident of type n = pure 
economic costs (net output losses, ambulance costs, medical costs, 
etc))*probability that an accident of severity n occurs between 
transport modes I and j and in which i is the victim*number of vehicle 
km travelled by transport mode; 
  (fatalities, injuries, and property damage): costs of deaths, injuries 
and property damage; 
Truck Freight Transport (Rw 
71) 
WTP for risk reduction;  
Per ton-mile external cost of general freight trucking=amount of 
compensation paid by affected trucking companies; 
External cost=total cost of society- Per ton-mile external cost of 
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Impact area External 
effect 
Measurement Paper context Valuation method 
general freight trucking; 
  impairment of life and health; Only personal injury is considered; 
 
Transport (Rw 100) o human capital approach (monetary valuation oh health impairment 
includes rehabilitation costs as well as the costs of lost production due 
to injuries and fatalities; rehabilitation costs comprise average costs of 
medical treatment, emergency service, police and legal activity per 
killed or inured person; Costs of lost production are estimated based on 
the national income per person of employable age and year); 
o WTP (provides an indicator for the subjective value which 
individuals put on the risk of losing their life in an accident); 
o Damage costs like costs of medical treatment, emergency service, 
police, and legal activity have to be taken into account as well as the 
net losses for society due to lost production; 
  Cost of the increased accident risk = direct economic costs 
associated with average accident risk; 
Transport (Rw 101) Marginal external accident costs=pure economic costs (net 
output loss, ambulance costs, police and medical costs) borne 
by the rest of society*probability that an accident of severity n 
occurs between transport modes j and v and in which j is the 
victim (accident risks); 
o Pure economic costs=output loss=police and medical costs-
discounted consumption; 
  damage and property loss the network operators and third parties, 
in addition to the loss of life and injuries to the affected people; 
Road freight transport (Rw 
105) 
 o frequency*external cost per frequency; 
o demand / (load factor*vehicle capacity) * external cost per 
frequency; 
 Respiratory 
effects 
• Life expectancy (emission to the air); 
• Severe unhealthy conditions (emission to the air); 
• Moderate discomfort (emissions to the air); 
• Moderate unhealthy conditions (emissions to the air) 
Expressed as DALY (Disability Adjusted Life Years). It links 
health effects to DALYs, using estimates of the number of Years 
Lived Disabled, and Years of Life Lost; 
Manufacturing and 
functioning of a heat pump 
(Rw 49) 
Eco-indicator methodology and, EPS2000 methodology; 
 Pesticide use impact on respiratory system, neurological system, skin, eye and 
the gastro-intestinal system; studied  by a statistical model (logit 
model); The independent variables are individual characteristics, 
indicators of exposure to pesticides, and other factors that might 
influence health; 
Pesticide use (Rw 74) Health costs=expenses of medical services (medications or 
consultation fees)=loss of productive work time; 
 
 Airbone 
pollutants 
Chronic mortality: KECU per year of life lost Urban transport (Rw 99) (market prices or WTP): takes into account the loss of income and the 
value people attach toa  reduced mortality risk; The estimation takes 
into account the estimated number of years lost; 
Infrastructure Motorway 
costs 
infrastructure costs of a heavy vehicle moving on a motorway at 
100km/h under the conditions of non-intensive traffic (€): 
Transport sector (Rw 63) Not specified 
 Road damage increased repair cost of the road borne by the 
government; They arise when the passage of trucks causes damage 
to the road surface; Two types distinguished: the increased repair 
Transport (Rw 101) o increased repair cost of the road=fraction of the average repair cost 
allocated over the total number of equivalent standard axles; 
o the increased vehicle operating costs for the other road users=are 
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Impact area External 
effect 
Measurement Paper context Valuation method 
cost of the road, borne by the government and the increased 
vehicle operating costs for the other road users; 
negligible; 
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Appendix 3.8 Impact, measures and valuation methods: negative external effects on the production side 
 
Impact area External 
effect 
Measurement Paper context Valuation method 
Environment Natural 
resources 
Water resources: a)treatment of surface water for microbial 
pathogens (microorganisms in livestock); b)facility infrastructure 
needs for nitrate treatment; c)facility infrastructure needs for 
pesticide treatment; 
Soil resources:  a)cost to water resources; b)cost to replace lost 
capacity of reservoirs; c)water conveyance costs; d)flood damages; 
e)damages to recreational activities; f)cost to 
navigation:shipping,dredging; g)Instream impacts:commercial 
fisheries,preservation; h)off-stream impacts:industrial users, steam 
power plants; 
Air resources: a)cost of greenhouse gas emissions from cropland; 
b)cost of greenhouse gas emissions from livestock production; 
Agricultural Production (Rw 
38) 
Water (costs of treatment to control major pollutants): 
• Pathogens: annualised national cost of implementing surface water 
treatment rule*% of damage associated to these pathogens; 
• Nitrate: cost for water treatment facilities to meet federal nitrate 
standards* % of nitrate pollution is due to agriculture; 
• Pesticide: cost for treatment facilities to meet Safe Drinking Water 
Act*% of pesticides (something in between the % of existing 
pesticides and % of conventional pesticide usage); 
Soil resources:  
• Water industry: % that cropland contributes o total suspended 
solids*water withdrawn for public supply from surface water sources 
(litres per day)*treatment costs (per million litres); 
• Reservoirs: %loss of total national capacity (between % of the 
nation´s water storage capacity lost annually and the average storage 
loss from sediment depletion)*per thousand cubic metres replacement 
value*% of sediment from cropland; 
• Conveyance: cost for sediment removal and maintenance to prevent 
local flooding*% for the contribution of sediment from cropland; 
• Flood damages ,recreational activities, navigation, commercial 
fisheries and preservation and, off-stream costs: total erosion 
effects*% damage due to cropland; 
Air resources: net emissions of carbon dioxide equivalents*market 
price carbon dioxide equivalents*% of this cost from crop production 
or livestock sources; 
  • Coal uncontrolled emissions (lbs k Wh^-1); 
• Coal SO2 controlled emissions (lbs k Wh^-1); 
• Natural gas steam (lbs k Wh^-1); 
• Natural gas combined cycle (lbs k Wh^-1); 
Electricity production (Rw 
55) 
Cost of emissions (1994$ lb^-1)*emissions (lbs kWh^-1); not 
specified 
 
  Effects on the treatment  or prevention costs (those incurred to 
clean up the environment and restore human health to comply with 
legislation or to return these to an undamaged state); 
Administration and monitoring costs (those incurred by public 
authorities and agencies for monitoring environmental, food and 
health parameters); 
Agriculture (Rw 47) water, air, soil and biodiversity and landscape ; 
• Water: Cost of remove pathogens from water (pesticides, nitrate, 
phosphate and zoonoses)=annual operating costs*% assumed to be 
agricultural treatment cost; 
Cost to pay for restoring water courses (eutrophication and pollution 
incidents)=costs incurred to restore rivers to their pre-incident 
condition; 
Monitoring and advice on pesticides=pesticide monitoring in food and 
livestock and on surface and groundwater sites=costs in providing 
advice; 
• Air:  
marginal external costs from methane, nitrous oxide and carbon 
 280
 
Impact area External 
effect 
Measurement Paper context Valuation method 
dioxide (adopted from ExternE project:CV (WTP)); 
External costs of ammonia: CV (WTP) using the more conservative 
value of life year (from literature); 
• Soil:  
Damage caused by soil erosion: costs estimated from soil carried off 
farms by water or wind blocks ditches and roads, damages property, 
induces traffic accidents, increases the risk of floods, and pollutes 
water through sediments and associated nitrate, phosphate and 
pesticides;  
Organic matter and carbon dioxide losses; 
  • Water quality aspect: pesticide contamination level is measured 
as micrograms per litre in finished public surface water; It is 
derived by summing contamination levels of seven commonly 
applied pesticides; 
Recreational fishing (Rw 87) • External cost of Pesticide contamination= average annual pesticide 
contamination level* annual chemical cost per million gallons of water 
treated; 
• Water quality aspect=average annual pesticide contamination level in 
finished surface water as a measure of water quality; 
• Water treatment cost effect=annual chemical cost per million gallons 
of water treated as a measure of water treatment costs; 
 Wildlife and 
ecosystem 
biodiversity 
a)honey bee and pollination losses from pesticide use; b)loss of 
beneficial predators by pesticide applications; c)fish kills due to 
pesticides; d)fish kills due to manure spills; e)bird kills due to 
pesticides; 
Agricultural Production (Rw 
38) 
• Honey bee and pollination losses: colony losses, reduced honey 
production and crop pollination and the cost of bee rentals; 
• Loss of beneficial predators: cost of additional applications of 
pesticide due to drops in the population of beneficial insects and crop 
losses associated with secondary pests; 
• Fish kills due to pesticides: fish deaths per year due to pesticides and 
values of freshwater fish, reflecting commercial hatchery production 
costs of various fish species*cost in $ per fish; 
• Fish kills due to manure spills: (info on feedlot spills and associated 
fish kills in 10 states for 3 years=rough proxy for a national 
estimate)*cost in $ per fish; 
• Bird kills due to pesticides: number of birds exposed to pesticides*% 
of birds dying*value of bird’s life (using lowest value from cost per 
bird watching, hunting costs per bird felled and the cost of rearing and 
releasing a bird to the wild); 
  Effects on the treatment  or prevention costs (those incurred to 
clean up the environment and restore human health to comply with 
legislation or to return these to an undamaged state); 
Administration and monitoring costs (those incurred by public 
authorities and agencies for monitoring environmental, food and 
health parameters); 
Agriculture (Rw 47) Costs of wildlife and habitat losses=costs or restoring species and 
habitats under the Biodiversity Action Plans (BAPs) as a proxy; 
Costs of hedgerows and drystone walls=amount that farmers receive 
for replacing hedgerows and drystone walls under agri-environment 
schemes used as a proxy; 
Cost of agricultural biodiversity=not possible to put a cost on these 
losses; 
 Shrimp 
farming 
• Eutrophication  
•  Abandonend farms: 
o Abandoned ponds are unsuitabe for raising shrimp or growing 
economic crops due to high salinity; 
Shrimp farming (Rw 
111) 
Damage function; 
Marginal external costs= Supply - rate of discharge*shadow price of 
the stock; 
 281
 
Impact area External 
effect 
Measurement Paper context Valuation method 
o Without soil reclamation, salt accumulation will be a point 
source of surface water and groundwater contamination; 
o The abandoned pond cannot purify itself without remediation; 
 Intense fusion 
economy 
Radioactive emissions in normal operation and from the final 
repository; 
Fusion power plant (Rw 51) Not specified 
 Water quality    
 Forest and soil impact on future generations of current use, thereby internalizing 
the social externality of individual household use of a rotating 
common property forest resource; 
Agriculture (Rw 103) 
 
Not valued 
 
Human health Agriculture • (pathogens): a)cost of illnesses caused by common foodborne 
pathogens; b)cost to industry to comply with HACCP rule; 
• (pesticides): a)pesticide poisonings and related illnesses; 
Agricultural Production (Rw 
38) 
• Pathogens 
o Foodborne illnesses: annual costs for bacteria damage estimates*% 
of health costs attributable to agricultural production; 
o Cost to industry to comply with HACCP: industry costs for meat and 
poultry plants to comply with HACCP regulations*% of health costs 
attributable to agricultural production; 
• Pesticides 
o Pesticide poisonings: costs of pesticide poisonings and deaths based 
on hospitalizations, outpatient treatment, loss of work and fatalities 
due to accidental poisonings and treatment costs for pesticide-induced 
cancers (based in part on speculation regarding the incidence of illness 
and death); 
 
  Effects on the treatment  or prevention costs (those incurred to 
clean up the environment and restore human health to comply with 
legislation or to return these to an undamaged state); 
Administration and monitoring costs (those incurred by public 
authorities and agencies for monitoring environmental, food and 
health parameters); 
Agriculture (Rw 47) Pesticides (acute effects)=(value of a symptom-day*(number of 
farmers are off work for one day=those are off half a day))*GP 
consultation cost; 
Pesticides (chronic effects)=not included; 
Nitrate=assumed zero; 
Cost of food poisoning=(lost wages=consultations with 
doctors=hospital beds)*% poisoned people from UK farming; 
Antibiotic resistance=impossible to estimate; 
BSE and CJD(transmissible disease occurring in animals and 
humans)=total costs BSE*% belonging to farming; 
 Emissions • Health impacts: Year of Life Lost (YOLL) approach; the loss of 
life expectancy is a meaningful indicator; 
o Mortality impact: acute and chronic impact; specific exposure-
response functions; proxies used: chronic mortality in adults and 
acute mortality; 
o Morbidity impact: cost of an acute crisis of asthma; proxies used: 
chronic bronchitis in adults, hospital admissions for respiratory 
causes, restricted activity days in adults, emergency room visits, 
and acute asthma crisis (asthmatic population); 
 
Electricity generation (Rw 
72) 
Not specified 
 
Environment Plant External costs of SO2,NOx and CO2 emissions (Euro/t CO2); Fusion power plant (Rw 51) Human life is assessed by CV (WTP/WTA): 
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effect 
Measurement Paper context Valuation method 
and health construction o Increase in traffic during the construction phase; 
o Increase in road accidents, due to increase in traffic, leads to 
deaths and injuries of the public involved in the accidents. The 
number and severity of the accidents are estimated using  an 
estimation of the total amount of materials necessary to be 
transported together with the national road and rail accident 
statistics; 
o Occupational accidents during the construction of the 
plant and components are based on the expected investment 
cost, which lead to an estimation of the value for the person 
years, and the accident statistics for the different branches 
involve; 
• WTP for a reduction in the risk of death. The ‘value of statistical life’ 
is calculated by dividing the cost of the measure to reduce the risk  by 
the reduction in the risk of death; 
• WTA compensation for a higher risk; 
• WTP or WTA a higher risk as evaluated from interviews or 
questionnaires; 
  o Emissions of the transport; 
o Road accidents; 
o Occupational accidents; 
Electricity generation (Rw 
60) 
Not specified 
 Normal 
operation 
Impacts due to the emissions and the effluents of 
radioactive isotopes, the impacts due to the occupational 
radioactive exposure and other ‘normal’ occupational 
accidents; 
Fusion power plant (Rw 51) Human life is assessed by CV (WTP/WTA): 
• WTP for a reduction in the risk of death. The ‘value of statistical life’ 
is calculated by dividing the cost of the measure to reduce the risk  by 
the reduction in the risk of death; 
• WTA compensation for a higher risk; 
• WTP or WTA a higher risk as evaluated from interviews or 
questionnaires; 
  o Routine releases; 
o Occupational exposure; 
o Other occupational accidents; 
Electricity generation (Rw 
60) 
Not specified 
  • Environmental degradation for which firms are not legally 
liable; 
• Adverse impacts on human beings, their property and 
their welfare that cannot always be compensated for 
through legal systems; 
Industry (Rw 109) Not specified 
 Decommission
ing  and 
recycling 
Human health impacts due to release of dust and radioactivity 
from the recycling plant; 
o Death and health impacts of the decommissioning workers 
(number of person-years was based on estimated 
decommissioning years; and the number of expected accidents 
were based on experience from fission plants); 
o Road and rail accidents; 
Fusion power plant (Rw 51) Human life is assessed by CV (WTP/WTA): 
• WTP for a reduction in the risk of death. The ‘value of statistical life’ 
is calculated by dividing the cost of the measure to reduce the risk  by 
the reduction in the risk of death; 
• WTA compensation for a higher risk; 
• WTP or WTA a higher risk as evaluated from interviews or 
questionnaires; 
  • Decommissioning: 
o Emissions of the transport; 
o Road accidents; 
o Occupational accidents; 
• Recycling: 
o Emissions of the transport; 
Electricity generation (Rw 60) Not specified 
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effect 
Measurement Paper context Valuation method 
o Road accidents; 
o Non radioactive dust emissions;Non radioactive dust emissions; 
o Radioactive emissions; 
o C-14; 
 
 
Site 
restoration 
o Emissions; 
o Traffic accidents; 
Electricity generation (Rw 
60) 
Not specified 
 Municipal 
solid Waste 
incinerator 
• Air pollution: Particles, NO2, SO2 (kg/person-year); 
• Health impacts: 
o morbidity: acute and chronic effects; Number of asthma attacks 
due to this O3, using dose-response functions; 
o mortality; 
Power plants, cars and 
waste incinerators (Rw 81) 
CV 
 Emissions 
(greenhouse) 
pollution concentration*population*dose-response function; 
The damage taken into consideration includes the effects on 
public health, agriculture, forests (acid rain), the ecosystem in 
general, materials (deterioration of buildings and monuments) 
and the damage related to global warming due to greenhouse gas 
emissions; 
Dose-response functions provide the marginal damage caused by 
increment of concentration due to plant emissions (USD/Kg); 
Gas-based energy (Rw 48) WTP or WTA 
  • Damage caused to health and the environment by emissions 
other than those associated with climate change:  
o damage from acid rain and health damage from oxides of 
sulphur and nitrogen from coal-fired power stations; 
o power industry accidents (whether they occur in coal mines, on 
offshore oil or gas rigs, in nuclear plant, on wind farms or at 
hydro plants); 
o visual pollution; 
o noise; 
• Net costs of climate change attributable to greenhouse gas (and 
particularly CO2) emissions: 
o Flooding; 
o Changes in agriculture pattern; 
o Other effects; 
Electric power generation 
(Rw 108) 
• WTP to avoid damage arising from the emissions 
 
Infrastructure Unrecovered 
costs on 
provision, 
operation, 
and 
maintenance 
of public 
facilities 
assess which vehicle  classes, on balance, overpay and which 
underpay relative to other classes; 
Truck Freight Transport (Rw 
71) 
estimates of the magnitude of government subsidies to freight trucks 
are based on the equity ratios (user charges paid / cost 
responsibilities) produced by the Federal Highway Cost Allocation 
Study (Federal HCAS); 
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Appendix 3.9 Impact, measures and valuation methods: positive external effects on the consumption and production side 
 
Side Impact area External 
effect 
Measurement Paper context Valuation method 
C
o
n
s
u
m
p
t
i
o
n
 
Education Effect of 
Standard 
Bank 
National 
Arts Festival 
Support from low income groups to the festival Value of arts to 
society (Rw 45) 
CV(after being given certain basic information about the cost of the 
Festival and the level of government sponsorship, Grahamstown 
respondents were  asked in a closed-ended, yes or no, question 
whether they would be willing to pay an extra R5 in taxes per month 
to support the Festival, first non-liable and then liable) 
Health Reduction 
on the CHD 
incidence 
Reducing saturated fat acid consumption Evaluation of 
agricultural policy 
(Rw 46) 
External cost savings=costs of annual CHD reduction  due to a 
reduction in SFA (from literature)*(% of costs being external to the 
individual (assumption)); 
Kilograms of SFA consumed by the population=population*SFA per 
individual; 
Per-unit externality=External cost savings/kilograms of SFA 
consumed by population; 
External cost saved=per-unit externality*reduced kilograms of SFA 
consumed by the population; 
 Accidents Value of life saved Provision of urban transport 
(Rw 69) 
CHM (stated choice experiment; Discrete Choice Modelling); 
Through a multinomial logit and mixed logit it is possible to obtain 
value of travel time and the subjective value of accident reduction; 
 Herd-
immunity 
Effect on the incidence of infection Routine varicella 
vaccination (Rw 85 (7)) 
Not valued 
 Mortality Reduction of risk Sulphur and nitrogen 
emission (Rw 113) 
WTP: to avoid health and safety risks from transport by conducting a 
conjoint experiment where respondents rank housing choices based 
on various attributes including the distance from the transport route; 
WTA: with a contingent valuation model that analyzes household-
relocation preferences for an increase in the level of neighborhood 
health risks from nuclear-waste transport. By using the same sample 
of households and the same good (housing) under different property-
right assignments, they hope to offer estimates that are free of bias 
arising from uncertainty about the good; 
 Morbidity Respiratory symptom, asthma attacks, respiratory hospital 
admissions 
Sulphur and nitrogen 
emission (Rw 84) 
WTP and cost of illness of the overall health related damage costs; 
Infrastructure Materials Replacement frequency of zinc, galvanised steel, limestone, 
mortar, sandstone, paint, and rendering for utilitarian buildings 
Sulphur and nitrogen 
emission (Rw 84) 
effect of SO2 and wet acid deposition on corrosion valued using 
market prices; the material inventories are quantified in terms of the 
exposed material area from representative buildings; 
Environment Make 
unsightly a 
favourite 
view 
Stopping a development that would obscure their favourite view Estimation of the 
value of the 
environment in the 
underground space 
use (Rw 52) 
Emailed questionnaires where respondents were asked how much 
money they would pay to stop a development that would obscure or 
make unsightly their favorite view; 
 Tropical Adding one year of schooling Ways to lower tropical • Annual value of externality=average area of old-growth forest 
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Side Impact area External 
effect 
Measurement Paper context Valuation method 
forest deforestation (Rw 57) cleared by a household each year*mean total value of a rain forest 
excluding food, raw materials, and recreation ($)*annual value of the 
positive externality produced by education (%); 
• Additional environmental externality from not cutting the fallow 
forest= average area of old-growth forest cleared by a household 
each year*mean total value of a rain forest excluding food, raw 
materials, and recreation ($)*% of area reduction of cut fallow forest 
of one more year of schooling; 
 Air pollution Housing choice behaviour considering accessibility either to 
work or  to study 
Provision of urban transport 
(Rw 69) 
SP; Through a multinomial logit and mixed logit it is possible to 
obtain WTP values for travel time to work  by individual h from 
location I and, travel time to study by individual h from location i; 
 Noise Valuing reductions in urban noise levels (quietness) Provision of urban transport 
(RW 69) 
CHM (Discrete Choice Modelling); Through a multinomial logit and 
mixed logit it is possible to obtain WTP values for noise level and 
travel time to work; 
 Crops Wheat, barley, potato, rye, oats and, sugar beets Sulphur and nitrogen 
emission (Rw 84) 
direct effects of SO2 on crop yield; The costs of changing the amount 
of lime needed to deal with acidification of agricultural soils, and the 
benefits of N deposition as fertiliser has been estimated; The 
estimated yield cross is valued with world market prices to obtain 
resulting damage costs. Costs of liming and benefits of oxidised N 
deposition are calculated from market prices for lime and ferlitiser; 
Welfare Altruism Benefit from knowledge that by being vaccinated will not infect 
other children 
Vaccination program (Rw 
85 (7)) 
Not valued 
  Benefit from possibility to be cured from seven hypothetical 
different severity levels 
Comparison of individual 
preferences of  different 
health states (Rw 22) 
• CV: The respondents drew a line from each box representing a 
health state to a box representing the amount of money the 
respondent was willing to pay for someone else’s possibility to be 
cured from each health state. The method was similar to payment 
cards. This type of open-ended question was also used to get as much 
information as possible from each respondent; 
 Health and 
safety risk 
Reducing nuclear-waste transport risk Nuclear-waste transport 
(Rw 113) 
WTP: to avoid health and safety risks from transport by conducting a 
conjoint experiment where respondents rank housing choices based 
on various attributes including the distance from the transport route; 
WTA: with a contingent valuation model that analyzes household-
relocation preferences for an increase in the level of neighborhood 
health risks from nuclear-waste transport. By using the same sample 
of households and the same good (housing) under different property-
right assignments, they hope to offer estimates that are free of bias 
arising from uncertainty about the good; 
P
r
o
d
u
c
t
i
o
n Knowledge Innovation 
and 
employment 
Knowledge expanded from electronics industry to the aerospace 
industry and, increase in the employment rate in the aerospace 
industry 
Additional activities 
generated with the F-35 
joint strike fighter (JSF) 
programme (Rw 40) 
Knowledge expanded= valuation method not specified but monetary 
valuated; 
Employment=not monetary valuated; 
Revenue (revenue for the aerospace industry=(number of hours 
needed for one shipset*total number of shipsets)/annual workable 
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Side Impact area External 
effect 
Measurement Paper context Valuation method 
hours per employee; (Maintenance, Repair and Overhaul activities 
are not included in the estimates); 
Innovation Research 
and 
Developmen
t (R&D) 
Proximity of the firms in technology space R & D of other firms (Rw 
41) 
Mean, median and standard deviation of annual spillover pool 
measured in millions of 1972 dollars (the potential spillover pool is 
constructed using the proximities as weights in a summation of all 
other firms' R&D spending; 
Competition 
between firms 
Interactions 
between 
firms  
Consumers' utility derived from the bundle, and consumers' 
utility derived from the network of consumers who purchase 
from the same firm 
Interactions between firms 
in the electronic channel 
(Rw 59) 
Not valued 
Industrial 
development 
Employment Model of local individual employment, using variables such as: 
concentration of own industry country employment, non diversity 
index, market variables, wages and, metro area 
employment(excluding own industry country employment) 
Capital goods industries 
(Rw 77) 
Not valued 
Investment Infrastructur
e investment 
Level of investments in one country affecting the 
productivity of investments in the other country 
Level of investment in 
trade-related transport 
infrastructure (Rw 112) 
Not valued 
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Appendix 3.10 Impact, measures and valuation methods: negative and positive external effects on the consumption and production side 
 
Side Impact area External 
effect 
Measurement Paper context Valuation method 
C
o
n
s
u
m
p
t
i
o
n
 
Welfare Insecurity 
(=) 
Subjective perception of insecurity that influences their choice of 
transport mode for current and future pedestrians and cyclists 
Use of non-motorized transport (Rw 
62) 
Nor specified 
Health Accidents (-) People injured Use of non-motorized transport (Rw 
62) 
Nor specified 
 Severe 
diseases and 
short-term 
absence (=) 
Average wage cost Use of non-motorized transport (Rw 
62) 
Nor specified 
 Severe 
diseases and 
ailments and 
long-term 
absence/disa
bility (=) 
Risk of premature mortality related to four types of severe 
diseases or ailments for which has been estimated costs to society 
in the form of medical costs, treatment costs and potential 
productivity loss 
Use of non-motorized transport (Rw 
62) 
Nor specified 
Time Travel time 
(-) 
Travel times for car drivers who do substitute walking or cycling 
for driving 
Use of non-motorized transport (Rw 
62) 
Nor specified 
Road transport Emissions 
(=) 
Physical amounts and damafe effects from: CO2 emissions, local 
emissions to air, sulphur dioxide (SO2), nitrogen oxides (NOX), 
volatile organic components (VOC and NMVOC), particles with 
diameter less than 10 µm in diameter (PM10) 
 
Use of non-motorized transport (Rw 
62) 
Nor specified 
 Noise (=) We measure the physical side of noise as the number of people 
disturbed by noise and 
unwanted sounds. The level of noise may be assessed from the 
average sound levels caused 
by different transport modes, in populated areas. The measure is 
decibels (dBA). 
Theoretically it is possible to link the change in traffic that is 
necessary for a certain change 
in dBA and thereby the subjective change in the noise level for 
the people affected by noise 
Use of non-motorized transport (Rw 
62) 
Nor specified 
 Congestion 
(=) 
The total time and driving cost that is charged on the whole 
system from one extra vehicle entering the system 
Use of non-motorized transport (Rw 
62) 
Nor specified 
Traffic Wear 
infrastructur
e (-) 
wear is a function of type of infrastructure traffic volume, weight 
of vehicle, speed, vehicle type, way of operation etc 
Use of non-motorized transport (Rw 
62) 
Nor specified 
 Parking 
costs (=) 
Rental prices companies pay for parking spaces in the different 
cities 
Use of non-motorized transport (Rw 
62) 
Nor specified 
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Side Impact area External 
effect 
Measurement Paper context Valuation method 
P
r
o
d
u
c
t
i
o
n
 
Environment Water 
control 
structure (=) 
and (-) 
Not specified System Rehabilitation Project; 
development project (Rw 50) 
Net present value (NPV): the result of discounting  and summing of 
annual net benefits stream overtime over the lifetime of the project; 
NPV=(NDB-DBP=ENB)*e^rt; 
 
NDB=net development benefits (difference between benefits and 
costs of development over time); 
DBP=disbenefits as a result of the project (estimated using the 
survey information); 
ENB=environmental benefits (CV method); 
 Reforestatio
n 
(eucalyptus) 
(=): erosion control and carbon sequestration 
(-): nutrient loss in harvesting and costs of transpiration due to 
water consumption 
Devastating floods (Rw 54) • Benefits in erosion control: replacement cost method (used to 
estimate the on-site costs of soil erosion; This involved pricing the 
amount of commercial fertilizers that were needed to replace lost 
nutrients in eroded material); 
• Costs of nutrient loss in harvesting: replacement cost technique; 
• Cost of transpiration: transpiration ratio (basal area of the tree at 
breast height) and water use efficiency approaches (describe the 
volume of water in liters that is consumed by a plant during the 
growing season per kilogram of dry matter produced; 
• Benefits in carbon sequestration: method used by Nabuurs and 
Mohren (1993) based on the assumption that the estimation of 
carbon sequestration of the trees’ different structures is possible 
when the annual stem volume increment in known; 
 Landfill 
disposal and 
incineration 
of waste 
• Incineration: Air emissions (mortality and morbidity; 
ecosystem; and, damage to buildings), Wastewater emissions 
(ecosystem and mortality and morbidity); Solid waste residues 
from incineration plants; Energy recovery; disamenity impacts: 
nuisance caused as a result of the presence of an incineration 
plant including noise, dust, odours, visual pollution and the 
national presence of vermin; Risk of accidents; 
• Landfill disposal: Timing of emissions from landfills; Air 
emissions; dust and emissions resulting from using landfill gas; 
Emissions to soil and water, Land use, displaced impacts: net 
energy recovered, disamenity impacts, and risk of accidents 
(explosions and leachate emissions); 
Evaluation of waste management 
policies (Rw 80) 
HP, CV, Dose-response functions, and clean-up costs; 
 Resources, 
natural 
patrimony, 
Resources : Soil (landslide and erosion), water (pollution and 
eutrophication) and air (pollution, contamination); 
Natural Patrimony: fauna, flora and habitats, diversity and 
Agriculture (Rw 86) • CV, TC or HP; 
• Benefits and costs 
o Amenities (landscape upkeep and structuring, rural sightseeing); 
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Side Impact area External 
effect 
Measurement Paper context Valuation method 
climate and 
natural 
hazards 
environmental domains (soil and water protection); 
Climate: micro-climate, CO; 
Natural hazards: avalanches; 
o Costs (pollution correction) – only costs; 
o Natural patrimony (recreational areas, water pollution and 
distribution, fauna and flora); 
o Climate, health, hazards (diversity and CO2 
production/absorption); 
• Examples of values used for appraising external costs and benefits 
of agriculture: 
o Landscape: WTP in Germany for landscape upkeep; 
o Recreation: TCM estimating relation between recreation and 
agriculture in Italy; 
o Soil protection: expenses in CH to maintain soil fertility; 
o Diversity: WTP for biodiversity in Swiss Jura Mountains; 
• Costs: 
o Nitrates: Cost to equip STEPs for denitrification; 
o Phosphates: Cost of chemicals used to precipitate in STEPs; 
 Water 
pollution 
Terrestrial benefits: Marginal benefits from water pollution are 
obtained by computing the shadow value for sediment loads at 
the margin 
•Marine costs: The effects of water pollution in the GBR-lagoon 
on reef quality and fish stocks  
Agriculture (Rw 102) Not valued 
Technolgy Diffusion of 
information 
and 
communicati
ons (IC) 
technology 
on other 
industrial 
sectors 
Productivity (production cost)  and employment (labour demand, 
labour price function) of other industrial sectors (= and -) 
Technology industry  (Rw 61) Not specified 
Infrastrucuctur
e 
Societal and 
spatial 
structures 
Roads, railways Agriculture (Rw 86) • CV, TC or HP; 
• Benefits and costs 
o Amenities (landscape upkeep and structuring, rural sightseeing); 
o Costs (pollution correction) – only costs; 
o Natural patrimony (recreational areas, water pollution and 
distribution, fauna and flora); 
o Climate, health, hazards (diversity and CO2 production/absorption); 
• Examples of values used for appraising external costs and benefits of 
agriculture: 
o Landscape: WTP in Germany for landscape upkeep; 
o Recreation: TCM estimating relation between recreation and 
agriculture in Italy; 
o Soil protection: expenses in CH to maintain soil fertility; 
o Diversity: WTP for biodiversity in Swiss Jura Mountains; 
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Side Impact area External 
effect 
Measurement Paper context Valuation method 
• Costs: 
o Nitrates: Cost to equip STEPs for denitrification; 
o Phosphates: Cost of chemicals used to precipitate in STEPs; 
Welfare Landscape 
image, 
recreation, 
education, 
well-being 
health, 
animal well-
being,  
Landscape image: landscape unkeep and structuring; 
Recreation: rural sightseeing, recreation and sports; 
Education: education values; 
Well-being health: noise; 
Animal well-being: detention condition; 
Agriculture (Rw 86) • CV, TC or HP; 
• Benefits and costs 
o Amenities (landscape upkeep and structuring, rural sightseeing); 
o Costs (pollution correction) – only costs; 
o Natural patrimony (recreational areas, water pollution and 
distribution, fauna and flora); 
o Climate, health, hazards (diversity and CO2 
production/absorption); 
• Examples of values used for appraising external costs and benefits 
of agriculture: 
o Landscape: WTP in Germany for landscape upkeep; 
o Recreation: TCM estimating relation between recreation and 
agriculture in Italy; 
o Soil protection: expenses in CH to maintain soil fertility; 
o Diversity: WTP for biodiversity in Swiss Jura Mountains; 
• Costs: 
o Nitrates: Cost to equip STEPs for denitrification; 
o Phosphates: Cost of chemicals used to precipitate in STEPs; 
Traded goods Environment
al 
degradation, 
resource 
exhaustion, 
habitat 
destruction 
and, positive 
cultural 
spillovers 
Negative (agricultural or mineral in nature): land degradation and 
species extinction (timber, sugar), excess use of a critical 
resource (rice), or outright pollution/poisoning of the 
environment (gold); Positive: usually involve preservation of 
indigenous culture or techniques of production (handicrafts) 
International trade (Rw 104) CV and cost of undoing a negative spillover and to examine the 
magnitude of public expenditures that are undertaken to achieve the 
same outcome; 
(8) The most common is to utilize some measure of the premium 
consumers would be willing to pay for a substitute product that does 
not have the negative externality attached to it (or, in the case of 
positive externalities, does have the benefit imbedded. For negative 
spillovers, such as environmental damage, this is likely to produce, at 
best, a lower boundary for the valuation placed upon elimination of 
the externality; 
• (8) A value can also be placed upon externalities by measuring the 
cost of undoing a negative, or achieving a positive, spillover; 
• (8) A third means of measuring external costs and benefits is to 
examine the magnitude of public expenditures that are undertaken to 
achieve the same outcome, as this may best reflect the public's 
valuation of these goals; 
• (9) Estimates of what consumers would be willing to pay to 
purchase Green Products that reduce pollution; 
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Appendix 4.1 Review of incorporation of external effects in economic evaluations 
of smoking cessation programmes 
Aim 
The aim of this review was to find an economic evaluation of smoking cessation 
programmes in the UK setting. 
Methods 
Search and selection criteria 
A review of existing cost-effectiveness studies of smoking cessation interventions was 
undertaken using CRD (NHS-EED), NICE and Health Technology Assessment (HTA) 
databases.  The search terms used were “cost-effectiveness” or “cost effectiveness” or 
“economic evaluation” or “intervention*” and “smoking”. Studies were included in the 
cost-effectiveness review if they were economic evaluation which considered the costs 
and outcomes associated with two or more interventions in the treatment of smoking 
cessation focused in the general population.  
Results 
 
The study selection process for economic evaluation of smoking cessation programmes 
is represented in next figure. 
 
 
54    titles identified 
       CRD-NHS EED   52 
       HTA                       1 
       NICE                      1 
4 articles included 
51    titles identified 
       CRD-NHS EED   49 
       HTA                       1 
       NICE                      1 
 
3 excluded for duplication 
(CRD-NHS EED) 
47 excluded because: 
Measuring one public int. 14 
Focus on a target population 
(i.e.youth, out-patients)      3 
Not an Econ. Evaluation  30 
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Four full economic evaluations assessing the cost-effectiveness for smoking cessation 
interventions were found, one in NICE published literature, and three in CRD (NHS-
EED). One of the studies, Salize et al (2009) focused on primary care-based strategies. 
Hall et al (2005) focused on economic evaluation of two pharmaceutical interventions 
and one psychological, whereas Mueller-Riemenschneider et al. (2008) focused on 
economic evaluation of behavioural strategies. Although these three papers met the 
inclusion criteria, the economic evaluation commissioned by NICE and built by Flack et 
al (2007) was selected. The reason was that had eleven public health interventions 
compared, in three different settings: NHS and workplace; workplace; and pharmacist-
based. Therefore, it showed a better picture of current public health interventions 
debated. 
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Appendix 4.2 Review of economic evaluations of smoking cessation programmes 
 
Aim 
The aim of this review was to find an economic evaluation of smoking cessation 
programmes which incorporated external effects. 
Methods 
Search and selection criteria 
A review of existing cost-effectiveness studies of smoking cessation interventions was 
undertaken using CRD (NHS-EED and HTA databases) Web of Knowledge during 
September 2010.  The search term used in the NHS EED and HTA databases was 
“smoking cessation”. However, for the “Web of Knowledge” the terms used were: 
“smoking cessation” and (“cost-benefit” or costbenefit or cost benefit or cost-
effectiveness or costeffectiveness or cost effectiveness or economic evaluation or cost* 
or valu* or critical appraisal or model). Studies were included if they were economic 
evaluations of smoking cessation programmes.  
Results 
 
The study selection process for economic evaluation of smoking cessation programmes 
is represented in next figure. 
 
 
609   titles identified 
          NHS EED                        153 
          HTA                                   43 
          Web of Knowledge         413            
1 
0 articles included 
489    titles identified 
        
 
120 excluded for duplication 
489 excluded because no 
incorporation of external 
effects  
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Appendix 4.3 Transition probabilities for mortality by smoking status, age and 
gender  
Age Smokers 
 
Former smokers 
 
Non-smokers 
 
Male Female Male Female Male Female 
16 0.000402 0.000260 0.000281 0.000182 0.000295 0.000191 
17 0.000608 0.000283 0.000426 0.000198 0.000446 0.000208 
18 0.000806 0.000309 0.000564 0.000217 0.000591 0.000227 
19 0.000766 0.000375 0.000536 0.000263 0.000561 0.000275 
20 0.000923 0.000313 0.000647 0.000219 0.000677 0.000230 
21 0.000832 0.000334 0.000583 0.000234 0.000610 0.000245 
22 0.000973 0.000339 0.000682 0.000237 0.000714 0.000249 
23 0.000950 0.000367 0.000665 0.000257 0.000696 0.000269 
24 0.000896 0.000345 0.000627 0.000242 0.000657 0.000253 
25 0.000990 0.000397 0.000693 0.000278 0.000726 0.000291 
26 0.000949 0.000434 0.000664 0.000304 0.000696 0.000318 
27 0.000923 0.000413 0.000647 0.000289 0.000677 0.000303 
28 0.000984 0.000439 0.000689 0.000307 0.000721 0.000322 
29 0.001027 0.000495 0.000719 0.000347 0.000753 0.000363 
30 0.001114 0.000545 0.000780 0.000382 0.000817 0.000400 
31 0.001131 0.000575 0.000792 0.000403 0.000829 0.000422 
32 0.001252 0.000594 0.000877 0.000416 0.000918 0.000435 
33 0.001240 0.000636 0.000868 0.000445 0.000909 0.000466 
34 0.001270 0.000743 0.000889 0.000521 0.000931 0.000545 
35 0.001574 0.000828 0.001124 0.000591 0.000899 0.000473 
36 0.001704 0.000922 0.001217 0.000659 0.000974 0.000527 
37 0.001823 0.000975 0.001302 0.000697 0.001042 0.000557 
38 0.001791 0.001182 0.001279 0.000844 0.001023 0.000675 
39 0.002040 0.001238 0.001457 0.000884 0.001166 0.000707 
40 0.002233 0.001318 0.001595 0.000941 0.001276 0.000753 
41 0.002307 0.001398 0.001648 0.000998 0.001318 0.000799 
42 0.002551 0.001604 0.001822 0.001146 0.001458 0.000917 
43 0.002985 0.001824 0.002132 0.001303 0.001706 0.001042 
44 0.003002 0.002045 0.002144 0.001460 0.001715 0.001168 
45 0.003579 0.002397 0.002165 0.001450 0.001767 0.001184 
46 0.004003 0.002775 0.002422 0.001679 0.001977 0.001370 
47 0.004511 0.003082 0.002729 0.001864 0.002228 0.001522 
48 0.004885 0.003339 0.002955 0.002020 0.002412 0.001649 
49 0.005424 0.003520 0.003281 0.002129 0.002678 0.001738 
50 0.005953 0.003988 0.003601 0.002412 0.002940 0.001969 
51 0.006462 0.004290 0.003909 0.002595 0.003191 0.002118 
52 0.007083 0.004523 0.004285 0.002736 0.003498 0.002234 
53 0.007582 0.005073 0.004587 0.003069 0.003744 0.002505 
54 0.008220 0.005414 0.004972 0.003275 0.004059 0.002673 
55 0.009025 0.006065 0.005958 0.004003 0.004224 0.002838 
56 0.009695 0.006649 0.006400 0.004389 0.004537 0.003112 
57 0.011148 0.007187 0.007359 0.004744 0.005217 0.003363 
58 0.012040 0.007928 0.007948 0.005233 0.005635 0.003710 
59 0.013327 0.008787 0.008797 0.005800 0.006237 0.004112 
60 0.015309 0.009936 0.010105 0.006559 0.007164 0.004650 
61 0.016731 0.010653 0.011044 0.007032 0.007830 0.004985 
62 0.018992 0.011739 0.012537 0.007749 0.008888 0.005494 
63 0.020089 0.012821 0.013261 0.008463 0.009401 0.006000 
64 0.022815 0.014515 0.015060 0.009581 0.010677 0.006793 
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Age Smokers 
 
Former smokers 
 
Non-smokers 
 
Male Female Male Female Male Female 
65 0.024788 0.015770 0.016666 0.010603 0.012500 0.007952 
66 0.027133 0.017579 0.018243 0.011819 0.013682 0.008864 
67 0.030149 0.019298 0.020270 0.012975 0.015203 0.009731 
68 0.033568 0.021754 0.022569 0.014626 0.016927 0.010970 
69 0.037351 0.023899 0.025113 0.016068 0.018835 0.012051 
70 0.040610 0.026053 0.027304 0.017517 0.020478 0.013138 
71 0.045593 0.029528 0.030654 0.019853 0.022990 0.014890 
72 0.050793 0.033690 0.034150 0.022651 0.025613 0.016988 
73 0.056207 0.037734 0.037790 0.025370 0.028343 0.019028 
74 0.063166 0.042403 0.042469 0.028509 0.031852 0.021382 
75 0.063717 0.042503 0.046465 0.030995 0.040514 0.027025 
76 0.070623 0.047283 0.051502 0.034481 0.044906 0.030065 
77 0.078201 0.052398 0.057028 0.038211 0.049724 0.033317 
78 0.085962 0.058900 0.062688 0.042953 0.054659 0.037452 
79 0.096776 0.064821 0.070574 0.047270 0.061535 0.041216 
80 0.105485 0.073101 0.076924 0.053308 0.067073 0.046481 
81 0.116436 0.081242 0.084910 0.059246 0.074036 0.051658 
82 0.127432 0.091574 0.092929 0.066780 0.081028 0.058227 
83 0.136373 0.099383 0.099450 0.072475 0.086713 0.063193 
84 0.148824 0.111578 0.108529 0.081367 0.094630 0.070947 
85 0.144552 0.109653 0.118775 0.090099 0.111438 0.084534 
86 0.165692 0.126041 0.136145 0.103565 0.127735 0.097167 
87 0.181541 0.139956 0.149167 0.114998 0.139953 0.107895 
88 0.198050 0.155477 0.162732 0.127751 0.152680 0.119860 
89 0.215215 0.171825 0.176836 0.141184 0.165913 0.132463 
90 0.226968 0.189450 0.186494 0.155666 0.174974 0.146051 
91 0.245152 0.207741 0.201435 0.170695 0.188993 0.160151 
92 0.269136 0.231570 0.221142 0.190275 0.207482 0.178522 
93 0.292858 0.254269 0.240634 0.208926 0.225770 0.196021 
94 0.307673 0.276868 0.252807 0.227495 0.237191 0.213443 
95 0.342798 0.296317 0.281668 0.243476 0.264269 0.228437 
96 0.357484 0.321547 0.293735 0.264206 0.275591 0.247887 
97 0.380309 0.344356 0.312490 0.282948 0.293188 0.265471 
98 0.404971 0.367641 0.332754 0.302081 0.312200 0.283422 
99 0.422426 0.390998 0.347097 0.321273 0.325657 0.301428 
100 0.443596 0.417878 0.364491 0.343359 0.341976 0.322150 
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 Appendix 4.4  Population weights by age and gender 
 
Age Total Male Female 
16 0.87% 0.43% 0.44% 
17 0.87% 0.43% 0.44% 
18 0.87% 0.43% 0.44% 
19 0.87% 0.43% 0.44% 
20 0.87% 0.43% 0.44% 
21 0.87% 0.43% 0.44% 
22 0.87% 0.43% 0.44% 
23 0.87% 0.43% 0.44% 
24 0.87% 0.43% 0.44% 
25 1.85% 0.93% 0.93% 
26 1.85% 0.93% 0.93% 
27 1.85% 0.93% 0.93% 
28 1.85% 0.93% 0.93% 
29 1.85% 0.93% 0.93% 
30 2.10% 1.05% 1.05% 
31 2.10% 1.05% 1.05% 
32 2.10% 1.05% 1.05% 
33 2.10% 1.05% 1.05% 
34 2.10% 1.05% 1.05% 
35 2.09% 1.03% 1.05% 
36 2.09% 1.03% 1.05% 
37 2.09% 1.03% 1.05% 
38 2.09% 1.03% 1.05% 
39 2.09% 1.03% 1.05% 
40 1.84% 0.92% 0.92% 
41 1.84% 0.92% 0.92% 
42 1.84% 0.92% 0.92% 
43 1.84% 0.92% 0.92% 
44 1.84% 0.92% 0.92% 
45 1.69% 0.84% 0.85% 
46 1.69% 0.84% 0.85% 
47 1.69% 0.84% 0.85% 
48 1.69% 0.84% 0.85% 
49 1.69% 0.84% 0.85% 
50 1.83% 0.91% 0.92% 
51 1.83% 0.91% 0.92% 
52 1.83% 0.91% 0.92% 
53 1.83% 0.91% 0.92% 
54 1.83% 0.91% 0.92% 
55 1.48% 0.73% 0.75% 
56 1.48% 0.73% 0.75% 
57 1.48% 0.73% 0.75% 
58 1.48% 0.73% 0.75% 
59 1.48% 0.73% 0.75% 
60 1.31% 0.64% 0.67% 
61 1.31% 0.64% 0.67% 
62 1.31% 0.64% 0.67% 
63 1.31% 0.64% 0.67% 
64 1.31% 0.64% 0.67% 
65 1.18% 0.56% 0.61% 
66 1.18% 0.56% 0.61% 
67 1.18% 0.56% 0.61% 
68 1.18% 0.56% 0.61% 
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Age Total Male Female 
69 1.18% 0.56% 0.61% 
70 1.06% 0.48% 0.58% 
71 1.06% 0.48% 0.58% 
72 1.06% 0.48% 0.58% 
73 1.06% 0.48% 0.58% 
74 1.06% 0.48% 0.58% 
75 0.92% 0.38% 0.54% 
76 0.92% 0.38% 0.54% 
77 0.92% 0.38% 0.54% 
78 0.92% 0.38% 0.54% 
79 0.92% 0.38% 0.54% 
80 0.57% 0.21% 0.36% 
81 0.57% 0.21% 0.36% 
82 0.57% 0.21% 0.36% 
83 0.57% 0.21% 0.36% 
84 0.57% 0.21% 0.36% 
85 0.35% 0.10% 0.24% 
86 0.35% 0.10% 0.24% 
87 0.35% 0.10% 0.24% 
88 0.35% 0.10% 0.24% 
89 0.35% 0.10% 0.24% 
90 0.08% 0.02% 0.06% 
91 0.08% 0.02% 0.06% 
92 0.08% 0.02% 0.06% 
93 0.08% 0.02% 0.06% 
94 0.08% 0.02% 0.06% 
95 0.08% 0.02% 0.06% 
96 0.08% 0.02% 0.06% 
97 0.08% 0.02% 0.06% 
98 0.08% 0.02% 0.06% 
99 0.08% 0.02% 0.06% 
100 0.08% 0.02% 0.06% 
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Appendix 4.5 Description of variables in mortality equation by Flack et al (2007) 
 
Equation variables Data Source 
A: Mortality odds ratio 
comparing smokers with 
former smokers 
Mortality rates in relation to 
smoking status 
Doll et al (1994) 
B: Mortality odds ratio 
comparing smokers versus 
non-smokers 
Mortality rates in relation to 
smoking status 
Doll et al (1994) 
C: ‘Real’ mortality by age and 
gender 
Actuary Life Tables Government Actuary's 
Department (2004) 
D1: Prevalence of smoking by 
age and gender 
Prevalence of smoking Department of Health (HSE 
2004) 
D2: Prevalence of former 
smokers by age and gender 
Prevalence of former smokers Department of Health (HSE 
2004) 
D3: Prevalence of never 
regularly smoked by age and 
gender 
Prevalence of never smokers Department of Health (HSE 
2004) 
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Appendix 4.6 Male mortality rates in relation to smoking status by age 
 
Age at death Current 
smoker 
Former smoker Non-smoker 
Under 35 0,15 0,10 0,11 
35-44 2,80 2,00 1,60 
45-54 8,10 4,90 4,00 
55-64 20,30 13,40 9,50 
65-74 47,00 31,60 23,70 
75-84 106,4 77,30 67,40 
85 and over 218,70 179,70 168,60 
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Appendix 4.7 Actuary life tables for mortality rates by age and sex 
 
Age Male Female 
16 0.000321 0.000210 
17 0.000486 0.000229 
18 0.000644 0.000250 
19 0.000612 0.000303 
20 0.000738 0.000253 
21 0.000665 0.000270 
22 0.000778 0.000274 
23 0.000759 0.000297 
24 0.000716 0.000279 
25 0.000820 0.000318 
26 0.000786 0.000348 
27 0.000765 0.000331 
28 0.000815 0.000352 
29 0.000851 0.000397 
30 0.000923 0.000437 
31 0.000937 0.000461 
32 0.001037 0.000476 
33 0.001027 0.000510 
34 0.001052 0.000596 
35 0.001124 0.000590 
36 0.001217 0.000657 
37 0.001302 0.000695 
38 0.001279 0.000842 
39 0.001457 0.000882 
40 0.001595 0.000939 
41 0.001648 0.000996 
42 0.001822 0.001143 
43 0.002132 0.001300 
44 0.002144 0.001457 
45 0.002345 0.001548 
46 0.002623 0.001792 
47 0.002956 0.001990 
48 0.003201 0.002156 
49 0.003554 0.002273 
50 0.003901 0.002575 
51 0.004234 0.002770 
52 0.004641 0.002921 
53 0.004968 0.003276 
54 0.005386 0.003496 
55 0.005915 0.003832 
56 0.006354 0.004201 
57 0.007306 0.004541 
58 0.007891 0.005009 
59 0.008734 0.005552 
60 0.010033 0.006278 
61 0.010965 0.006731 
62 0.012447 0.007417 
63 0.013166 0.008101 
64 0.014799 0.008994 
65 0.016079 0.009772 
66 0.017600 0.010893 
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Age Male Female 
67 0.019556 0.011958 
68 0.021774 0.013480 
69 0.024228 0.014809 
70 0.026342 0.016144 
71 0.029574 0.018297 
72 0.032947 0.020876 
73 0.036459 0.023382 
74 0.040973 0.026275 
75 0.045751 0.029814 
76 0.050710 0.033167 
77 0.056151 0.036755 
78 0.061724 0.041316 
79 0.069489 0.045469 
80 0.075742 0.051277 
81 0.083605 0.056988 
82 0.091501 0.064235 
83 0.097921 0.069713 
84 0.106861 0.078267 
85 0.118207 0.088763 
86 0.135494 0.102029 
87 0.148454 0.113293 
88 0.161954 0.125857 
89 0.175991 0.139091 
90 0.185602 0.153358 
91 0.200472 0.168164 
92 0.220085 0.187454 
93 0.239483 0.205828 
94 0.251598 0.224122 
95 0.280321 0.239866 
96 0.292331 0.260289 
97 0.310996 0.278753 
98 0.331163 0.297602 
99 0.345437 0.316509 
100 0.362748 0.338268 
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Appendix 4.8 Prevalence of smoking by age interval and sex  
Age Current smoker (S) Former (F) Non-smoker (NS) 
Men Women Men Women Men Women 
16-24 0.25 0.29 0.05 0.07 0.69 0.64 
25-34 0.37 0.28 0.14 0.16 0.49 0.56 
35-44 0.26 0.27 0.21 0.18 0.53 0.55 
45-54 0.25 0.25 0.30 0.24 0.44 0.51 
55-64 0.19 0.20 0.44 0.30 0.36 0.50 
65-74 0.10 0.13 0.56 0.29 0.34 0.57 
75 and over 0.07 0.09 0.61 0.34 0.32 0.57 
All ages 0.24 0.23 0.29 0.22 0.47 0.56 
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 Appendix 4.9 Description of variables in prevalence equation of Flack et al (2007) 
 
Equation variables Data Source 
H: Prevalence of each condition 
by age 
Prevalence of LC, CHD, 
COPD, MI, ST 
Forman et al (2003), Allender 
et al (2006) and Britton (2003) 
I: Relative risk of each condition 
by smoking status (smokers 
versus former smokers) 
Relative risk of LC, CHD, 
COPD, MI and ST of smokers 
versus former smokers 
Peto et al  (2000) and US 
Department of Health (2004) 
J: Relative risk of each condition 
by smoking status (smokers 
versus non-smokers) 
Relative risk of LC, CHD, 
COPD, MI and ST of smokers 
versus non-mokers 
Peto et al  (2000) and US 
Department of Health (2004) 
D1: Prevalence of smoking by age 
and gender 
Prevalence of smoking Department of Health (HSE 
2004) 
D2: Prevalence of former smokers 
by age and gender 
Prevalence of former smokers Department of Health (HSE 
2004) 
D3: Prevalence of never regularly 
smoked by age and gender 
Prevalence of never smokers Department of Health (HSE 
2004) 
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Appendix 4.10 Prevalence of each condition by age and sex 
Appendix 4.10.1 Lung cancer 
 
Appendix 4.10.1.1 Prevalence of lung cancer 
Age Prevalence 
0-44 0.00% 
45-64 0.15% 
65+ 0.80% 
All ages 0.14% 
 
Appendix 4.10.1.2 Relative risk of lung cancer by smoking status 
Sex Smokers Former smokers Non-smokers 
men 1 0.44 0.03 
women 1 0.21 0.05 
 
Appendix 4.10.1.3 Prevalence of lung cancer by smoking status, age and gender 
Age 
 
Smokers Former Smokers Non-smokers 
Men Women Men Women Men Women 
16 0.00007 0.00006 0.00003 0.00001 0.00000 0.00000 
17 0.00007 0.00006 0.00003 0.00001 0.00000 0.00000 
18 0.00007 0.00006 0.00003 0.00001 0.00000 0.00000 
19 0.00007 0.00006 0.00003 0.00001 0.00000 0.00000 
20 0.00007 0.00006 0.00003 0.00001 0.00000 0.00000 
21 0.00007 0.00006 0.00003 0.00001 0.00000 0.00000 
22 0.00007 0.00006 0.00003 0.00001 0.00000 0.00000 
23 0.00007 0.00006 0.00003 0.00001 0.00000 0.00000 
24 0.00007 0.00006 0.00003 0.00001 0.00000 0.00000 
25 0.00005 0.00006 0.00002 0.00001 0.00000 0.00000 
26 0.00005 0.00006 0.00002 0.00001 0.00000 0.00000 
27 0.00005 0.00006 0.00002 0.00001 0.00000 0.00000 
28 0.00005 0.00006 0.00002 0.00001 0.00000 0.00000 
29 0.00005 0.00006 0.00002 0.00001 0.00000 0.00000 
30 0.00005 0.00006 0.00002 0.00001 0.00000 0.00000 
31 0.00005 0.00006 0.00002 0.00001 0.00000 0.00000 
32 0.00005 0.00006 0.00002 0.00001 0.00000 0.00000 
33 0.00005 0.00006 0.00002 0.00001 0.00000 0.00000 
34 0.00005 0.00006 0.00002 0.00001 0.00000 0.00000 
35 0.00005 0.00006 0.00002 0.00001 0.00000 0.00000 
36 0.00005 0.00006 0.00002 0.00001 0.00000 0.00000 
37 0.00005 0.00006 0.00002 0.00001 0.00000 0.00000 
38 0.00005 0.00006 0.00002 0.00001 0.00000 0.00000 
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Age 
 
Smokers Former Smokers Non-smokers 
Men Women Men Women Men Women 
39 0.00005 0.00006 0.00002 0.00001 0.00000 0.00000 
40 0.00005 0.00006 0.00002 0.00001 0.00000 0.00000 
41 0.00005 0.00006 0.00002 0.00001 0.00000 0.00000 
42 0.00005 0.00006 0.00002 0.00001 0.00000 0.00000 
43 0.00005 0.00006 0.00002 0.00001 0.00000 0.00000 
44 0.00005 0.00006 0.00002 0.00001 0.00000 0.00000 
45 0.00383 0.00214 0.00169 0.00045 0.00012 0.00011 
46 0.00383 0.00214 0.00169 0.00045 0.00012 0.00011 
47 0.00383 0.00214 0.00169 0.00045 0.00012 0.00011 
48 0.00383 0.00214 0.00169 0.00045 0.00012 0.00011 
49 0.00383 0.00214 0.00169 0.00045 0.00012 0.00011 
50 0.00383 0.00214 0.00169 0.00045 0.00012 0.00011 
51 0.00383 0.00214 0.00169 0.00045 0.00012 0.00011 
52 0.00383 0.00214 0.00169 0.00045 0.00012 0.00011 
53 0.00383 0.00214 0.00169 0.00045 0.00012 0.00011 
54 0.00383 0.00214 0.00169 0.00045 0.00012 0.00011 
55 0.00384 0.00241 0.00169 0.00051 0.00012 0.00012 
56 0.00384 0.00241 0.00169 0.00051 0.00012 0.00012 
57 0.00384 0.00241 0.00169 0.00051 0.00012 0.00012 
58 0.00384 0.00241 0.00169 0.00051 0.00012 0.00012 
59 0.00384 0.00241 0.00169 0.00051 0.00012 0.00012 
60 0.00384 0.00241 0.00169 0.00051 0.00012 0.00012 
61 0.00384 0.00241 0.00169 0.00051 0.00012 0.00012 
62 0.00384 0.00241 0.00169 0.00051 0.00012 0.00012 
63 0.00384 0.00241 0.00169 0.00051 0.00012 0.00012 
64 0.00384 0.00241 0.00169 0.00051 0.00012 0.00012 
65 0.02236 0.01007 0.00984 0.00211 0.00067 0.00050 
66 0.02236 0.01007 0.00984 0.00211 0.00067 0.00050 
67 0.02236 0.01007 0.00984 0.00211 0.00067 0.00050 
68 0.02236 0.01007 0.00984 0.00211 0.00067 0.00050 
69 0.02236 0.01007 0.00984 0.00211 0.00067 0.00050 
70 0.02236 0.01007 0.00984 0.00211 0.00067 0.00050 
71 0.02236 0.01007 0.00984 0.00211 0.00067 0.00050 
72 0.02236 0.01007 0.00984 0.00211 0.00067 0.00050 
73 0.02236 0.01007 0.00984 0.00211 0.00067 0.00050 
74 0.02236 0.01007 0.00984 0.00211 0.00067 0.00050 
75 0.02304 0.01167 0.01014 0.00245 0.00069 0.00058 
76 0.02304 0.01167 0.01014 0.00245 0.00069 0.00058 
77 0.02304 0.01167 0.01014 0.00245 0.00069 0.00058 
78 0.02304 0.01167 0.01014 0.00245 0.00069 0.00058 
79 0.02304 0.01167 0.01014 0.00245 0.00069 0.00058 
80 0.02304 0.01167 0.01014 0.00245 0.00069 0.00058 
81 0.02304 0.01167 0.01014 0.00245 0.00069 0.00058 
82 0.02304 0.01167 0.01014 0.00245 0.00069 0.00058 
83 0.02304 0.01167 0.01014 0.00245 0.00069 0.00058 
84 0.02304 0.01167 0.01014 0.00245 0.00069 0.00058 
85 0.02304 0.01167 0.01014 0.00245 0.00069 0.00058 
86 0.02304 0.01167 0.01014 0.00245 0.00069 0.00058 
87 0.02304 0.01167 0.01014 0.00245 0.00069 0.00058 
88 0.02304 0.01167 0.01014 0.00245 0.00069 0.00058 
89 0.02304 0.01167 0.01014 0.00245 0.00069 0.00058 
90 0.02304 0.01167 0.01014 0.00245 0.00069 0.00058 
91 0.02304 0.01167 0.01014 0.00245 0.00069 0.00058 
92 0.02304 0.01167 0.01014 0.00245 0.00069 0.00058 
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Age 
 
Smokers Former Smokers Non-smokers 
Men Women Men Women Men Women 
93 0.02304 0.01167 0.01014 0.00245 0.00069 0.00058 
94 0.02304 0.01167 0.01014 0.00245 0.00069 0.00058 
95 0.02304 0.01167 0.01014 0.00245 0.00069 0.00058 
96 0.02304 0.01167 0.01014 0.00245 0.00069 0.00058 
97 0.02304 0.01167 0.01014 0.00245 0.00069 0.00058 
98 0.02304 0.01167 0.01014 0.00245 0.00069 0.00058 
99 0.02304 0.01167 0.01014 0.00245 0.00069 0.00058 
100 0.02304 0.01167 0.01014 0.00245 0.00069 0.00058 
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Appendix 4.10.2 Coronary heart disease 
 
Appendix 4.10.2.1 Prevalence of coronary heart disease 
Age Prevalence 
16-24 0.00% 
25-34 0.00% 
35-44 0.90% 
45-54 3.50% 
55-64 11.10% 
65-74 21.50% 
75+ 26.40% 
Appendix 4.10.2.2 Relative risk of coronary heart disease by smoking status 
Smokers Former smokers Non-smokers 
3.12 1.55 1 
 
Appendix 4.10.2.3 Prevalence of coronary heart disease by smoking status, age and 
gender 
Age 
 
Smokers Former Smokers Non-smokers 
Men Women Men Women Men Women 
16 0.00000 0.00378 0.00000 0.00188 0.00000 0.00121 
17 0.00000 0.00378 0.00000 0.00188 0.00000 0.00121 
18 0.00000 0.00378 0.00000 0.00188 0.00000 0.00121 
19 0.00000 0.00378 0.00000 0.00188 0.00000 0.00121 
20 0.00000 0.00378 0.00000 0.00188 0.00000 0.00121 
21 0.00000 0.00378 0.00000 0.00188 0.00000 0.00121 
22 0.00000 0.00378 0.00000 0.00188 0.00000 0.00121 
23 0.00000 0.00378 0.00000 0.00188 0.00000 0.00121 
24 0.00000 0.00378 0.00000 0.00188 0.00000 0.00121 
25 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 
26 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 
27 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 
28 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 
29 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 
30 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 
31 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 
32 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 
33 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 
34 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 
35 0.01677 0.00747 0.00833 0.00371 0.00538 0.00239 
36 0.01677 0.00747 0.00833 0.00371 0.00538 0.00239 
37 0.01677 0.00747 0.00833 0.00371 0.00538 0.00239 
38 0.01677 0.00747 0.00833 0.00371 0.00538 0.00239 
39 0.01677 0.00747 0.00833 0.00371 0.00538 0.00239 
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Age 
 
Smokers Former Smokers Non-smokers 
Men Women Men Women Men Women 
40 0.01677 0.00747 0.00833 0.00371 0.00538 0.00239 
41 0.01677 0.00747 0.00833 0.00371 0.00538 0.00239 
42 0.01677 0.00747 0.00833 0.00371 0.00538 0.00239 
43 0.01677 0.00747 0.00833 0.00371 0.00538 0.00239 
44 0.01677 0.00747 0.00833 0.00371 0.00538 0.00239 
45 0.06416 0.03767 0.03188 0.01871 0.02057 0.01207 
46 0.06416 0.03767 0.03188 0.01871 0.02057 0.01207 
47 0.06416 0.03767 0.03188 0.01871 0.02057 0.01207 
48 0.06416 0.03767 0.03188 0.01871 0.02057 0.01207 
49 0.06416 0.03767 0.03188 0.01871 0.02057 0.01207 
50 0.06416 0.03767 0.03188 0.01871 0.02057 0.01207 
51 0.06416 0.03767 0.03188 0.01871 0.02057 0.01207 
52 0.06416 0.03767 0.03188 0.01871 0.02057 0.01207 
53 0.06416 0.03767 0.03188 0.01871 0.02057 0.01207 
54 0.06416 0.03767 0.03188 0.01871 0.02057 0.01207 
55 0.20977 0.11597 0.10421 0.05761 0.06724 0.03717 
56 0.20977 0.11597 0.10421 0.05761 0.06724 0.03717 
57 0.20977 0.11597 0.10421 0.05761 0.06724 0.03717 
58 0.20977 0.11597 0.10421 0.05761 0.06724 0.03717 
59 0.20977 0.11597 0.10421 0.05761 0.06724 0.03717 
60 0.20977 0.11597 0.10421 0.05761 0.06724 0.03717 
61 0.20977 0.11597 0.10421 0.05761 0.06724 0.03717 
62 0.20977 0.11597 0.10421 0.05761 0.06724 0.03717 
63 0.20977 0.11597 0.10421 0.05761 0.06724 0.03717 
64 0.20977 0.11597 0.10421 0.05761 0.06724 0.03717 
65 0.44038 0.20962 0.21878 0.10414 0.14115 0.06718 
66 0.44038 0.20962 0.21878 0.10414 0.14115 0.06718 
67 0.44038 0.20962 0.21878 0.10414 0.14115 0.06718 
68 0.44038 0.20962 0.21878 0.10414 0.14115 0.06718 
69 0.44038 0.20962 0.21878 0.10414 0.14115 0.06718 
70 0.44038 0.20962 0.21878 0.10414 0.14115 0.06718 
71 0.44038 0.20962 0.21878 0.10414 0.14115 0.06718 
72 0.44038 0.20962 0.21878 0.10414 0.14115 0.06718 
73 0.44038 0.20962 0.21878 0.10414 0.14115 0.06718 
74 0.44038 0.20962 0.21878 0.10414 0.14115 0.06718 
75 0.55568 0.41478 0.27606 0.20606 0.17810 0.13294 
76 0.55568 0.41478 0.27606 0.20606 0.17810 0.13294 
77 0.55568 0.41478 0.27606 0.20606 0.17810 0.13294 
78 0.55568 0.41478 0.27606 0.20606 0.17810 0.13294 
79 0.55568 0.41478 0.27606 0.20606 0.17810 0.13294 
80 0.55568 0.41478 0.27606 0.20606 0.17810 0.13294 
81 0.55568 0.41478 0.27606 0.20606 0.17810 0.13294 
82 0.55568 0.41478 0.27606 0.20606 0.17810 0.13294 
83 0.55568 0.41478 0.27606 0.20606 0.17810 0.13294 
84 0.55568 0.41478 0.27606 0.20606 0.17810 0.13294 
85 0.55568 0.41478 0.27606 0.20606 0.17810 0.13294 
86 0.55568 0.41478 0.27606 0.20606 0.17810 0.13294 
87 0.55568 0.41478 0.27606 0.20606 0.17810 0.13294 
88 0.55568 0.41478 0.27606 0.20606 0.17810 0.13294 
89 0.55568 0.41478 0.27606 0.20606 0.17810 0.13294 
90 0.55568 0.41478 0.27606 0.20606 0.17810 0.13294 
91 0.55568 0.41478 0.27606 0.20606 0.17810 0.13294 
92 0.55568 0.41478 0.27606 0.20606 0.17810 0.13294 
93 0.55568 0.41478 0.27606 0.20606 0.17810 0.13294 
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Age 
 
Smokers Former Smokers Non-smokers 
Men Women Men Women Men Women 
94 0.55568 0.41478 0.27606 0.20606 0.17810 0.13294 
95 0.55568 0.41478 0.27606 0.20606 0.17810 0.13294 
96 0.55568 0.41478 0.27606 0.20606 0.17810 0.13294 
97 0.55568 0.41478 0.27606 0.20606 0.17810 0.13294 
98 0.55568 0.41478 0.27606 0.20606 0.17810 0.13294 
99 0.55568 0.41478 0.27606 0.20606 0.17810 0.13294 
100 0.55568 0.41478 0.27606 0.20606 0.17810 0.13294 
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Appendix 4.10.3 Chronic obstructive pulmonary disease 
 
Appendix 4.10.3.1 Prevalence of chronic obstructive pulmonary disease 
Age Prevalence 
0-64 1.00% 
65-74 5.00% 
75+ 10.00% 
 
Appendix 4.10.3.2 Relative risk of chronic obstructive pulmonary disease by 
smoking status 
Sex Smokers Former smokers Non-smokers 
Men 1 0.84 0.68 
Women 1 0.96 0.92 
 
Appendix 4.10.3.3 Prevalence of chronic obstructive pulmonary disease by 
smoking status, age and gender 
Age 
 
Smokers Former Smokers Non-smokers 
Men Women Men Women Men Women 
16 0.013 0.01057 0.01091 0.01015 0.00883 0.00973 
17 0.013 0.01057 0.01091 0.01015 0.00883 0.00973 
18 0.013 0.01057 0.01091 0.01015 0.00883 0.00973 
19 0.013 0.01057 0.01091 0.01015 0.00883 0.00973 
20 0.013 0.01057 0.01091 0.01015 0.00883 0.00973 
21 0.013 0.01057 0.01091 0.01015 0.00883 0.00973 
22 0.013 0.01057 0.01091 0.01015 0.00883 0.00973 
23 0.013 0.01057 0.01091 0.01015 0.00883 0.00973 
24 0.013 0.01057 0.01091 0.01015 0.00883 0.00973 
25 0.01216 0.01054 0.01022 0.01012 0.00827 0.00970 
26 0.01216 0.01054 0.01022 0.01012 0.00827 0.00970 
27 0.01216 0.01054 0.01022 0.01012 0.00827 0.00970 
28 0.01216 0.01054 0.01022 0.01012 0.00827 0.00970 
29 0.01216 0.01054 0.01022 0.01012 0.00827 0.00970 
30 0.01216 0.01054 0.01022 0.01012 0.00827 0.00970 
31 0.01216 0.01054 0.01022 0.01012 0.00827 0.00970 
32 0.01216 0.01054 0.01022 0.01012 0.00827 0.00970 
33 0.01216 0.01054 0.01022 0.01012 0.00827 0.00970 
34 0.01216 0.01054 0.01022 0.01012 0.00827 0.00970 
35 0.01254 0.01054 0.01053 0.01012 0.00853 0.00970 
36 0.01254 0.01054 0.01053 0.01012 0.00853 0.00970 
37 0.01254 0.01054 0.01053 0.01012 0.00853 0.00970 
38 0.01254 0.01054 0.01053 0.01012 0.00853 0.00970 
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Age 
 
Smokers Former Smokers Non-smokers 
Men Women Men Women Men Women 
39 0.01254 0.01054 0.01053 0.01012 0.00853 0.00970 
40 0.01254 0.01054 0.01053 0.01012 0.00853 0.00970 
41 0.01254 0.01054 0.01053 0.01012 0.00853 0.00970 
42 0.01254 0.01054 0.01053 0.01012 0.00853 0.00970 
43 0.01254 0.01054 0.01053 0.01012 0.00853 0.00970 
44 0.01254 0.01054 0.01053 0.01012 0.00853 0.00970 
45 0.01236 0.01053 0.01038 0.01011 0.00840 0.00969 
46 0.01236 0.01053 0.01038 0.01011 0.00840 0.00969 
47 0.01236 0.01053 0.01038 0.01011 0.00840 0.00969 
48 0.01236 0.01053 0.01038 0.01011 0.00840 0.00969 
49 0.01236 0.01053 0.01038 0.01011 0.00840 0.00969 
50 0.01236 0.01053 0.01038 0.01011 0.00840 0.00969 
51 0.01236 0.01053 0.01038 0.01011 0.00840 0.00969 
52 0.01236 0.01053 0.01038 0.01011 0.00840 0.00969 
53 0.01236 0.01053 0.01038 0.01011 0.00840 0.00969 
54 0.01236 0.01053 0.01038 0.01011 0.00840 0.00969 
55 0.01231 0.01055 0.01034 0.01013 0.00837 0.00971 
56 0.01231 0.01055 0.01034 0.01013 0.00837 0.00971 
57 0.01231 0.01055 0.01034 0.01013 0.00837 0.00971 
58 0.01231 0.01055 0.01034 0.01013 0.00837 0.00971 
59 0.01231 0.01055 0.01034 0.01013 0.00837 0.00971 
60 0.01231 0.01055 0.01034 0.01013 0.00837 0.00971 
61 0.01231 0.01055 0.01034 0.01013 0.00837 0.00971 
62 0.01231 0.01055 0.01034 0.01013 0.00837 0.00971 
63 0.01231 0.01055 0.01034 0.01013 0.00837 0.00971 
64 0.01231 0.01055 0.01034 0.01013 0.00837 0.00971 
65 0.06235 0.05306 0.05237 0.05093 0.04240 0.04881 
66 0.06235 0.05306 0.05237 0.05093 0.04240 0.04881 
67 0.06235 0.05306 0.05237 0.05093 0.04240 0.04881 
68 0.06235 0.05306 0.05237 0.05093 0.04240 0.04881 
69 0.06235 0.05306 0.05237 0.05093 0.04240 0.04881 
70 0.06235 0.05306 0.05237 0.05093 0.04240 0.04881 
71 0.06235 0.05306 0.05237 0.05093 0.04240 0.04881 
72 0.06235 0.05306 0.05237 0.05093 0.04240 0.04881 
73 0.06235 0.05306 0.05237 0.05093 0.04240 0.04881 
74 0.06235 0.05306 0.05237 0.05093 0.04240 0.04881 
75 0.12504 0.10627 0.10504 0.10202 0.08503 0.09777 
76 0.12504 0.10627 0.10504 0.10202 0.08503 0.09777 
77 0.12504 0.10627 0.10504 0.10202 0.08503 0.09777 
78 0.12504 0.10627 0.10504 0.10202 0.08503 0.09777 
79 0.12504 0.10627 0.10504 0.10202 0.08503 0.09777 
80 0.12504 0.10627 0.10504 0.10202 0.08503 0.09777 
81 0.12504 0.10627 0.10504 0.10202 0.08503 0.09777 
82 0.12504 0.10627 0.10504 0.10202 0.08503 0.09777 
83 0.12504 0.10627 0.10504 0.10202 0.08503 0.09777 
84 0.12504 0.10627 0.10504 0.10202 0.08503 0.09777 
85 0.12504 0.10627 0.10504 0.10202 0.08503 0.09777 
86 0.12504 0.10627 0.10504 0.10202 0.08503 0.09777 
87 0.12504 0.10627 0.10504 0.10202 0.08503 0.09777 
88 0.12504 0.10627 0.10504 0.10202 0.08503 0.09777 
89 0.12504 0.10627 0.10504 0.10202 0.08503 0.09777 
90 0.12504 0.10627 0.10504 0.10202 0.08503 0.09777 
91 0.12504 0.10627 0.10504 0.10202 0.08503 0.09777 
92 0.12504 0.10627 0.10504 0.10202 0.08503 0.09777 
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Smokers Former Smokers Non-smokers 
Men Women Men Women Men Women 
93 0.12504 0.10627 0.10504 0.10202 0.08503 0.09777 
94 0.12504 0.10627 0.10504 0.10202 0.08503 0.09777 
95 0.12504 0.10627 0.10504 0.10202 0.08503 0.09777 
96 0.12504 0.10627 0.10504 0.10202 0.08503 0.09777 
97 0.12504 0.10627 0.10504 0.10202 0.08503 0.09777 
98 0.12504 0.10627 0.10504 0.10202 0.08503 0.09777 
99 0.12504 0.10627 0.10504 0.10202 0.08503 0.09777 
100 0.12504 0.10627 0.10504 0.10202 0.08503 0.09777 
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Appendix 4.10.4 Myocardial infarction 
 
Appendix 4.10.4.1 Prevalence of myocardial infarction 
Age Prevalence 
0-54 0.00% 
55-64 6.70% 
65-74 12.10% 
 
Appendix 4.10.4.2 Relative risk of myocardial infarction by smoking status 
Sex Smokers Former smokers Non-smokers 
Men 1.6 1.11 1 
Women 2.76 1.05 1 
 
Appendix 4.10.4.3 Prevalence of myocardial infarction by smoking status, age and 
gender 
Age 
 
Smokers Former Smokers Non-smokers 
Men Women Men Women Men Women 
16 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 
17 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 
18 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 
19 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 
20 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 
21 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 
22 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 
23 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 
24 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 
25 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 
26 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 
27 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 
28 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 
29 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 
30 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 
31 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 
32 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 
33 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 
34 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 
35 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 
36 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 
37 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 
38 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 
39 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 
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Age 
 
Smokers Former Smokers Non-smokers 
Men Women Men Women Men Women 
40 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 
41 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 
42 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 
43 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 
44 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 
45 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 
46 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 
47 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 
48 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 
49 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 
50 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 
51 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 
52 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 
53 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 
54 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 
55 0.09210 0.04250 0.06390 0.01617 0.05756 0.01540 
56 0.09210 0.04250 0.06390 0.01617 0.05756 0.01540 
57 0.09210 0.04250 0.06390 0.01617 0.05756 0.01540 
58 0.09210 0.04250 0.06390 0.01617 0.05756 0.01540 
59 0.09210 0.04250 0.06390 0.01617 0.05756 0.01540 
60 0.09210 0.04250 0.06390 0.01617 0.05756 0.01540 
61 0.09210 0.04250 0.06390 0.01617 0.05756 0.01540 
62 0.09210 0.04250 0.06390 0.01617 0.05756 0.01540 
63 0.09210 0.04250 0.06390 0.01617 0.05756 0.01540 
64 0.09210 0.04250 0.06390 0.01617 0.05756 0.01540 
65 0.17246 0.09283 0.11965 0.03532 0.10779 0.03363 
66 0.17246 0.09283 0.11965 0.03532 0.10779 0.03363 
67 0.17246 0.09283 0.11965 0.03532 0.10779 0.03363 
68 0.17246 0.09283 0.11965 0.03532 0.10779 0.03363 
69 0.17246 0.09283 0.11965 0.03532 0.10779 0.03363 
70 0.17246 0.09283 0.11965 0.03532 0.10779 0.03363 
71 0.17246 0.09283 0.11965 0.03532 0.10779 0.03363 
72 0.17246 0.09283 0.11965 0.03532 0.10779 0.03363 
73 0.17246 0.09283 0.11965 0.03532 0.10779 0.03363 
74 0.17246 0.09283 0.11965 0.03532 0.10779 0.03363 
75 0.17463 0.09811 0.12115 0.03732 0.10914 0.03555 
76 0.17463 0.09811 0.12115 0.03732 0.10914 0.03555 
77 0.17463 0.09811 0.12115 0.03732 0.10914 0.03555 
78 0.17463 0.09811 0.12115 0.03732 0.10914 0.03555 
79 0.17463 0.09811 0.12115 0.03732 0.10914 0.03555 
80 0.17463 0.09811 0.12115 0.03732 0.10914 0.03555 
81 0.17463 0.09811 0.12115 0.03732 0.10914 0.03555 
82 0.17463 0.09811 0.12115 0.03732 0.10914 0.03555 
83 0.17463 0.09811 0.12115 0.03732 0.10914 0.03555 
84 0.17463 0.09811 0.12115 0.03732 0.10914 0.03555 
85 0.17463 0.09811 0.12115 0.03732 0.10914 0.03555 
86 0.17463 0.09811 0.12115 0.03732 0.10914 0.03555 
87 0.17463 0.09811 0.12115 0.03732 0.10914 0.03555 
88 0.17463 0.09811 0.12115 0.03732 0.10914 0.03555 
89 0.17463 0.09811 0.12115 0.03732 0.10914 0.03555 
90 0.17463 0.09811 0.12115 0.03732 0.10914 0.03555 
91 0.17463 0.09811 0.12115 0.03732 0.10914 0.03555 
92 0.17463 0.09811 0.12115 0.03732 0.10914 0.03555 
93 0.17463 0.09811 0.12115 0.03732 0.10914 0.03555 
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Smokers Former Smokers Non-smokers 
Men Women Men Women Men Women 
94 0.17463 0.09811 0.12115 0.03732 0.10914 0.03555 
95 0.17463 0.09811 0.12115 0.03732 0.10914 0.03555 
96 0.17463 0.09811 0.12115 0.03732 0.10914 0.03555 
97 0.17463 0.09811 0.12115 0.03732 0.10914 0.03555 
98 0.17463 0.09811 0.12115 0.03732 0.10914 0.03555 
99 0.17463 0.09811 0.12115 0.03732 0.10914 0.03555 
100 0.17463 0.09811 0.12115 0.03732 0.10914 0.03555 
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Appendix 4.10.5 Stroke 
 
Appendix 4.10.5.1 Prevalence of stroke 
Age Prevalence 
16-24 0.00% 
25-34 0.00% 
35-44 0.30% 
45-54 1.20% 
55-64 2.20% 
65-74 7.60% 
75+ 13.30% 
 
Appendix 4.10.5.2 Relative risk of stroke by smoking status 
Smokers Former smokers Non-smokers 
1.37 1.11 1 
 
Appendix 4.10.5.3 Prevalence of stroke by smoking status, age and gender 
Age 
 
Smokers Former Smokers Non-smokers 
Men Women Men Women Men Women 
16 0.00125 0.00246 0.00101 0.00199 0.00091 0.00179 
17 0.00125 0.00246 0.00101 0.00199 0.00091 0.00179 
18 0.00125 0.00246 0.00101 0.00199 0.00091 0.00179 
19 0.00125 0.00246 0.00101 0.00199 0.00091 0.00179 
20 0.00125 0.00246 0.00101 0.00199 0.00091 0.00179 
21 0.00125 0.00246 0.00101 0.00199 0.00091 0.00179 
22 0.00125 0.00246 0.00101 0.00199 0.00091 0.00179 
23 0.00125 0.00246 0.00101 0.00199 0.00091 0.00179 
24 0.00125 0.00246 0.00101 0.00199 0.00091 0.00179 
25 0.00475 0.00367 0.00385 0.00297 0.00347 0.00268 
26 0.00475 0.00367 0.00385 0.00297 0.00347 0.00268 
27 0.00475 0.00367 0.00385 0.00297 0.00347 0.00268 
28 0.00475 0.00367 0.00385 0.00297 0.00347 0.00268 
29 0.00475 0.00367 0.00385 0.00297 0.00347 0.00268 
30 0.00475 0.00367 0.00385 0.00297 0.00347 0.00268 
31 0.00475 0.00367 0.00385 0.00297 0.00347 0.00268 
32 0.00475 0.00367 0.00385 0.00297 0.00347 0.00268 
33 0.00475 0.00367 0.00385 0.00297 0.00347 0.00268 
34 0.00475 0.00367 0.00385 0.00297 0.00347 0.00268 
35 0.00367 0.00734 0.00297 0.00595 0.00268 0.00536 
36 0.00367 0.00734 0.00297 0.00595 0.00268 0.00536 
37 0.00367 0.00734 0.00297 0.00595 0.00268 0.00536 
38 0.00367 0.00734 0.00297 0.00595 0.00268 0.00536 
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Age 
 
Smokers Former Smokers Non-smokers 
Men Women Men Women Men Women 
39 0.00367 0.00734 0.00297 0.00595 0.00268 0.00536 
40 0.00367 0.00734 0.00297 0.00595 0.00268 0.00536 
41 0.00367 0.00734 0.00297 0.00595 0.00268 0.00536 
42 0.00367 0.00734 0.00297 0.00595 0.00268 0.00536 
43 0.00367 0.00734 0.00297 0.00595 0.00268 0.00536 
44 0.00367 0.00734 0.00297 0.00595 0.00268 0.00536 
45 0.01459 0.01103 0.01182 0.00894 0.01065 0.00805 
46 0.01459 0.01103 0.01182 0.00894 0.01065 0.00805 
47 0.01459 0.01103 0.01182 0.00894 0.01065 0.00805 
48 0.01459 0.01103 0.01182 0.00894 0.01065 0.00805 
49 0.01459 0.01103 0.01182 0.00894 0.01065 0.00805 
50 0.01459 0.01103 0.01182 0.00894 0.01065 0.00805 
51 0.01459 0.01103 0.01182 0.00894 0.01065 0.00805 
52 0.01459 0.01103 0.01182 0.00894 0.01065 0.00805 
53 0.01459 0.01103 0.01182 0.00894 0.01065 0.00805 
54 0.01459 0.01103 0.01182 0.00894 0.01065 0.00805 
55 0.02691 0.03095 0.02181 0.02507 0.01965 0.02259 
56 0.02691 0.03095 0.02181 0.02507 0.01965 0.02259 
57 0.02691 0.03095 0.02181 0.02507 0.01965 0.02259 
58 0.02691 0.03095 0.02181 0.02507 0.01965 0.02259 
59 0.02691 0.03095 0.02181 0.02507 0.01965 0.02259 
60 0.02691 0.03095 0.02181 0.02507 0.01965 0.02259 
61 0.02691 0.03095 0.02181 0.02507 0.01965 0.02259 
62 0.02691 0.03095 0.02181 0.02507 0.01965 0.02259 
63 0.02691 0.03095 0.02181 0.02507 0.01965 0.02259 
64 0.02691 0.03095 0.02181 0.02507 0.01965 0.02259 
65 0.09473 0.06840 0.07675 0.05542 0.06914 0.04993 
66 0.09473 0.06840 0.07675 0.05542 0.06914 0.04993 
67 0.09473 0.06840 0.07675 0.05542 0.06914 0.04993 
68 0.09473 0.06840 0.07675 0.05542 0.06914 0.04993 
69 0.09473 0.06840 0.07675 0.05542 0.06914 0.04993 
70 0.09473 0.06840 0.07675 0.05542 0.06914 0.04993 
71 0.09473 0.06840 0.07675 0.05542 0.06914 0.04993 
72 0.09473 0.06840 0.07675 0.05542 0.06914 0.04993 
73 0.09473 0.06840 0.07675 0.05542 0.06914 0.04993 
74 0.09473 0.06840 0.07675 0.05542 0.06914 0.04993 
75 0.16675 0.11377 0.13510 0.09218 0.12172 0.08304 
76 0.16675 0.11377 0.13510 0.09218 0.12172 0.08304 
77 0.16675 0.11377 0.13510 0.09218 0.12172 0.08304 
78 0.16675 0.11377 0.13510 0.09218 0.12172 0.08304 
79 0.16675 0.11377 0.13510 0.09218 0.12172 0.08304 
80 0.16675 0.11377 0.13510 0.09218 0.12172 0.08304 
81 0.16675 0.11377 0.13510 0.09218 0.12172 0.08304 
82 0.16675 0.11377 0.13510 0.09218 0.12172 0.08304 
83 0.16675 0.11377 0.13510 0.09218 0.12172 0.08304 
84 0.16675 0.11377 0.13510 0.09218 0.12172 0.08304 
85 0.16675 0.11377 0.13510 0.09218 0.12172 0.08304 
86 0.16675 0.11377 0.13510 0.09218 0.12172 0.08304 
87 0.16675 0.11377 0.13510 0.09218 0.12172 0.08304 
88 0.16675 0.11377 0.13510 0.09218 0.12172 0.08304 
89 0.16675 0.11377 0.13510 0.09218 0.12172 0.08304 
90 0.16675 0.11377 0.13510 0.09218 0.12172 0.08304 
91 0.16675 0.11377 0.13510 0.09218 0.12172 0.08304 
92 0.16675 0.11377 0.13510 0.09218 0.12172 0.08304 
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Age 
 
Smokers Former Smokers Non-smokers 
Men Women Men Women Men Women 
93 0.16675 0.11377 0.13510 0.09218 0.12172 0.08304 
94 0.16675 0.11377 0.13510 0.09218 0.12172 0.08304 
95 0.16675 0.11377 0.13510 0.09218 0.12172 0.08304 
96 0.16675 0.11377 0.13510 0.09218 0.12172 0.08304 
97 0.16675 0.11377 0.13510 0.09218 0.12172 0.08304 
98 0.16675 0.11377 0.13510 0.09218 0.12172 0.08304 
99 0.16675 0.11377 0.13510 0.09218 0.12172 0.08304 
100 0.16675 0.11377 0.13510 0.09218 0.12172 0.08304 
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Appendix 5.1  Search strategy and search terms of passive smoking health effects 
and mortality review 
 
Search strategy 
An established search protocol was used to identify reviews and meta-analysis of risk 
and mortality of health effects caused by passive smoking. The decision to restrict this 
to reviews was taken to avoid the maximum variability among estimates, and to 
introduce sensible average values in the model. Comprehensive searches were 
conducted using bibliographic databases, bibliographies of relevant reviews and internet 
sites for epidemiological data on passive smoking in Europe, US and UK. Searches 
were carried out on May 2009, and involved 3 electronic databases (MEDLINE -Ovid 
and Pubmed-, Cochrane Library -Wiley Internet version-, and Office of Health 
Economics Health Economic Evaluation Database –HEED). The World Health 
Organization (WHO), The Office of Surgeon General US, the Centers for Disease 
Control and Prevention, and the Information Centre of NHS sites were also consulted 
by email. This search was restricted to English language, humans, review papers, and 
without time restrictions and included a combination of text words. The free text terms 
were “passive smoking”, “environmental tobacco smoke”, “second hand smoke”, 
“second-hand smoke”, “secondhand smoke”, “indoor air pollution” and “air pollution”. 
Only the Cochrane reviews results were considered for revision. Search terms were 
contrived to retrieve papers on risk and mortality of passive smoking health effects.  
 
Databases 
Cochrane Library 
Cochrane Database of Systematic Reviews 
 
World Health Organization (Internet access) 
European data on tobacco (http://data.euro.who.int/tobacco/) 
 
 US  Department of Health & Human Services (Internet access) 
Office of the Surgeon general – data on smoking consequences  
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(http://www.surgeongeneral.gov/library/smokingconsequences/) 
 
Centers for Disease Control and Prevention (Internet access) 
Statistics on smoking  
(http://www.cdc.gov/tobacco/data_statistics/sgr/sgr_2006/index.htm) 
 
NHS The Information Centre for health and social care 
Publications on smoking (http://www.ic.nhs.uk/pubs/smoking08) 
 
Bibliographic database 
MEDLINE (Ovid and Pubmed) – systematic review 
Office of Health Economics Health Economic Evaluation Database (HEED) 
 
 
Search terms 
 
Source - Cochrane Library (Wiley) 
#1  “passive smoking in Title, Abstract or Keywords or environmental tobacco smoke 
in Title, Abstract or Keywords or secondhand smoke in Title, Abstract or Keywords or 
second hand smoke in Title, Abstract or Keywords or indoor air pollution in Title, 
Abstract or Keywords in Cochrane Database of Systematic Reviews” 
10 
 
Source - Health Economic Evaluation Database 
#1  passive smoking and review  
4 
#2  environmental tobacco smoke and review 
1 
#3  secondhand smoke and review 
0 
#4  second-hand smoke and review 
0 
#5  second hand smoke and review 
0 
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#6  indoor air pollution and review 
0 
Not possible to limit the search to English language and humans. Restricted search to all 
type of data. Not possible to restrict it to title abstract & key words. 
 
Source Ovid MEDLINE 2000 to August 2009 
1 Passive smoking.mp.or Tobacco Smoke Pollution (7839) 
2 Environmental tobacco smoke.mp. (2273) 
3 Second hand smoke or second-hand smoke or secondhand smoke).mp. [mp=title, 
original title, abstract, name of substance word, subject heading word] (725) 
4 Indoor air pollution.mp. or Air Pollution, Indoor (6862) 
5 4 or 1 or 3 or 2 (14851) 
6 Limit 5 to (English language and humans) (10605) 
7 Limit 6 to “review articles” (1413) 
All titles and abstracts were screened for relevance. Full paper copies of any titles or 
abstracts judged of potential relevance were obtained. The relevance of each full 
abstract was assessed. Studies that failed to satisfy all criteria were excluded and the 
reason for their exclusion recorded. References from searched papers were scrutinized 
to add relevant references to the search. If no papers were found related either to clinical 
effects or mortality, experts on smoking in UK suggested data sources. 
 
Study selection criteria  
A selected paper had to satisfy all the requirements of the following criteria: (a) to 
present meta-analytic data or pooled data on relative risks or odds ratios of clinical 
effects on human due to passive smoking; (b) to estimate the causes of mortality among 
adults passive smokers who have never smoked; (c) be written in English, because there 
were no resources for translations. Studies were excluded if the data they reported were 
updated in other papers published in following years or if the epidemiological evidence 
was reported as not strong enough for clear conclusions.                    
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Data extraction strategy 
Data were extracted into two summary tables: one to describe the important health 
effects of passive smoking in adults and the other to describe the health effects for 
children. 
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Appendix 5.2 Study selection process of systematic review for passive smoking 
health effects  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* 6 articles were included from the literature review and 6 papers were added from experts’ recommendations 
2319 titles and abstracts identified 
Medline (Ovid)           1413 
Medline (Pubmed)                        886 
HEED                  5 
Cochrane Library                                15 
700 excluded for duplication: 
Medline Ovid                      115 
Medline Pubmed                                      584 
HEED                      1 
1414 excluded because: 
 
Not smoking related                                  597 
Related to smoking but                                241 
not to passive smoking 
Not reporting quantitative                           538  
epidemiological data on  
passive smoking 
Reporting quantitative                    21  
epidemiological data on passive  
smoking, but at workplace 
Not found                    17 
1619 Potentially relevant titles & abstracts 
identified 
Medline Ovid            1298 
Medline Pubmed                        302 
HEED                 15 
Cochrane Library                                  4 
 
205 articles retrieved for more detailed evaluation  
Medline Ovid                152 
Medline Pubmed                          46 
HEED                     2 
Cochrane Library                                     5 
 
12*  articles included 
199 excluded because: 
 
Not meta or pooled data 
Not relevant data 
Data updated 
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Appendix 5.3 References included in the systematic literature search of health 
effects of passive smoking 
 
 
Barnoya J, Glantz SA. Cardiovascular effects of second-hand smoke. Nearly as large as 
smoking. Circulation, 2005;111:2684-2698. 
 
Cook DG, Strachan DP. Summary of effects of parental smoking on the respiratory 
health of children and implications for research. Thorax, 1999; 54(4):357-366. 
 
Hackshaw AK, Law MR, Wald NJ. The accumulated evidence on lung cancer and 
environmental tobacco smoke. British Medical Journal, 1997; 315(7114):980-988. 
 
He J, Vupputuri S, Allen K, Prerost MR, Hughes J, Whelton PK. Passive smoking and 
the risk of coronary heart disease – a meta-analysis of the epidemiologic studies. The 
New England Journal of Medicine, 1999; 340(12): 920-926. 
 
Law MR, Morris JK, Wald NJ. Environmental tobacco smoke exposure and ischaemic 
heart disease: an evaluation of the evidence. British Medical Journal, 1997; 315:973-
980. 
 
Leonardi-Bee J, Smyth A, Britton J, Coleman T. Environmental tobacco smoke and 
fetal health: systematic review and meta-analysis. Archives of Disease Children Fetal 
Neonatal, 2008; 93:F351-F361. 
 
Li JSM, Peat JK, Xuan W, Berry G. Meta-analysis on the association between 
environmental tobacco smoke (ETS) exposure and the prevalence of lower respiratory 
tract infection in early childhood. Pediatric Pulmonology, 1999; 27:5-13.  
 
Pattenden S, Antova T, Neuberger M, Nikiforov B, De Sario M, Grize L, Heinrich J, 
Hruba F, Janssen N, Luttmann-Gibson H, Privalova L, Rudnai P, Splichalova A, 
Zlotkowska R, Fletcher T. Parental smoking and children’s respiratory health: 
independent effects of prenatal and postnatal exposure. Tobacco control, 2006; 15:294-
301. 
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Scientific Committee on Tobacco and Health (SCOTH). Secondhand Smoke: Review of 
evidence since 1998. Update of evidence on health effects of secondhand smoke. UK: 
Department of Health, 2004. 
 
Taylor R, Najafi F, Dobson A. Meta-analysis of studies of passive smoking and lung 
cancer: effects of study type and continent. International Journal of Epidemiology, 
2007;36(5):1048-1059. 
 
Thun M, Henley J, Apicella L. Epidemiologic studies of fatal and nonfatal 
cardiovascular disease and ETS exposure from spousal smoking. Environmental Health 
Perspectives, 1999; 107(6):841-846. 
 
Uhari M,  Mäntysaari K, Niemelä M. A meta-analytic review of the risk factors for 
acute otitis media. Clinical Infectious Diseases, 1996; 22(6):1079-1083.  
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Appendix 5.4 Mortality transition probabilities for smokers, former smokers, 
never smokers’ non passive and passive 
 
Age Smokers Former smokers Never smokers non passive Never smokers passive 
Men Women Men Women Men Women Men Women 
16 0.000068 0.000059 0.000030 0.000012 1.962085E-06 2.865111E-06 2.432986E-06 3.552737E-06 
16.5 0.000068 0.000059 0.000030 0.000012 1.962085E-06 2.865111E-06 2.432986E-06 3.552737E-06 
17 0.000068 0.000059 0.000030 0.000012 1.962085E-06 2.865111E-06 2.432986E-06 3.552737E-06 
17.5 0.000068 0.000059 0.000030 0.000012 1.962085E-06 2.865111E-06 2.432986E-06 3.552737E-06 
18 0.000068 0.000059 0.000030 0.000012 1.962085E-06 2.865111E-06 2.432986E-06 3.552737E-06 
18.5 0.000068 0.000059 0.000030 0.000012 1.962085E-06 2.865111E-06 2.432986E-06 3.552737E-06 
19 0.000068 0.000059 0.000030 0.000012 1.962085E-06 2.865111E-06 2.432986E-06 3.552737E-06 
19.5 0.000068 0.000059 0.000030 0.000012 1.962085E-06 2.865111E-06 2.432986E-06 3.552737E-06 
20 0.000068 0.000059 0.000030 0.000012 1.962085E-06 2.865111E-06 2.432986E-06 3.552737E-06 
20.5 0.000068 0.000059 0.000030 0.000012 1.962085E-06 2.865111E-06 2.432986E-06 3.552737E-06 
21 0.000068 0.000059 0.000030 0.000012 1.962085E-06 2.865111E-06 2.432986E-06 3.552737E-06 
21.5 0.000068 0.000059 0.000030 0.000012 1.962085E-06 2.865111E-06 2.432986E-06 3.552737E-06 
22 0.000068 0.000059 0.000030 0.000012 1.962085E-06 2.865111E-06 2.432986E-06 3.552737E-06 
22.5 0.000068 0.000059 0.000030 0.000012 1.962085E-06 2.865111E-06 2.432986E-06 3.552737E-06 
23 0.000068 0.000059 0.000030 0.000012 1.962085E-06 2.865111E-06 2.432986E-06 3.552737E-06 
23.5 0.000068 0.000059 0.000030 0.000012 1.962085E-06 2.865111E-06 2.432986E-06 3.552737E-06 
24 0.000068 0.000059 0.000030 0.000012 1.962085E-06 2.865111E-06 2.432986E-06 3.552737E-06 
24.5 0.000068 0.000059 0.000030 0.000012 1.962085E-06 2.865111E-06 2.432986E-06 3.552737E-06 
25 0.000045 0.000059 0.000020 0.000012 1.322742E-06 2.885844E-06 1.640200E-06 3.578447E-06 
25.5 0.000045 0.000059 0.000020 0.000012 1.322742E-06 2.885844E-06 1.640200E-06 3.578447E-06 
26 0.000045 0.000059 0.000020 0.000012 1.322742E-06 2.885844E-06 1.640200E-06 3.578447E-06 
26.5 0.000045 0.000059 0.000020 0.000012 1.322742E-06 2.885844E-06 1.640200E-06 3.578447E-06 
27 0.000045 0.000059 0.000020 0.000012 1.322742E-06 2.885844E-06 1.640200E-06 3.578447E-06 
27.5 0.000045 0.000059 0.000020 0.000012 1.322742E-06 2.885844E-06 1.640200E-06 3.578447E-06 
28 0.000045 0.000059 0.000020 0.000012 1.322742E-06 2.885844E-06 1.640200E-06 3.578447E-06 
28.5 0.000045 0.000059 0.000020 0.000012 1.322742E-06 2.885844E-06 1.640200E-06 3.578447E-06 
29 0.000045 0.000059 0.000020 0.000012 1.322742E-06 2.885844E-06 1.640200E-06 3.578447E-06 
29.5 0.000045 0.000059 0.000020 0.000012 1.322742E-06 2.885844E-06 1.640200E-06 3.578447E-06 
30 0.000045 0.000059 0.000020 0.000012 1.322742E-06 2.885844E-06 1.640200E-06 3.578447E-06 
30.5 0.000045 0.000059 0.000020 0.000012 1.322742E-06 2.885844E-06 1.640200E-06 3.578447E-06 
31 0.000045 0.000059 0.000020 0.000012 1.322742E-06 2.885844E-06 1.640200E-06 3.578447E-06 
31.5 0.000045 0.000059 0.000020 0.000012 1.322742E-06 2.885844E-06 1.640200E-06 3.578447E-06 
32 0.000045 0.000059 0.000020 0.000012 1.322742E-06 2.885844E-06 1.640200E-06 3.578447E-06 
32.5 0.000045 0.000059 0.000020 0.000012 1.322742E-06 2.885844E-06 1.640200E-06 3.578447E-06 
33 0.000045 0.000059 0.000020 0.000012 1.322742E-06 2.885844E-06 1.640200E-06 3.578447E-06 
33.5 0.000045 0.000059 0.000020 0.000012 1.322742E-06 2.885844E-06 1.640200E-06 3.578447E-06 
34 0.000045 0.000059 0.000020 0.000012 1.322742E-06 2.885844E-06 1.640200E-06 3.578447E-06 
34.5 0.000045 0.000059 0.000020 0.000012 1.322742E-06 2.885844E-06 1.640200E-06 3.578447E-06 
35 0.000054 0.000060 0.000024 0.000013 1.612977E-06 2.928342E-06 2.000091E-06 3.631144E-06 
35.5 0.000054 0.000060 0.000024 0.000013 1.612977E-06 2.928342E-06 2.000091E-06 3.631144E-06 
36 0.000054 0.000060 0.000024 0.000013 1.612977E-06 2.928342E-06 2.000091E-06 3.631144E-06 
36.5 0.000054 0.000060 0.000024 0.000013 1.612977E-06 2.928342E-06 2.000091E-06 3.631144E-06 
37 0.000054 0.000060 0.000024 0.000013 1.612977E-06 2.928342E-06 2.000091E-06 3.631144E-06 
37.5 0.000054 0.000060 0.000024 0.000013 1.612977E-06 2.928342E-06 2.000091E-06 3.631144E-06 
38 0.000054 0.000060 0.000024 0.000013 1.612977E-06 2.928342E-06 2.000091E-06 3.631144E-06 
38.5 0.000054 0.000060 0.000024 0.000013 1.612977E-06 2.928342E-06 2.000091E-06 3.631144E-06 
39 0.000054 0.000060 0.000024 0.000013 1.612977E-06 2.928342E-06 2.000091E-06 3.631144E-06 
39.5 0.000054 0.000060 0.000024 0.000013 1.612977E-06 2.928342E-06 2.000091E-06 3.631144E-06 
40 0.000054 0.000060 0.000024 0.000013 1.612977E-06 2.928342E-06 2.000091E-06 3.631144E-06 
40.5 0.000054 0.000060 0.000024 0.000013 1.612977E-06 2.928342E-06 2.000091E-06 3.631144E-06 
41 0.000054 0.000060 0.000024 0.000013 1.612977E-06 2.928342E-06 2.000091E-06 3.631144E-06 
41.5 0.000054 0.000060 0.000024 0.000013 1.612977E-06 2.928342E-06 2.000091E-06 3.631144E-06 
42 0.000054 0.000060 0.000024 0.000013 1.612977E-06 2.928342E-06 2.000091E-06 3.631144E-06 
42.5 0.000054 0.000060 0.000024 0.000013 1.612977E-06 2.928342E-06 2.000091E-06 3.631144E-06 
43 0.000054 0.000060 0.000024 0.000013 1.612977E-06 2.928342E-06 2.000091E-06 3.631144E-06 
43.5 0.000054 0.000060 0.000024 0.000013 1.612977E-06 2.928342E-06 2.000091E-06 3.631144E-06 
44 0.000054 0.000060 0.000024 0.000013 1.612977E-06 2.928342E-06 2.000091E-06 3.631144E-06 
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Age Smokers Former smokers Never smokers non passive Never smokers passive 
Men Women Men Women Men Women Men Women 
44.5 0.000054 0.000060 0.000024 0.000013 1.612977E-06 2.928342E-06 2.000091E-06 3.631144E-06 
45 0.003871 0.002117 0.001703 0.000445 1.143538E-04 1.043277E-04 1.417988E-04 1.293664E-04 
45.5 0.003871 0.002117 0.001703 0.000445 1.143538E-04 1.043277E-04 1.417988E-04 1.293664E-04 
46 0.003871 0.002117 0.001703 0.000445 1.143538E-04 1.043277E-04 1.417988E-04 1.293664E-04 
46.5 0.003871 0.002117 0.001703 0.000445 1.143538E-04 1.043277E-04 1.417988E-04 1.293664E-04 
47 0.003871 0.002117 0.001703 0.000445 1.143538E-04 1.043277E-04 1.417988E-04 1.293664E-04 
47.5 0.003871 0.002117 0.001703 0.000445 1.143538E-04 1.043277E-04 1.417988E-04 1.293664E-04 
48 0.003871 0.002117 0.001703 0.000445 1.143538E-04 1.043277E-04 1.417988E-04 1.293664E-04 
48.5 0.003871 0.002117 0.001703 0.000445 1.143538E-04 1.043277E-04 1.417988E-04 1.293664E-04 
49 0.003871 0.002117 0.001703 0.000445 1.143538E-04 1.043277E-04 1.417988E-04 1.293664E-04 
49.5 0.003871 0.002117 0.001703 0.000445 1.143538E-04 1.043277E-04 1.417988E-04 1.293664E-04 
50 0.003871 0.002117 0.001703 0.000445 1.143538E-04 1.043277E-04 1.417988E-04 1.293664E-04 
50.5 0.003871 0.002117 0.001703 0.000445 1.143538E-04 1.043277E-04 1.417988E-04 1.293664E-04 
51 0.003871 0.002117 0.001703 0.000445 1.143538E-04 1.043277E-04 1.417988E-04 1.293664E-04 
51.5 0.003871 0.002117 0.001703 0.000445 1.143538E-04 1.043277E-04 1.417988E-04 1.293664E-04 
52 0.003871 0.002117 0.001703 0.000445 1.143538E-04 1.043277E-04 1.417988E-04 1.293664E-04 
52.5 0.003871 0.002117 0.001703 0.000445 1.143538E-04 1.043277E-04 1.417988E-04 1.293664E-04 
53 0.003871 0.002117 0.001703 0.000445 1.143538E-04 1.043277E-04 1.417988E-04 1.293664E-04 
53.5 0.003871 0.002117 0.001703 0.000445 1.143538E-04 1.043277E-04 1.417988E-04 1.293664E-04 
54 0.003871 0.002117 0.001703 0.000445 1.143538E-04 1.043277E-04 1.417988E-04 1.293664E-04 
54.5 0.003871 0.002117 0.001703 0.000445 1.143538E-04 1.043277E-04 1.417988E-04 1.293664E-04 
55 0.003879 0.002396 0.001707 0.000503 1.148048E-04 1.185546E-04 1.423580E-04 1.470077E-04 
55.5 0.003879 0.002396 0.001707 0.000503 1.148048E-04 1.185546E-04 1.423580E-04 1.470077E-04 
56 0.003879 0.002396 0.001707 0.000503 1.148048E-04 1.185546E-04 1.423580E-04 1.470077E-04 
56.5 0.003879 0.002396 0.001707 0.000503 1.148048E-04 1.185546E-04 1.423580E-04 1.470077E-04 
57 0.003879 0.002396 0.001707 0.000503 1.148048E-04 1.185546E-04 1.423580E-04 1.470077E-04 
57.5 0.003879 0.002396 0.001707 0.000503 1.148048E-04 1.185546E-04 1.423580E-04 1.470077E-04 
58 0.003879 0.002396 0.001707 0.000503 1.148048E-04 1.185546E-04 1.423580E-04 1.470077E-04 
58.5 0.003879 0.002396 0.001707 0.000503 1.148048E-04 1.185546E-04 1.423580E-04 1.470077E-04 
59 0.003879 0.002396 0.001707 0.000503 1.148048E-04 1.185546E-04 1.423580E-04 1.470077E-04 
59.5 0.003879 0.002396 0.001707 0.000503 1.148048E-04 1.185546E-04 1.423580E-04 1.470077E-04 
60 0.003879 0.002396 0.001707 0.000503 1.148048E-04 1.185546E-04 1.423580E-04 1.470077E-04 
60.5 0.003879 0.002396 0.001707 0.000503 1.148048E-04 1.185546E-04 1.423580E-04 1.470077E-04 
61 0.003879 0.002396 0.001707 0.000503 1.148048E-04 1.185546E-04 1.423580E-04 1.470077E-04 
61.5 0.003879 0.002396 0.001707 0.000503 1.148048E-04 1.185546E-04 1.423580E-04 1.470077E-04 
62 0.003879 0.002396 0.001707 0.000503 1.148048E-04 1.185546E-04 1.423580E-04 1.470077E-04 
62.5 0.003879 0.002396 0.001707 0.000503 1.148048E-04 1.185546E-04 1.423580E-04 1.470077E-04 
63 0.003879 0.002396 0.001707 0.000503 1.148048E-04 1.185546E-04 1.423580E-04 1.470077E-04 
63.5 0.003879 0.002396 0.001707 0.000503 1.148048E-04 1.185546E-04 1.423580E-04 1.470077E-04 
64 0.003879 0.002396 0.001707 0.000503 1.148048E-04 1.185546E-04 1.423580E-04 1.470077E-04 
64.5 0.003879 0.002396 0.001707 0.000503 1.148048E-04 1.185546E-04 1.423580E-04 1.470077E-04 
65 0.022434 0.010255 0.009871 0.002154 6.678525E-04 5.081599E-04 8.281371E-04 6.301182E-04 
65.5 0.022434 0.010255 0.009871 0.002154 6.678525E-04 5.081599E-04 8.281371E-04 6.301182E-04 
66 0.022434 0.010255 0.009871 0.002154 6.678525E-04 5.081599E-04 8.281371E-04 6.301182E-04 
66.5 0.022434 0.010255 0.009871 0.002154 6.678525E-04 5.081599E-04 8.281371E-04 6.301182E-04 
67 0.022434 0.010255 0.009871 0.002154 6.678525E-04 5.081599E-04 8.281371E-04 6.301182E-04 
67.5 0.022434 0.010255 0.009871 0.002154 6.678525E-04 5.081599E-04 8.281371E-04 6.301182E-04 
68 0.022434 0.010255 0.009871 0.002154 6.678525E-04 5.081599E-04 8.281371E-04 6.301182E-04 
68.5 0.022434 0.010255 0.009871 0.002154 6.678525E-04 5.081599E-04 8.281371E-04 6.301182E-04 
69 0.022434 0.010255 0.009871 0.002154 6.678525E-04 5.081599E-04 8.281371E-04 6.301182E-04 
69.5 0.022434 0.010255 0.009871 0.002154 6.678525E-04 5.081599E-04 8.281371E-04 6.301182E-04 
70 0.022434 0.010255 0.009871 0.002154 6.678525E-04 5.081599E-04 8.281371E-04 6.301182E-04 
70.5 0.022434 0.010255 0.009871 0.002154 6.678525E-04 5.081599E-04 8.281371E-04 6.301182E-04 
71 0.022434 0.010255 0.009871 0.002154 6.678525E-04 5.081599E-04 8.281371E-04 6.301182E-04 
71.5 0.022434 0.010255 0.009871 0.002154 6.678525E-04 5.081599E-04 8.281371E-04 6.301182E-04 
72 0.022434 0.010255 0.009871 0.002154 6.678525E-04 5.081599E-04 8.281371E-04 6.301182E-04 
72.5 0.022434 0.010255 0.009871 0.002154 6.678525E-04 5.081599E-04 8.281371E-04 6.301182E-04 
73 0.022434 0.010255 0.009871 0.002154 6.678525E-04 5.081599E-04 8.281371E-04 6.301182E-04 
73.5 0.022434 0.010255 0.009871 0.002154 6.678525E-04 5.081599E-04 8.281371E-04 6.301182E-04 
74 0.022434 0.010255 0.009871 0.002154 6.678525E-04 5.081599E-04 8.281371E-04 6.301182E-04 
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Age Smokers Former smokers Never smokers non passive Never smokers passive 
Men Women Men Women Men Women Men Women 
74.5 0.022434 0.010255 0.009871 0.002154 6.678525E-04 5.081599E-04 8.281371E-04 6.301182E-04 
75 0.022989 0.011848 0.010115 0.002488 6.843569E-04 5.840074E-04 8.486026E-04 7.241691E-04 
75.5 0.022989 0.011848 0.010115 0.002488 6.843569E-04 5.840074E-04 8.486026E-04 7.241691E-04 
76 0.022989 0.011848 0.010115 0.002488 6.843569E-04 5.840074E-04 8.486026E-04 7.241691E-04 
76.5 0.022989 0.011848 0.010115 0.002488 6.843569E-04 5.840074E-04 8.486026E-04 7.241691E-04 
77 0.022989 0.011848 0.010115 0.002488 6.843569E-04 5.840074E-04 8.486026E-04 7.241691E-04 
77.5 0.022989 0.011848 0.010115 0.002488 6.843569E-04 5.840074E-04 8.486026E-04 7.241691E-04 
78 0.022989 0.011848 0.010115 0.002488 6.843569E-04 5.840074E-04 8.486026E-04 7.241691E-04 
78.5 0.022989 0.011848 0.010115 0.002488 6.843569E-04 5.840074E-04 8.486026E-04 7.241691E-04 
79 0.022989 0.011848 0.010115 0.002488 6.843569E-04 5.840074E-04 8.486026E-04 7.241691E-04 
79.5 0.022989 0.011848 0.010115 0.002488 6.843569E-04 5.840074E-04 8.486026E-04 7.241691E-04 
80 0.022989 0.011848 0.010115 0.002488 6.843569E-04 5.840074E-04 8.486026E-04 7.241691E-04 
80.5 0.022989 0.011848 0.010115 0.002488 6.843569E-04 5.840074E-04 8.486026E-04 7.241691E-04 
81 0.022989 0.011848 0.010115 0.002488 6.843569E-04 5.840074E-04 8.486026E-04 7.241691E-04 
81.5 0.022989 0.011848 0.010115 0.002488 6.843569E-04 5.840074E-04 8.486026E-04 7.241691E-04 
82 0.022989 0.011848 0.010115 0.002488 6.843569E-04 5.840074E-04 8.486026E-04 7.241691E-04 
82.5 0.022989 0.011848 0.010115 0.002488 6.843569E-04 5.840074E-04 8.486026E-04 7.241691E-04 
83 0.022989 0.011848 0.010115 0.002488 6.843569E-04 5.840074E-04 8.486026E-04 7.241691E-04 
83.5 0.022989 0.011848 0.010115 0.002488 6.843569E-04 5.840074E-04 8.486026E-04 7.241691E-04 
84 0.022989 0.011848 0.010115 0.002488 6.843569E-04 5.840074E-04 8.486026E-04 7.241691E-04 
84.5 0.022989 0.011848 0.010115 0.002488 6.843569E-04 5.840074E-04 8.486026E-04 7.241691E-04 
85 0.022989 0.011848 0.010115 0.002488 6.843569E-04 5.840074E-04 8.486026E-04 7.241691E-04 
85.5 0.022989 0.011848 0.010115 0.002488 6.843569E-04 5.840074E-04 8.486026E-04 7.241691E-04 
86 0.022989 0.011848 0.010115 0.002488 6.843569E-04 5.840074E-04 8.486026E-04 7.241691E-04 
86.5 0.022989 0.011848 0.010115 0.002488 6.843569E-04 5.840074E-04 8.486026E-04 7.241691E-04 
87 0.022989 0.011848 0.010115 0.002488 6.843569E-04 5.840074E-04 8.486026E-04 7.241691E-04 
87.5 0.022989 0.011848 0.010115 0.002488 6.843569E-04 5.840074E-04 8.486026E-04 7.241691E-04 
88 0.022989 0.011848 0.010115 0.002488 6.843569E-04 5.840074E-04 8.486026E-04 7.241691E-04 
88.5 0.022989 0.011848 0.010115 0.002488 6.843569E-04 5.840074E-04 8.486026E-04 7.241691E-04 
89 0.022989 0.011848 0.010115 0.002488 6.843569E-04 5.840074E-04 8.486026E-04 7.241691E-04 
89.5 0.022989 0.011848 0.010115 0.002488 6.843569E-04 5.840074E-04 8.486026E-04 7.241691E-04 
90 0.022989 0.011848 0.010115 0.002488 6.843569E-04 5.840074E-04 8.486026E-04 7.241691E-04 
90.5 0.022989 0.011848 0.010115 0.002488 6.843569E-04 5.840074E-04 8.486026E-04 7.241691E-04 
91 0.022989 0.011848 0.010115 0.002488 6.843569E-04 5.840074E-04 8.486026E-04 7.241691E-04 
91.5 0.022989 0.011848 0.010115 0.002488 6.843569E-04 5.840074E-04 8.486026E-04 7.241691E-04 
92 0.022989 0.011848 0.010115 0.002488 6.843569E-04 5.840074E-04 8.486026E-04 7.241691E-04 
92.5 0.022989 0.011848 0.010115 0.002488 6.843569E-04 5.840074E-04 8.486026E-04 7.241691E-04 
93 0.022989 0.011848 0.010115 0.002488 6.843569E-04 5.840074E-04 8.486026E-04 7.241691E-04 
93.5 0.022989 0.011848 0.010115 0.002488 6.843569E-04 5.840074E-04 8.486026E-04 7.241691E-04 
94 0.022989 0.011848 0.010115 0.002488 6.843569E-04 5.840074E-04 8.486026E-04 7.241691E-04 
94.5 0.022989 0.011848 0.010115 0.002488 6.843569E-04 5.840074E-04 8.486026E-04 7.241691E-04 
95 0.022989 0.011848 0.010115 0.002488 6.843569E-04 5.840074E-04 8.486026E-04 7.241691E-04 
95.5 0.022989 0.011848 0.010115 0.002488 6.843569E-04 5.840074E-04 8.486026E-04 7.241691E-04 
96 0.022989 0.011848 0.010115 0.002488 6.843569E-04 5.840074E-04 8.486026E-04 7.241691E-04 
96.5 0.022989 0.011848 0.010115 0.002488 6.843569E-04 5.840074E-04 8.486026E-04 7.241691E-04 
97 0.022989 0.011848 0.010115 0.002488 6.843569E-04 5.840074E-04 8.486026E-04 7.241691E-04 
97.5 0.022989 0.011848 0.010115 0.002488 6.843569E-04 5.840074E-04 8.486026E-04 7.241691E-04 
98 0.022989 0.011848 0.010115 0.002488 6.843569E-04 5.840074E-04 8.486026E-04 7.241691E-04 
98.5 0.022989 0.011848 0.010115 0.002488 6.843569E-04 5.840074E-04 8.486026E-04 7.241691E-04 
99 0.022989 0.011848 0.010115 0.002488 6.843569E-04 5.840074E-04 8.486026E-04 7.241691E-04 
99.5 0.022989 0.011848 0.010115 0.002488 6.843569E-04 5.840074E-04 8.486026E-04 7.241691E-04 
100 0.022989 0.011848 0.010115 0.002488 6.843569E-04 5.840074E-04 8.486026E-04 7.241691E-04 
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Appendix 5.5 Search strategy and search terms of systematic literature review 
on prevalence, costs and QALYs of passive smoking health effects 
 
Methods 
 
Cochrane Library 
Cochrane Database of Systematic Reviews 
 
Health Technology Assessment (Internet access) 
Office of Technology Assessment 
 
Office for National Statistics database (Internet access) 
National statistics data 
 
Bibliographic database 
MEDLINE – systematic review 
Office of Health Economics Health Economic Evaluation Database (HEED) 
 
 
Search terms 
Source - Cochrane Library (Wiley) 
#1  asthma and children, from 2000 to 2009 
52 
#2  wheeze and children, from 2000 to 2009 
5 
#3  cough and children, from 2000 to 2009 
16 
#4  phlegm and children, from 2000 to 2009 
0 
#5  breathlessness and children, from 2000 to 2009 
0 
#6  recurrent otitis media and children, from 2000 to 2009 
1 
#7  otitis media with effusion and children, from 2000 to 2009 
4 
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#8  acute otitis media and children, from 2000 to 2009 
7 
#9  glue ear and children, from 2000 to 2009 
0 
 
Source - Health Economic Evaluation Database 
#1  asthma and children 
52 
#2  wheeze and children 
1 
#3  cough and children 
9 
#4  phlegm and children 
0 
#5  breathlessness and children 
0 
#6  recurrent otitis media and children 
1 
#7  otitis media with effusion and children 
5 
#8  acute otitis media and children 
22 
#9  glue ear and children 
2 
 
Source Ovid MEDLINE 2000 to August 2009 
8 asthma.ti. (50322) 
9 wheez*.ti. (1551) 
10 cough.ti. (6016) 
11 phlegm.ti. (80) 
12 breathless*.ti (487) 
13 recurrent otitis media.ti. (157) 
14 otitis media with effusion.ti. (1045) 
15 glue ear.ti. (184) 
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16 acute otitis media.ti. (1752) 
17 prevalence.ti. (56707) 
18 (cost* or economic).ti. (75668) 
19 (QALY* or utilit* or quality of life or quality-of life or quality adjusted life years or 
quality-adjusted life years).ti. (35886) 
20 1 and 10 (960) 
21 limit 13 to last 10 years (626) 
22 10 and 2 (56) 
23 limit 15 to last 10 years (33) 
24 3 and 10 (30) 
25 limit 17 to last 10 years (14) 
26 4 and 10 (2) 
27 limit 19 to last 10 years (0) 
28 10 and 5 (0) 
29 6 and 10 (3) 
30 limit 22 to last 10 years (2) 
31 7 and 10 (20) 
32 limit 24 to last 10 years (9) 
33 10 and 9 (3) 
34 limit 26 to last 10 years (2) 
35 11 and 1 (434) 
36 limit 28 to last 10 years (321) 
37 1 and 12 (450) 
38 limit 30 to last 10 years (355) 
39 11 and 2 (5) 
40 limit 32 to last 10 years (4) 
41 12 and 2 (8) 
42 limit 34 to last 10 years (7) 
43 11 and 3 (13) 
44 limit 36 to last 10 years (5) 
45 3 and 12 (21) 
46 limit 38 to last 10 years (18) 
47 11 and 4 (0) 
48 4 and 12 (1) 
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49 limit 41 to last 10 years (1) 
50 11 and 5 (1) 
51 limit 43 to last 10 years (0) 
52 12 and 5 (5) 
53 limit 45 to last 10 years (4) 
54 6 and 11 (2) 
55 limit 47 to last 10 years (1) 
56 6 and 12 (1) 
57 limit 49 to last 10 years (0) 
58 11 and 7 (2) 
59 limit 51 to last 10 years (2) 
60 7 and 12 (3) 
61 limit 53 to last 10 years (2) 
62 11 and 9 (14) 
63 limit 55 to last 10 years (7) 
64 9 and 12 (4) 
65 limit 57 to last 10 years (3) 
66 8 and 11 (0) 
67 8 and 12 (0) 
68 8 and 10 (0) 
 
 
Search strategy 
A comprehensive search for literature on prevalence, costs and QALYs of passive 
smoking health effects was conducted. Studies on costs and QALYs were identified 
from: MEDLINE (Ovid) 2000-July 2009; Office of Health Economics Health Economic 
Evaluation Database (HEED); Cochrane Library -Wiley Internet version 2000-July 
2009; Health Technology Assessment database (HTA); and the National Institute for 
Health and Clinical Excellence (NICE). An additional search was conducted on the 
Office for National Statistics database. 
This search was restricted to English language, humans, and with no time restrictions, 
with the exceptions of Medline Ovid and Cochrane Library because of the high number 
of inputs resulting from the search. Search terms were contrived to retrieve papers on 
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prevalence, risk and mortality of passive smoking health effects. Details of searches can 
be found in Appendix 6.8.  
All titles and abstracts were screened for relevance. Full paper copies of any titles or 
abstracts judged of potential relevance were obtained. The relevance of each full 
abstract was judged according to predefined criteria (see below). Studies that failed to 
satisfy all criteria were excluded and the reason for their exclusion was recorded. 
References from searched papers were scrutinized to add relevant references to the 
search. 
 
Inclusion criteria 
Studies that specify utility values or episode costs of health effects due to passive 
smoking were included. Studies were excluded if they did not express the costs in terms 
of cost per episode. The following types of paper were also excluded: papers reporting 
utilities values in a different scale than 0-10 or 0-100, papers not stating prevalence, not 
UK estimates on prevalence data, and papers written not in English, because there were 
no resources for translations. 
 
Data extraction strategy 
The data was extracted according to the guidelines produced by the Centre for Reviews 
and Dissemination (CRD) for the critical appraisal of economic evaluations. Data 
extraction focused on costs episode and utility values using 0-10 or 0-100 scales. 
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Appendix 5.6 Study selection process for health effects of passive smoking 
systematic review 
 
 
 
1649 titles and abstracts identified 
Medline (Ovid)           1413 
HEED                40 
Cochrane Library                                85 
HTA                93 
NICE                18 
50 excluded for duplication: 
Medline Ovid                      50 
1366 excluded because: 
Not related to prevalence, and episode costs  
and QALYs of passive smoking health  825 
data for adults    108 
not UK data    357 
specific treatment cost rather than  
episode cost      76 
1599 Potentially relevant titles & abstracts 
identified 
Medline (Ovid)           1363 
HEED                40 
Cochrane Library                                85 
HTA                93 
NICE                18 
 
233 articles retrieved for more detailed evaluation  
Medline (Ovid)            223 
HEED                     9 
HTA                      1 
37 articles included  
 
196 excluded because: 
quality of life scale different from  
0-10 or 0-100          5 
not stating quality of life value                            13 
data for adults        49 
not useful data                         51     
not UK prevalence data                                       72 
No understandable language         1 
Duplicate           2 
Not found           3 
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Appendix 5.7 References included in the systematic literature review of 
prevalence, costs and QALYs of passive smoking health effects 
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Appendix 5.8  Selection of datasets for incidence parameter calculation 
 
 
Methods 
This section highlights how the dataset were identified and selected for review.  
 
Search strategy 
A search for datasets was conducted in July 2009 in the UK Data Archive (UKDA)78. In 
addition, some institutions were contacted in the search for data. 
Table 5.1.1 provides a list of the institutions and individuals who were contacted in the 
search for data. 
 
Table 5.1.1: List of contacted individuals 
Lesley Owen, Analyst, National Institute for Clinical Excellence (NICE), UK 
Alison Toczek, NHS Information Centre, UK 
Hershbinder Mann, Senior data and support services officer, UK Data Archive, UK 
Andy McEwen, Senior research nurse, assistant director tobacco studies, Cancer Research UK Health 
Behaviour Research Centre, Unicersity College of London, UK 
Economic and Social Data service (ESDS), Universities of Essex and Manchester, UK 
 
Selection criteria 
Datasets that satisfied the following criteria were selected for review: (a) dataset based 
on the UK or English general adult (16 years and older) population; (b) data collection 
conducted from 2000 up to date; and, (c) dataset having smoking specific indicators. 
 
Datasets were also browse by drug abuse, alcohol and smoking subject. 
 
Results 
The search strategy identified a total of 30 datasets that were subjected to the selection 
criteria. All of them were selected for review. None of the data sets had longitudinal 
data specifically to calculate uptake of smoking. Nonetheless, Lesley Owen, analyst 
from NICE, advised to follow same proxy as Raikou and McGuire (2008) used to 
approximate this data. Therefore, the age adults started smoking regularly was used to 
calculate the number of new smokers, by age, generated in the population. Either the 
                                                 
78
 The UKDA is a custodian of the biggest collection of digital data in the social sciences and humanities 
in the UK. It is also in charge of the management of the Economic and Social Data Service (ESDS) as a 
lead collaborator. 
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HSE or GHS contained this information. But, meanwhile the HSE is designed to 
monitor trends in the nation's health, the GHS tries to document the major picture of UK 
households and, to monitor trends in the prevalence of smoking and drinking. Even 
though that was not possible to cluster the information by households in this last survey 
because the household member’s numbers were changing across survey waves, the 
information reported by GHS was considered for this analysis. Moreover, Raikou and 
McGuire (2008) did also consider the same data source for the same analysis.                                                                         
Therefore, the General Household Survey (2006) was used to calculate the incidence of 
smoking by age. 
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Appendix 5.9 Incidence transition probability by age and sex 
 
Age Never smokers non 
passive 
Never smokers passive 
Men Women Men Women 
16 0,059751 0,037739 0,215350 0,165186 
16.5 0,059751 0,037739 0,215350 0,165186 
17 0,034373 0,020869 0,128625 0,094240 
17.5 0,034373 0,020869 0,128625 0,094240 
18 0,041287 0,024961 0,152928 0,111868 
18.5 0,041287 0,024961 0,152928 0,111868 
19 0,018213 0,012916 0,069798 0,059186 
19.5 0,018213 0,012916 0,069798 0,059186 
20 0,016238 0,011265 0,062409 0,051779 
20.5 0,016238 0,011265 0,062409 0,051779 
21 0,014733 0,007702 0,056750 0,035636 
21.5 0,014733 0,007702 0,056750 0,035636 
22 0,006821 0,005088 0,026582 0,023655 
22.5 0,006821 0,005088 0,026582 0,023655 
23 0,002463 0,002324 0,009660 0,010861 
23.5 0,002463 0,002324 0,009660 0,010861 
24 0,003374 0,001885 0,013215 0,008814 
24.5 0,003374 0,001885 0,013215 0,008814 
25 0,006305 0,004066 0,041718 0,033557 
25.5 0,006305 0,004066 0,041718 0,033557 
26 0,002069 0,001890 0,013858 0,015727 
26.5 0,002069 0,001890 0,013858 0,015727 
27 0,002166 0,001258 0,014503 0,010495 
27.5 0,002166 0,001258 0,014503 0,010495 
28 0,001689 0,001015 0,011322 0,008469 
28.5 0,001689 0,001015 0,011322 0,008469 
29 0,000593 0,000467 0,003989 0,003902 
29.5 0,000593 0,000467 0,003989 0,003902 
30 0,003412 0,003551 0,022764 0,029365 
30.5 0,003412 0,003551 0,022764 0,029365 
31 0,000268 0,000644 0,001806 0,005380 
31.5 0,000268 0,000644 0,001806 0,005380 
32 0,000773 0,000980 0,005196 0,008182 
32.5 0,000773 0,000980 0,005196 0,008182 
33 0,000509 0,000320 0,003425 0,002674 
33.5 0,000509 0,000320 0,003425 0,002674 
34 0,000791 0,000348 0,005317 0,002912 
34.5 0,000791 0,000348 0,005317 0,002912 
35 0,000883 0,001108 0,009040 0,007657 
35.5 0,000883 0,001108 0,009040 0,007657 
36 0,000134 0,000221 0,001376 0,001531 
36.5 0,000134 0,000221 0,001376 0,001531 
37 0,000429 0,000000 0,004407 0,000000 
37.5 0,000429 0,000000 0,004407 0,000000 
38 0,000177 0,000328 0,001815 0,002270 
38.5 0,000177 0,000328 0,001815 0,002270 
39 0,000000 0,000000 0,000000 0,000000 
39.5 0,000000 0,000000 0,000000 0,000000 
40 0,000658 0,001229 0,006748 0,008486 
40.5 0,000658 0,001229 0,006748 0,008486 
41 0,000000 0,000046 0,000000 0,000319 
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Age Never smokers non 
passive 
Never smokers passive 
Men Women Men Women 
41.5 0,000000 0,000046 0,000000 0,000319 
42 0,000174 0,000000 0,001784 0,000000 
42.5 0,000174 0,000000 0,001784 0,000000 
43 0,000000 0,000059 0,000000 0,000406 
43.5 0,000000 0,000059 0,000000 0,000406 
44 0,000000 0,000000 0,000000 0,000000 
44.5 0,000000 0,000000 0,000000 0,000000 
45 0,000000 0,000183 0,000000 0,001645 
45.5 0,000000 0,000183 0,000000 0,001645 
46 0,000333 0,000261 0,002897 0,002345 
46.5 0,000333 0,000261 0,002897 0,002345 
47 0,000000 0,000117 0,000000 0,001050 
47.5 0,000000 0,000117 0,000000 0,001050 
48 0,000109 0,000000 0,000949 0,000000 
48.5 0,000109 0,000000 0,000949 0,000000 
49 0,000000 0,000000 0,000000 0,000000 
49.5 0,000000 0,000000 0,000000 0,000000 
50 0,000000 0,000313 0,000000 0,002811 
50.5 0,000000 0,000313 0,000000 0,002811 
51 0,000108 0,000000 0,000938 0,000000 
51.5 0,000108 0,000000 0,000938 0,000000 
52 0,000000 0,000000 0,000000 0,000000 
52.5 0,000000 0,000000 0,000000 0,000000 
53 0,000000 0,000000 0,000000 0,000000 
53.5 0,000000 0,000000 0,000000 0,000000 
54 0,000000 0,000000 0,000000 0,000000 
54.5 0,000000 0,000000 0,000000 0,000000 
55 0,000146 0,000099 0,001600 0,001099 
55.5 0,000146 0,000099 0,001600 0,001099 
56 0,000000 0,000000 0,000000 0,000000 
56.5 0,000000 0,000000 0,000000 0,000000 
57 0,000000 0,000086 0,000000 0,000955 
57.5 0,000000 0,000086 0,000000 0,000955 
58 0,000000 0,000000 0,000000 0,000000 
58.5 0,000000 0,000000 0,000000 0,000000 
59 0,000000 0,000000 0,000000 0,000000 
59.5 0,000000 0,000000 0,000000 0,000000 
60 0,000000 0,000065 0,000000 0,000721 
60.5 0,000000 0,000065 0,000000 0,000721 
61 0,000000 0,000000 0,000000 0,000000 
61.5 0,000000 0,000000 0,000000 0,000000 
62 0,000000 0,000078 0,000000 0,000868 
62.5 0,000000 0,000078 0,000000 0,000868 
63 0,000000 0,000000 0,000000 0,000000 
63.5 0,000000 0,000000 0,000000 0,000000 
64 0,000000 0,000000 0,000000 0,000000 
64.5 0,000000 0,000000 0,000000 0,000000 
65 0,000000 0,000000 0,000000 0,000000 
65.5 0,000000 0,000000 0,000000 0,000000 
66 0,000000 0,000000 0,000000 0,000000 
66.5 0,000000 0,000000 0,000000 0,000000 
67 0,000000 0,000000 0,000000 0,000000 
67.5 0,000000 0,000000 0,000000 0,000000 
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Age Never smokers non 
passive 
Never smokers passive 
Men Women Men Women 
68 0,000000 0,000000 0,000000 0,000000 
68.5 0,000000 0,000000 0,000000 0,000000 
69 0,000000 0,000000 0,000000 0,000000 
69.5 0,000000 0,000000 0,000000 0,000000 
70 0,000000 0,000076 0,000000 0,000791 
70.5 0,000000 0,000076 0,000000 0,000791 
71 0,000000 0,000000 0,000000 0,000000 
71.5 0,000000 0,000000 0,000000 0,000000 
72 0,000000 0,000000 0,000000 0,000000 
72.5 0,000000 0,000000 0,000000 0,000000 
73 0,000000 0,000000 0,000000 0,000000 
73.5 0,000000 0,000000 0,000000 0,000000 
74 0,000000 0,000000 0,000000 0,000000 
74.5 0,000000 0,000000 0,000000 0,000000 
75 0,000000 0,000000 0,000000 0,000000 
75.5 0,000000 0,000000 0,000000 0,000000 
76 0,000000 0,000000 0,000000 0,000000 
76.5 0,000000 0,000000 0,000000 0,000000 
77 0,000000 0,000000 0,000000 0,000000 
77.5 0,000000 0,000000 0,000000 0,000000 
78 0,000000 0,000000 0,000000 0,000000 
78.5 0,000000 0,000000 0,000000 0,000000 
79 0,000000 0,000000 0,000000 0,000000 
79.5 0,000000 0,000000 0,000000 0,000000 
80 0,000000 0,000000 0,000000 0,000000 
80.5 0,000000 0,000000 0,000000 0,000000 
81 0,000000 0,000000 0,000000 0,000000 
81.5 0,000000 0,000000 0,000000 0,000000 
82 0,000000 0,000000 0,000000 0,000000 
82.5 0,000000 0,000000 0,000000 0,000000 
83 0,000000 0,000000 0,000000 0,000000 
83.5 0,000000 0,000000 0,000000 0,000000 
84 0,000000 0,000000 0,000000 0,000000 
84.5 0,000000 0,000000 0,000000 0,000000 
85 0,000000 0,000000 0,000000 0,000000 
85.5 0,000000 0,000000 0,000000 0,000000 
86 0,000000 0,000000 0,000000 0,000000 
86.5 0,000000 0,000000 0,000000 0,000000 
87 0,000000 0,000000 0,000000 0,000000 
87.5 0,000000 0,000000 0,000000 0,000000 
88 0,000000 0,000000 0,000000 0,000000 
88.5 0,000000 0,000000 0,000000 0,000000 
89 0,000000 0,000000 0,000000 0,000000 
89.5 0,000000 0,000000 0,000000 0,000000 
90 0,000000 0,000071 0,000000 0,000460 
90.5 0,000000 0,000071 0,000000 0,000460 
91 0,000000 0,000000 0,000000 0,000000 
91.5 0,000000 0,000000 0,000000 0,000000 
92 0,000000 0,000000 0,000000 0,000000 
92.5 0,000000 0,000000 0,000000 0,000000 
93 0,000000 0,000000 0,000000 0,000000 
93.5 0,000000 0,000000 0,000000 0,000000 
94 0,000000 0,000000 0,000000 0,000000 
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Age Never smokers non 
passive 
Never smokers passive 
Men Women Men Women 
94.5 0,000000 0,000000 0,000000 0,000000 
95 0,000000 0,000000 0,000000 0,000000 
95.5 0,000000 0,000000 0,000000 0,000000 
96 0,000000 0,000000 0,000000 0,000000 
96.5 0,000000 0,000000 0,000000 0,000000 
97 0,000000 0,000000 0,000000 0,000000 
97.5 0,000000 0,000000 0,000000 0,000000 
98 0,000000 0,000000 0,000000 0,000000 
98.5 0,000000 0,000000 0,000000 0,000000 
99 0,000000 0,000000 0,000000 0,000000 
99.5 0,000000 0,000000 0,000000 0,000000 
100 0,000000 0,000000 0,000000 0,000000 
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Appendix 5.10 Selection of datasets for passive and non passive prevalence 
parameters 
 
 
Methods 
This section highlights how the dataset were identified and selected for review.  
 
Search strategy 
A search for datasets was conducted in July 2008 in the UK Data Archive (UKDA)79. In 
addition, some institutions were contacted in the search for data. 
Lesley Owen, Analyst from National Institute for Clinical Excellence (NICE), was 
contacted in the search for prevalence data. 
 
Selection criteria 
Datasets that satisfied the following criteria were selected for review: (a) dataset based 
on the UK or English general (children and adults) population; (b) data collection 
conducted from 2000 up to date; and, (c) dataset having smoking specific indicators. 
 
Datasets were also browse by drug abuse, alcohol and smoking subject. 
 
Results 
The search strategy identified a total of 30 datasets that were subjected to the selection 
criteria. All of them were selected for review. Only one database (Welsh Health Survey 
(2007)) had data on adults regularly exposed to other people’s tobacco smoke at own 
home, though it was not a requirement being exposed by a member of that household. 
However, the Health Survey for England (HSE) collects data of adults and children 
being often near people who smoke at home, though has the same problem of including 
smokers not from that particular household. 
 
Since the HSE dataset was UK representative and also contained children’s data, this 
was the selected dataset to calculate this model parameter. 
                                                 
79
 The UKDA is a custodian of the biggest collection of digital data in the social sciences and humanities in the UK. It is also in 
charge of the management of the Economic and Social Data Service (ESDS) as a lead collaborator. 
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Appendix 5.11 Prevalence of smokers, former smokers and, never smokers’ non passive and passive according to HSE (2006) 
 
 
 
 
Population distribution 
Infants (< 2 years) 
Children (2-15 years) 
Adults (≥ 16 years) 
TOTAL 
 
368 
6889 
14142 
21399 
Age CURRENT SMOKERS FORMER SMOKERS NEVER SMOKERS TOTAL 
PASSIVE NON PASSIVE TOTAL PASSIVE NON PASSIVE TOTAL PASSIVE NON PASSIVE TOTAL 
m f tot m f tot m f tot m f tot m f tot m f tot m f tot m f tot m f tot m f tot 
16-24 81 95 177 88 115 203 169 211 379 11 15 26 50 66 116 61 81 142 74 71 147 315 400 713 391 471 863 650 794 1444 
25-34 87 101 190 207 187 394 294 288 594 6 15 20 185 273 456 191 288 476 22 35 56 352 536 881 374 570 937 862 1148 2010 
35-44 106 129 236 227 218 445 333 347 687 18 27 45 263 335 597 281 362 643 25 61 83 540 719 1255 564 781 1338 1183 1494 2677 
45-54 89 113 202 160 197 357 249 310 559 30 26 57 280 319 601 310 345 658 29 37 66 456 585 1038 485 622 1104 1050 1279 2329 
55-64 75 90 164 140 164 304 215 253 468 39 30 70 484 406 896 524 436 966 18 27 45 367 552 914 385 579 958 1126 1269 2395 
65-74 22 36 58 94 81 175 116 117 233 43 21 63 431 298 728 474 318 791 10 21 30 253 477 731 262 498 761 852 933 1785 
>75 10 20 31 43 55 98 53 76 128 22 22 43 336 349 681 359 371 725 9 24 33 180 425 609 189 449 642 601 901 1502 
All 
ages 
470 585 1057 958 1017 1975 1428 1603 3048 170 156 325 2030 2046 4075 2200 2201 4400 186 276 460 2462 3694 6141 2650 3970 6604 6324 7818 14142 
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Appendix 5.12 UK national statistics 200780 – general population 
        
Age Males Females Total 
0 387490 368252 755742 
1 374492 357420 731912 
2 366879 349867 716746 
3 361908 344186 706094 
4 350164 331940 682104 
5 339269 324486 663755 
6 339165 325821 664986 
7 348840 331770 680610 
8 358606 342340 700946 
9 364536 349347 713883 
10 375180 358181 733361 
11 372773 355777 728550 
12 375786 356911 732697 
13 384399 365270 749669 
14 390132 369852 759984 
15 404902 383424 788326 
16 415,336 389,480 804,816 
17 410,939 385,903 796,842 
18 412,009 387,797 799,806 
19 425,520 400,458 825,978 
20 423,152 397,038 820,190 
21 422,938 405,985 828,923 
22 434,506 412,631 847,137 
23 427,022 402,710 829,732 
24 416,846 397,677 814,523 
25 402,328 398,559 800,887 
26 413,763 407,342 821,105 
27 411,698 406,258 817,956 
28 391,325 390,033 781,358 
29 372,872 372,086 744,958 
30 368,010 365,938 733,948 
31 377,902 376,458 754,360 
32 386,879 388,176 775,055 
33 395,474 398,261 793,735 
34 415,719 420,396 836,115 
35 434,136 445,657 879,793 
36 447,129 457,628 904,757 
37 445,709 451,643 897,352 
38 456,511 465,385 921,896 
39 462,294 467,969 930,263 
40 473,564 477,594 951,158 
41 469,776 478,334 948,110 
42 471,131 481,140 952,271 
43 464,077 476,644 940,721 
44 453,432 468,339 921,771 
45 441,317 455,384 896,701 
46 431,496 443,447 874,943 
47 415,392 425,614 841,006 
48 408,108 416,467 824,575 
                                                 
80
 It was the last observed data on the UK national Statistics. From 2008 onwards there was projection data. 
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Age Males Females Total 
49 402,606 410,398 813,004 
50 386,739 395,648 782,387 
51 372,588 381,644 754,232 
52 362,498 371,245 733,743 
53 362,768 372,425 735,193 
54 357,758 366,564 724,322 
55 353,494 363,546 717,040 
56 354,730 365,545 720,275 
57 363,135 375,744 738,879 
58 374,443 386,134 760,577 
59 399,142 412,199 811,341 
TOTAL 23,982,732 23,730,367 47,713,099 
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Appendix 5.13 Standard deviation values for probabilistic analysis of M4 and M5 
 
Variable 
 
Mean 
 
SD calculated SD reported 
by study 
95% Confidence Interval 
 
Distribution 
Low interval Upper interval  
Clinic health state (RR) 
LC 
CHD 
asthma 
wheeze 
cough 
OME 
AOM 
 
1.24 
1.25 
1.21 
1.24 
1.40 
1.38 
1.30 
 
0.12400 
0.12500 
0.06122 
0.03571 
0.06632 
0.08163 
0.15306 
 
- 
- 
- 
- 
- 
- 
- 
 
- 
- 
1.10 
1.17 
1.27 
1.23 
1.00 
 
- 
- 
1.34 
1.31 
1.53 
1.55 
1.60 
 
lognormal 
lognormal 
lognormal 
lognormal 
lognormal 
lognormal 
lognormal 
Smoking cessation and 
relapse (rates) 
quit BA 
quit BAS 
quit BASNRT 
quit BASNRTSC 
quit LICB 
quit MICB 
quit NPGC 
quit NPIC 
quit NPNC 
quit NPPC 
quit NPPCBP 
 
 
 
3.00% 
4.00% 
6.00% 
15.00% 
23.60% 
31.40% 
26.00% 
20.00% 
15.00% 
31.00% 
44.00% 
 
 
 
0.00300 
0.00400 
0.00600 
0.02551 
0.01071 
0.00918 
0.02372 
0.01276 
0.01531 
0.03100 
0.04400 
 
 
 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
 
 
 
- 
- 
- 
10.00% 
21.50% 
29.60% 
21.80% 
17.60% 
11.00% 
- 
- 
 
 
 
- 
- 
- 
20.00% 
25.70% 
33.20% 
31.10% 
22.60% 
17.00% 
- 
- 
 
 
 
beta 
beta 
beta 
beta 
beta 
beta 
beta 
beta 
beta 
beta 
beta 
Utilities (Qol values) 
smokers 
former smokers 
LC 
CHD 
COPD 
MI 
ST 
asthma 
wheeze 
cough 
OME 
AOM 
 
0.75 
0.78 
0.58 
0.80 
0.73 
0.80 
0.48 
0.85 
0.95 
0.76 
0.70 
0.79 
 
0.2500 
0.2300 
0.1167 
0.0800 
0.00327 
0.08000 
0.04800 
0.08500 
0.09500 
0.07600 
0.07000 
0.07900 
 
0.2500 
0.2300 
0.1;0.14;0.2;0.0
7;0.07;0.12 
- 
- 
- 
- 
- 
- 
- 
- 
- 
 
- 
- 
- 
- 
(0.771; 0.731; 
0.598) 
- 
- 
- 
- 
- 
- 
 
 
- 
- 
- 
- 
(0.802; 0.768; 
0.695) 
- 
- 
- 
- 
- 
- 
 
 
beta 
beta 
beta 
beta 
beta 
beta 
beta 
beta 
beta 
beta 
beta 
beta 
Costs (£ 2009) 
Clinic health states 
LC 
CHD 
COPD 
MI 
ST 
asthma 
wheeze 
cough 
OME 
AOM 
Interventions 
BA 
BAS 
BASNRT 
BASNRTSC 
LICB 
MICB 
NPGC 
NPIC 
NPNC 
NPPC 
NPPCBP 
 
 
5912.43 
1142.50 
995.26 
2337.67 
2215.15 
85.80 
555.23 
29.48 
198.68 
117.93 
 
7.67 
11.47 
119.41 
132.16 
86.21 
129.20 
153.46 
102.64 
48.90 
301.48 
406.03 
 
 
1690.59 
114.25 
99.53 
233.77 
221.51 
8.58 
55.52 
2.95 
19.87 
11.79 
 
0.77 
1.15 
11.94 
13.22 
8.62 
12.92 
15.35 
10.26 
4.89 
30.15 
40.60 
 
 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
 
 
2599 
- 
- 
- 
- 
- 
- 
- 
- 
- 
 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
 
 
9226 
- 
- 
- 
- 
- 
- 
- 
- 
- 
 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
 
 
gamma 
gamma 
gamma 
gamma 
gamma 
gamma 
gamma 
gamma 
gamma 
gamma 
 
gamma 
gamma 
gamma 
gamma 
gamma 
gamma 
gamma 
gamma 
gamma 
gamma 
gamma 
 
Indicence Accordin
g to age 
and sex 
10% men 
estimate 
- - - beta 
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Appendix 5.14 Cost-effectiveness acceptability curves for M4 (LICB and 
NPPCBP) and M5 (LICB EE and NPPCBP EE) compared to no 
intervention 
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Appendix 6.1 Search strategy and search terms of systematic literature review on 
health effects due to smoking during pregnancy 
 
 
Databases 
Cochrane Library 
Cochrane Database of Systematic Reviews 
 
National Institute of Clinical Excellence 
NHS evidence 
 
Health Technology Assessment (Internet access) 
Office of Technology Assessment 
 
The Office of Surgeon General US (Internet access) 
 
Bibliographic database 
MEDLINE – systematic review 
Office of Health Economics Health Economic Evaluation Database (HEED) 
 
 
Search terms 
Source - Cochrane Library (Wiley) 
#1  smok* pregnancy 
6 
Source – NICE (NHS Evidence) 
#1  smoking pregnancy 
4033 
Source – Health Technology Assessment 
#1  pregnancy 
0 
Source – The Office of Surgeon General US 
#1  pregnancy 
1 
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Source Ovid MEDLINE  
#1 Smoking pregnancy.m_titl (11) 
Source - Health Economic Evaluation Database 
#1  smok* pregnancy 
0 
 
Search strategy 
An established search protocol was used to identify reviews and meta-analysis of health 
effects risk on pregnant women due to smoking. Comprehensive searches were 
conducted using bibliographic databases, bibliographies of relevant reviews and internet 
sites for epidemiological data on passive smoking in Europe, US and UK. Searches 
were carried out June 2009, and involved 3 electronic databases (MEDLINE -Ovid-, 
Cochrane Library -Wiley Internet version-, and Office of Health Economics Health 
Economic Evaluation Database –HEED). The World Health Organization (WHO), The 
Office of Surgeon General US, the Centers for Disease Control and Prevention, and the 
Information Centre of NHS sites were also consulted. This search was restricted to 
English language, humans, review papers, and without time restrictions and included a 
combination of text words. The free text term used was “smok* pregnan*”. Moreover, 
only the Cochrane reviews results were included for revision. Search term was 
contrived to retrieve papers on relative risk of smoking during pregnancy health effects.  
 
All titles and abstracts were screened for relevance. Full paper copies of any title or 
abstract judged to be potentially relevant were obtained. The relevance was judged of 
each full abstract according to predefined criteria (see below). Studies that failed to 
satisfy all criteria were excluded and the reason for their exclusion was recorded. 
References from searched papers were scrutinized to add relevant references to the 
search.  
 
Selection criteria 
A selected paper had to satisfy all the requirements of the following criteria: (a) to 
present meta-analytic data or pooled data on relative risks or odds ratios of clinical 
effects on women due to smoking during pregnancy; (b) be written in English, because 
there were no resources for translations. Studies were excluded if the data they reported 
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were updated in other papers published or if the epidemiological evidence was reported 
as not strong enough for clear conclusions.                    
 
 
 
Data extraction strategy 
Data were extracted into a summary table to describe the important health effects of 
smoking during pregnancy in women. 
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Appendix 6.2 Study selection process for smoking during pregnancy papers 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 4051 titles and abstracts identified 
Medline (Ovid)      11 
Cochrane Library       6 
NICE                                  4033 
Office Surgeon General US          1 
2 excluded for duplication: 
Medline Ovid                       1 
Cochrane library                  1 
4048 excluded because: 
Not related to risks associated to smoking during 
pregnancy     
4049 titles & abstracts identified 
Medline (Ovid)     10 
Cochrane Library       5 
NICE                   4033 
 1 article included  
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Appendix 6.3 Search strategy and search terms of systematic literature review on 
prevalence, costs and utilities of smoking during pregnancy health 
effects 
 
Aim 
The aim of this systematic review was to identify and critically appraise all published 
prevalence, costs and quality adjusted life years (QALYs) of the health effects 
associated with smoking during pregnancy earlier identified, for the purpose of: 
providing insights into the main cost-effectiveness trade-off relevant to our decision 
problem. 
 
Search strategy 
A comprehensive search for literature on prevalence, costs and QALYs of passive 
smoking health effects was conducted. Studies on costs and QALYs were identified 
from: MEDLINE (Ovid) 2000-July 2009; Office of Health Economics Health Economic 
Evaluation Database (HEED); Cochrane Library -Wiley Internet version 2000-July 
2009; Health Technology Assessment database (HTA); and the National Institute for 
Health and Clinical Excellence (NICE). An additional search was conducted on the 
Office for National Statistics database. 
This search was restricted to English language, humans, and with no time restrictions, 
with the exceptions of Medline Ovid and Cochrane Library. Search terms were 
contrived to retrieve papers on prevalence, risk and mortality of passive smoking health 
effects. Details of searches can be found in Appendix 7.5.  
All titles and abstracts were screened for relevance. Full paper copies of any titles or 
abstracts judged of potential relevance were obtained. The relevance was judged of each 
full abstract according to predefined criteria (see below). Studies that failed to satisfy all 
criteria were excluded and the reason for their exclusion was recorded. References from 
searched papers were scrutinized to add relevant references to the search. 
 
Databases 
Cochrane Library 
Cochrane Database of Systematic Reviews 
National Institute of Clinical Excellence 
NHS evidence 
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Health Technology Assessment (Internet access) 
Office of Technology Assessment 
Office for National Statistics database (Internet access) 
National statistics data 
Bibliographic database 
MEDLINE – systematic review 
Office of Health Economics Health Economic Evaluation Database (HEED) 
Contacts 
Hema Mistry – Research Fellow from Health Economics Research Group (HERG), 
Brunel University 
Stavros Petrou - Senior Non-Clinical Research Fellow from Health Economics 
Research Centre (HERC), Oxford University 
 
Search terms 
Source - Cochrane Library (Wiley) 
#1  ectopic pregnancy, from 1999 to 2009 
2 
#2  placenta praevia, from 1999 to 2009 
1 
#3  placental abruption, from 1999 to 2009 
1 
#4  pre-eclampsia, from 1999 to 2009 
19 
#5  preeclampsia and children, from 1999 to 2009 
0 
#6  low birth weight, from 1999 to 2009 
41 
#7  suddent infant death, from 1999 to 2009 
0 
 
Source – NICE (NHS Evidence) 
#1  ectopic pregnancy 
0 
#2  placenta praevia 
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0 
#3  placental abruption 
0 
#4  pre-eclampsia 
0 
#5  preeclampsia and children 
0 
#6  low birth weight 
0 
#7  suddent infant death 
1 
 
Source – Health Technology Assessment 
#1  ectopic pregnancy 
2 
#2  placenta praevia 
0 
#3  placental abruption 
1 
#4  pre-eclampsia 
14 
#5  preeclampsia and children 
6 
#6  low birth weight 
12 
#7  suddent infant death 
6 
 
Source – Office for National Statistics 
#1  ectopic pregnancy 
0 
#2  placenta praevia 
0 
#3  placental abruption 
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0 
#4  pre-eclampsia 
0 
#5  preeclampsia and children 
0 
#6  low birth weight 
0 
#7  suddent infant death 
3 
 
Source - Health Economic Evaluation Database 
#1  ectopic pregnancy 
0 
#2  placenta praevia 
0 
#3  placental abruption 
0 
#4  pre-eclampsia 
3 
#5  preeclampsia 
2 
#6  low birth weight 
26 
#7  sudden infant death 
2 
 
Source Ovid MEDLINE 2000 to August 2009 
1 ectopic pregnanc*.ti. (3479) 
2 placenta praevia.ti. (459) 
3 placenta* abruption.ti. (210) 
4 pre-eclampsia.ti. (2626) 
5 preeclampsia*.ti (3705) 
6 low birth weight.ti. (5540) 
7 sudden infant death syndrome.ti. (2168) 
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8 prevalence.ti. (56707) 
9 (cost* or economic).ti. (75668) 
10 (QALY* or utilit* or quality of life or quality-of life or quality adjusted life years or 
quality-adjusted life years).ti. (35886) 
11 8 and 1 (4) 
12 1 and 9 (20) 
13 1 and 10 (5) 
14 8 and 2 (0) 
15 9 and 2 (0) 
16 10 and 2 (0) 
17 8 and 3 (0) 
18 3 and 9 (0) 
19 3 and 10 (2) 
20 8 and 4 (6) 
21 4 and 9 (4) 
22 4 and 10 (2) 
23 8 and 5 (6) 
24 9 and 5 (1) 
25 10 and 5 (2) 
26 8 and 6 (39) 
27 6 and 9 (34) 
28 6 and 10 (13) 
29 8 and 7 (17) 
30 7 and 9 (3) 
31 7 and 10 (0) 
 
Inclusion criteria 
Studies that specify utility values or episode costs of health effects due to smoking 
during pregnancy were included. Studies were excluded if they did not express the costs 
in terms of cost per episode. The following types of paper were also excluded: papers 
reporting utilities values in a different scale than 0-10 or 0-100,  papers not stating 
prevalence, not UK estimates on prevalence data, and papers written not in English,  
because there were no resources for translations. 
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Data extraction strategy 
The data was extracted according to the guidelines produced by the Centre for Reviews 
and Dissemination (CRD) for the critical appraisal of economic evaluations. Data 
extraction focused on costs episode and utility values using 0-10 or 0-100 scales. 
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Appendix 6.4 Study selection process for smoking during pregnancy prevalence, 
costs and QALYs  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* 13 articles were included from the literature review and 10 papers were added from experts’ contacted 
300 titles and abstracts identified 
Medline (Ovid)   158 
HEED      33 
Cochrane Library     64 
NICE        1 
HTA      41 
ONS        3 
19 excluded for duplication: 
Medline Ovid                      2 
HEED                10 
HTA                     7 
193 excluded because: 
Not related to prevalence, and episode costs  
and QALYs of smoking during pregnancy        179 
not UK data        14 
281 titles and abstracts identified 
Medline (Ovid)   156 
HEED      23 
Cochrane Library     64 
NICE        1 
HTA      34 
ONS        3 
 
88 articles retrieved for more detailed 
evaluation  
Medline (Ovid)     42 
HEED        4 
Cochrane Library       4 
NICE        1 
HTA      41 
ONS        3 
 
 23* articles included  
 
 75 excluded because: 
not data on prevalence, episode costs  
and QALYs of smoking during pregnancy    71 
Japanese language          2 
not uk data         2 
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Appendix 6.5 References included in the systematic literature search of 
prevalence, costs and utilities of health effects of passive smoking 
during pregnancy 
 
Boyle M, Torrance GW, Sinclair JC, Horwood SP. Economic evaluation of neonatal 
intensive care of very-low-birth-weight infants. The New England Journal of 
Medicine,1983; 308(22):1330-37. 
 
Dattani N, Cooper N (for the Office for National Statistics). Trends in cot deaths. Health 
Statistics Quarterly, 2000; 5:10-16. 
 
Davenport ES, Williams CECS, Sterne JAC, Sivapathasundram V, Fearne JM, Curtis 
MA. The east London study of maternal chronic periodontal disease and preterm low 
birth weight infants: study design and prevalence data. Annals of Periodontology, 1998; 
3(1):213-221. 
 
Gorsky RD, Colby JP. The cost effectiveness of prenatal care in reducing low birth 
weight in New Hampshire. Health Services Research, 1989; 24(5): 583–98. 
 
Herdman RC, Behney CJ, Wagner JL, Ehrenhaft PM (U.S. Congress, Office of 
Technology Assessment, Neonatal  Intensive Care for Low Birth-weight Infants: Costs 
and Effectiveness (Health Technology Case Study 38), OTA-HCS-38 (Washington, 
DC: U.S. Congress, Office of Technology Assessment, December 1987). This case 
study was performed as part of OTA’s assessment of Healthy Children: Investing in the 
Future. 
 
Lewit EM, Schuurmann Baker L, Corman H, Shiono PH. The direct cost of low birth 
weight. The Future of Children, 1995; 5(1):35-56. 
 
Lowe PJM, Mamers PM, Sturrock TV, Healy  D. A casemix cost comparison of 2 
treatments for ectopic pregnancy. Australian and New Zealand Journal of Obstetrics and 
Gynaecology, 1998; 38(3); 333 – 335. 
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McCormick MC, Bernbaum JC, Eisenberg JM, Kustra SL, Finnegan E. Costs incurred 
by parents of very low birth weight infants after the initial neonatal hospitalization. 
Pediatrics, 1991; 88(3):533-541. 
 
Meads CA, Cnossen JS, Meher S, Juarez-Garcia A, ter Riet G, Duley L, et al. Methods 
of prediction and prevention of pre-eclampsia: systematic reviews of accuracy and 
effectiveness literature with economic modelling. Health Technology Assessment, 
2008; 12(6). (pp.90-93). 
 
Messer J (for the Office for National Statistics). Unexplained deaths in infancy, England 
and Wales, 2007. Health Statistics Quarterly, 2009; 43:63-67. 
 
Mistry H, Dowie R, Franklin RCG, Jani BR. Costs of neonatal care for low-birthweight 
babies in English hospitals. Acta Pediatrica, 2009; 98:1123-1129. 
 
Moya MP, Goldberg RN. Cost-effectiveness of prophylactic indomethacin in very-low-
birth-weight infants. Annals of Pharmacotherapy, 2002; 36(2):218-224. 
 
Orme ME, Hogue SL, Kennedy LM, Paine AC, Godfrey C.  Development of the health 
and economic consequences of smoking interactive model. Tobacco Control, 2001; 
10(1):55-61. 
 
Petrou S. Economic consequences of preterm birth and low birthweight. British Journal 
of Obstetrics  and Gynaecology, 2003; 110(Suppl 20):17-23. 
 
Petrou S, Abangma G, Johnson S, Wolke D. Costs and health utilities associated with 
extremely preterm birth:evidence from the EPICure Study. Value in Health, 2009; 
12(8):1124-1134. 
 
Ringborg A, Berg J, Norman M, Westgren M, Jönsson B.  Preterm birth in Sweden: 
What are  the average lengths of hospital stay and the associated inpatients costs? Acta 
Pediatrica, 2006; 95(12):1550-1555. 
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Rogowski J. Cost-effectiveness of care for very low birth weight infants. Pediatrics, 
1998; 102:35-43. 
 
Russell RB, Green NS, Steiner CA, Meikle S, Howse JL, Poschman K, Dias T, Potetz 
L, Davidoff MJ, Damus K, Petrini JR.  Cost of hospitalization for preterm and low birth 
weight infants in the United States. Pediatrics, 2007; 120(1):e1-e9. 
 
Schmitt SK, Sneed L, Phibbs CS. Costs of newborn care in California: a population-
based study. Pediatrics, 2006; 117(1):154-160. 
 
Seror V, Gelfucci F, Gerbaud L, Pouly JL, Fernandez H, Job-Spira N, et al. Care 
pathways for ectopic pregnancy: a population-based cost-effectiveness analysis. 
Fertility and Sterility, 2007; 87(4):737-748. 
 
Simon J, Gray A, Duley L. on behalf of the Magpie Trial Collaborative Group. Cost-
effectiveness of prophylactic magnesium sulphate for 9996 women with pre-eclampsia 
from 33 countries: economic evaluation of the Magpie Trial. BJOG, 2006; 113:144-151. 
 
Tengs TO, Wallace AMA. One thousand health-related quality-of-life estimates. 
Medical Care, 2000; 38(6): 583-637. 
 
Walker DJ B, Vohr BR, Oh W. Economic analysis of regionalized neonatal care for 
very low-birth-weight infants in the state of Rhode Island. Pediatrics, 1985; 76:69-74. 
 
Walker JJ. Pre-eclampsia. Lancet, 2000; 356(9237):1260-1265. 
 
Wu O, Robertson L, Twaddle S, Lowe GDO, Clark P, Greaves M, Walker ID, 
Langhorne P, Brenkel I, Regan L, Greer IA. Screening for thrombophilia in high-risk 
situations: systematic review and cost-effectiveness analysis. The Thrombosis: risk and 
economic assessment of thrombophilia screening (TREATS) study. Health Technology 
Assessment, 2006; 10(11). (pp.13). 
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Appendix 6.6 Number of pregnant women according to smoking status and age 
(HSE, 2006) 
 
 
 
 Age 
  
Smokers 
 
Former 
Smokers 
 
Never Smokers No 
answer/refused 
TOTAL 
  Passive Non 
passive 
16-24    6.18 2.65 1.05 6.76 2.10 18.74 (794) 
25-34 6.77 20.43 2.83 36.46 0.00 66.48 (1148) 
35-44 2.39 4.68 0.88 14.68 0.00 22.62 (1494) 
All ages  15.33 27.76 4.76 57.90 2.10 107.85 (3436) 
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Appendix 6.7 Study selection process for smoking during pregnancy papers (Office for National Statistics, the Northern Ireland 
Statistics and Research Agency, and the National Services Scotland) 
 
2007   England & Wales Scotland N. Ireland 
All ages 
(ONS 
London) 
Under 
20 
20-24 25-29 30-34 35-39 40 
and 
over 
 All ages 
(GRO 
Scotland)  
Under 
20 
20-24 25-29 30-34 35-
39 
40 
and 
over 
All ages 
(NISRA)  
Under 
20 
20-
24 
25-
29 
30-
34 
35-
39 
40 
and 
over 
Singleton 672,528 44,424 129,001 178,714 185,216 110,909 24,264 56,309 4,316 10,771 14,618 15,135 9,625 1,844 23,824 1,392 3,970 6,658 7,015 4,048 741 
All 
multiples 
10,471 315 1,233 2,386 3,392 2,516 629 893 36 104 185 281 238 49 362 8 39 78 142 77 18 
Twins 10,334 315 1,223 2,361 3,352 2,478 605 882 36 104 182 277 235 48 357 8 39 77 138 77 18 
Triplets 135 0 10 25 39 37 24 9 0 0 2 4 3 0 5 0 0 1 4 0 0 
Quads 1 0 0 0 1 0 0 2 0 0 1 0 0 1 0 0 0 0 0 0 0 
Quins 1 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Sextuplets 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Total 
maternities 
682,999 44,739 130,234 181,100 188,608 113,425 24,893 57,202 4,352 10,875 14,803 15,416 9,863 1,893 24,186 1,400 4,009 6,736 7,157 4,125 759 
 
2007 UK UK rate/1000 mats UK average number of births 
Total All 
ages 
Under 
20 
20-24 25-29 30-34 35-39 40 and 
over 
All 
ages 
Under 
20 
20-24 25-29 30-34 35-
39 
40 and 
over 
Singleton 752,661 985 993 991 987 982 978 975 985 992.89 990.52 986.93 981.9 977.8 974.7323 
All 
multiples 
11,726 15 7 9 13 18 22 25               
Twins 11,573 15 7 9 13 18 22 24 30.2805 14.22 18.826 25.859 35.68 43.79 48.72028 
Triplets 149 0 0 0 0 0 0 1 0.5848 0 0.2067 0.4145 0.668 0.942 2.613905 
Quads 3 0 0 0 0 0 0 0 0.0157 0 0 0.0197 0.019 0 0.145217 
Quins 1 0 0 0 0 0 0 0 0.0065 0 0 0 0 0.039 0 
Sextuplets 0 0 0 0 0 0 0 0   0 0 0 0 0 0 
Total 
maternities 
764,387 1000 1000 1000 1000 1000 1000 1000 1.016 1.007 1.010 1.013 1.018 1.023 1.026 
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Appendix 6.8 Standard deviation values for the probabilistic analysis of M6 and 
M7 
 
Variable 
 
Mean 
 
SD 
calculated 
SD reported by study 95% Confidence 
Interval 
 
Distribution 
Low 
interval 
Upper 
interval  
Clinic health state 
(RR) 
LBW 
SIDS 
 
 
 
1.22 
2.13 
 
 
 
0.07398 
0.14541 
 
 
 
- 
- 
 
 
 
1.08 
1.86 
 
 
 
1.37 
2.43 
 
 
 
lognormal 
lognormal 
 
Smoking cessation and 
relapse (rates) 
 
 
Interventions cessation 
rate during pregnancy 
quitd_i_MBA 
quitd_i_CC 
quitd_i_HEM 
quitd_i_PCW 
quitd_i_PCB 
quitd_i_NRT 
quitd_i_PC 
quitd_i_BD 
quitd_i_BAD 
 
Interventions cessation 
rate after pregnancy 
quita_i_MBA 
quita_i_CC 
quita_i_HEM 
quita_i_PCW 
quita_i_PCB 
quita_i_NRT 
quita_i_PC 
quita_i_BD 
quita_i_BAD 
 
 
 
 
 
 
 
11.60% 
5.70% 
16% 
18.20% 
18.20% 
28% 
24% 
61% 
52% 
 
 
 
11.60% 
8.10% 
13% 
18.20% 
18.20% 
21% 
24% 
61% 
52% 
 
 
 
 
 
 
 
0.01160 
0.00570 
0.03316 
0.01820 
0.01820 
0.01020 
0.02400 
0.06100 
0.05200 
 
 
 
0.01160 
0.00810 
0.03316 
0.01820 
0.01820 
0.00765 
0.02400 
0.06100 
0.05200 
 
 
 
 
 
 
 
- 
- 
- 
- 
- 
- 
- 
- 
- 
 
 
 
- 
- 
- 
- 
- 
- 
- 
- 
- 
 
 
 
 
 
 
 
- 
- 
10% 
- 
- 
24% 
- 
- 
- 
 
 
 
- 
- 
8% 
- 
- 
21% 
- 
- 
- 
 
 
 
 
 
 
 
- 
- 
23% 
- 
- 
28% 
- 
- 
- 
 
 
 
- 
- 
21% 
- 
- 
24% 
- 
- 
- 
 
 
 
 
 
 
 
beta 
beta 
beta 
beta 
beta 
beta 
beta 
beta 
beta 
 
 
 
beta 
beta 
beta 
beta 
beta 
beta 
beta 
beta 
beta 
 
Utilities (Qol values) 
smokers 
former smokers 
LC 
CHD 
COPD 
MI 
ST 
LBW 
SIDS 
 
0.75 
0.78 
0.58 
0.80 
0.73 
0.80 
0.48 
0.85 
0 
 
0.2500 
0.2300 
0.1167 
0.0800 
0.00327 
0.08000 
0.04800 
0.085 
0 
 
0.2500 
0.2300 
0.1;0.14;0.2;0.07;0.07;0.12 
- 
- 
- 
- 
- 
- 
 
- 
- 
- 
- 
(0.771; 
0.731; 
0.598) 
- 
- 
- 
 
 
- 
- 
- 
- 
(0.802; 
0.768; 
0.695) 
- 
- 
- 
 
 
beta 
beta 
beta 
beta 
beta 
beta 
beta 
beta 
beta 
Costs (£ 2009) 
 
Clinic health states 
LC 
CHD 
COPD 
MI 
ST 
LBW 
SIDS 
 
Interventions 
MBA 
CC 
HEM 
PCW 
PCB 
NRT 
PC 
BD 
 
 
 
5912.43 
1142.50 
995.26 
2337.67 
2215.15 
29.48 
3156855.08 
 
 
5.00 
6.84 
12.00 
361.14 
1.14 
93.29 
169.14 
101.00 
 
 
 
1690.59 
114.25 
99.53 
233.77 
221.51 
2.95 
315685.51 
 
 
0.50 
0.68 
1.20 
36.11 
0.11 
9.33 
16.91 
10.10 
 
 
 
- 
- 
- 
- 
- 
- 
- 
 
 
- 
- 
- 
- 
- 
- 
- 
- 
 
 
 
2599 
- 
- 
- 
- 
- 
- 
 
 
- 
- 
- 
- 
- 
- 
- 
- 
 
 
 
9226 
- 
- 
- 
- 
- 
- 
 
 
- 
- 
- 
- 
- 
- 
- 
- 
 
 
 
gamma 
gamma 
gamma 
gamma 
gamma 
gamma 
gamma 
 
 
gamma 
gamma 
gamma 
gamma 
gamma 
gamma 
gamma 
gamma 
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Variable 
 
Mean 
 
SD 
calculated 
SD reported by study 95% Confidence 
Interval 
 
Distribution 
BAD 101.00 10.10 - - - gamma 
Indicence According to 
age and sex 
10% men 
estimate 
- - - beta 
RR: Relative Risk 
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Appendix 6.9 Cost-effectiveness acceptability curves for M6 (MBA and BAD) and 
M7 (MBA EE and BAD EE) compared to no intervention 
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Appendix 7.1 Search strategy and search terms of review on smoking dynamic 
models 
 
 
Databases 
Cochrane Library 
Cochrane Database of Systematic Reviews 
 
Bibliographic database 
Web of Knowledge  
ECONLIT 
MATHSCINET 
NHS EED 
HEED 
 
Search terms 
Source - Cochrane Library (Wiley) 
#1  “smok* behaviour in Title, Abstract or Keywords or dynamic in Title, Abstract or 
Keywords or extern* in Title, Abstract or Keywords in Cochrane Database of 
Systematic Reviews” 
0 
 
Source – Web of Knowledge 
#1 title=smoking* and (“cost-benefit” or “costbenefit” or “cost benefit” or “cost-
effectiveness” or “costeffectiveness” or “cost effectiveness” or “economic* valuation” 
or cost* or valu* or “critical appraisal” or “model”)) and (“pecuniary external*” or 
“technological external*” or “knowledge external*” or “network external*” or 
“external*” or “spillover*” or “spill-over*”) 
1 
 
Source ECONLIT 
#1 title=smoking* and “cost-benefit” or “costbenefit” or “cost benefit” or “cost-
effectiveness” or “costeffectiveness” or “cost effectiveness” or “economic* valuation” 
or cost* or valu* or “critical appraisal” or “model”)) and (“pecuniary external*” or 
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“technological external*” or “knowledge external*” or “network external*” or 
“external*” or “spillover*” or “spill-over*”) 
1 
 
Source MATHSCINET 
#1 (smoking) and (model* or external*) 
6 
 
Source NHS EED 
#1 (smoking*) and (dynamic*) 
7 
 
Source HEED 
#1 (smoking*) and (dynamic*) 
3
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Appendix 7.2 Study selection process for smoking dynamic models 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Two papers were derived from references 
18 titles and abstracts identified 
Cochrane Library       0 
Web of Knowledge       1 
Econlit                                          1 
Mathscinet       6 
NHS EED        7 
HEED        3 
3 excluded for duplication: 
HEED                3   
                  
15 excluded because: 
Not dynamic model structure was specified   11 
The model structure was not fully detailed       4 
17* titles and abstracts identified 
 
2 articles included 
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Appendix 7.3 References included in the systematic literature search on smoking 
dynamic models 
 
Ahmad S. The cost-effectiveness of raising the legal smoking age in California. Medical 
Decision Making, 2005a; 25(3):330-340. 
 
Ahmad S. Closing the youth access gap: The projected health benefits and cost savings 
of a national policy to raise the legal smoking age to 21 in the Unites States. Health 
Policy, 2005b; 75(1):74-84. 
 
Ahmad S, Franz GA. Raising taxes to reduce smoking prevalence in the US: A 
simulation of the anticipated health and economic impacts. Public Health, 2008; 
122(1):3-10. 
 
Castillo81 GC, Jordan SG, Rodriguez AH. Mathematical models for the dynamics of 
tobacco use, recovery and relapse. Technical Report Series, BU-1505-M. Department of 
Biometrics, Cornell University. 2000. 
 
Chan W, Kapadia AS, Chuang AZ. A stochastic model of smoking behaviour under a 
cessation program. Biomedical Journal, 2001; 43(1):53-62.  
 
Collins D, Lapsley H. Human capital and demographic approaches to estimating the 
external costs of smoking. In, Jeanrenaud C, Soguel NC (Eds). Valuing the cost of 
smoking: assessment methods, risk perception and policy options. Studies in Risk and 
Uncertainty, 1999; Vol.13. Boston, Dordrecht and London: Kluwer Academic.  
 
Feenstra TL, Hamberg-van Reenen HH, Hoogenveen RT, Rutten-van Molken MPMH. 
Cost-effectiveness of face-to-face smoking cessation interventions: a dynamic 
modelling study. Value in Health, 2005; 8(3):178-190. 
 
James G, Venn G. Developing an integral model for a cancer support programme. 
Psycho-Oncology, 2006; 15(S2):S462. Abstract 1085.  
                                                 
81
 Derived from: Sharomi O, Gumel AB. Curtailing smoking dynamics: a mathematical modelling approach. Applied Mathematics 
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Appendix 7.4 Flow diagram for a conventional transmission dynamic model  
(Susceptible-Infected-Recovered (SIR) model) 
 
 
An adaptation of this SIR model to my conventional markov-type approach would need: 
(a) no additional recruitment of individuals or new groups of population will be entering 
into the model.; (b) Potential Smokers group would be divided in non-passive (NPNS) 
and passive never smokers (PNS); and, (c) the Temporary quitters and Permanent 
Quitters group would be combined in the former smokers category (FS) and therefore, 
only one quitting rate for former smokers would be required. 
 
 
Therefore, the new SIR model will be represented as Box A7.4.  
 
Box A7.4 Structure of an adaptation of a smoking SIR health states model  
 
 
 
 
 
 
Definition of parameters and variables: 
 
 
NPNS  ≡Non-passive never-smokers  
PNS  ≡ Passive never-smokers 
S  ≡Smokers 
FS  ≡Smokers who quit smoking (former smokers) 
inpns ≡rate at which non-passive never-smokers can acquire smoking habits (and become smokers) via 
contacts with smokers 
ipns ≡rate at which passive never-smokers can acquire smoking habits (and become smokers) via 
contacts with smokers 
 Ψ  ≡
 
quit rate  
α  ≡rate of revert to smoking when you are a former smoker (relapse rate) 
µnpns  ≡
 
mortality rate for non-passive never smokers 
µpns  ≡
 
mortality rate for passive never smokers 
µs  ≡ mortality rate for smokers 
µfs  ≡ mortality rate for former smokers 
 
NPNS 
 
S 
 
FS 
   µsS µfsFS 
        
inpnsNPNS ΨS 
αFS 
 
PNS 
ipnsPNS 
   µpnsPNS 
   µnpnsNPNS 
X Y 
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The set of differential equations for the non-passive and passive never smokers SIR 
model would be: 
 
dNPNS/dt = - (inpns*NPNS) - (µnpns*NPNS) - (Y*NPNS) + (X*PNS)   
 
dPNS/dt = - (ipns*PNS) - (µpns*PNS) + (Y*NPNS) - (X*PNS)   
  
dS/dt = + (inpns*NPNS) + (ipns*PNS) + (α*FS) -  (Ψ*S) - (µs*S) 
 
     
dFS/dt = +(Ψ*S) - (α*FS) - (µfs*FS)          
 
dX/dt = +S*( Ψ+ µs) 
 
dY/dt = +(α*FS) 
      
X and Y are both functions of dS/dt.  For instance, for X as the number of smokers 
declines, their never-smoking contacts shift from the PNS to the NPNS state (and vice 
versa); and, for Y, as the number of smokers increases, their never-smoking contacts 
shift from NPNS to the PNS state. 
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Appendix 7.5 Cost-effectiveness acceptability curves for M8 (LICB and NPPCBP) 
and M9 (LICB EE and NPPCBP EE) compared to no intervention 
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Appendix 7.6 Cost-effectiveness acceptability curves for M10 (MBA and BAD) and 
M11 (MBA EE and BAD EE) compared to no intervention 
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Appendix 8.1 Summary of population characteristics and analytic horizon of models 
 
Models 
 
 
Cohort 
Sex 
 
 
Starting population Analytic horizon 
S FS NS NP NS P Death TOTAL Age Time  
M1 1000 0 - - 0 1000 16-200 
hundred years for each age cohort (i.e. age 16=116; age 45=145, 
etc) M&F 
M2 1000 0 - - 0 1000 16-200 
hundred years for each age cohort (i.e. age 16=116; age 45=145, 
etc) M&F 
M3 1000 0 - - 0 1000 16-100 
considering lifetime 100 years (each cohort stops when age 100 
years) M&F 
M4 
according to age 
prevalence 
according to 
age 
prevalence 
according to 
age 
prevalence 
according to 
age 
prevalence 0 1000 16-100 
considering lifetime 100 years (each cohort stops when age 100 
years) M&F 
M5 (EE) according to age prevalence 
according to 
age 
prevalence 
according to 
age 
prevalence 
according to 
age 
prevalence 0 
1000+96.5% 
of adult 
smokers’ 
children 16-100 
considering lifetime 100 years (each cohort stops when age 100 
years) 
M&F 
M6 
Pregnant smokers 
according to age 
prevalence 
according to 
age 
prevalence 
according to 
age 
prevalence 
according to 
age 
prevalence 0 1000 16-100 
considering pregnancy age from 16 to 44.5 plus five years of 
children's maximum age F 
M7 (EE) 
Pregnant smokers 
according to age 
prevalence 
according to 
age 
prevalence 
according to 
age 
prevalence 
according to 
age 
prevalence 0 
1000+average 
number of  
babies 
delivered by 
pregnant adult 16-100 
considering pregnancy age from 16 to 44.5 plus five years of 
children's maximum age 
F 
M8 
according to age 
prevalence 
according to 
age 
prevalence 
according to 
age 
prevalence 
according to 
age 
prevalence 0 1000 16-100 
considering lifetime 100 years (each cohort stops when age 100 
years) M&F 
M9 (EE) 
according to age 
prevalence 
according to 
age 
prevalence 
according to 
age 
prevalence 
according to 
age 
prevalence 0 
1000+96.5% 
of adult 
smokers’ 
children 16-100 
considering lifetime 100 years (each cohort stops when age 100 
years) 
M&F 
M10 
Pregnant smokers 
according to age 
prevalence 
according to 
age 
prevalence 
according to 
age 
prevalence 
according to 
age 
prevalence 0 1000 16-100 
considering pregnancy age from 16 to 44.5 plus five years of 
children's maximum age F 
M11 (EE) 
Pregnant smokers 
according to age 
prevalence 
according to 
age 
prevalence 
according to 
age 
prevalence 
according to 
age 
prevalence 0 
1000+average 
number of  
babies 
delivered by 
pregnant adult 16-100 
considering pregnancy age from 16 to 44.5 plus five years of 
children's maximum age 
F 
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Appendix 8.2 Summary of parameters and assumptions of models  
 
Models M1 M2 M3 M4 M5 M6 M7 M8 M9 M10 M11 Summary 
Discount rate 3,5 3,5 
 
3,5 3,5 
 
3,5 
 
3,5 
 
3,5 
 
3,5 3,5 3,5 3,5 Constant 
 
Background quite 
rate 
2% (trans 
prob and 
cycle) 
2% (trans 
prob and 
cycle) 
2% (trans 
prob and 
cycle) 
 
2% (trans 
prob and 
cycle) 
 
2% (trans 
prob and 
cycle) 
 
2% (trans 
prob and 
cycle) 
 
2% (trans 
prob and 
cycle) 
2% (trans 
prob and 
cycle) 
 
2% (trans 
prob and 
cycle) 
2% (trans 
prob and 
cycle) 
2% (trans 
prob and 
cycle) 
 
Constant 
Yearly quitting 
rates 
Adjusted by 
relapse 
Adjusted by 
relapse 
adjusted by 
relapse, trans 
prob,cycle 
adjusted by 
relapse, trans 
prob,cycle 
adjusted by 
relapse, trans 
prob,cycle 
adjusted by 
relapse, trans 
prob,cycle 
adjusted by 
relapse, trans 
prob,cycle 
adjusted by 
relapse, trans 
prob,cycle 
adjusted by 
relapse, trans 
prob,cycle 
adjusted by 
relapse, trans 
prob,cycle 
adjusted by 
relapse, trans 
prob,cycle 
no 
constant 
Six monthly 
quitting rates 
 
not adjusted not adjusted adjusted by 
relapse, trans 
prob 
adjusted by 
relapse, trans 
prob 
adjusted by 
relapse, trans 
prob 
adjusted by 
relapse, trans 
prob 
adjusted by 
relapse, trans 
prob 
adjusted by 
relapse, trans 
prob 
adjusted by 
relapse, trans 
prob 
adjusted by 
relapse, trans 
prob 
adjusted by 
relapse, trans 
prob 
no 
constant 
Relapse rate not adjusted 
 
not adjusted adjusted  by 
trans prob, 
cycle 
adjusted  by 
trans prob, 
cycle 
adjusted  by 
trans prob, 
cycle 
adjusted  by 
trans prob, 
cycle 
adjusted  by 
trans prob, 
cycle 
adjusted  by 
trans prob, 
cycle 
adjusted  by 
trans prob, 
cycle 
adjusted  by 
trans prob, 
cycle 
adjusted  by 
trans prob, 
cycle 
no 
constant 
 
Condition 
episode costs 
 
£2006 
 
£2006 
 
£2010 
 
£2010 
 
£2010 £2010 £2010 £2010 £2010 £2010 £2010 no 
constant 
Condition 
episode utilities 
according to 
disease 
according to 
disease 
according to 
disease 
according to 
disease 
according to 
disease 
according to 
disease 
according to 
disease 
 
according to 
disease 
according to 
disease 
according to 
disease 
according to 
disease 
Constant 
 
Intervention 
costs 
 
£2006 
 
£2006 
 
£2010 
 
£2010 
 
£2010 
 
£2010 £2010 
 
£2010 £2010 
 
£2010 
 
£2010 no 
constant 
Population 
weights 
according to 
age and sex 
according to 
age and sex 
according to 
age and sex 
according to 
age and sex 
according to 
age and sex 
according to 
age 
according to 
age 
 
according to 
age and sex 
according to 
age and sex 
 
according to 
age 
according to 
age 
no 
constant 
Health states 
 
 
S, FS, D (by 
age interval 
and sex) 
 
S, FS, D (by 
age interval 
and sex) 
 
S, FS, D (by 
age interval 
and sex) 
 
S, FS, NSNP, 
NSP, D (by 
age interval 
and sex) 
S, FS, NSNP, 
NSP, D (by 
age interval 
and sex) 
S, FS, NSNP, 
NSP, D (by 
age interval 
and sex) 
S, FS, NSNP, 
NSP, D (by 
age interval 
and sex) 
S, FS, NSNP, 
NSP, D (by 
age interval 
and sex) 
S, FS, NSNP, 
NSP, D (by 
age interval 
and sex) 
S, FS, NSNP, 
NSP, D (by 
age interval 
and sex) 
S, FS, NSNP, 
NSP, D (by 
age interval 
and sex) 
no 
constant 
 
 
Condition 
Prevalence 
 
S, FS, NS 
 
Given S, 
FS,NS 
 
Checked S, 
FS 
 
Checked and 
S, FS, NSNP, 
NSP 
Checked and 
S, FS, NSNP, 
NSP 
Checked and 
S, FS, NSNP, 
NSP 
Checked and 
S, FS, NSNP, 
NSP 
Checked and 
S, FS, NSNP, 
NSP 
Checked and 
S, FS, NSNP, 
NSP 
Checked and 
S, FS, NSNP, 
NSP 
Checked and 
S, FS, NSNP, 
NSP 
no 
constant 
Mortality S, FS, NS Checked S, 
FS, NS 
Checked S, 
FS, NS 
Checked and 
S, FS, NSNP, 
NSP 
Checked and 
S, FS, NSNP, 
NSP 
Checked and 
S, FS, NSNP, 
NSP 
Checked and 
S, FS, NSNP, 
NSP 
Checked and 
S, FS, NSNP, 
NSP 
Checked and 
S, FS, NSNP, 
NSP 
Checked and 
S, FS, NSNP, 
NSP 
Checked and 
S, FS, NSNP, 
NSP 
no 
constant 
Incidence 
 
- - - according to 
age and sex 
according to 
age and sex 
according to 
age and sex 
according to 
age and sex 
according to 
age and sex 
according to 
age and sex 
according to 
age and sex 
according to 
age and sex 
no 
constant 
 
